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5ABSTRACT
The skeletal muscle channelopathies are a group of inherited muscle diseases characterised
by the abnormal functioning of voltage-gated ion channels expressed in skeletal muscle. They
manifest as the non-dystrophic myotonias and the periodic paralyses.
This thesis increases the current understanding of the clinical and genetic basis of
this group of diseases. It identifies the overall prevalence in England as 1.12/100,000 and
determines the individual minimum prevalence of each disease, which has not previously
been documented. It presents a detailed phenotype study of periodic paralysis (PP),
paramyotonia congenita (PMC) and sodium channel myotonia (SCM), which is the first
comparative study of these diseases. In the process it uncovers the marked similarity between
PMC and SCM and suggests that these may be a spectrum of one disease, rather than two
distinct diseases as traditionally thought. It provides the first systematic study of pregnancy
and anaesthetics in a large number of channelopathy patients, identifying a marked increase
in severity of symptoms during pregnancy that has not previously been documented.
To widen the spectrum of genetic diagnosis and techniques in this group of diseases,
this thesis describes the first cases of large scale rearrangements in CLCN1 causing myotonia
congenita. It demonstrates how, using whole exome sequencing, the genetic diagnosis rate
can be improved and illustrates two cases that may be explained by variations in RYR1 and
another case in which a genetic diagnosis of Liddle’s syndrome may underlie secondary PP.
This suggests that RYR1 variations may account for some unconfirmed cases and others may
be explained by genetic causes of secondary PP.
Finally this thesis presents convincing evidence of the efficacy of mexiletine in
non-dystrophic myotonia in a double-blind placebo-controlled trial. It demonstrates
improvement of the primary outcome measure of patient-reported stiffness and the majority
of secondary outcome measures assessed.
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Chapter 1
INTRODUCTION
1.1 Skeletal Muscle Channelopathies
The skeletal muscle channelopathies are a heterogeneous group of inherited muscle
diseases. They are characterised by genetic variations that result in abnormal functioning
of voltage-gated ion channels expressed in skeletal muscle. This results in an alteration
in muscle membrane excitability which manifests either as episodic muscle weakness
or as stiffness. They are considered in two main groups: periodic paralysis (PP), in
which the muscle membrane is rendered inexcitable resulting in episodes of paralysis and
non-dystrophic myotonia (NDM) in which the muscle membrane becomes hyperexcitable
resulting in myotonia and stiffness.
Voltage-gated ion channels play a vital role throughout the nervous system and
dysfunction of these proteins are thought to be important in both rare Mendelian diseases,
such as the skeletal muscle channelopathies, and common paroxysmal diseases, such as
migraine and epilepsy. In these common diseases the precise genetic mechanisms that relate
the ion channel dysfunction to the clinical phenotype is complex and multi-factorial and
therefore remains poorly understood. The rarer Mendelian disorders, however, are better
understood and at present have a greater scope for in-depth investigation as the underlying
genetic defects are more clearly defined. Improving our knowledge of these rare disorders,
therefore forms a platform on which to further our understanding of the more common
disorders.
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1.2 Scope of thesis
This thesis aims to increase the understanding of the skeletal muscle channelopathies
with specific emphasis on non-dystrophic myotonia and periodic paralysis. It specifically
investigates the prevalence of these conditions in the UK. It also increases our understanding
of the phenotypes of these diseases and how they affect pregnancy and anaesthetic use. It
expands the current knowledge of genetic diagnosis and investigates the efficacy of treatment
in this group of diseases.
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Chapter 2
BACKGROUND
2.1 Ion Channels
Ion channels are essential membrane-spanning glycoproteins that allow the movement of ions
across a cell membrane. They may be categorised as voltage-gated, ligand-gated or sensory
transducers. Voltage-gated ion channels have a highly voltage-dependent open probability.
They contain charged amino acid residues that sense a change in the electrical field across the
membrane, triggering channel opening. Ligand-gated ion channels depend on the binding
of a ligand to initiate channel opening. Sensory transducers convert a sensory signal into
an electrical signal, transforming environmental properties into electrical potentials (Hille,
2001).
2.1.1 Voltage-gated Ion Channels
Voltage-gated ion channels play a crucial role in the generation and propagation of electrical
signals. They consist of a combination of principal pore-forming subunits, which determine
the primary channel properties and secondary auxiliary subunits, which modify channel
function. Ion selectivity in these channels is determined by the selectivity filter which consists
of hydrophilic loops located within the pore. Gating is voltage-sensitive and is therefore
coupled to a sensor that detects changes in transmembrane voltage. In the majority of
channels this voltage sensor originates from a membrane-spanning α-helical segment with
positively charged amino acids known as the S4 segment. Membrane depolarisation causes
this segment to move outwards, altering the channel conformation and increasing the open
probability (Hille, 2001) (Figure 2.1).
The main voltage-gated ion channels in skeletal muscle are the chloride, potassium,
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Figure 2.1: Schematic diagram representing the main components of a voltage-gated ion
channel
sodium and calcium channels. The chloride channels are markedly different from the others,
not having an S4 segment for voltage sensing and being made up of a homodimer with two
distinct pores. The voltage-gated potassium, sodium and calcium channels are all derived
from the same gene superfamily with marked sequence homology. Diseases of voltage-gated
ion channels are caused by mutations that affect the key aspects of channel function: gating,
voltage-sensing, permeation, assembly and trafficking. The clinical manifestations of these
diseases, however, are mainly dictated by the tissue distribution of the particular channel.
2.1.1.1 Voltage-gated Potassium Channels
Potassium channels play a role in stabilising the membrane potential. When these channels
open, potassium ions flow outward making the cell less depolarised and less excitable.
They consist of three main families: the six transmembrane domain family, the four
transmembrane two-P (leak) potassium channels and the two transmembrane domain inward
rectifying potassium channels (Figure 2.2). To date over 90 genes have been identified for
potassium-sensitive channels (Seal et al., 2011), many with alternative splicing leading to the
production of multiple isoforms.
2.1.1.2 Inward Rectifying Potassium Channels
Although inward rectifying potassium (Kir) channels are not true voltage-gated channels with
a distinct S4 segment, they are still voltage-sensitive and mutations in these channels have
been shown to cause muscle channelopathies. They aid in maintaining the resting potential,
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Figure 2.2: Topology of the 3 different classes of potassium channel. a) 2 transmembrane
domain family, inward-rectifying potassium channels; b) 4 transmembrane domain family,
two-pore potassium channels; c) 6 transmembrane domain potassium channels. (P = pore-loops)
acting as a one-way valve by allowing potassium ions to enter during hyperpolarisation but
not to exit during depolarisation. Their inward rectifying properties are derived from the
voltage-dependent binding of intracellular polyvalent ions that block the channel (Bichet
et al., 2003). These channels consist of two transmembrane domains linked by a pore-forming
region which contains the selectivity filter (Figure 2.2a). Four subunits come together to form
a tetramer resulting in a functional channel (Glowatzki et al., 1995).
The main Kir channels found in skeletal muscle are the Kir2.x family and the
ATP-sensitive potassium channels, Kir6.x (Table 2.1). The Kir2.x channels are constitutively
active with steep inward rectification which is regulated by magnesium and polyamines
(Lopatin et al., 1994). They are thought to be important in setting the resting membrane
potential and maintaining membrane stability. Kir2.1 is expressed in skeletal, smooth and
cardiac muscle as well as the brain, eye and kidney (de Boer et al., 2010). Mutations in
this channel are known to cause Andersen-Tawil Syndrome (ATS) (Plaster et al., 2001). The
Kir2.6 channel was recently discovered with 98% sequence identity with Kir2.2 and is also
expressed in skeletal muscle. Mutations in this channel are associated with susceptibility to
thyrotoxic periodic paralysis (Ryan et al., 2010).
2.1.1.3 Voltage-gated Sodium Channels
The voltage-gated sodium channels play a crucial role in the generation and propagation
of action potentials in myocytes and neurons (Hodgkin and Huxley, 1952). They are
selective ion channels that activate following initial membrane depolarisation and then rapidly
inactivate. They consist of a complex of an α-subunit that associates with a number of
auxiliary β -subunits. Each α-subunit consists of four domains (I-IV), each made up of six
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Figure 2.3: Membrane topology of the voltage-gated sodium and calcium channel. (The
location of the S4 segments are indicated with + signs)
transmembrane sections (Figure 2.3). Each domain has an S4 voltage-sensing domain with
positively charged arginine residues at every third position. X-ray crystallography of NavAb
in Arcobacter butzleri suggests that the ion selectivity is determined by glutamate side chains
in the narrowest part of the pore and that the combination of the movement of the S4 segments
and the S4-S5 linker, open out to dilate the central pore allowing partially hydrated sodium
ions into the water-filled central pore (Payandeh et al., 2011). Inactivation is thought to occur
via the binding of the intracellular loop between domains III and IV to the intracellular part
of the pore like a hinged lid (Vassilev et al., 1988, 1989).
To date nine distinct α-subunits (NaV1.1-1.9) have been identified but only NaV1.4
and 1.6 are expressed in skeletal muscle (Table 2.1). NaV1.4 is highly expressed in skeletal
muscle (Bailey et al., 2003) and is co-expressed with the β1-subunit which increases the
current through the channel. The importance of its action in skeletal muscle is evidenced by
mutations in the channel causing NDM and PP. NaV1.6 is primarily expressed in denervated
muscle. The β3-subunit is also expressed in skeletal muscle and acts by facilitating fast gating
so may play a role in modulating the muscle action potential (Jurkat-Rott et al., 2006).
2.1.1.4 Voltage-gated Calcium Channels
The voltage-gated calcium channels aid in regulating neurotransmission, contraction and
secretion as well as shaping action potentials. They act as a coupling mechanism between
electrical signals and the physiological events in cells. They consist of four or five different
subunits. The primary subunit, α1-subunit, has a similar arrangement to the sodium channel
as it is made up of four domains (I-IV) each with six transmembrane segments. The S4
segment confers voltage sensitivity and the loop between S5 to S6 determines ion selectivity.
In this loop, three amino acids in domains I, III and IV confer calcium ion selectivity.
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Figure 2.4: Representation of the P/Q-type calcium channel with the central pore-forming
subunit (α1) and its auxiliary subunits (α2, β ,γ & δ ).
The auxiliary subunits modify the properties of the channel. Most calcium channels have
an intracellular β -subunit, a disulphide-linked α2δ -subunit and, in skeletal muscle cells, a
γ-subunit1 (Figure 2.4).
26 different mammalian calcium channel subunit genes have been identified to date
(Seal et al., 2011), 10 of these encode the α1-subunit (Table 2.1). The L-type CaV1.1
(CACNA1S) is the one most predominantly expressed in skeletal muscle. The β -subunits
are known to accelerate current activation kinetics (Lacerda et al., 1991) and γ1-subunit can
increase the inactivation rate (Ursu et al., 2004). This channel is also known to interact
with the ryanodine receptor (RYR1) via the interlinker between domains II and III, helping
to mediate excitation-contraction coupling and activate RYR1 (Paolini et al., 2004). Its vital
role in skeletal muscle is illustrated by mutations in the gene causing hypokalaemic periodic
paralysis and susceptibility to malignant hyperthermia.
2.1.1.5 Chloride Channels
Chloride channels play a number of important roles throughout the mammalian system. They
stabilise membrane potential, regulate cell volume and intracellular pH, modulate neuronal
excitability and are vital in signal transduction and epithelial salt transport.
The only group of chloride channels that are voltage-gated belong to the ClC family
(Table 2.1). This family consists of nine genes, four of which encode voltage-gated chloride
channels and the other five encode chloride/hydrogen ion exchangers. The mammalian
voltage-gated chloride channels are activated on depolarisation and slowly inactivate with
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hyperpolarising steps. They are distinct from the other voltage-gated channels as they form a
homodimer with two separate pores (protochannels). A key characteristic is that each of the
protochannels have individual voltage-sensors, selectivity filters and are independently gated
(Miller and White, 1984) with a “fast” gate with independent opening and a “slow” gate
which can close both pores simultaneously. Both gates are sensitive to changes in voltage,
chloride ion concentration and pH (Pusch, 2004) (Figure 2.5b).
ClC channels consist of 18 transmembrane domains per subunit with a cytoplasmic
amino-terminus and two cystathionine β -synthase (CBS) domains in the cytoplasmic
C-terminus (Dutzler et al., 2002) (Figure 2.5a). The ClC-1 channel is the main isoform
expressed in skeletal muscle (Steinmeyer et al., 1991). It is important for maintaining the
resting membrane potential and repolarisation, accounting for 85% of the resting membrane
conductance (Bryant and Morales-Aguilera, 1971; Palade and Barchi, 1977). The importance
of this channel in skeletal muscle is illustrated by mutations causing myotonia congenita
(MC). In this disease patients have increased membrane excitability which triggers repetitive
sodium channel opening resulting in stiffness.
Figure 2.5: Chloride channel, ClC-1 (a) Representation of the membrane topology of the
chloride channel (b) Schematic diagram of the double-barrelled ClC-1 channel. This shows
two separate pores formed by each ClC-1 subunit, the common slow intracellular gate and the
individual fast inactivation gates.
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Table 2.1: Table of voltage-gated ion channels and corresponding genes
	  	  	  
	   Ion	  channels	   Gene	  	  
Inward	  rectifying	  potassium	  channels	  
	   Kir1.1	   KCNJ1	  
	   Kir2.1	   KCNJ2	  
	   Kir2.2	   KCNJ12	  
	   Kir2.3	   KCNJ4	  
	   Kir2.4	   KCNJ14	  
	   Kir3.1	   KCNJ3	  
	   Kir3.2	   KCNJ6	  
	   Kir3.3	   KCNJ9	  
	   Kir3.4	   KCNJ5	  
	   Kir4.1	   KCNJ10	  
	   Kir4.2	   KCNJ15	  
	   Kir5.1	   KCNJ16	  
	   Kir6.1	   KCNJ8	  
	   Kir6.2	   KCNJ11	  
	   Kir7.1	   KCNJ13	  
Voltage-­‐gated	  sodium	  channels	  
	   Nav1.1	   SCN1A	  
	   Nav1.2	   SCN2A	  
	   Nav1.3	   SCN3A	  
	   Nav1.4	   SCN4A	  
	   Nav1.5	   SCN5A	  
	   Nav1.6	   SCN8A	  
	   Nav1.7	   SCN9A	  
	   Nav1.8	   SCN10A	  
	   Nav1.9	   SCN11A	  
Voltage-­‐gated	  calcium	  channels	  
	   Cav1.1	   CACNA1S	  
	   Cav1.2	   CACNA1C	  
	   Cav1.3	   CACNA1D	  
	   Cav1.4	   CACNA1F	  
	   Cav2.1	   CACNA1A	  
	   Cav2.2	   CACNA1B	  
	   Cav2.3	   CACNA1E	  
	   Cav3.1	   CACNA1G	  
	   Cav3.2	   CACNA1H	  
	   Cav3.3	   CACNA1I	  
Voltage-­‐gated	  chloride	  channels	  
	   ClC-­‐1	   CLCN1	  
	   ClC-­‐2	   CLCN2	  
	   ClC-­‐Ka	   CLCNKA	  
	   ClC-­‐Kb	   CLCNKB	  
	   ClC-­‐3	   CLCN3	  
	   ClC-­‐4	   CLCN4	  
	   ClC-­‐5	   CLCN5	  
	   ClC-­‐6	   CLCN6	  
	   ClC-­‐7	   CLCN7	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2.2 Skeletal Muscle Channelopathies
As described, the skeletal muscle channelopathies are associated with variations in genes
encoding key voltage-gated ion channels expressed in skeletal muscle. They form two distinct
groups, the NDMs and the PPs.
The NDMs are a group of conditions characterised by muscle stiffness on voluntary
movement due to delayed relaxation of the skeletal muscle. This group consists of MC,
paramyotonia congenita (PMC) and sodium channel myotonia (SCM) (Figure 2.6). They are
caused by mutations in either the chloride channel (CLCN1) or sodium channel (SCN4A)
genes and are clinically distinct from the dystrophic myotonias, myotonic dystrophy type 1
(DM1) and type 2 (DM2), by the absence of systemic symptoms and progressive weakness.
The PPs are characterised by episodic muscle weakness often related to potassium
levels. They consist of hyperkalaemic periodic paralysis (HyperPP), hypokalaemic periodic
paralysis (HypoPP) and ATS, caused by mutations in the calcium (CACNA1S), sodium
(SCN4A) and potassium channel (KCNJ2) genes respectively (Figure 2.6).
Figure 2.6: Flow chart of the different diseases associated with non-dystrophic myotonia
and periodic paralysis and the associated genes.
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2.3 Prevalence of Skeletal Muscle Channelopathies
Prevalence estimates are an important aspect of healthcare. They aid in estimating the burden
of disease which aids in planning healthcare. They give an indication to patients of the rarity
of a disease and are also useful in determining key patterns in the distribution of the disease,
thereby offering insights into disease mechanisms. Performing prevalence studies also aids
in establishing databases of affected patients which further aids research and clinical trials.
2.3.1 Current Prevalence Data
Estimates of the prevalence of skeletal muscle channelopathies vary widely depending on
region. Published studies suggest a prevalence range from 1 to 10/100,000 (Jurkat-Rott et al.,
2010), but worldwide the prevalence has not been accurately determined and the majority of
studies pre-date genetic diagnosis which may compromise their accuracy.
2.3.1.1 UK Prevalence
To date there has only been one study looking at the prevalence of channelopathies in the UK.
This study was conducted in 1954 and only investigated the prevalence of MC in North East
England (Walton and Nattrass, 1954), estimating it at 0.3/100,000. A prevalence study in the
UK is therefore timely.
2.3.1.2 Worldwide Prevalence
Prevalence studies in the rest of the world vary widely, from 0.4/100,000 in Switzerland
(Emery, 1991) to 9.0/100,000 in Northern Norway (Sun et al., 2001). There are pockets
of high prevalence, specifically of MC in the Scandinavian countries due to geographical
location and the founder effect. The results of all of these studies are detailed in Table 2.2.
Previous studies have been very limited, only covering the more common diseases: MC,
HypoPP and PMC. None of the published studies investigate the individual prevalence of
HyperPP, ATS or SCM. These studies have also primarily focused on prevalence within small
population groups making it difficult to be certain that they are true estimates over a larger
region. The majority of studies have been conducted in the Scandinavian countries, which
seem to have a much higher prevalence than other countries worldwide and therefore cannot
be extrapolated to give an accurate estimate of prevalence in the UK. This lack of data further
suggests that a comprehensive study of the prevalence of all the skeletal channelopathies is
necessary and therefore this thesis investigates the prevalence in England.
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Table 2.2: Studies evaluating the prevalence of non-dystrophic myotonias and periodic
paralyses
	  
Date Reference Geographical area n Total population 
Prevalence 
(per 100,000) 
Myotonia congenita 
1954 Walton et al, 1954 North East Englanda 6 2,262,292 0.3 
1954 Kurland, 1958 Rochester, USA 1 29,885 3.3 
1956 Emery, 1991 Switzerland* 18 4,714,992 0.4 
1960 Becker, 1977 West Germany* 284 55,958,000 0.5 
1963 Gudmundsson, 1968 Iceland 2 187,200 1.1 
1979 Pinessi et al, 1982 Turin, Italy* 10 1,160,686 0.9 
1988 Ahlström et al, 1993 Örebro, Sweden 3 269,341 1.1 
1989 Ferrero et al, 1991 Central Spainb 11 235,976 4.7 
1989 Al Rajeh et al, 1993 Thugbah, Saudi Arabia 2 23,227 8.6 
1990 Emery, 1991 Ljubljana, Slovenia 10 1,996,377 0.5 
1994 Hughes et al, 1996 Northern Irelandc 17 1,573,282 1.1 
1995 Darin et al, 2000 Western Swedend 3 359,676 0.8 
1997 El-Tallawy et al, 2005 Assiut, Egypt 2 52,203 3.8 
1998 Baumann et al, 1998 Northern Finland* 54 732,000 7.3 
2001 Sun et al, 2001 Northern Norway* 45 500,000 9.0 
2001 Chung et al, 2003 Hong Kong, Chinae 7 1,335,469 0.5 
Average estimated prevalence# 475 71,390,606 0.67 
Paramyotonia congenita 
1965 Emery, 1991 West Germany* 160 57,000,000 0.3 
1983 Tangsrud et al, 1988 Southern Norwayf 1 573,762 0.2 
1995 Darin et al, 2000 Western Swedend 4 359,676 1.1 
Average estimated prevalence# 165 57,933,438 0.28 
Hypokalemic periodic paralysis 
1978 Johnsen et al, 1981 Denmark*g 66 5,096,959 1.3 
1983 Araki et al, 1987 Kumamoto, Japan 18 1,800,000 1.0 
1983 Tangsrud et al, 1988 Southern Norwayf 3 573,762 0.5 
1989 Ferrero et al, 1991 Central Spainb 4 235,976 1.7 
1992 Kantola et al, 1992 Finland*h 21 4,998,478 0.4 
Average estimated prevalence# 112 12,705,175 0.88 
*Studies specifically conducted to evaluate the prevalence of the periodic paralyses or the non–dystrophic myotonias. #Average estimated 
prevalence based on the total number of patients identified in the studies/total population.  aTotal population from 1951 Census of England 
and Wales. bPrevalence among 18 year–old males. cPrevalence of non–dystrophic myotonia. dPrevalence among children <16 years. 
ePrevalence among children <19 years. fPrevalence among children <18 years. gOnly familial cases; total population data from Statistics 
Denmark. hTotal population data from Statistics Finland. 
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2.4 Clinical Phenotypes of Skeletal Muscle Channelopathies
The skeletal muscle channelopathies form a spectrum of disorders with significant phenotypic
overlap, which often creates difficulties in diagnosis. Overall they are characterised
as conditions that cause episodic symptoms marked by either stiffness and/or weakness
depending on the channel defect and its effect on muscle membrane excitability. Given the
phenotypic and genotypic heterogeneity, phenotyping these patients is not only important for
determining the diagnosis but also for informing management and understanding the natural
history of the disease.
2.4.1 Phenotype of Non-Dystrophic Myotonia
NDM is a term used to describe the group of diseases characterised by predominant clinical
and electrical myotonia. Myotonia is caused by membrane hyperexcitability, which triggers
repetitive sodium channel opening, manifesting symptomatically as stiffness. The NDMs
were traditionally distinguished from the “dystrophic” myotonias, DM1 and DM2, because
patients with the condition did not demonstrate muscle degeneration on muscle biopsy. It
is now known that this is not always the case, however genetically these are very distinct
diseases. The myotonic dystrophies are multi-system disorders related to abnormal splicing
of multiple genes whereas NDM is related to the abnormal function of a single ion channel
gene only affecting skeletal muscle.
Prior to the advent of genetic testing the NDMs were divided according to inheritance
and phenotype. Since the discovery of the causative genes they are now divided into two
main groups, the chloride channelopathies (recessive and dominant MC) and the sodium
channelopathies (PMC and SCM).
2.4.1.1 Chloride Channelopathies
The chloride channelopathies are made up of recessive MC and dominant MC and are
characterised by impaired relaxation of skeletal muscle after voluntary contraction following
a period of rest. The myotonia classically improves after repeated exertion, known as the
“warm-up” phenomenon (Becker et al., 1977). Age of onset is approximately 10 years old
(Trip et al., 2009b; Dupre et al., 2009; Trivedi et al., 2013), and patients primarily experience
stiffness in the legs (Fialho et al., 2007; Trivedi et al., 2013). Some patients also report
worsening in the cold (50-60%) and suffer with pain (approximately 30-50%) (Thomsen,
1876; Trivedi et al., 2013; Fialho et al., 2007; Trip et al., 2009b; Dupre et al., 2009).
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Dominant versus Recessive Myotonia Congenita
MC has traditionally been subdivided according to inheritance into dominant MC (Thomsen’s
disease) (Thomsen, 1876) and recessive MC (Becker’s myotonia) (Becker et al., 1977).
Although these two subgroups have marked overlap in features, both having warm-up and
varying degrees of muscle hypertrophy, some distinguishing clinical features have been
reported (Fialho et al., 2007) (Table 2.3). Originally Becker reported dominant MC as having
an earlier onset of symptoms, often being noticed in the first few of years of life, but more
recent studies have illustrated that recessive MC has a younger age of onset which mirrors its
increased severity (Trivedi et al., 2013; Fialho et al., 2007; Dupre et al., 2009). In dominant
MC, symptoms are milder and more commonly seen in the upper limbs (Becker et al., 1977).
Recessive MC, however, is associated with more severe myotonia, often with episodes of
transient weakness on initiation of movement. It is also more commonly associated with
generalised muscle hypertrophy (Trivedi et al., 2013; Fialho et al., 2007; Dupre et al., 2009).
Of the two conditions, recessive MC is thought to have a higher prevalence (Becker et al.,
1977; Baumann et al., 1998).
Much of the original phenotypic information on MC is derived from the original papers
published by Thomsen and Becker before genetic testing was available. More recently
however, there have been a number of comprehensive analyses of genetically confirmed
groups of patients expanding the knowledge available on the phenotype of MC and looking
closely at phenotype-genotype correlations, which is summarised in Table 2.3.
2.4.1.2 Sodium Channelopathies
The sodium channelopathies can be divided into PMC and SCM. The two types are
distinguished clinically by the presence or absence of weakness, with patients with PMC
having clear episodes of weakness, often with accompanying paramyotonia (worsening of
myotonia with exercise) and cold sensitivity. SCM is the term now commonly used to
encompass the traditional group of “pure myotonic” syndromes including the potassium
aggravated myotonias (PAM) and cold-sensitive pure myotonic syndromes (Fournier et al.,
2004, 2006; Matthews et al., 2010). The sodium channelopathies tend to have a younger
age of onset than the chloride channelopathies, usually beginning between 3-5 years old
(Trivedi et al., 2013; Trip et al., 2009b; Miller et al., 2004). Recent data suggests that cold is
a common trigger (90-100%) (Trivedi et al., 2013; Matthews et al., 2010; Miller et al., 2004).
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The sodium channelopathies are best distinguished clinically from MC by the presence of
myotonia of face, eyes and tongue which, although may not be sensitive, is very specific to
the sodium channelopathies (Matthews et al., 2010; Trip et al., 2009b) (Table 2.3).
Table 2.3: Clinical phenotype of the non-dystrophic myotonias
	   Dominant	  MC	   Recessive	  MC	   PMC	   SCM	  
Clinical	  Features:	  
Onset:	  
	  
Later	  onset	  (7-­‐16yrs)	  
	  
Early	  onset	  (4-­‐12yrs)	  
	  
Early	  onset	  (3-­‐5yrs)	  
	  
Early	  onset	  (3-­‐5yrs)	  
	  
Distribution:	   Upper	  limbs	  >	  lower	   Lower	  limbs	  >	  upper	   Face	  &	  eyes	   Face	  &	  eyes	  
Muscle	  Weakness:	   No	  weakness	   Transient	  weakness	   Muscle	  weakness,	  may	  
be	  prolonged	  
No	  weakness	  
	  
Other	  findings:	   Mild	  symptoms	   Muscle	  hypertrophy	  
Severe	  symptoms	  
Paramyotonia	   Painful	  myotonia	  
Precipitants	   	  Improves	  with	  exercise	  -­‐	  “warm	  up”	  
phenomenon	  
Cold	  &	  exertion	   Potassium	  
ingestion,	  cold,	  
exertion	  
Electrophysiology	  
Short	  Ex	  Test:	  
	  
	  
	  
	  
No	  change	  but	  fall	  in	  
CMAP	  with	  cooling	  
	  
	  
Early	  fall	  in	  CMAP	  with	  
early	  recovery	  with	  
exercise	  
	  
	  
Gradual	  decrease	  in	  
CMAP	  with	  further	  
exercise,	  Marked	  fall	  
with	  cold,	  does	  not	  
recover	  with	  rewarming	  	  
	  
No	  change	  even	  after	  
cooling	  
EMG:	   Myotonic	  potentials	  
	  
Myotonic	  potentials	  
	  
Myotonic	  potentials	  
	  
Myotonic	  
potentials	  
Fournier	  pattern:	   Type	  III	   Type	  II	   Type	  I	   Type	  III	  
Muscle	  Biopsy	   Normal	  /	  absence	  of	  type	  2b	  fibres	   Normal/may	  have	  myopathic	  changes,	  large	  
vacuoles	  &	  tubular	  aggregates	  
	  
Distinguishing Paramyotonia Congenita and Sodium Channel Myotonia
PMC was first described in 1886 by Eulenburg as episodic muscle cramps and paralysis,
markedly worsened by exercise and cold (Eulenburg, 1886). This weakness may typically
persist for hours or even days (Miller et al., 2004). It was considered distinct from MC
as patients with PMC worsened rather than improved with exercise. A century later three
other types of myotonia, characterised by lack of cold-sensitivity and episodic weakness were
described which were felt to be distinct from PMC and MC. In 1987 Trudell et al identified
a kindred with painful myotonia worsened by potassium and improved by acetazolamide
that they termed Acetazolamide-responsive myotonia congenita (Trudell et al., 1987). In
1990, Ricker et al described a fluctuating type of myotonia with no weakness but worsening
myotonia with delayed onset after exercise or ingestion of potassium and termed it myotonia
fluctuans (Ricker et al., 1990). Finally a more severe type of myotonia fluctuans, myotonia
permanens was described in patients with ventilation impairment from myotonia of the
respiratory muscles (Lerche et al., 1993). These three conditions were grouped together
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and called the “potassium-aggravated myotonias”. Further cold-sensitive, pure myotonic
phenotypes were also described that were thought to be clinically distinct from the PAMs
as they were insensitive to potassium ingestion (Heine et al., 1993; Koch et al., 1995; Wu
et al., 2001). Genetic testing unified these diseases as they and PMC were all found to
be caused by mutations in the sodium channel SCN4A (Koch et al., 1991a; McClatchey
et al., 1992a,b; Lerche et al., 1993; Ptacek et al., 1991, 1993, 1994; Ru¨del et al., 1993).
Following this discovery the term “sodium channel myotonia” began to be used to describe
the PAMs and pure myotonic phenotypes associated with SCN4A mutations (Ru¨del et al.,
1993; Lehmann-Horn et al., 1993; Fournier et al., 2004, 2006; Ru¨del and Lehmann-Horn,
1997; Matthews et al., 2010). They were always felt to be distinct from PMC because of
the absence of episodes of weakness and this formed the basis for the definition of these two
diseases for the last 30 years.
SCM is characterised by pure myotonia of varying severity without weakness. Some
patients may show marked worsening with potassium but are often unaffected by cold. Out
of all the NDMs they tend to show the most marked painful myotonic episodes although
pain often occurs in both subtypes (Ptacek et al., 1994). There is very little data comparing
the phenotypes of PMC and SCM as much of the data focusses on the characteristics of all
of the sodium channelopathies. The data that does exist, suggests that SCM patients often
have warm-up and tend to be less cold sensitive making them appear clinically very similar
to dominant MC and are often very difficult to distinguish (Trip et al., 2009b). There is
therefore a need for more research looking into the key differences between these groups of
patients.
Neurophysiology techniques also emerged to further aid diagnosis of patients with
NDM. Fournier et al described the use of short and long exercise testing at room temperature
and cooling to help differentiate between PMC and SCM (Fournier et al., 2004, 2006). They
identified that patients with PMC commonly had a type I pattern with progressive decrease in
compound muscle action potentials (CMAP) with subsequent trials of exercise and a decrease
on long exercise testing. SCM patients had a type III pattern with no decrement on short
or long exercise testing. As a result in current clinical practice, patients are diagnosed as
PMC or SCM based on a combination of the presence or absence of weakness and their
pattern of decrement on neurophysiology exercise testing. However, as groups have begun
to correlate phenotype and genotype in larger numbers of patients with specific SCN4A
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mutations it has become apparent that certain mutations can be associated with both PMC
and SCM phenotypes and that neurophysiology types may not be as clearly differentiating
as first thought (Lerche et al., 1993; Ferriby et al., 2006; Matthews et al., 2008b; Trivedi
et al., 2013). This has led to questions about how a specific mutation could cause two distinct
diseases and about how best to differentiate between PMC and SCM given the genotypic
heterogeneity.
2.4.2 Phenotype of Periodic Paralysis
The primary periodic paralyses can be subdivided into HypoPP, HyperPP and ATS. They are
characterised by episodes of weakness often associated with a change in serum potassium
concentration. Secondary PP has also been documented when patients develop hypo or
hyperkalaemia as a result of a secondary condition (Table 2.4). More recently, a fourth type
of PP, thyrotoxic PP, causing episodes of paralysis in the context of thyrotoxicosis, has been
discovered to have an underlying genetic basis rather than being a secondary type of PP.
Table 2.4: Common causes of secondary periodic paralysis
Secondary	  Hypokalaemia	   Secondary	  Hyperkalaemia	  
• Thyroxicosis/	  hypothyroidism	   • Hyporeninemic	  hypoaldosteronism	  (secondary	  to	  chronic	  kidney	  disease)	  
• Drugs	  -­‐ Thiazide/Loop	  diuretic	  -­‐ Liquorice	  -­‐ Steroids	  -­‐ Alcohol,	  cocaine	  
• Drugs	  -­‐	  Potassium-­‐sparing	  diuretics	  
• Hyperaldosteronism	   • Metabolic	  acidosis	  
• Renal	  Tubular	  Acidosis	   • Type	  IV	  renal	  tubular	  acidosis	  
• Gastro-­‐intestinal	  potassium	  loss	   • Rhabdomyolysis	  	  
2.4.2.1 Hypokalaemic Periodic Paralysis
HypoPP is characterised by attacks of weakness associated with an initial low serum
potassium, beginning in the first or second decade of life. Attacks most commonly occur
in the night or early morning and may last from hours to days. They are often precipitated
by a carbohydrate load or rest after exercise and they may be focal or more generalised and
involve all four limbs and neck, but usually sparing facial and respiratory muscles. In rare
cases, respiratory compromise has been noted (Miller et al., 2004; Kil and Kim, 2010).
Approximately 72% of patients develop a persistent proximal myopathy that in some cases
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may become disabling over time (Miller et al., 2004; Links et al., 1990).
HypoPP1 versus HypoPP2
There are two forms of HypoPP, one caused by calcium channel mutations (HypoPP1) and
the other caused by sodium channel mutations (HypoPP2). Clinical differentiation between
these subtypes of HypoPP is difficult given the sparsity of evidence available. The few studies
that exist suggest that those with calcium channel mutations may have an earlier age of onset,
usually around 10 years compared to 16 years for HypoPP2. HypoPP1 is thought to have a
higher incidence of fixed proximal weakness and longer duration of episodes (20 hours versus
1 hour) (Miller et al., 2004) (Table 2.5). Further studies are needed in this area to identify
differences between these two groups and to further delineate genetically confirmed cases.
2.4.2.2 Hyperkalaemic Periodic Paralysis
HyperPP manifests earlier than HypoPP, often in the first decade, although in a recent study
25% of patients manifested in the second decade (Charles et al., 2013). Attacks tend to be
worst in adolescence and early adulthood and decrease in frequency and severity later in life
(Charles et al., 2013; Miller et al., 2004). Attacks are thought to be brief, lasting around one
to two hours, although there have been reports of longer attacks lasting several days (Charles
et al., 2013; Miller et al., 2004). Attacks primarily occur in early morning or during sleep.
Patients are typically potassium sensitive and may have a high potassium at the start of the
attack. A separate term, normokalaemic periodic paralysis, was coined to describe those with
normal potassium levels during an attack. Initially this was considered a separate intermediate
disease but following genotyping, all patients had typical HyperPP mutations, suggesting it
is a phenotypic variant of HyperPP (Chinnery et al., 2002). Other attack precipitants include
rest after exercise, cold exposure and stress. Patients may develop a fixed proximal myopathy
but this is less common than in HypoPP (Miller et al., 2004) (Table 2.5).
A key distinguishing feature from HypoPP is the presence of electrical myotonia which
is not found in either type of HypoPP (Sugiura et al., 2000). Around 75% of patients may
have clinical or electrical myotonia (Charles et al., 2013; Miller et al., 2004). Due to the
presence of myotonia, some patients may have overlapping clinical phenotypes with PMC
and it can be difficult to distinguish between the two. Charles et al suggested a distinction
between types of HyperPP as: (i) those without myotonia, (ii) those with clinical or electrical
myotonia and (iii) those with a PMC phenotype (Charles et al., 2013). This clinically allows
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Table 2.5: Clinical phenotype of the primary periodic paralyses
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a useful differentiation of where these patients lie on the spectrum of PP and NDM.
The recent trial by Charles et al has aided in further phenotyping HyperPP (Charles
et al., 2013) but this study demonstrated significant differences with the earlier literature and
included patients with mutations associated with PMC and SCM. The data therefore has to be
regarded with a little caution and further evidence would be useful to clarify the phenotypes
in this group of patients.
2.4.2.3 Andersen Tawil Syndrome
ATS is a distinct type of PP, marked by the fact that it affects multiple organs. It is
characterised by the triad of episodes of paralysis, cardiac abnormalities and distinctive
facial and skeletal features. The episodes of paralysis begin in the first or second decade
and are exacerbated by prolonged rest or rest following exertion. The attacks are most
commonly associated with hypokalaemia, but may also be associated with hyperkalaemia
or normokalaemia (Andersen et al., 1971; Tawil et al., 1994) (Table 2.5).
The distinctive features seen include micrognathia, low set ears, hypertelorism
and skeletal abnormalities, such as clinodactyly and syndactyly (Tawil et al., 1994;
Tristani-Firouzi et al., 2002) (Figure 2.7). Cardiac arrhythmias are commonly seen, the
most frequent ECG finding being long QT, but a range of ECG changes are described
including premature ventricular contractions, ventricular arrhythmias, ventricular bigeminy
and prominent U waves even in the presence of a normal potassium. Bidirectional ventricular
tachycardia may also occur. Fatal arrhythmias are reported, but are rare compared with other
genetically-determined long QT syndromes (Haruna et al., 2007).
Figure 2.7: Images of a patient with ATS. (a) Face demonstrates micrognathia, low set ears and
hypertelorism. (b) Small hands with clinodactyly and syndactyly
In a recent study investigating 45 genetically confirmed KCNJ2 patients with a large
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variety of phenotypes only 13% had all three features of the triad, 67% had arrhythmias, 40%
had periodic paralysis and 36% had dysmorphisms. 88% however, had abnormal U waves on
ECG. This suggests that the ATS phenotype does not require all three components of the triad
as suggested previously (Kimura et al., 2012). Very little data has been collected comparing
patients with ATS with those with other types of PP and a comparative study may further the
understanding of this disease.
2.4.2.4 Thyrotoxic Periodic Paralysis
Secondary HypoPP has always been considered as a separate entity to inherited primary PP.
More recently however, there has been the discovery of a susceptibility gene for thyrotoxic
PP, suggesting this acquired disease may have a genetic basis (Ryan et al., 2010).
Thyrotoxic PP was thought to be an acquired muscle disorder, characterised by typical
HypoPP attacks in the context of thyrotoxicosis, which resolves with the treatment of
the thyrotoxicosis. Clinically it is indistinguishable from familial HypoPP except for the
presence of thyrotoxicosis and the lack of family history. It occurs in approximately 2%
of thyrotoxicosis cases in East Asians and Hispanics (Okinaka et al., 1957) and around
0.1-0.2% of non-Hispanic Caucasians (Kelley et al., 1989). It is more common in males and
occurs at around 20-40 years. Attacks predominantly occur at night following triggers such
as a carbohydrate load, alcohol or strenuous activity (Kung, 2006); (Falhammar et al., 2013).
Mutations in KCNJ18 have now been reported in both thyrotoxic PP cases and some sporadic
PP cases (Ryan et al., 2010; Cheng et al., 2011) (Table 2.5).
2.4.3 Anaesthetics in Skeletal Muscle Channelopathies
There is very little data available on the effect of anaesthetics in patients with muscle
channelopathies. Much of the current knowledge is based on case reports. MC has
traditionally been associated with the risk of malignant hyperthermia (MH)-like episodes.
This is based on a handful of case reports that pre-date genetic testing. In one report a boy
with a MC phenotype developed a hyperthermia-like episode following administration of a
non-triggering anaesthetic and subsequently died despite pretreatment with dantrolene, but
this child developed a very high creatine kinase (CK) and other complications (Haberer
et al., 1989). In another, a girl with possible MC was given a depolarising anaesthetic
and died after a typical MH reaction (Saidman et al., 1964). The only other case studies
report severe myotonia after the use of depolarising muscle relaxants such as suxamethonium
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(Heiman-Patterson et al., 1988; Farbu et al., 2003). Given that there are no further case
reports of MH-like reactions since genetic diagnosis was developed it does suggest that these
reactions could be due to other causes. There is however the suggestion that myotonia may
be worsened by depolarising muscle relaxants and therefore these are commonly avoided.
In PMC and SCM there are no reports of MH with general anaesthetic. In HyperPP there
are a few reports of potassium-releasing drugs such as succinylcholine inducing weakness
(Weller et al., 2002) or spasm (Paterson, 1962; Cody, 1968). There have been no reports
of problems with non-depolarising anaesthetic. In patient surveys 20-30% of patients
reported developing an attack of weakness following general anaesthesia although the type
of anaesthetic was not specified (Miller et al., 2004; Charles et al., 2013).
In HypoPP there have been case reports of MH in patients, however the only patient
that was genetically confirmed had an RYR1 mutation, which is known to be associated with
MH (Marchant et al., 2004). In a survey of patients, very few reported weakness following
anaesthetic (Miller et al., 2004). There has, however, been an association with a mutation
in the CACNA1S gene that confers susceptibility to MH and therefore caution is exercised
when giving these patients anaesthetic (Monnier et al., 1997). In ATS no data was available
on responses to anaesthesia.
2.4.4 Pregnancy in Skeletal Muscle Channelopathies
There is even less information regarding pregnancy in muscle channelopathies than for the
use of anaesthetics in this cohort. Data suggests that pregnancy and menstruation may worsen
symptoms in 25% of female MC patients and 44% of female sodium channelopathy patients
(Trivedi et al., 2013). In HyperPP 92% of women reported an increase in attack frequency
although 80% thought their attacks were less severe. 75% had worsening stiffness and 25%
had an improvement in stiffness (Charles et al., 2013). In ATS no data was available in
pregnancy.
2.4.5 Investigating Clinical Phenotypes
Prior to the advent of genetic testing in muscle channelopathies, extensive phenotyping
of patients was performed to try and understand and categorise these diseases. With the
identification of causative mutations, phenotyping has become more complex and large
studies investigating patient phenotype have become more sparse. Much of the current
wisdom is still based on the original work pre-dating genetic testing and therefore may be
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inaccurate. It is therefore timely that a large scale study of clinical phenotypes is done to
better understand the natural history and prognosis of these diseases and better inform patients
and direct treatment trials.
In the UK, extensive phenotyping data has already been published for the MC cohort by
Fialho et al (Fialho et al., 2007) and therefore this thesis will concentrate on the phenotyping
of the other muscle channelopathies. Very little data exists on the effect of pregnancy and
anaesthetics in all channelopathy patients and therefore this is another aspect investigated in
this thesis.
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2.5 Genetic Diagnosis in Skeletal Muscle Channelopathies
2.5.1 Genotypes of Skeletal Muscle Channelopathies
Across the two main groups of skeletal muscle channelopathies, PP and NDM, a number of
different genes are known to be responsible for disease, although there is extensive genotypic
heterogeneity (Figure 2.6).
2.5.1.1 Hypokalaemic Periodic Paralysis
HypoPP is associated with variations in the calcium channel gene, CACNA1S, causing
HypoPP type 1 (HypoPP1) (Fontaine et al., 1994) and more rarely variations in the
sodium channel gene, SCN4A, causing HypoPP type 2 (HypoPP2) (Bulman et al., 1999).
HypoPP1 was first associated with mutations in CACNA1S after linkage mapped the locus to
chromosome 1 (Fontaine et al., 1994). 90% of mutations affect key arginine residues in the
S4 segments causing loss of the positive charge. The majority of patients have mutations that
affect the Arg528 or Arg1239 positions in domains II and IV (Matthews et al., 2009) (Figure
2.8). Mutations in SCN4A that are associated with HypoPP2 are also located at arginine
residues of the S4 segments, highlighting the importance of the voltage-sensing regions of
these channels in causing disease (Matthews et al., 2009) (Figure 2.9).
Figure 2.8: Variations in CaV1.1 known to be associated with HypoPP and malignant
hyperthermia
Mutations in CACNA1S have also been associated with a small number of cases of
MH. MH occurs when there is increased release of calcium into the myoplasm under
certain conditions (exposure to inhaled anaesthetics and suxamethonium), causing increased
muscle metabolism and leading to hypoxia, metabolic acidosis and rhabdomyolysis. It
is thought to be due to uncoupling of the ryanodine receptor, RyR1, from the calcium
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Figure 2.9: Known NaV1.4 mutations associated with HyperPP, HypoPP, PMC and SCM.
channel, CaV1.1 (encoded by CACNA1S) (Weiss et al., 2004). The majority of cases are
due to mutations in the RYR1 gene but a small number of cases have been identified with
mutations in CACNA1S (Monnier et al., 1997; Stewart et al., 2001; Carpenter et al., 2009)
(Figure 2.8). Conversely there has also been a case of atypical periodic paralysis with
multi-minicore disease associated with a variation in RYR1 which suggests that disruption
of excitation-contraction coupling may also lead to episodic attacks of paralysis (Zhou et al.,
2010).
Recently it was discovered that mutations in KCNJ18 predispose individuals to
thyrotoxic PP (Ryan et al., 2010). This gene is expressed in muscle and transcriptionally
regulated by the thyroid hormone. However, mutations in this gene were only identified in
33% of patients with this phenotype, suggesting it may be a susceptibility factor. With such a
large diversity of potassium channels in the human genome it also leads to the suspicion that
other genes expressed in skeletal muscle may be responsible for undiagnosed cases of PP.
2.5.1.2 Hyperkalaemic Periodic Paralysis
HyperPP (including normokalaemic PP) is also associated with variations in SCN4A
(Fontaine et al., 1990; Koch et al., 1991b). Approximately 60% of mutations are located
in exons 13 and 24, with the commonest variations being Thr704Met and Met1592Val
(Jurkat-Rott and Lehmann-Horn, 2007). The remaining variations are spread throughout the
gene (Figure 2.9).
2.5.1.3 Andersen Tawil Syndrome
ATS is associated with variations in the potassium channel gene, KCNJ2 which encodes
Kir2.1, an inward-rectifying potassium channel (Plaster et al., 2001). To date over 30
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different missense mutations or small in-frame deletions have been described throughout
the gene, with many families having private mutations. Variations in this gene, however,
only account for 60% of cases and the original case described by Tawil remains undiagnosed
making it extremely likely that there is genetic heterogeneity in this disease (Donaldson et al.,
2004). This has been illustrated by the recent finding of a variation in KCNJ5 (encoding
the Kir3.4 channel), implicated in a case of ATS with episodic weakness and arrhythmias
without dysmorphic features. The mutated Kir3.4 was shown to reduce potassium current
when co-expressed with Kir2.1 (Kokunai et al., 2014).
2.5.1.4 Paramyotonia Congenita and Sodium Channel Myotonia
Variations in SCN4A are also associated with PMC and SCM (McClatchey et al., 1992a;
Koch et al., 1991a). At present, 16 mutations in SCN4A have been documented as causing a
PMC phenotype (Matthews et al., 2010). The majority of mutations lie in exons 22 and 24
(90% in UK cohort and 100% in Dutch cohort) (Trip et al., 2008; Matthews et al., 2008b),
the commonest being the Thr1313Met mutation and those at the Arg1448 position (Figure
2.9).
Over 30 mutations in SCN4A have been associated with the SCM phenotype (Matthews
et al., 2010) but unlike PMC they are spread throughout the sodium channel. The commonest
variations, however are still in exons 22 and 24 and are associated with Val1589Met and
those at position Gly1306 (Vicart et al., 2005) (Figure 2.9). Although SCM is thought to
be clinically distinct from PMC, there is significant heterogeneity, with many of the same
variations causing either SCM or PMC in both different pedigrees and within the same
pedigree (Matthews et al., 2008b; Vicart et al., 2005). It is unclear why this phenotypic
variability occurs for the same mutations.
2.5.1.5 Myotonia Congentia
MC is associated with variations in the chloride channel gene, CLCN1, resulting in dominant
or recessive MC (Koch et al., 1992). This gene has 23 exons and is composed of 18
transmembrane domains. To date over 120 mutations have been published in the literature
with further variations still being identified (Matthews et al., 2010) (Figure 2.10). Variations
associated with dominant MC primarily cluster around exon 8 whereas recessively inherited
mutations may occur anywhere in the channel and in many cases are specific to individual
pedigrees (Fialho et al., 2007).
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Figure 2.10: Known pathogenic ClC-1 mutations
2.5.2 Making a Genetic Diagnosis in Skeletal Muscle Channelopathies
2.5.2.1 Current Diagnostic Methods
In current clinical practice, patients are diagnosed following detailed phenotype analysis
to determine the appropriate genetic test. This allows classification of patients into PP or
NDM and then further disease-specific classification to direct testing. Patients then typically
have Sanger sequencing of key genes, directed by the most likely diagnosis (Figure 2.11)
(Raja Rayan and Hanna, 2010).
Genetic Diagnosis in Periodic Paralysis
Patients with probable PP are split into HyperPP, HypoPP or ATS phenotypes. HyperPP
patients have sequencing of exons 13 and 24b of SCN4A. Patients with a HypoPP phenotype
have exons 11 and 30 of CACNA1S sequenced and patients with probable ATS have the
coding exon of KCNJ2 sequenced. This strategy was developed on the basis of the location
of the common mutations in each of these diseases. In HyperPP this strategy will cover the
mutations Thr704Met and Met1592Val, which account for approximately 30% and 13% of
known mutations respectively (Jurkat-Rott and Lehmann-Horn, 2007). In HypoPP, mutations
at positions 528 and 1239 (in exons 11 and 30) account for approximately 55-70% of
mutations (Sternberg et al., 1993). In ATS the mutations are spread throughout the coding
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exon and so the whole exon is sequenced but this still only identifies approximately 60% of
cases (Donaldson et al., 2003) (Figure 2.11).
If patients do not have a causative mutation identified using the initial strategy then
second level testing is initiated which involves expanding the number of exons sequenced
(Figure 2.11). In HypoPP, second level testing involves sequencing the voltage-sensing
S4 segments of CACNA1S and SCN4A. These are located in exons 4,11,12,21 and 30 of
CACNA1S and exons 5,12,13,18 and 24 in SCN4A. Evidence suggests that 90% of known
HypoPP mutations are located within these regions. These S4 segments include the key
arginine residues that, when substituted, lead to the formation of a gating pore current which
is thought underlie the episodes of paralysis (Matthews et al., 2009).
As the mechanism behind HyperPP is different and does not specifically involve S4
segments, mutations may occur throughout the gene. In these cases, second level testing
therefore involves sequencing the whole of SCN4A if initial targeted sequencing is negative
(Figure 2.11).
Genetic Diagnosis in Non-dystrophic Myotonia
Prior to testing, patients with NDM are split into either sodium channel (PMC/SCM) or
chloride channel (MC) phenotypes. If PMC/SCM is suspected, patients have sequencing
of exons 22 and 24 of SCN4A, which identifies approximately 69% of mutations (Trip et al.,
2008; Matthews et al., 2008b). If no mutations are found then the remaining exons of SCN4A
are sequenced and this typically gives a diagnostic rate of approximately 93% (Trip et al.,
2008) (Figure 2.11).
If MC is suspected then patients have all 23 exons of CLCN1 sequenced. This is because
many patients have private mutations that are spread throughout the gene (Fialho et al., 2007)
(Figure 2.11).
There are a number of patients with MC that only have one mutation identified after
sequencing all 23 CLCN1 exons. In the majority of cases these patients have a dominant
pedigree and a phenotype consistent with Thomsen’s disease (Koch et al., 1992). In those
cases, the mutations cause dominant-negative inhibition of the homodimer leading to disease.
This can be illustrated by whole cell patch clamping of Xenopus oocytes that co-express the
mutated and a normal ClC-1 channel and demonstrating a drop in current in heterozygous
oocytes compared with wild-type (WT) (Pusch et al., 1995). However, there are a number
of cases where only one mutation is identified but the patient has a recessive pedigree, a
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recessive MC phenotype and a mutation that only causes a drop in current significant enough
to cause myotonia when homozygously expressed (Trip et al., 2008). In these cases it is
hard to explain the patients’ phenotype with a single loss of function mutation as clinical
myotonia occurs when there is a minimum of 60% drop in chloride conductance (Barchi,
1975; Kwiecinski et al., 1988) and a single loss of function mutation would not be sufficient
to cause this degree of drop. These single mutations in recessive MC cases are found in
approximately 12-14% of MC cases (Trip et al., 2008; Fialho et al., 2007) and therefore
these cases need further investigation.
2.5.2.2 Rate of Genetic Diagnosis in Clinical Practice
Using the current schema the rate of genetic diagnosis in clinical practice is approximately
70-80% and in ATS may be as low as 60% (Donaldson et al., 2003). In PP the rate is
80% when key exons and S4 segments are sequenced (Sternberg et al., 1993; Jurkat-Rott
and Lehmann-Horn, 1993). In NDM it is as high as 93% when the whole of CLCN1 and
SCN4A are sequenced (Trip et al., 2008), however this does include the 12% of patients
with recessive MC that only have a single mutation identified.
2.5.3 Possible Explanations for Undiagnosed Patients
20-40% of patients remain undiagnosed despite extensive Sanger sequencing of the known
genes. This suggests that there are novel variations that remain to be identified in these
patients. There are a number of possible reasons for this including limitations of the
current techniques preventing discovery of the variations and the possibility of novel genes
underlying some of these cases.
2.5.3.1 Limitations of Current Techniques
Sanger sequencing has a number of limitations which may account for some of the
undiagnosed patients. Firstly, current sequencing utilises primers that only cover the coding
exons of genes with a small overlap of 100-150 base pairs of the intron at the intron-exon
and exon-intron boundaries. This means that any pathogenic variations that lie deep within
the introns would not be detected. Secondly, although Sanger sequencing can detect small
insertions or deletions, it may miss any whole exon or group of exon deletions as it is unable
to accurately detect a reduction in the volume of sequence data. This means it would not
identify large scale rearrangements in patient DNA. Finally Sanger sequencing has a false
negative rate which is caused by a combination of operator error, the presence of variations
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within the PCR or sequencing primer binding site and tissue mosaicism.
Intronic Variations
Intronic variations may underlie the diagnosis in some of the undiagnosed cases. Typically
intronic mutations have been associated with disease in recessive MC where they affect
the splicing of CLCN1 exons (Chen et al., 2004; Brugnoni et al., 1999; Meyer-Kleine
et al., 1995). However, the majority of intronic mutations discovered in MC were identified
during routine sequencing of the exons as they are located near to intron-exon boundaries
affecting conserved splice sites. Traditionally it has been difficult to prove pathogenicity of
these variations without tissue samples but the recent development of a mini-gene assay has
established an effective method of determining pathogenicity of these variations (Ulzi et al.,
2012).
Deeper intronic variations were traditionally felt to be unlikely to cause disease but
numerous reports now exist of variations that create cryptic splice donor and acceptor sites
(Dobkin et al., 1983). These sites cause the creation of a pseudoexon that lies out-of-frame
causing a frameshift of the coding exon and resulting in nonsense mediated decay of the
transcript. Confirmation of the pathogenicity of these variations requires a tissue sample
making it difficult (Tuffery-Giraud et al., 2003).
As intronic mutations typically cause disease by altering splicing and ultimately
triggering nonsense-mediated decay of the transcript, they would be most likely to cause
disease in recessive MC. It was thought that they would be unlikely to cause disease in
dominant MC, PMC, SCM and PP as these diseases are all caused by gain of function
mutations that alter channel properties and therefore are typically caused by an exonic change.
However, there is one case of an intronic single nucleotide insertion with a five nucleotide
deletion in SCN4A which caused a gain of function. This combination of insertion and
deletion caused aberrant splicing with the insertion of 35 amino acids into a cytoplasmic
loop which allowed the formation of a viable abnormal sodium channel with impaired fast
inactivation (Kubota et al., 2011). This implies that it may be the mechanism for disease in
all types of skeletal muscle channelopathy.
Large Scale Rearrangements
Large deletions and duplications account for 7-10% of all reported mutations in the human
genome (Stenson et al., 2009) and it therefore follows that it may be an important mechanism
in skeletal muscle channelopathies. As with intronic mutations it would be more likely to
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cause disease by loss of function as the loss or gain of a number of exons would most
commonly produce significantly abnormal mRNA (messenger ribonucleic acid) which would
be targeted for nonsense mediated decay. It would therefore be most likely to underlie disease
in patients with recessive MC.
It is theoretically possible that it could cause disease in dominantly inherited skeletal
muscle channelopathies as there have been cases of small deletions associated with these
diseases. In PMC the case above of the small intronic insertion and deletion in SCN4A
associated with impaired inactivation of the channel is one example (Kubota et al., 2011),
however it seems unlikely that a large exonic deletion or duplication would have a similar
effect. In ATS there have been reports of loss of function variations causing a mild form of
primarily cardiac disease, one of which included an in-frame deletion (Fodstad et al., 2004).
There has also recently been a case of a whole KCNJ2 gene deletion identified using array
comparative genomic hybridisation resulting in a pure cardiac phenotype ATS without the
episodes of paralysis and dysmorphic features (Marquis-Nicholson et al., 2014), suggesting
that large deletions and duplications could underlie some cases of ATS.
2.5.3.2 Novel Genes and Atypical Diagnoses
Aside from the limitations of Sanger sequencing, there are other possible factors that may
contribute to patients remaining undiagnosed. Firstly there may be as yet undiscovered genes
that are responsible for the disease. A second possibility is that these patients have an atypical
presentation of another known disease. Finally, in those patients with only a single loss of
function mutation in CLCN1 the second mutation may be in a different gene causing “double
trouble”.
Novel Genes
Currently, patients are diagnosed by sequencing genes known to be associated with skeletal
muscle channelopathies as this is the quickest and most efficient process (Figure 2.11).
However, as the rate of diagnosis is only 70-80% there is a high likelihood that there may
be other genes responsible for a small number of cases, especially in patients with an atypical
presentation of the disease. This is illustrated by the recent discovery of a number of patients
with thyrotoxic HypoPP who have variations in KCNJ18 (Ryan et al., 2010). Variations
in this gene were identified in 33% of patients with this phenotype, all of which alter
muscle membrane excitability. There has also been the recent discovery of a variation in
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KCNJ5 associated with a case of atypical ATS without facial dysmorphism. The mutated
channel when co-expressed with WT KCNJ2 resulted in reduced potassium currents across
the membrane and suggests it has a modifying effect (Kokunai et al., 2014). With such a
large diversity of ion channels in the human genome, it leads to the suspicion that other ion
channel genes expressed in skeletal muscle may be responsible for the undiagnosed cases.
Atypical Phenotypes
Another possibility is that patients with a channelopathy may have an unusual presentation of
another known muscle disease. The key feature of channelopathies compared with other
conditions is the paroxysmal nature of the condition and it is this that often directs the
diagnosis towards a channelopathy. It may be the case, however, in some diseases that early
on symptoms may appear episodic progressing later on in the disease to more typical features.
In one example of an unusual presentation, the patient had signs and symptoms of a
congenital myopathy at birth accompanied by atypical normokalaemic attacks of periodic
paralysis. Her histopathology and limb magnetic resonance imaging (MRI) was suggestive of
multi-minicore disease. She had normal sequencing of the channel genes but was compound
heterozygote for mutations in RYR1 which is associated with multi-minicore disease. The
RYR1 gene encodes the main ryanodine receptor in skeletal muscle sarcoplasmic reticulum
which has a vital role in excitation-contraction coupling via its interaction with the CaV1.1
channel. Variations in the gene have been associated with the autosomal dominant diseases,
malignant hyperthermia susceptibility and central core disease, and autosomal recessive
diseases, multi-minicore disease and congenital fibre-type disproportion. In this particular
patient, the long exercise test was negative but she had cold-induced excitation-contraction
uncoupling on electromyography (EMG). As RYR1 is coupled to CaV1.1 this suggests that
disruption of the excitation-contraction coupling may lead to PP-type attacks (Zhou et al.,
2010).
There has also been a recent report of a patient with myalgia, muscle stiffness and
myotonia on EMG with normal sequencing of CLCN1, SCN4A and testing for DM1 and
DM2 who had a mutation in the caveolin-3 gene, which is normally associated with rippling
muscle disease and limb-girdle muscular dystrophy (LGMD) (Milone et al., 2012). These
examples suggest that mutations in known disease-causing genes may be important in
explaining some undiagnosed cases.
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“Double Trouble” - Variations in Multiple Genes
Patients with only one loss of function mutation in CLCN1 and a recessive pedigree do not
have a complete diagnosis. In these cases the undiscovered “second mutation” may either
be missed by Sanger sequencing or alternatively may be in a second related gene whose
protein interacts with CLCN1 or contributes to the muscle membrane excitability. There are
a number of cases of patients with both a single CLCN1 mutation and expansions in ZNF9
causing DM2 which underlies the patient’s diagnosis (Suominen et al., 2008; Lamont, 2004;
Cardani et al., 2012) and it therefore follows that some cases may be explained by mutations
in ZNF9 or other related genes such as DMPK or SCN4A. In these cases it is anticipated
that patients may have a more severe phenotype or atypical presentation due to the effect of
the mutations in both genes. It also follows that patients with a more severe phenotype that
were considered fully diagnosed, could potentially have another mutation in a second gene to
account for their increased severity.
2.5.4 Investigating Undiagnosed Patients
The likely explanation for many of the genetically unconfirmed cases either lies in missing the
variation using standard Sanger sequencing of known genes or identifying novel variations
in novel or different genes. The best way to investigate these unconfirmed cases would be to
systematically address these two aspects.
2.5.4.1 Addressing Limitations in Current Techniques
There are a number of ways that the limitations of Sanger sequencing may be addressed.
The false negative rate can be minimised by firstly repeating all negative samples with
fresh samples to check there has not been operator or machine error when extracting and
sequencing the deoxyribonucleic acid (DNA). This would also reduce the error related to
tissue mosaicism. Any exons that failed analysis could be repeated with different primers to
account for the presence of variations located in the primer binding sites.
Identifying Intronic Variations
Intronic mutations can be identified by Sanger sequencing if primers are added to cover the
introns as well. The introns, however, are very large and therefore would require a large
volume of sequencing. Alternatively, high throughput methods could be used to sequence the
intronic regions, which would be faster and allow simultaneous analysis of other genes.
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Identifying Deletions and Duplications
There are a number of ways that exonic deletions and duplications can be identified. For a
small number of genes, Mulitplex Ligation-dependent Probe Amplification (MLPA) can be
used to detect copy number variations (CNVs) and large scale rearrangements. This technique
requires only a small quantity of DNA and can detect a single nucleotide deletion or insertion
as well as whole exon deletions (Schouten et al., 2002).
Another traditionally used technique is Fluorescence In Situ Hybridisation (FISH) which
is used to identify large deletions, duplications or rearrangements (Landegent et al., 1985).
This technique can only detect deletions and duplications of around 10kbp and therefore will
miss small variations. It can, however, be used to look at the whole genome rather than a
small number of genes.
A variation on FISH is array-based comparative genomic hybridisation (aCGH) which
detects loss or gain of chromosomal material throughout the whole genome without needing
to look directly at the chromosomes (Pinkel et al., 1998). This technique is now advanced
enough to pick up CNVs of a few exons in a gene and therefore is a more efficient tool for
screening the entire genome. It is therefore a powerful technique for investigating the DNA
of syndromic patients that may have complex rearrangements whilst also picking up smaller
CNVs in a single gene.
2.5.4.2 Identifying Novel Genes
In some patients, variations in novel genes, or in known genes with a novel phenotype, may
be the cause of their disease. In patients with large families of affected members it is possible
to identify the causative gene using linkage studies. However, in many of the channelopathy
cases there is no family history, suggesting sporadic mutations, or only a small number of
affected family members because of smaller family units. Trying to identify the causative
gene with Sanger sequencing without any candidate genes is a time consuming and complex
job with low yield. Therefore a different process is needed to identify causative genes.
Next-generation Sequencing
In the past decade, next-generation sequencing has become a viable method (Metzker, 2010).
This is a high throughput automated screening technique that can be used to sequence an
individual’s entire genome, exome or targeted genes in a short period of time. It is therefore
a more efficient way of identifying mutations in all of the patient’s known genes and could
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be used to identify the causative gene in an undiagnosed patient.
The utility of next-generation sequencing has been shown in a proof of concept
experiment to identify the known causal gene in 12 unrelated patients with a rare genetic
disorder (Ng et al., 2009). It was later used to identify the novel gene responsible for a
previously uncharacterised rare Mendelian disorder in four affected individuals from three
independent kindreds (Ng et al., 2010). It is therefore a proven technique for identifying
unknown disease genes in groups of phenotypically similar patients and can be targeted to
specific genes, the whole exome or the entire genome of a patient. This could therefore be a
useful technique for identifying mutations in novel genes and intronic regions.
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Figure 2.11: Diagnostic genetic testing algorithm for non-dystrophic myotonia and periodic
paralysis (1st line testing in green, 2nd line testing in blue)
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2.6 Investigating the Skeletal Muscle Channelopathies
A combination of clinical phenotyping and investigations are currently the most effective way
of guiding genetic analysis. Traditionally clinical electrophysiology has played a large part
in identifying and defining these disorders. Currently emerging work indicates that muscle
magnetic resonance techniques and ultrasound may also have a role in identifying muscle
damage and in disease monitoring.
2.6.1 Clinical Electrophysiology
Needle EMG is used to identify the presence of electrical myotonia. Myotonia is caused
by membrane hyperexcitability, allowing mild depolarisation of the muscle membrane and
resulting in spontaneous self-sustained runs of muscle fibre action potentials. In PP and PMC
the sarcolemmal depolarisation becomes severe enough to make the muscle fibre inexcitable
resulting in weakness. Exercise can act as a trigger to the sarcolemmal depolarisation and
therefore specialised short and long exercise testing can be used to help to differentiate
between the types of channelopathy (McManis et al., 1986; Fournier et al., 2004, 2006).
2.6.1.1 Needle EMG
Needle EMG can be used in NDM to demonstrate the presence of myotonia. Key
characteristics of the myotonia can also vary between the different diseases and aids in
narrowing the diagnosis.
In recessive MC, needle EMG shows extensive myotonic potentials and post-exercise
myotonic potentials (Fournier et al., 2004). In dominant MC, EMG may only show scanty
discharges (Tan et al., 2011).
PMC patients may also demonstrate post exercise myotonic potentials following cooling
(Fournier et al., 2006). In some patients with PMC, higher frequency “musical” discharges
are seen as well as lower frequency myotonic discharges (Tan et al., 2011).
HyperPP patients may have myotonia on their EMG. HypoPP and ATS patients do not
have myotonia on EMG but may have a myopathy (Fournier et al., 2004; Katz et al., 1999).
2.6.1.2 Short Exercise Test
The short exercise test monitors the CMAP amplitude following three short bursts of
isometric exercise. The CMAP amplitude is an indirect measure of sarcolemmal excitability,
giving an indication of the ability of active fibres to depolarise and repolarise (Streib, 1987a).
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This test shows distinct patterns depending on the channel defect and therefore can be helpful
in guiding diagnosis and genetic testing.
Patients with recessive MC typically show a Fournier type II pattern of neurophysiological
changes as described by Fournier et al (Fournier et al., 2004). This is a transient fall in CMAP
amplitude after short exercise testing with recovery following subsequent trials of exercise.
In some cases this pattern is only seen in patients after cooling and rewarming (Tan et al.,
2011), although cooling on its own does not usually alter the CMAP amplitude. Occasionally
this pattern is seen in dominant MC and can be seen in DM1 and DM2 as these diseases also
reduce chloride conductance (Charlet et al., 2002) (Table 2.3).
In the majority of dominant MC patients there is no fall in CMAP (Fournier type III
pattern), a pattern also seen in SCM and controls. However, when the test is repeated with
cooling they may demonstrate the typical fall in CMAP and improvement following exercise
that is normally seen in recessive MC (Fournier et al., 2006) (Table 2.3).
Patients with PMC typically show a Fournier type I pattern of electrophysiology, with
a prolonged decrement in CMAP after short exercise testing and gradual progression with
further trials of exercise. This decrease in CMAP is exacerbated by cooling and in some
cases only apparent after cooling (Fournier et al., 2004, 2006). The SCMs typically have
normal responses to short exercise testing (Fournier type III) even after cooling and their
only finding may be myotonia on EMG (Fournier et al., 2004, 2006) (Table 2.3).
HyperPP patients have a Fournier type IV pattern on exercise testing. They may have an
increase in CMAP after short exercise testing. HypoPP1, patients have no change in CMAP
following short exercise testing (Fournier et al., 2004). ATS patients tend to show the pattern
appropriate for their type of episodes of paralysis (Katz et al., 1999) (Table 2.5).
Short exercise testing can therefore be extremely useful in diagnosing the different types
of channelopathy. Tan et al suggest that a combination of short exercise testing and clinical
characterisation into those with eye closure myotonia versus those with prominent falls can
increase the diagnostic accuracy in determining the appropriate genetic test (Tan et al., 2011).
2.6.1.3 Long Exercise Test
The long exercise test (McManis test) involves repeated exercise over five minutes
interspersed with rest with regular CMAP measurements for 50 minutes afterwards. This test
is thought to identify reduced muscle membrane excitability triggered by vigorous exercise
(McManis et al., 1986).
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The long exercise test is most useful in patients with periodic paralysis. A decrement
of CMAP greater than 40% from maximum during the 50 minute period after exercise is
considered significant. In HypoPP1, patients may have a significant prolonged decrement of
CMAP area and amplitude at around 10 to 20 minutes after exercise. In HypoPP2, however
they may show a late decrement (Fournier et al., 2004) (Table 2.5).
In HyperPP, patients may have an initial increase in CMAP followed by a late decrement
(Fournier et al., 2004). In ATS, patients may have an abnormal amplitude decrement but more
frequently have an abnormal CMAP area decrement (>40%) which may be a more sensitive
marker in this group of patients (Tan et al., 2011) (Table 2.5).
The long exercise test is also occasionally positive in NDM patients. A small number
of MC patients have positive tests with the decrement commonly occurring during the five
minutes of exercise (Tan et al., 2011; Kuntzer et al., 2000). In PMC the long exercise test
is frequently abnormal with progressive decrement during exercise and slow recovery in the
rest period. In patients with SCM the long exercise test is normal (Fournier et al., 2004; Tan
et al., 2011).
Although the long exercise test is a useful positive in PP it is not always abnormal,
especially when patients are on treatment. However, it can also give false positives,
particularly amongst the Afro-Caribbean population as normal controls from this group have
been shown to have a decrement of greater than 40%. In this population a positive result must
be treated with caution and a decrement greater than 54% may be necessary to be sure of a
true positive test (Tan et al., 2011).
2.6.1.4 Quantitative Muscle Testing
Although neurophysiology is helpful in aiding diagnosis, it does not provide a sensitive
outcome measure to monitor change and is often variable between visits. Semi-quantitative
functional measures of clinical myotonia such as grip and eyelid relaxation time following
maximum voluntary contraction are useful bedside tests but are relatively insensitive
measures (Kwiecinski et al., 1992).
A more sensitive and objective quantitative muscle analysis system has therefore been
devised for measuring myotonia in DM1 and NDM. This quantitative hand grip system uses
a strain gauge to measure the force of contraction on the handle of a grip ergometer and
plots this over time. The decrease in force over time (from maximum voluntary isometric
contraction) from when the subject is asked to relax their grip is called the relaxation time. In
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DM1 this is significantly increased compared to controls and is proportional to the severity
of myotonia. It can be quantified by measuring the time taken to drop from 90% to 5% of
maximum force (Logigian et al., 2005; Moxley R. T. et al., 2007). This has been successfully
used as a sensitive outcome measure in a drug treatment trial of mexiletine in DM1 (Logigian
et al., 2010). We have also recently published a study of 91 patients with NDM where it
aided in differentiating between sodium and chloride channel mutation patients and may also
provide a useful outcome measure for clinical trials in NDM (Statland et al., 2012).
2.6.1.5 Muscle Biopsy
Muscle biopsy is a useful tool in many of the genetic muscle diseases, however in NDM the
findings are non-specific. Some MC patients may have an absence of type 2b fibres (Crews
et al., 1976), whereas in PMC, myopathic changes, large vacuoles and tubular aggregates
may be seen (Table 2.3).
In PP, more extensive but often non-specific changes may be seen including vacuolar
myopathy, tubular aggregates and myopathic changes (Miller et al., 2004). In ATS, tubular
aggregates are more frequently seen (Table 2.5). As the changes in all these conditions are
non-specific, muscle biopsy is no longer commonly done.
2.6.1.6 Muscle MRI
Muscle MRI in skeletal muscle channelopathies is an evolving technique that may have
potential in a clinical setting. For example, detecting patterns of fatty infiltration and muscle
atrophy on limb MRI may aid in diagnosis as has been done in other genetic diseases (Wattjes
et al., 2010). Studies using MRI in muscle channelopathies is just starting to emerge. One
recent study involved three patients with MC and used whole-body 3 Tesla (3T) MRI images
with T1-weighted and T2-weighted turbo spin echo to evaluate changes in eight muscles
(Kornblum et al., 2010). They did not show any abnormalities in these patients, but this was
a small study in young patients with no corresponding muscle strength recorded.
MR spectroscopy may be a useful tool in understanding the disease mechanism
in channelopathies. It was shown that MRI with ultra-short echo times detected an
accumulation of intramuscular 23Na and ‘oedema-like’ changes in patients with PMC
following cold-induced weakness and in patients with HyperPP after cold-induced and
exercise-induced weakness (Weber et al., 2006). These changes were not seen in SCM
patients with a PAM phenotype. In a more recent study, MR spectroscopy was employed
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in HypoPP patients. 21/25 patients with permanent weakness had fatty muscle degeneration
and 18/25 had oedema on 1H-MRI of the lower limbs. They also noted that patients’ weaker
muscles had a higher sodium signal at rest and this signal increased with weakness induced
by cooling. Interestingly, treatment of the severely affected patients with acetazolamide and
potassium for 4 weeks showed a reduction in sodium signal that matched the increased muscle
strength (Jurkat-Rott et al., 2009). These studies illustrate the potential value of 23Na-MRI
for diagnosis and monitoring of treatment in particular muscle channelopathies.
As quantitative MRI techniques become more readily available they may also provide
us with non-invasive outcome measures in clinical trials.
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2.7 Treatment of the Skeletal Muscle Channelopathies
Current management of the skeletal muscle channelopathies is primarily symptomatic and
based on small case studies done in the 1970s and 80s. There is therefore much scope for
identifying effective treatments using high quality evidence.
2.7.1 Current Treatments
At present, there is little randomised control trial (RCT) level evidence for treatments in NDM
or PP.
2.7.1.1 Treatment of Non-dystrophic Myotonia
In cases of NDM with mild myotonia, patients are advised to avoid triggers such as cold
or strenuous exercise. In patients with more severe myotonia, a number of different
treatments have been tried. Most of the drug treatments used for myotonia in the clinical
setting are sodium channel blockers as they reduce the open probability of the sodium
channel responsible for the membrane hyperexcitability that underlies myotonia. At present,
only the sodium channel has been targeted as there are no safe ClC-1-specific drugs
available (Verkman and Galietta, 2009).
The main drugs that have been used to treat myotonia are: quinine (Leyburn and Walton,
1959), procainamide (Leyburn and Walton, 1959; Griggs et al., 1975), phenytoin (Griggs
et al., 1975; Ricker et al., 1978); (Fouad et al., 1997), carbamazepine (Ricker et al., 1978),
tocainide (Streib, 1987b), mexiletine (Kwiecinski et al., 1992) and flecainide (Rosenfeld
et al., 1997). Low level evidence from an uncontrolled trial suggested that tocainide and
mexiletine were effective in NDM (Kwiecinski et al., 1992). Although tocainide was shown
to be as effective as mexiletine, it has been withdrawn due to the risk of agranulocytosis.
Procainamide and prednisolone were shown to be effective in a small double-blind RCT in
patients with DM1 or MC but were not recommended due to their poor side effect profile.
Quinine, although it has a better side effect profile, was shown to be relatively ineffective
(Leyburn and Walton, 1959). Overall the 2006 Cochrane review, which was updated in 2009,
concluded that there was insufficient data to consider any of the published treatments safe
and effective for myotonia (Trip et al., 2006).
More recently a randomised controlled crossover study showed mexiletine to be safe and
effective for reducing myotonia in patients with DM1 (Logigian et al., 2010). It was however
unclear if there was any improvement in quality of life for these patients, especially since in
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DM1 hand grip myotonia only rarely affects quality of life. There is no good RCT evidence
for the efficacy of mexiletine in NDM although it is commonly used in clinical practice.
2.7.1.2 Treatment of Periodic Paralysis
One of the key aspects of treatment in PP is the avoidance of precipitants. In HyperPP, this
includes avoidance of potassium-rich foods and prolonged fasting. Treatment options during
an attack include inhalation of salbutamol, glucose/insulin therapy or even mild exercise to
help shorten the episode (Ricker et al., 1989).
In HypoPP, patients are advised to eat small, regular meals and avoid carbohydrate loads
and alcohol. During an attack, oral potassium can be prescribed to alleviate or shorten attacks
(Cleland and Griggs, 2008). The evidence for all of these recommendations however, are
based on guidelines and small epidemiological studies.
Some studies have been conducted investigating the prevention of attacks with
acetazolamide in HyperPP and HypoPP. It was shown to be effective in improving inter-attack
strength in an observational study (Griggs et al., 1970) and anecdotally in reducing attack
frequency, but at present there is no RCT evidence. There is however, case study evidence
that acetazolamide may worsen attacks in genetically defined HypoPP2, (Sternberg et al.,
2001), although there are also reports of some patients benefiting (Davies et al., 2001;
Venance et al., 2004; Vicart et al., 2004).
Dichlorphenamide was shown in a double-blinded placebo-controlled trial to reduce
attack frequency in both clinically defined HyperPP and HypoPP (Tawil et al., 2000). The
mechanism of action of the carbonic anhydrase inhibitors is unclear; they may act by opening
calcium-activated potassium channels located in the muscle or by acidifying and stabilising
intracellular potassium levels (Camerino et al., 2007; Tricarico et al., 2006).
In ATS anecdotal evidence suggests that carbonic anhydrase inhibitors may help to
prevent attacks of paralysis. From a cardiac perspective, patients are often put on beta
blockers for ventricular tachycardia, although there is little evidence that they alter its
frequency. Those with tachycardia-induced syncope may benefit from an implantable
cardioverter-defibrillator (Chun et al., 2004), and a single case study has reported that
flecainide may be effective in suppressing bidirectional ventricular tachycardia (Pellizzon
et al., 2008). However, further research is required to determine the optimum management of
ATS.
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2.7.2 Mexiletine in the Treatment of NDM
As highlighted in the Cochrane review, there is currently insufficient level I evidence for
the treatment of myotonia (Trip et al., 2006). This is primarily because of the difficulty
in recruiting a sufficient number of patients to demonstrate a treatment effect in this rare
disease. This causes problems for the care of patients with NDM as no licensed treatments
exist and many of the treatments are difficult to source. The current evidence for the efficacy
of mexiletine is a combination of anecdotal evidence (Pouget and Serratrice, 1983; Leheup
et al., 1986; Kwiecinski et al., 1992; Jackson et al., 1994) and convincing in vitro and in vivo
evidence.
In vitro data suggests that mutations seen in NDM cause a persistent inward current,
depolarizing the sarcolemmal membrane, resulting in myotonia. Mexiletine causes a tonic
and use-dependent block of muscle sodium channels, correcting the increased excitability
caused by the persistent inward current (Catterall, 1987). In mutated human sodium channel
constructs, mexiletine has been shown to correct the delay in inactivation (Mohammadi et al.,
2005; Wang et al., 2004).
In the animal model of recessive MC, the arrested development of righting response
(ADR) mouse, mexiletine was shown to significantly reduce the prolonged righting reflex
time (De Luca et al., 2004). In 1994, Jackson and Barohn demonstrated the efficacy
of mexiletine in a patient with a missense mutation on chromosome 17q in the SCN4A
gene (Jackson et al., 1994). They demonstrated improvement of the short exercise test, with
increased CMAPs following mexiletine therapy. In a study that included an evaluation of 9
myotonic dystrophy patients along with 9 patients with dominant MC, and 12 patients with
recessive MC (Kwiecinski et al., 1992) the investigators compared the efficacy of phenytoin,
disopyramide, mexiletine (200mg TDS), and tocainide to placebo. Based upon their analysis,
these researchers concluded that mexiletine and tocainide were the most potent anti-myotonic
agents, showing a decrease in time to open eyes after forced eye closure, to open the hand
after forced hand grip and to climb ten steps as well as decreased relaxation times on EMG.
More recently investigators at the University of Rochester studied the effectiveness of
mexiletine in reducing myotonia in a placebo-controlled crossover trial in DM1. Mexiletine
was shown to be superior to placebo in improving a quantitative measure of hand grip
myotonia by reducing relaxation times following forced hand grip (Logigian et al., 2010).
Given this evidence mexiletine appears to be an appropriate choice for further investigation.
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Chapter 3
AIMS AND OBJECTIVES
This thesis aims to increase the understanding of the phenotype, genotype and management
of skeletal muscle channelopathies. To achieve this I have the following objectives:
1. To determine the prevalence of skeletal muscle channelopathies in England.
2. To investigate the key phenotypic characteristics of patients with PMC, SCM,
HypoPP, HyperPP and ATS, including:
(a) identifying key differentiating features between the conditions
(b) determining genotype-phenotype correlations.
(c) understanding the main problems during pregnancy and with anaesthetics in
patients with skeletal muscle channelopathies.
3. To identify the novel variations in a cohort of genetically undiagnosed patients
with skeletal muscle channelopathies, including:
(a) identifying novel genes in patients with a NDM or PP phenotype
(b) identifying the “second mutation” in recessive MC patients with only a single loss
of function mutation.
4. To ascertain the efficacy of mexiletine in the treatment of NDM in a double-blind
randomised control study.
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Chapter 4
METHODS
4.1 Standard Protocol Approvals, Registration and Patient
Consents
Ethical approval was obtained from the University College London Hospital (UCLH) ethics
committee for all the research done in this thesis. All patients gave written informed consent
for genetic and clinical testing.
4.2 Prevalence Study
4.2.1 Patient Selection
Patients for the prevalence study were selected from those referred by neurologists or other
specialists to the MRC Centre for Neuromuscular Diseases, London, between April 1997 to
April 2011 for further clinical or genetic assessment for possible NDM or PP.
Inclusion criteria were individuals of any age, living in the UK with clinical and
neurophysiological features of NDM or PP and confirmed mutations in genes encoding the
skeletal muscle voltage-gated potassium (KCNJ2), calcium (CACNA1S), sodium (SCN4A)
or chloride (CLCN1) channels. Genetically unconfirmed or uncertain cases were excluded.
Alternative causes, such as thyrotoxic PP or DM1 or DM2, were ruled out by appropriate
tests when indicated. Patients living outside the UK were excluded.
4.2.2 Data Collection
Demographic, clinical, electrophysiological and genetic data from patients was prospectively
collected in a database. Genetic analysis was performed by the National Hospital for
Neurology and Neurosurgery (NHNN) neurogenetics laboratory by Sanger sequencing as
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outlined below. All NDM patients had sequencing of all exons of CLCN1 and exons 22 and
24 of SCN4A. If appropriate this was extended to all exons of SCN4A and MLPA of CLCN1
to ensure a full genetic diagnosis was made. All PP patients had sequencing of exons 11 &
30 CACNA1S, exons 13, 22 & 24 of SCN4A and the coding exon of KCNJ2. If negative
this was extended to S4 segments of CACNA1S and all exons of SCN4A to ensure that the
maximum possible number of genetically confirmed cases were included in the study.
4.2.3 Data Analysis
Point prevalence rates were calculated as the number of patients in the study area on the
prevalence day divided by the total number of individuals who were at risk at that time.
December 31st 2011 was chosen as the prevalence day.
England was selected as the geographical area for the prevalence analysis, with
a total population of 53,012,500 according to the latest available data (UK National
Statistics;www.statistics.gov.uk). All patients in England can be referred to the National
Commissioning Group funded service at the MRC Centre for Neuromuscular Diseases for
genetic diagnosis making it likely that we would have a good ascertainment in this area.
Patients from Scotland, Wales and Northern Ireland were not included in the calculation
because these areas have alternative centres to which they may send DNA and therefore
complete ascertainment of cases was less likely. Prevalence rates were expressed as
cases/100,000, and 95% confidence intervals (CI) were calculated using the method proposed
by Schoenberg (Schoenberg, 1983), based on the Poisson distribution.
The frequency of mutations in each gene was also determined. For this analysis, all
patients from any UK location were included. Descriptive statistics were performed using
IBM SPSS Statistics v20.
All patient selection and data collection was performed by myself. Data analysis was
done with the help of Dr Alejandro Horga.
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4.3 Clinical Phenotype Study
4.3.1 Patient Selction
Clinical phenotype data was collected from a comprehensive clinical database of all
channelopathy patients seen or assessed at the MRC Centre for Neuromuscular Diseases.
Further information was also gathered from patient notes and letters from referring clinicians
if data was incomplete. Patients from the natural history study in NDM conducted as part of
the Clinical Investigation of Neurological Channelopathies (CINCH) consortium were also
included. The data for those patients was collected by the specialist muscle clinicians at the
individual centres.
The inclusion criteria was all patients with genetic confirmation of a skeletal muscle
channelopathy with symptoms and signs of disease. Patients with MC and mutations in
CLCN1 were excluded from phenotype analysis as they had been incorporated in a previous
published study.
4.3.2 Data Collection
Patients were assessed for severity of myotonia, pain and attacks of weakness, based on their
symptoms and clinical examination. Severity of myotonia and weakness were graded on a
scale of 1-4 with 1 being mild and 4 being severe. Pain was graded on a scale of 1-3 for mild,
moderate and severe, respectively. Functional status was graded from 0-4 with 0-normal
walking, 1-difficulty with stairs, 2- mobilising with one stick, 3-mobilising with two sticks
or frame and 4-wheelchair bound. Muscle strength was assessed using the standard Medical
Research Council (MRC) score from 0-5, with 5 being normal strength and 0 being no muscle
movement (Medical Research Council, 1976).
Neurophysiology testing was performed on 86 patients and included short exercise
testing as described by Fournier et al (Fournier et al., 2004), needle electromyography
(EMG) and long exercise testing as described by McManis (McManis et al., 1986). Short
exercise testing involved recording CMAPs over the abductor digiti minimi (ADM) of the
right hand after a period of 10 minutes rest prior to starting the test. The hand was
immobilized and supramaximal stimulation (20-30% above maximum) of the ulnar nerve
performed every 60 seconds for two minutes to establish the baseline CMAP. The ADM was
then maximally contracted for 10 seconds with CMAPs recorded immediately after exercise
and then every 10 seconds for one minute. This was repeated three times. The long exercise
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test involved recording CMAPs over the ADM with surface electrodes, similar to the short
exercise test. The hand was rested for 10 minutes prior to starting the test. The hand was
immobilized and supramaximal stimulation (20-30% above maximum) of the ulnar nerve
performed every 60 seconds for two minutes to establish the baseline CMAP. The ADM
was maximally contracted for five 72-second periods, each consisting of four 15-second
activation intervals followed by a three-second rest period. After each 72-second interval, a
supramaximal stimulus was delivered. After completion of exercise, the patient was asked to
relax completely and CMAPs were recorded every two minutes for a minimum of 30 minutes
and to a maximum of 50 minutes. Some patients also had EMG and short exercise testing
following cooling and rewarming of the muscle (Fournier et al., 2006). All neurophysiology
tests were performed by specialist neurophysiologists at the centre. 13 patients also had MRI
of the lower limbs with both T1 and STIR sequences as previously described (Morrow et al.,
2013).
4.3.3 Pregnancy and Anaesthetics Data
Data on pregnancy and anaesthetics was collected using a questionnaire given to patients who
attended the muscle channelopathy patient day or who attended the specialist channelopathy
clinic (Appendix C). Only patients who were genetically confirmed were included.
4.3.4 Statistical Analysis
Statistical analysis was performed on all data. All categorical data was analysed using
Pearson’s Chi-squared test to assess for differences between groups. When significant
differences were found, adjusted residuals were used to determine the groups that contributed
most strongly to the statistical result. Adjusted residuals of greater than±2.0 were considered
significant. The Mann-Whitney U test was used to analyse continuous data between
two groups that were not normally distributed and Kruskal-Wallis was used for analysing
continuous data analysis of multiple groups. A small number of categories were normally
distributed and they were analysed using a one way ANOVA for multiple group comparisons
and independent samples t-test for two group comparison. Normality of continuous data was
assessed using Shapiro-Wilk test for normality and confirmed with Normal Q-Q plots. The
p-values were all two tailed and a p-value of <0.05 was considered significant. Correlations
were performed using Spearman’s rank order. A Bonferroni correction was calculated for all
multiple comparisons by diving the significance level by the number of tests. Comparisons
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that were significant after Bonferroni correction are indicated in the tables. All analysis was
performed using SPSS version 21. Graphs were produced using GraphPad Prism 6.
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4.4 Genetic Diagnosis study
4.4.1 Strategy for Genetic Diagnosis
To try and identify the underlying genetic diagnosis in this cohort of patients, I took the
following approach. Patients were split into three main groups and analysed accordingly
(Figure 4.1):
1. Cases with a single loss of function variation in CLCN1 from a recessive pedigree with
no “second mutation” identified.
– These cases underwent MLPA testing of CLCN1 to look for deletions and
duplications at exon level.
2. Cases with an unusual phenotype who either did not have a pathogenic mutation
identified or who had a variation that was inconsistent with the clinical features.
– These cases had Sanger sequencing of other possible causative genes done in a
systematic fashion based on their phenotype.
3. Cases with a phenotype consistent with a skeletal muscle channelopathy but with no
pathogenic variations identified following first line genetic testing (all CLCN1 exons,
KCNJ2 coding exon, SCN4A exons 13, 22 and 24 , CACNA1S exons 11 and 30).
– These were split into those with a PP phenotype and those with a NDM
phenotype. Those with a PP phenotype first had sequencing of all SCN4A exons
and the exons that encode S4 segments of CACNA1S as well as MLPA of KCNJ2.
Those that were still unexplained went on to have aCGH and whole exome
sequencing. Those with a NDM phenotype had MLPA of CLCN1, sequencing
of all SCN4A exons and DM1 and DM2 gene analysis. Those that remained
unexplained went on to have aCGH and whole exome sequencing
4.4.1.1 Patient Selection for Genetic Analysis
Patients were selected from a database of 1464 patients referred to the National
Channelopathy reference laboratory (as part of the National Commissioning Group
channelopathy service) at NHNN. Approximately 20% of these patients (296) either did
not have any pathogenic mutations identified following standard genetic screening, had an
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Figure 4.1: Flow chart of patient selection and overall results in genetic diagnostic study
unusual clinical phenotype in the context of their identified variation or had a single CLCN1
variation with a recessive pedigree. I carefully assessed these cases to identify only patients
with convincing signs and symptoms consistent with a skeletal muscle channelopathy and
accompanying objective neurophysiological evidence of a change in muscle membrane
excitability. This identified 182 patients from 165 pedigrees for further analysis (Figure 4.1).
4.4.1.2 Further Analysis of Selected Patients
Of the 182 patients, 9 from 4 pedigrees were classified as having an unusual clinical
phenotype and had strategic targeted genetic sequencing. 60 patients were found to have
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a phenotype consistent with recessive MC and either no variations, a single loss of function
CLCN1 variation or homozygous variations.
129 patients from 117 pedigrees (16 of which were also analysed in the CLCN1 group)
had further genetic analysis. These patients all had full genetic sequencing of all known
exons of CLCN1, SCN4A, KCNJ2 and the S4 segments of CACNA1S (exons 4,11,12,21
and 30) (either using Sanger sequencing by E.Matthews and S.Durran, or by A.Gardiner who
analysed 69 patients using a muscle channel panel containing the same genes). Patients with
myotonia also had testing for DM1 and DM2 at the appropriate UK service laboratory.
26 patients from 21 pedigrees (20%) had mutations identified in one of the four
channelopathy genes following further sequencing. The remaining 103 patients were
reassessed by myself to identify a smaller cohort of those with the highest likelihood of a
channelopathy. 16 patients were identified as possible candidates for further testing using
whole exome and aCGH techniques. Of these, 6 patients did not have sufficient DNA
remaining, or DNA of insufficient quality to perform whole exome sequencing and aCGH
(Figure 4.1).
4.4.2 Multiplex Ligation-dependent Probe Amplification
MLPA analysis of CLCN1 was used to investigate the possibility that patients with a
phenotype of MC may have deletions or duplications in CLCN1 that underlie their disease.
4.4.2.1 Patient Selection
Samples were collected from patients referred to the National Channelopathy reference
laboratory at the NHNN as described above, which included a small cohort of Sicilian patients
(assessed by S.Portaro). All patients selected had a clear clinical diagnosis of recessive MC
based on clinical assessment and electrophysiological studies with evidence of myotonia on
EMG.
In total 350 MC cases, including patients from the cohort described in Fialho et al
(Fialho et al., 2007), were assessed for suitability. These cases had previously had sequencing
of all 23 coding exons of CLCN1 by the Neurogenetics laboratory at NHNN. From these a
total of 50 UK patients and 10 Sicilian patients from 60 pedigrees were selected as candidates
for MLPA testing (Figure 4.2). They were selected because they either had features of NDM
and no pathogenic mutation, a single mutation despite a recessive pedigree or were apparent
homozygotes for a novel or known pathogenic mutation (16 patients). Homozygous patients
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were included because it is impossible to distinguish between a homozygous and hemizygous
result by sequencing alone and parental samples were unobtainable in those cases to confirm
the inheritance pattern.
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Figure 4.2: Flow chart of patient selection for MLPA and breakdown of results
Alongside this cohort, a group of patients who had a PP phenotype but no mutations
identified were tested to look for CNVs in KCNJ2 as this was provided in the same MLPA
kit (performed by V. Gibbons).
124 control chromosomes were also tested using the same technique from the European
Collection of Cell Cultures Human Random Control DNA panels. This consisted of randomly
selected UK Caucasian subjects.
4.4.2.2 MLPA Analysis
MLPA was performed using a commercially available kit (SALSA®MLPA kit P350-A1
CLCN1-KCNJ2), manufactured by MRC-Holland, Amsterdam. This kit contains probes for
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all 23 exons of CLCN1, 4 probes for KCNJ2 and 16 reference probes detecting 16 different
autosomal chromosomal locations. MLPA was performed as directed by the manufacturer’s
guidelines.
MLPA Technique
For denaturation, 1µl DNA mixed with 4µl Tris EDTA buffer was heated to 98°C for 5
minutes and then added to 1.5µl SALSA® Probemix and 1.5µl of SALSA® MLPA buffer.
The DNA mix was heated to 95°C for 1 minute and kept at 60°C for 16 hours.
For ligation the DNA mix was added to a ligase mix of 3µl each of Ligase Buffer A &
B, 1µl SALSA® Ligase-65 and 25µl water. The ligase and DNA mix was heated to 54°C for
15 minutes and then 98°C for 5 minutes and finally cooled to 4°C.
The polymerase chain reaction (PCR) was set up with 4µl SALSA® PCR buffer and
26µl Water added to 10µl of the DNA ligation mix. This was then combined at 60°C with
a polymerase mix of 2µl SALSA® PCR primer mix, 2µl SALSA® Enzyme dilution, 0.5µl
SALSA® polymerase and 5.5µl water. The PCR reaction was run at 35 cycles of 30s at 95°C,
30s at 60°C and 60s at 72°C with 20 minutes at 72°C at the end followed by cooling to 4°C.
Finally electrophoresis was done with 1µl of the MLPA PCR product mixed with
9µl Formamide and 0.3µl of GeneScan 500 LIZ® size standard. Amplified fragments
were analysed using an ABI 3730xl capillary sequencer (Applied Biosystems, Foster City,
California, USA).
A minimum of three reference samples were used per MLPA experiment and all positive
samples were repeated. A peak ratio range of >1.25 and <0.75 was used to determine
duplications and deletions.
MLPA Data Analysis
Results were quantitatively analysed using GeneMarker v1.85 software (SoftGenetics, State
College, Pennsylvania, USA). Individual peaks corresponding to each probe were identified
based on their difference in length. The peak heights were used, after standardisation, to
determine the copy number status, using the MLPA ratio method: intra-sample normalisation
by dividing the peak height of each probe’s amplification product by the total height of the
reference probes, followed by inter-sample normalisation by dividing the intra-normalised
probe ratio in a test sample by the average intra-normalised probe ratio of all reference
samples. Probe sequences were checked and it was confirmed that no point mutations or
rare polymorphisms described in this cohort were located under the probe binding site. The
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maximum size of the large scale alteration was calculated based on the maximum distance
between the unaffected probe binding sites. The minimum size was calculated based on the
minimum distance between the affected probe binding sites.
4.4.3 Array-based Comparative Genomic Hybridisation
aCGH was used to identify possible pathogenic CNVs throughout the genome in
channelopathy patients without a genetic diagnosis.
4.4.3.1 Patient Selection
Of the 16 cases identified for testing, 7 were analysed with aCGH. This was because 9 patients
had insufficient quantity or quality of DNA for testing and were not contactable to give further
samples. 1 patient’s sample failed analysis.
4.4.3.2 aCGH Technique
High-resolution aCGH was performed on genomic DNA and analysed against reference
DNA (Kreatech, Amsterdam, The Nederlands). Two types of array were used for different
purposes, the 720K probe exon-focused array and a 1.4 M probe whole-genome tiling array.
The 1.4M array was used for patients with an ATS phenotype as, given their syndromic
appearance, they were more likely to have large rearrangements located throughout the
genome rather than small exonic deletions or duplications. The 720K exon-focussed arrays
were used to test patients with a PP or NDM phenotype as they were more likely to have
small exonic deletions or duplications and this array gave a better coverage of exons.
The standard NimbleGen 720K exon-focused CGH microarray had enhanced coverage
at all known exons in the Human Genome 18 build. It had 701,702 probes with a probe
spacing of 65 base pairs (bp) at the exons and 2,509bp for the rest of the gene. The array
also included a genomic backbone probe set with an average probe spacing of 7,200bp. The
standard NimbleGen 1.4M whole-genome tiling array had 1,400,139 probes with an even
probe spacing of 916bp across the whole genome in the Human Genome 19 build. For both
arrays, the DNA samples were labelled, the test sample with Cyanine(Cy)3 and reference
with Cy5 and co-hybridised to the custom microarray in accordance with the manufacturer’s
instructions (NimbleGen Arrays User’s Guide: CGH and CGH/LOH Arrays v9.1, Roche
NimbleGen, Madison, WI USA). The microarray was washed and then scanned on an Axon
GenePix 4400A Scanner using GenePix Pro 7 software (Molecular Devices, Sunnyvale, CA,
USA). Raw data was normalized, LOESS correction applied and the data ratios calculated
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using NimbleScan Software (Roche NimbleGen). The normalized data was processed using
Infoquant Fusion v6.0 software (Infoquant, London, UK) with analysis call settings of 3
consecutive probes ± 0.4 Cy3/Cy5 ratio.
aCGH testing was performed by the North Thames Regional Cytogenetics Unit at Great
Ormond Street Hospital, London, UK. Results were analysed by myself using oneClickCGH
software from InfoQuant.
4.4.3.3 aCGH Analysis
All CNV calls with insufficient probe coverage (fewer than 4 probes) were eliminated as were
those also identified in the Database of Genomic Variants (Iafrate et al., 2004). All remaining
CNVs were cross-checked visually in a genome browser, checking firstly for any CNVs in
the regions of the known channelopathy genes and then in the other ion channel genes. If
negative the remaining CNVs were then checked.
4.4.4 Next-Generation Sequencing
4.4.4.1 Whole Exome Sequencing
Samples were processed by either Illumina or Axeq technologies and quality control
checked and standard analysis performed by UCL genomics. Illumina TruSeq 62Mb exome
enrichment kit was used for target enrichment with an average coverage of 50x for the
targets. Illumina Hiseq DNA analyser was used to sequence the samples. Raw sequence
data was aligned to the reference genome University of California, Santa Cruz (UCSC) hg19
(http://genome.ucsc.edu) using the Burrows-Wheeler Aligner (BWA) alignment algorithm
version 0.5.9 (http://bio-bwa.sourceforge.net). All post alignment processing was done by
Picard (http://picard.sourceforge.net) which includes sorting and marking PCR duplicates.
4.4.4.2 Variant Calling
Variant calling was done with the Genome Analysis ToolKit following best practice
guidelines v3. This included quality score recalibration to normalise base quality score, indel
realignment to improve indel detection and variable quality score recalibration which builds
a model for accurate variant detection using publicly available data and ancillary datasets.
Variant annotation was carried out using ANNOVAR (www.openbioinformatics.org/annovar)
and SNPEFF (http://snpeff.sourceforge.net). Variants were filtered based on the assumption
that the variant of interest is rare within the normal population, to this end dbSNP135,
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1000genomes (2012 February release) and NHLBI ESP data were used. Furthermore, all
variants with a minor allele frequency above 0.01 were not considered as likely candidates as
the causative variant was likely to be a rare variant.
4.4.4.3 Identifying Causative Variants
Variants were narrowed down using the following techniques. All synonymous variants were
excluded as it is highly likely that the causative variant would cause disease by altering an
amino acid. Known causative genes were first cross-checked for possible variants to ensure
none had been previously missed by Sanger sequencing. Samples were all checked for the
presence of variants identified by Sanger sequencing previously, to check for accuracy of
sequencing. Variants were then narrowed down to those located in genes known to cause
muscle disease and those in ion channel genes. I specifically looked at ion channels that
were expressed in skeletal muscle. All variants included in dbSNP were also excluded unless
thought to be pathogenic. In patients with a KCNJ2 phenotype, genes known to cause long
QT syndrome were also checked (Appendix B, Table B.3).
A list of all known muscle disease causing genes was identified using a combination
of OMIM, DisGeNET and KEGG databases giving 130 possible genes (Appendix B, Table
B.1). These were used for the first level of filtering of single nucleotide variants (SNVs)
to identify patients who may have a known muscle disease presenting with an atypical
channelopathy-like phenotype. A list of ion channels were then identified using the National
Centre for Biotechnology Information (NCBI) Gene database (http://www.ncbi.nlm.nih.gov).
I identified 374 voltage-gated ion channel genes and known associated genes in the genome
by searching for human voltage-gated channel genes in NCBI Gene database (Appendix B,
Table B.2). These genes were then checked for expression levels in skeletal muscle in the
Database of mRNA gene expression profiles of multiple human organs (Son et al., 2005)
and the UCSC genome bioinformatics database (Kent et al., 2002). Using this method
I identified 88 genes that were expressed in low to high levels in normal skeletal muscle
mRNA. I hypothesised that mutations in voltage-gated ion channels are most likely to be
responsible for disease in this cohort, given the clinical and electrophysiological phenotypes.
Since symptoms and signs were localised to the skeletal muscle it therefore follows that the
critical genes should be expressed in normal skeletal muscle.
Once a list of potential variants for each patient was identified, they were then ranked
according to whether they were indels, nonsense mutations or missense mutations. They
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were analysed using SIFT, PolyPhen2 and Mutation taster to predict the likelihood of
pathogenicity. Their protein expression and RNA expression in skeletal muscle were also
checked using The Human Protein Atlas (www.proteinatlas.org).
4.4.5 Sanger Sequencing
All novel pathogenic variations identified by whole exome sequencing were validated by
Sanger sequencing in the proband and any available relatives.
4.4.5.1 Primer Design
Possible pathogenic variations identified by whole exome sequencing in commonly
tested genes were checked by the Neurogenetics department as part of standardised
testing. The other variations were checked by Sanger sequencing by myself. Exon
sequences were identified from the Ensembl database (www.ensembl.org/index.html) for
each gene. These sequences were input into Primer 3, an online primer design tool
(http://bioinfo.ut.ee/primer3), to identify potential primers. Primers were designed to include
approximately 25 base pairs of intronic sequence upstream and downstream of the exon and
produce a fragment size of approximately 400 base pairs. Potential forward and reverse
primer sequences were then checked against the sequence in the in silico PCR software
in the UCSC genome bioinformatics website (http://genome.ucsc.edu/cgi-bin/hgPcr), to
cross-check its specificity to the particular gene and ensure it would not anneal to any other
sequence in the genome.
Finally the potential primer sequence was input into a single nucleotide polymorphism
(SNP) checker, SNP Check 3 (https://secure.ngrl.org.uk/SNPCheck/snpcheck.htm), to ensure
it did not cover a region with any polymorphisms that would give a false positive result.
Any primers that did not pass these checks were redesigned. Primers were ordered from
SIGMA and tagged with a M13 universal primer sequence and had High Performance Liquid
Chromatography purification (Table 4.1).
4.4.5.2 Sanger Sequencing Technique
Polymerase Chain Reaction
For the PCR, 200ng DNA was added to 12.5µl AmpliTaq Gold 360 PCR Master Mix (ABI),
10pmol/µl of forward and reverse primers and 9.5µl autoclaved nanopure water. This was
added to a 96 well plate and covered and centrifuged for one minute at low speed. A negative
and positive control were added for each set of primers. 2700 PCR machines were used for
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Gene	   Exon	   Forward
/Reverse	  
Sequence	  5'	  to	  3'	  CRYAB	   3	   F	   TGTAAAACGACGGCCAGTTCATCTCCAGGGAGTTCCAC	  CRYAB	   3	   R	   CAGGAAACAGCTATGACCTCATTCACTGGTGGGGAAAC	  SCNN1B	   9	   F	   TGTAAAACGACGGCCAGTacctcctcctgccacctaac	  SCNN1B	   9	   R	   CAGGAAACAGCTATGACCGGGTGTCActgaaagagaagg	  RYR1	   24	   F	   TGTAAAACGACGGCCAGTGATGAGCAATGGGTACAAGC	  RYR1	   24	   R	   CAGGAAACAGCTATGACCgggctgagtcaggtcagaga	  
Table 4.1: Primers designed for Sanger sequencing of novel variations(Red indicates M13
tag)
the reaction with the following cycling conditions: Denaturing at 95°C for 10min then 30
cycles of 95°C for 30s, 58°C for 30s, 72°C for 30s and the final extension step of 72°C for
7min.
Gel Electrophoresis
Gel electrophoresis was performed to analyse the quality and yield of the PCR. Gels were
made with 1g agarose gel mixed with 50ml of 5ml 10% Tris Borate EDTA and 45ml water
and microwaved for one to two minutes until the gel was fully dissolved. 1µl ethidium
bromide was added to the gel and the gel was poured into a chamber and a gel comb inserted
and left to set for approximately 15mins. Once set a further 50mls of 5ml 10% Tris Borate
EDTA and 45ml water was added to the plate.
4µl of orange G dye was added to 4µl of the PCR reaction mix and 7µl of this mixture
pipetted into the well. One well had 4µl of orange G added to 2µl of a 100 base pair DNA
ladder to estimate the size of fragments. Electrodes were attached to the electrophoresis
chamber and 65V was applied across it for 30min. The gel was then removed and placed
under an ultraviolet illuminator to visualise the DNA fragments and estimate their size and
confirm a successful PCR reaction.
PCR Purification
The PCR reaction mix was then purified by adding 79µl of nanopure water to the PCR
product, centrifuging the mix and transferring to a clean-up plate. It was then placed on a
vacuum manifold and a vacuum of 24mmHg applied for 10min until the wells had emptied.
Samples were then reconstituted with 50µl of nanopure water and left to shake on a R100
rotatest shaker for 30min.
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DNA Sequencing
All samples were sequenced bidirectionally using ABI Prism BigDye Terminator Cycle
Sequencing Ready Reaction kit version 1.1 with M13 universal primers. The sequencing
was analysed on the ABI 3730 automated DNA sequencer.
For DNA sequencing, 3.5µl of purified PCR product was added to a mix of 1µl BigDye
Premix, 2µl 5X BigDye sequencing buffer, 3.2pmol of either forward or reverse M13 primer
(depending on which strand was being sequenced) and 2.5µl nanopure water. Samples were
centrifuged and then placed into the ABI 9800 PCR machine. They were then run for 25
cycles at 96°C for 1min, 96°C for 10s, 50°C for 5s and then 60°C for 75s.
The extension product was then purified using the ABI gene Dye Terminator Removal
Kit. This was first activated with centrifugation for 3 minutes at 2150rpm. 20µl of sterile
deionized water was then added to each sequencing reaction and this mix was inserted into
the removal plate. This was then centrifuged again for 3 minutes at 2150rpm and the collected
sample was then sequenced using the ABI 3730 DNA sequencer. Data was analysed using
2.5 SeqScape Analysis software (ABI).
4.4.6 Expression Studies
Expression studies were performed to provide supporting evidence for pathogenicity for
some novel variations. Xenopus oocyte studies were performed by R. Mannikko and ClC-1
expression in HEK293T cells by J. Burge.
4.4.6.1 Xenopus oocyte Studies
Molecular Biology and Oocyte Preparation
Human CLCN1 in pTLN vector (Lorenz et al., 1996) was used for this study. Site-directed
mutagenesis was performed using the QuickChange®XL system (Stratagene, La Jolla,
CA, USA). Successful mutagenesis was confirmed by sequencing. Capped mRNA was
prepared using the mMESSAGE mMACHINE (Ambion, Austin, TX, USA). Integrity and
concentration of the product was checked by ethidium bromide stained gel electrophoresis
and spectrophotometry. Female Xenopus laevis frogs were sacrificed in accordance with the
Animals (Scientific Procedures) Act 1986. Clusters of oocytes were incubated in 2mg/ml
Collagenase A (Roche) in OR-2 (in mM: NaCl 82.5, KCl 2, MgCl2 1, Hepes 5, pH 7.5-7.6
with NaOH) for 2h, and stored in modified Barth’s solution (in mM: NaCl 88, KCl 1, MgSO4
1.68, Hepes 10, Ca(NO3)2 0.47, NaHCO3 2.4, CaCl2 0.41, pH 7.4 with NaOH) at 16°C. Stage
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V and VI oocytes were injected with WT RNA, mutant RNA, or a 1:1 mixture of WT and
mutant RNA to simulate the heterozygous state (2.5ng total RNA). Oocytes were incubated
for 36-72 hours before the electrophysiological recordings.
Electrophysiology
Standard whole cell two-electrode voltage-clamp recordings were performed at room
temperature (GeneClamp 500B and DigiData 1200 Interface, Axon Instruments) with ND96
(in mM: NaCl 96, KCl 2, MgCl2 1, CaCl2 1.8, Hepes 5, pH 7.4 with NaOH) as extracellular
solution. Recording electrodes were filled with 3M KCL and had a tip resistance between
0.1-1MΩ. Data was filtered at 1kHz and sampled at 5kHz using Clampex (Axon Instruments)
software. From holding potential of -80mV a 250ms pre-pulse to +60mV was applied,
followed by 250ms step to test voltages between -150 and +150mV in 10 mV increments.
Tail current amplitude was recorded at -100mV, 4ms after the end of the test voltage steps.
Tail current amplitude was plotted against the test voltage and fitted with Boltzmann equation
using Clampfit software (Axon Instruments):
I(V ) = Io +(Imax− Io)/(1+ exp((V1/2−V )/dV )
Where Io is the minimum offset current at negative test voltages, Imax the maximal current
amplitude, V1/2 the voltage where half of the channels are activated and dV the slope factor.
Value of Io was fixed as the baseline current at most negative voltages. The data was acquired
from >2 batches of oocytes, WT and mutant experiments were performed on the same day
in time matched manner to avoid time dependent variation on expression levels and channel
properties.
Data illustration and statistical analysis (Student’s t-test) were performed using Excel 9
(Microsoft) and Origin 8.6 (Microcal) software. Data are given as mean ±S.E.M.
4.4.6.2 HEK293T Cell Studies
The Pro744Thr point mutation was introduced into the cDNA for WT CLCN1 in a
mammalian cell expression vector (pCDH1, System Biosciences) using a Stratagene
QuickChange Site-directed Mutagenesis Kit and overlapping primers encoding the mutation.
HEK293T cells were maintained in Dulbecco’s modified Eagles Medium supplemented
with L-glutamine and 10% fetal bovine serum. They were transfected in 1 well of a 6-well
plate with 0.5µg of wild-type or mutant DNA using Fugene HD Transfection Reagent
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(Roche) according to the user manual. Six hours after transfection the cells were plated onto
glass coverslips coated with poly-D-lysine, and were studied by patch clamp 24-48 hours
later.
Microelectrodes were pulled from borosilicate capillary glass on a Stutter 97 puller and
backfilled with intracellular solution. Cells on a poly-D-lysine coated coverslip were placed
in a 35mm dish containing extracellular solution to wash away culture medium before being
transferred to the patch clamp set up. The intracellular solution contained in mM Cs Aspartate
110, CsCl 30, MgCl2 5, EGTA 10, HEPES 10. Extracellular solution contained in mM
TEA-Cl 145, CaCl2 10, HEPES 10. Both solutions were pH 7.4.
Series resistance was 2-4mOhms, and was compensated 50-70%. From a holding
potential of -40mV, channels were first activated by a 200ms step to +60mV. Then, to obtain
the voltage dependence of activation, the instantaneous current (tail current) on stepping to
-100 mV for 400ms was measured after 400ms prepulses to different voltages (-140mV to
+120mV in 20mV increments).
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4.5 Mexiletine in the Treatment of Non-dystrophic Myotonia
To investigate the efficacy of mexiletine in patients with NDM, a large multi-centred trial was
set up. This enabled us to recruit sufficient patient numbers to adequately power the study.
The study was designed by the CINCH consortium.
4.5.1 Trial Design
The study had a multi-centred randomised double-blind placebo-controlled crossover design.
This was based over seven different centres in four different countries. I was responsible for
recruiting, investigating and analysing the data from the UK cohort.
There were two treatment periods of four weeks, each with a one week wash out period
in-between. Patients were randomised to either mexiletine 200mg three times a day or
placebo three times a day for the first treatment period. Following the wash out they were
then given the treatment that they had not previously received (Figure 4.3).
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Figure 4.3: Flow chart of mexiletine study design
Mexiletine was purchased from TEVA Pharamaceutical. Placebo was Microcrystalline
Cellulose (Avicel PH102). Both tablets were encapsulated to ensure blinding at the University
of Iowa Research Pharmacy with Swedish Orange Capsule. A qualified person from Brecon
Pharmaceuticals Limited inspected both sites to ensure compliance with EU regulations.
Mexiletine drug level testing was conducted at Mayo Medical Laboratory.
The study was conducted between April 2008 and March 2011.
4.5.1.1 Sample Size
The power was set at a minimum of 90% with an alpha level of 0.05. The optimum sample
size with these values was 60 patients. This allowed for a standard attrition rate of 10%. A
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full data set (minimum of 5 data points in each collection period) for 54 patients allowed a
93% power to detect an effect-size of a quarter of a standard deviation within a subject for
the primary outcome measure.
A linear mixed model was used for the power calculations. The primary model was:
Yi jk ∼ µ0 +βMXi j + γ j +bi + εi jk
Where Yijk is the severity score of stiffness occurring for the ith patient, in the jth treatment
period, and the kth daily episode (assumed that each patient called in 10 days of the possible
14 for the simulation). The symbol µ0 represents the mean severity of stiffness score in the
NDM population with no treatment (assumed to be 4 for the simulation - it has no substantive
effect on the power), βM is the fixed effect of mexiletine, Xij is the design matrix (treatment
assignment: placebo:0 and mexiletine:1), γ j is the period effect (assumed to be zero for the
simulation), bi is the random effect of patient, and εi jk is the variation within patient. The
two random terms are assumed to be normally distributed with a mean of zero and variance
σ2b and σ
2
ε respectively. The effect size is expressed in standard deviation units (i.e.
βM
σε )
because the variance of the endpoint is unknown. The degree of correlation between two
outcome measurements within the same participant is a product of the relative size of the
variance of the two random components. The statistical power varies from 0.93 to 0.98 for an
effect size of 0.25 (∆= |βM |σε ), a σb ranging from 0.5σε to 2σε , and a two-sided Wald test with
the α-level = 0.05. These results are based on 1000 Monte Carlo samples. The dependent
variable (severity score) was generated by a random (normally distributed) number generator
then rounding to the nearest whole number from 0 to 9. The random effect of subject has an
inverse relationship with statistical power due to the truncated distribution of severity score
at the extremes (i.e., 0 and 9).
The variation in power was due to the varying degree of between-participant standard
deviation. Larger standard deviations lowered the power since the effect in the active
treatment period for low-severity scores cannot be less than 0. These values were set before
data was available but since the publication of the natural history study these values were
shown to be reasonable. In that study the mean severity was 3.85 with a within-participant
standard deviation (SD) of 1.5 and between participant standard deviation of 1.82 (Statland
et al., 2011). The effect size of one-quarter of an SD was chosen to be conservative to
4.5. Mexiletine in the Treatment of Non-dystrophic Myotonia 91
compensate for the unknown degree of participant adherence to treatment, and to have a
sufficient sample size available for the secondary interactive voice response (IVR) diary end
points for which some participants do not have the symptom.
4.5.1.2 Randomisation
Patients were randomised remotely using a computerised system that generated a
randomisation list using fixed block sizes. The trial team had no knowledge of the
randomisation codes. Sealed envelopes were held for safety but no envelopes were unsealed
during the trial. All medication bottles were returned after each treatment period to check
compliance.
4.5.2 Ethics and Safety
The UK part of the study had full ethical approval from the UCLH ethics committee and the
Medicines and Healthcare products Regulatory Agency (MHRA). The US part of the study
had Federal Drug Administration (FDA) and local US institutional review board approval.
All patients gave full written informed consent.
The safety of the study was reviewed every six months by a Data Safety Monitoring
Board established by the National Institute of Health in the US. In the UK the trial sponsor,
UCL, also monitored the safety of UK patients and any serious adverse effects were reported
to the MHRA.
4.5.3 Patient Selection
All UK patients were at least 18 years old. They had clinical, electrical and genetic
confirmation of NDM. Patients from other centres without genetic confirmation either had
clinical and electrical evidence of NDM and an affected first degree relative or were DM1 and
DM2 negative. Patients were excluded if they were: unable or unwilling to provide informed
consent; had other neurological, renal or hepatic disease, heart failure or seizure disorder;
had genetically confirmed DM1 or DM2; had pre-existing cardiac conduction defects or
a permanent pacemaker; were on an anti-arrhythmic, anti-myotonic or myotonia-inducing
medications. Patients on fibrate acid derivatives or hydroxymethylglutaryl CoA reductase
inhibitors were only included if they had been on a stable dose for at least 30 days. Pregnant
or lactating women were excluded.
All patients were screened prior to starting the trial. This included confirming that
patients were symptomatic, had a diagnosis of NDM and had no contraindications to taking
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mexiletine. All patients had an electrocardiogram that was assessed by a cardiologist in the
US. Patients also had baseline blood tests prior to randomisation.
4.5.4 Outcome Measures
The choice of outcome measures is central to the validity of a trial. Prior to this study the
CINCH group performed a natural history study to understand the nature and progression of
the disease and identify the optimum outcome measures. Some of these results have already
been reported (Statland et al., 2011, 2012; Trivedi et al., 2013). The FDA have put recent
emphasis on patient-reported outcome measures and ensuring that outcome measures are
clinically meaningful and based on the patient’s perspective (US Department of Health and
Human Services Food and Drug Administration., 2009) therefore this was taken into account
when identifying outcome measures.
4.5.4.1 Primary Outcome measures
The primary outcome measure was severity of patient-assessed stiffness in the third and
fourth weeks of treatment. This was measured using an IVR diary which was an automated
telephone service that patients called every day during the trial and ranked their stiffness
severity from 1–9, one being minimal and nine being the worst ever experienced. The
responses were automatically stored on a centralised database and patients did not have access
to how they had previously ranked their stiffness, effectively blinding them to their previous
responses. This system was previously validated in the NDM natural history study (Statland
et al., 2011), which verified that patient-reported stiffness was the most severe and common
symptom in NDM patients and therefore it was used as the primary outcome measure.
4.5.4.2 Secondary Outcome Measures
The secondary outcome measures included:
1. Daily patient-reported pain, weakness and fatigue, measured using the same IVR
system over the last two weeks of treatment.
2. Clinical myotonia assessment: this included detecting percussion myotonia, triggered
by a reflex hammer to the extensor digitorum communis and abductor pollicis brevis. It
also included bedside measurement of eyelid myotonia and hand grip myotonia, when
patients were asked to close their eyes or fist tightly for three seconds and then asked
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to rapidly open it. The speed of opening was measured in seconds with a stopwatch.
This was repeated five times to identify the presence of warm-up or paramyotonia.
3. Quantitative hand grip myotonia, measured using a strain gauge to measure the force of
contraction on the handle of a grip ergometer, which was recorded on a computerised
system. This was a standardised setup across all sites. Right hand grip relaxation times
after maximal voluntary isometric contraction was recorded and relaxation time from
90% to 5% of maximal force measured as has been used by other groups (Logigian
et al., 2005; Moxley R. T. et al., 2007). Patients did this for six trials, with maximal
contraction for three seconds with a 10 second rest between each contraction. Each
set of measurements was repeated two further times with a 10 minute rest period
inbetween.
4. Measurement of CMAP amplitude during long and short exercise testing (Fournier
et al., 2004, 2006).
5. Myotonia on needle EMG in the right ADM and tibialis anterior which was graded
according to severity, 0 being no myotonia, 1+ being minimal myotonia, 2+ being
myotonic discharges in more than half of needle locations and 3+ being myotonic
discharges with each needle movement in all examined areas.
6. Quality of life measures as measured by the SF-36 and INQoL questionnaires for
neuromuscular disorders (Trip et al., 2009a; Vincent et al., 2007).
4.5.5 Statistical Analysis
Statistical analysis and design for the entire cohort was performed by the trial statistician,
Brian Bundy. All UK cohort data was collected and analysed by myself. An intention-to-treat
principle was used but modified to remove missing values that were assumed to be missing
at random. The primary endpoint and the secondary endpoints derived from the IVR
patient-reported results were all ordinal data and therefore summary statistics used were
medians. The majority of analysis was done using either the paired t-test or the linear
mixed effects model. The mixed model adjusted for a number of variables including gender,
age and difference in time period and took into account the linear structure of endpoints
for the quantitative hand grip, short exercise test and long exercise test. It also included
data from dropouts. The paired t-test was used for all the main treatment comparisons and
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closely matched the results derived from the mixed model. It was however limited to subjects
who provided data for both treatment periods. The mixed model was also used to perform
homogeneity testing of the treatment effect in mutation subgroup analysis accounting for the
variability in result depending on type of mutation.
For EMG myotonia, the score was converted to a numeric value as follows: no myotonia
was set to 0, 1+ was set to 1, 2+ was set to 2, and 3+ was set to 3. The endpoint was the sum
of the numerical scores of the two muscles. The paired Wilcoxon test was used to test the
hypothesis that the medians of the two samples were equal.
Normality assumptions were made for all analyses. QQ plots were done for all the IVR
severity scores and demonstrated deviation from normal. Therefore average severity score
per week was used instead as these values were normally distributed. Modifications had to be
made for some of the other outcomes to fulfil normality criteria. For clinical hand grip and
eye closure times a log(ti+0.1) transformation was used. For quantitative hand grip myometry
a log (ti) transformation was used. It was also assumed that there was no carry-over effect
and that the treatment effect was the same across periods and the Wald test was used to check
for carry-over effect. A significant carry-over effect was identified for cases where the Wald
test gave a p<0.10 and the data for those categories were analysed for each period separately.
Since this trial identified a primary endpoint, all other p-values presented were for secondary
endpoints and are not adjusted for multiple testing. All p-values were two sided and 0.05 was
considered statistically significant.
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Chapter 5
RESULTS
5.1 Prevalence of Skeletal Muscle Channelopathies
5.1.1 Total Minimum Prevalence of Skeletal Muscle Channelopathies
665 patients from 453 pedigrees were selected according to the inclusion criteria. Of these,
593 (89%) were living in England, giving a minimum point prevalence of skeletal muscle
channelopathies of 1.12/100,000 (95% CI: 1.03-1.21) (Figure 5.1). Overall 424 (63.8%)
patients were male. The median age was 37.6 years (range:1.5-89.4 years) (Table 5.1).
5.1.2 Minimum Prevalence of Non-dystrophic Myotonia
Overall 449 patients had NDM, of which 395 patients were from England giving a minimum
point prevalence of 0.75/100,000 (95% CI 0.67–0.82). The male to female ratio was 1.57
(Table 5.1, Figure 5.2).
5.1.2.1 Minimum Prevalence of MC
321 patients had MC with mutations in CLCN1, of which 277 were from England giving
a minimum prevalence of MC in England of 0.52/100,000 (Table 5.1). 168 patients had
a positive family history, of these, 99 patients (59%) from 50 pedigrees were classified as
dominant MC and 69 patients (41%) from 49 pedigrees as recessive MC (Table 5.1). The
type of MC was classified based on the patient’s inheritance pattern and genotype. Of the
remaining 153 patients, five were sporadic cases with de novo mutations and 148 had an
uncertain family history. The male to female ratio was 1.97 for MC but varied significantly
between dominant MC (1.30) and recessive MC (2.00) (Table 5.1, Figure 5.2).
Overall 104 different CLCN1 mutations were identified in this group, of which 65 could
be classed as “private mutations”. Of the remaining mutations, 15 particular mutations
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Figure 5.1: Graph of the minimum prevalence of the skeletal muscle channelopathies in
England. (a) Minimum prevalence of individual skeletal muscle channelopathies in England (b)
Distribution of skeletal muscle channelopathies in England
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All Patients 
(pedigrees) 
Age (yr), 
mean ± 
SDa 
Male/ 
female 
ratio 
Patients from 
England, n (%) 
Minimum 
Prevalence (x10-5), 
rate in England 
(95% CI) 
Skeletal Muscle 
Channelopathies 
665 (453) 38.3 ± 17.7 1.78 593 (89%) 1.12 (1.03–1.21) 
NDM 449 (322) 38.0 ± 17.5 1.57 395 (88) 0.75 (0.67–0.82) 
  MC 321 (252) 39.0 ± 16.3 1.97 277 (86) 0.52 (0.46–0.59) 
Dominant MC 99 (50) 40.8 ± 17.3 1.30 73 (74) 0.14 (0.11–0.17) 
Recessive MC 69 (49) 33.5 ± 17.7 2.00 63 (91) 0.12 (0.09–0.15) 
      Otherb 153 (153) 40.2 ± 14.5 2.64 141 (92) 0.27 (0.22–0.31) 
  PMCc, d 96 (56) 35.1 ± 19.5 0.88 88 (92) 0.17 (0.13–0.20) 
  SCM 32 (14) 37.7 ± 21.3 1.00 30 (94) 0.06 (0.04–0.08) 
PP 216 (131) 39.1 ± 18.3 2.27 198 (92) 0.37 (0.32–0.43) 
  HypoPP 95 (59) 36.6 ± 18.1 3.52 88 (93) 0.17 (0.13–0.20) 
  HyperPP 77 (48) 40.2 ± 19.3 2.08 70 (91) 0.13 (0.10–0.17) 
  ATS 44 (24) 42.7 ± 16.2 1.20 40 (91) 0.08 (0.05–0.10) 
a At the time of the prevalence day. b Sporadic cases and patients with uncertain family history of MC. 
c Three patients from three pedigrees displayed an overlapping PCM/SCM phenotype. 
d Two patients with p.Arg1448Cys and one with p.Ile693Thr also had episodes of paralysis. 
Table 5.1: Demographic characteristics of prevalence study data and minimum point
prevalence rates
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Figure 5.2: Graph of male to female ratios in the skeletal muscle channelopathies in the UK.
were responsible for disease in 83% of all MC patients (96% of dominant MC; 67% of
recessive MC). The three commonest mutations were Gly230Glu(18%), Gly285Glu(10%)
and Trp303Arg(9%) (Figure 5.3a, Figure 5.4a,Table 5.2).
186 heterozygous patients were identified, as well as 85 compound heterozygotes and
41 patients with homozygous mutations. 9 patients had a heterozygous mutation and a
synonymous nucleotide substitution. Of the heterozygous patients, 95%(94) had dominant
MC. Of the compound heterozygotes and homozygous cases, 95%(88) had recessive MC
(Table 5.3, Figure 5.5). Seven mutations were identified that are commonly associated with
dominant MC. 139 patients were identified with these mutations, of which 88%(123) were
heterozygous (Table 5.3). The Phe307Ser mutation was the commonest dominant-acting
mutation associated with a second mutation (36% of cases). Three mutations which are
more commonly associated with recessive MC were found to be expressed heterozygously:
Gly285Glu (35% of cases), Phe167Leu (38%) and Val327Ile (43%) (Figure 5.3a, Table 5.3).
5.1.2.2 Minimum Prevalence of PMC and SCM
93 patients had a diagnosis of PMC (88 from England), 32 had a diagnosis of SCM (30 from
England) and three displayed an overlapping PMC/SCM phenotype based on clinical and
electrophysiological features. This gives a minimum prevalence of 0.17/100,000 for PMC
and 0.06/100,000 for SCM (Table 5.1, Figure 5.1). The male to female ratio was 0.88 for
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Figure 5.3: Diagrammatic representation of the skeletal muscle ion channels and the
location of the common mutations identified in this prevalence study. (a) ClC-1 (b) NaV1.4
(c) CaV1.1. The location of the most common mutations and their percentage frequency in the
study sample are shown in each figure.
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Table 5.2: Frequency of common mutations in patients with chloride channel mutations in
the prevalence study
	  
CLCN1 
mutations 
All patients with 
MC, n (%) 
(n = 321) 
Patients with positive family history 
AD MC, n (%) 
(n = 99) 
AR MC, n (%) 
(n = 69) 
p.Gly230Glu 58 (18) 34 (34) 1 (1) 
p.Gly285Glu 31 (10) 0 10 (14) 
p.Trp303Arg 29 (9) 21 (21) 0 
c.180+3A>T (splice site) 25 (8) 1 (1)b 16 (23) 
p.Arg894X 18 (6) 2 (2) 5 (7) 
p.Ala313Thr 15 (5) 8 (8) 0 
c.1437_1450del 15 (5) 1 (1)c 2 (3) 
p.Phe297Ser 13 (4) 9 (9) 0 
p.Phe413Cys 13 (4) 0 4 (6) 
p.Phe307Ser 11 (3) 7 (7) 1 (1) 
p.Phe167Leu 8 (2) 1 (1) 2 (3) 
p.Met485Val 8 (2) 1 (1)d 3 (4) 
p.Ala313Val 7 (2) 5 (5) 0 
p.Phe306Leu 7 (2) 5 (5) 0 
p.Val327Ile 7 (2) 0 2 (3) 
a Non–private mutations present in >2 pedigrees and ≥2% of all patients with MC. 
b–d Compound heterozygous with a dominant mutation: b p.Arg894X; c p.Phe307Ser; d p.Gly230Glu. 
Blue shading indicates common mutations associated with dominant MC. 
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Distribution of common mutations in CLCN1
Gly230Glu
Gly285Glu
Trp303Arg
180+3A>T
Arg894XAla313Thr/Val
1437_1450del
Phe297Ser
Phe413Cys
Phe307Ser
Phe167Leu
Met485Val
Phe306Leu
Val327Ile
Private
Mutati
ons
Total = 321
18%
10%
9%
8%
5%7%
5%
4%
4%
3%
2%
2%
2%
2%
17%
Distribution of common mutations in SCN4A 
associated with PMC and SCM
Total = 128
Thr1313Met
Arg1448
Val1589Met
Gly1306
Leu1436Pro
Ile693Thr
Val1293Ile
Other
17%
22%
21%
13%
14%
5%
5%
2%
(a)
(b)
Figure 5.4: Pie charts of distribution of common mutations in Non-dystrophic myotonia (a)
Mutations in CLCN1 associated with myotonia congenita (b) Mutations in SCN4A associated
with PMC and SCM
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Table 5.3: Breakdown of homozygous and heterozygous variations in MC patients in the
prevalence study.(a) Overall breakdown of homozygous and heterozygous variations in MC
patients, (b) Frequency of heterozygous, homozygous and compound heterozygous mutations
amongst the common mutations in MC patients
a) 
b) 
	  
Myotonia congenita cases 
(CLCN1 mutations) 
Dominant MC 
n (%) 
(n = 99) 
Recessive MC 
n (%) 
(n = 69) 
Other 
n (%) 
(n = 153) 
Total 
n (%) 
(n = 321) 
Heterozygous 94 (95) 2 (3) 90 (59) 186 (58) 
Compound heterozygous 3 (3) 39 (57) 43 (28) 85 (26) 
Homozygous 2 (2) 22 (32) 17 (11) 41 (13) 
Heterozygous + synonymous 
nucleotide substitution 
0 6 (9) 3 (2) 9 (3) 
CLCN1 
Mutations 
(n = 321) 
Heterozygous 
n (%) 
(n = 186) 
Heterozygous 
+ p.(=) 
n (%) 
(n = 9) 
Compound 
Heterozygous 
n (%) 
(n = 85) 
Homozygous 
n (%) 
(n = 41) 
p.Gly230Glu 54 (29) 1 (11) 3 (4) 0 
p.Gly285Glu 11 (6) 0 20 (24) 0 
p.Trp303Arg 28 (15) 0 1 (1) 0 
c.180+3A>T  1 (1) 0 22 (26) 2 (5) 
p.Arg894X 4 (2) 0 13 (15) 1 (2) 
p.Ala313Thr 14 (8) 0 0 1 (2) 
c.1437_1450del 3 (2) 1 (11) 9 (11) 2 (5) 
p.Phe297Ser 13 (7) 0 0 0 
p.Phe413Cys 3 (2) 0 9 (11) 1 (2) 
p.Phe307Ser 7 (4) 0 3 (4) 1 (2) 
p.Phe167Leu 3 (2) 0 5 (6) 0 
p.Met485Val 1 (1) 0 7 (8) 0 
p.Ala313Val 6 (3) 0 1 (1) 0 
p.Phe306Leu 7 (4) 0 0 0 
p.Val327Ile 3 (2) 0 4 (5) 0 
Na 158 (85) 0 27 (32) 8 (20) 
Table looking at non–private mutations present in >2 pedigrees and ≥2% of all patients with MC. 
aNumber of patients with myotonia congenita in which only common CLCN1 mutations were detected. 
Blue shading indicates common mutations associated with dominant MC. 
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Figure 5.5: Graph of distribution of heterozygous and multiple mutations in myotonia
congenita patients
PMC and 1.00 for SCM (Figure 5.2).
Overall, of the 22 different SCN4A mutations detected in patients with PMC and SCM,
11 were present in 86% of all pedigrees and 11 were private mutations (Figure 5.3b, Figure
5.4b). Of the common mutations, two were only seen in PMC patients, Thr1313Met and
changes at the Arg1448 location. Two mutations were seen with equal frequency in both
PMC and SCM patients, Val1589Met and changes at the Gly1306 location, although at this
location, substitutions to a valine were more likely to be associated with PMC and those to
alanine more likely to be associated with SCM (Table 5.4). Two patients with PMC from
the same pedigree had one SCN4A mutation and a sequence variant of unknown clinical
significance.
5.1.3 Minimum Prevalence of Periodic Paralysis
Overall, 216 patients from 131 pedigrees had PP, of which 198 were from England giving a
minimum prevalence of 0.37/100,000 (Table 5.1).
5.1.3.1 Minimum Prevalence of HypoPP and HyperPP
95 patients (88 in England) had a diagnosis of HypoPP and 77 (70 in England) of HyperPP,
giving a minimum prevalence of 0.17 and 0.13/100,000 respectively (Figure 5.1). The male
to female ratio for HypoPP was 3.52 and for HyperPP 2.08 (Table 5.1, Figure 5.2). In patients
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Table 5.4: Frequency of common mutations in patients with PMC and SCM a) Frequency
of individual mutations across all patients, b) Frequency of mutations by clinical diagnosis (PMC
versus SCM)
a)	  
	  
b)	  
	  
 
SCN4A mutations 
Clinical diagnosis 
PMC SCM 
         p.Thr1313Met 22 0 
         p.Arg1448Cys/His/Leu 26 2 
         p.Val1589Met 14 13 
         p.Gly1306Alaa/Glu/Val 8 (+1) 8 (+1) 
         p.Leu1436Proa 4 (+2) 1 (+2) 
         p.Ile693Thr 4 0 
         p.Val1293Ile 1 2 
a 1 patient had an overlapping PMC/SCM phenotype 
 
SCN4A mutations 
Patients, n (%) 
(n = 128) 
Pedigrees, n (%) 
(n=70) 
         p.Thr1313Met 22 (17) 15 (21) 
         p.Arg1448Cys/His/Leu 28 (22) 13 (19) 
         p.Val1589Met 27 (21) 11 (16) 
         p.Gly1306Alaa/Glu/Val 17 (13) 9 (13) 
         p.Leu1436Proa 7 (5) 6 (9) 
         p.Ile693Thr 4 (3) 4 (6) 
         p.Val1293Ile 3 (2) 2 (3) 
Non–private mutations present in all patients with PMC, SCM 
a SCN4A mutations associated with an overlapping PMC/SCM phenotype 
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with HypoPP, a total of five different CACNA1S mutations causing HypoPP1 and nine
SCN4A mutations causing HypoPP2 were detected. Of these mutations, six accounted for
86% of pedigrees (Figure 5.3b & c, Figure 5.6a, Table 5.5). Six different SCN4A mutations
were found in patients with HyperPP, of which three accounted for 94% of pedigrees (Figure
5.3b, Figure 5.6b, Table 5.5).
	  
 Patients, n (%) Pedigrees, n (%) 
HypoPP   
    CACNA1S mutations 78 (82) 47 (80) 
         p.Arg528His 34 (36) 24 (41) 
         p.Arg1239His 39 (41) 19 (32) 
         p.Arg1239Gly 3 (3) 2 (3) 
    SCN4A mutations 17 (18) 12 (20) 
         p.Arg1135His 4 (4) 2 (3) 
         p.Arg672His/Ser 4 (2) 4 (7) 
HyperPP   
    SCN4A mutations 77 (100) 48 (100) 
         p.Thr704Met 53 (69) 32 (67) 
         p.Met1592Val 14 (18) 11 (23) 
         p.Arg675Gly 5 (7) 2 (4) 
Non–private mutations present in all patients with HypoPP and HyperPP  
Table 5.5: Frequency of common mutations in patients with HypoPP and HyperPP
5.1.3.2 Minimum Prevalence of ATS
44 patients (40 in England) in 24 pedigrees with ATS were identified with a minimum
prevalence of 0.08/100,000 (Table 5.1, Figure 5.1). All had episodes of weakness with or
without other features of the disorder (cardiac arrhythmias and distinctive physical features).
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Figure 5.6: Pie charts of the distribution of common mutations in periodic paralysis (a) in
Hypokalaemic Periodic Paralysis (b) in Hyperkalaemic Periodic Paralysis
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The male to female ratio was 1.20. 17 different KCNJ2 mutations were detected: three were
present in 42% of pedigrees and the remaining 14 were private mutations.
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5.2 Clinical Phenotype Study of patients with Periodic
Paralysis, PMC and SCM
Overall 220 patients with HypoPP, HyperPP, ATS, PMC and SCM were characterised (Figure
5.7). Comparative studies were then done to identify key differences between the groups.
Patients identi ed
n = 220
Periodic Paralysis
n = 119
HypoPP
n = 50
Non-dystrophic Myotonia
n = 101
HyperPP
n = 36
ATS
n = 33
PMC
n = 85
SCM
n = 16
PMC/HyperPP 
overlap
n=3
Figure 5.7: Flow chart of patients analysed in the clinical phenotypes study.
5.2.1 Distinguishing Clinical Phenotypes in PMC and SCM
5.2.1.1 Demographics
101 patients were identified as having myotonia and variations consistent with either PMC or
SCM. Of these, 82 were classed by the reviewing clinician as having PMC, 3 had a diagnosis
of PMC/HyperPP overlap and 16 as SCM (Figure 5.8). There was an equal distribution of
males and females, with 70 males and 67 females. The median age was 45 years with a range
of 7 to 86 years. All patients with either PMC or SCM had myotonia observed clinically and
electrically.
5.2.1.2 Differences in Groups with and without Weakness
As the traditional differentiation between patients with PMC and SCM is based on the
presence or absence of weakness, I assessed the number of patients classified as PMC or
SCM that had either episodic or fixed weakness. I unexpectedly discovered that 3 (21%)
patients with SCM had episodes of weakness and 27% of PMC patients (18/68) had no
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Patients with SCN4A mutation 
and NDM phenotype
n = 101
Paramyotonia Congenita
n = 82
Sodium Channel Myotonia
n = 16
Weakness
n = 50
HyperPP/PMC overlap
 n = 3
Weakness
n = 3
Insu!  cient clinical data
n = 2
Insu!  cient clinical data
n = 14
No weakness
n = 18
No weakness
n = 11
Figure 5.8: Flow chart of breakdown of patients with PMC and SCM and proportion of
those with weakness.
episodes of weakness, despite traditionally being the key differentiating factor in diagnosing
PMC and SCM (Figure 5.8). Due to these inconsistencies, I performed analysis of patients
according to the presence or absence of weakness (rather than clinician diagnosis), with those
with weakness being assigned a diagnosis of “PMC” and those without weakness assigned
a diagnosis of “SCM”. Data analysis using this breakdown demonstrated no significant
differences between the two groups (Table 5.6).
The median age of onset for both groups was 5.0 years and frequency of attacks were
very similar at 8.2 attacks per week for those with weakness, compared to 6.6 attacks per
week for those without (p=0.621) (Figure 5.9a & b). Paramyotonia, which is thought to
be more frequent in PMC, was very common in both groups, present in 77% (n=24) of
patients with weakness versus 78% (n=14) of patients without weakness (p=0.561)(Figure
5.9e). Patients with PMC have also been reported to be more cold sensitive but in this
group 89% (n=46) of patients with weakness were cold sensitive compared to 96% without
weakness (p=0.214)(Figure 5.9e). Another key factor thought to distinguish these groups
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 n Weakness No weakness P-value 
Number of cases 82 53 29  
Median age of onset of myotonia (range) 71 5.0 (0-58) 5.0 (0-50) 0.937 
Frequency of attacks of myotonia per week (SD) 31 8.2 (5.7) 6.6 (3.7) 0.621 
Severity of myotonia (1-4) (SD) 59 2.7 (0.9) 2.1 (1.0) 0.037 
Distribution of myotonia 
- eyes 69 36 (78) 19 (83) 0.672 
- hands 72 36 (80) 23 (85) 0.580 
- limbs -­‐ arms & legs -­‐ legs only 59  18 (47) 16 (42)  10 (47) 9 (43) 0.999 
- trunk 53 11 (33) 4 (20) 0.296 
Precipitants of myotonia 
- cold 81 46 (89) 28 (96) 0.214 
- exertion 64 36 (90) 20 (83) 0.435 
- rest after exercise 54 15 (41) 7 (41) 0.965 
- carbohydrates 33 3 (14) 0 (0) 0.199 
- potassium 33 3 (13) 0 (0) 0.231 
Relievers for myotonia 
- warmth 19 11 (79) 5 (100) 0.259 
- exercise 11 5 (63) 1 (33) 0.545 
Painful myotonia 50 28 (78) 10 (71) 0.637 
Severity of pain (1-3) (SD) 34 2.2 (0.64) 2.0 (1.1) 0.686 
Improvement with mexiletine 34 21 (96) 10 (83) 0.114 
Examination 
Clinical myotonia 75 48 (100) 27 (100) - 
Eyelid myotonia 71 39 (87) 23 (89) 0.827 
Warm-up myotonia 48 6 (19) 3 (18) 0.885 
Paramyotonia 49 24 (77) 14 (78) 0.977 
Limb hypertrophy 49 16 (49) 8 (50) 0.333 
Investigations 
Creatine Kinase, IU/L (SD) 44 388 (597) 196 (105) 0.485 
Interictal potassium, mmol/L (SD) 42 4.2 (0.4) 3.9 (0.5) 0.059 
Neurophysiology Fournier pattern 
- I 
- III 
- IV 
51  
19 (54) 
15 (43) 
1 (100) 
 
8 (50) 
8 (50) 
0 (0) 
 
EMG myotonia 62 42 (100) 20 (100) - 
Change in EMG with cooling 
- increased myotonia 
- reduced myotonia 
18  
6 (46) 
5 (39) 
 
3 (60) 
0 (0) 
0.218 
Myopathic EMG 27 2 (12) 0 (0) 0.260 
Short exercise test positive 49 7 (21) 6 (37.5) 0.226 
Short exercise test positive following cooling 36 16 (70) 7 (54) 0.346 
Long exercise test abnormal 44 10 (33) 5 (36) 0.877 
MRI abnormal 10 8 (100) 2 (100) - 
Table 5.6: Characteristics of patients with PMC and SCM divided by the presence and
absence of weakness. (Percentages are in brackets unless otherwise indicated. Continuous data
have standard deviation in brackets as indicated)
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was the presence of pain in patients with SCM but I did not see a difference between those
without weakness (71% , n=10) versus those with weakness (78%, n=28) (p=0.637) (Figure
5.9e). The severity of pain was also comparable, with those without weakness having a
mean score of 2.0/3 compared to those with weakness having a score of 2.2/3 (p=0.686).
Interestingly there was also no significant difference in the neurophysiology pattern between
patients in these two groups (p=0.734). There was also no difference in the number of patients
with positive short exercise tests, with 70% (n=16) in those with weakness and 63% (n=10)
in those without (p=0.226) (Figure 5.9e). The percentage decrement in the positive short
exercise tests of both groups was also similar (p=0.337).
The only category in which I detected any difference was in the severity of myotonia.
Severity of myotonia tended to be greater in patients with weakness than without (2.7/4 versus
2.1/4) with a p-value of 0.037, however this difference was not significant when multiple
comparisons were taken into account (Figure 5.9c).
5.2.1.3 Differences in Groups Divided by Fournier Type I and Type III
Classification
As there was no significant phenotypic difference between patients with and without
weakness, I investigated whether splitting patients according to their neurophysiology
patterns may be a better differentiator. All patients, apart from two with the Ile693Thr
variation, had either Fournier type I or type III neurophysiology patterns. The two with
Ile693Thr had type IV patterns, which are commonly seen in patients with a HyperPP/PMC
overlap (Plassart et al., 1996). 29 patients had type I patterns suggestive of a PMC phenotype
and 24 had type III patterns suggestive of a SCM phenotype. Again using this differentiation
the phenotypes of the two groups were the same (Table 5.7). There was no significant
difference in age of onset of myotonia (Figure 5.10a), frequency of myotonia (Figure 5.10b),
sensitivity to cold or presence or severity of pain (Figure 5.10e). Attacks of weakness were
common in both groups, 70% (n=19) of type I versus 65% (n=15) of type III (p=0.697)
(Figure 5.10e). The frequency of paramyotonia on examination was greater in type 1 patients,
83% (19 patients), than in type III, 57% (9 patients), although this did not reach statistical
significance due to the small numbers (0.072) (Figure 5.10e).
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Figure 5.9: Graphs of comparison of phenotypes of myotonic patients with and without
weakness. a) Age of onset of myotonia; b) Frequency of attacks of myotonia per week; c)
Severity of myotonia (score 1-4); d) Creatine kinase levels; e) Key phenotypic comparisons in
patients.
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Figure 5.10: Graphs of comparison of phenotypes of myotonic patients divided by Fournier
type I and type III neurophysiology patterns a) Age of onset of myotonia; b) Frequency of
attacks of myotonia per week; c) Severity of myotonia (score 1-4); d) Interictal potassium levels;
e) Key phenotypic comparisons in patients.
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Table 5.7: Characteristics of patients divided by Fournier type I and type III
neurophysiology patterns (Percentages are in brackets unless otherwise indicated. Continuous
data have standard deviation in brackets as indicated)
 n Type I Type III p-value 
Number of cases 53 29 (53) 24 (44)  
Age of onset of myotonia (median & range) 50 5 (0-48) 5 (0-50) 0.280 
Characteristics of myotonia 
Frequency of attacks of myotonia per week (SD) 30 6.9 (4.0) 8.9 (6.6) 0.472 
Severity of myotonia (1-4) (SD) 48 2.5 (1.0) 2.5 (1.0) 0.940 
Distribution of myotonia 
- eyes 45 18 (72) 15 (75) 0.821 
- hands 48 19 (73) 18 (82) 0.473 
- limbs -­‐ arms & legs -­‐ legs only 43  7 (32) 11 (50)  12 (57) 9 (43) 0.139 
Precipitants of myotonia 
- cold 53 28 (97) 21 (88) 0.214 
- exertion 46 21 (91) 18 (78) 0.218 
- rest after exercise 39 10 (50) 11 (58) 0.621 
- carbohydrates 25 1 (7) 1 (10) 0.763 
- potassium 24 1 (7) 1 (10) 0.803 
Relievers for myotonia 
- warmth 18 11 (92) 4 (67) 0.180 
- exercise 10 3 (60) 3 (60) 1.000 
Painful myotonia 39 17 (81) 14 (78) 0.807 
Severity of pain (1-3) (SD) 29 2.0 (0.8) 2.4 (0.7) 0.195 
Characteristics of attacks of weakness 
Attacks of weakness 50 19 (70) 15 (65) 0.697 
Distribution of weakness in limbs -­‐ arms & legs -­‐ legs only 21  6 (50) 3 (25)  4 (44) 4 (44) 0.812 
Precipitants of attacks of weakness 
- strenuous exercise 26 10 (67) 10 (91) 0.147 
- rest after exercise 21 4 (29) 4 (57) 0.204 
- cold 23 14 (93) 6 (75) 0.214 
- potassium 16 1 (11) 0 (0) 0.362 
Fixed progressive weakness 29 3 (21) 6 (40) 0.280 
Improvement of myotonia with mexiletine 28 17 (85) 8 (100) 0.511 
Examination 
Clinical myotonia 51 27 (100) 24 (100) - 
Eyelid myotonia 48 23 (89) 20 (91) 0.782 
Warm-up myotonia 39 3 (13) 6 (38) 0.075 
Paramyotonia 39 19 (83) 9 (57) 0.072 
Proximal limb weakness 27 1 (10) 2 (12) 0.888 
Limb hypertrophy 39 7 (37) 12 (60) 0.251 
Investigations 
Creatine Kinase, IU/L (SD) 38 303 (463) 287 (221) 0.231 
Interictal potassium, mmol/L (SD) 39 4.1 (0.4) 4.3 (0.4) 0.049 
MRI abnormal 10 5 (100) 5 (100) - 
5.2. Clinical Phenotype Study of Patients with PP, PMC and SCM 115
5.2.1.4 Phenotype of Common Variations in SCN4A
To investigate whether there were any distinctive characteristics for specific genotypes, I
analysed phenotypes of the four main variations present in the cohort of PMC and SCM
patients. I investigated phenotypes for variations at positions Gly1306, Arg1448 and
mutations Thr1313Met and Val1589Met. For variations at position Gly1306, phenotypes
were first analysed individually for the individual mutations Gly1306Ala and Gly1036Val
and as there was no significant difference the data was combined for this analysis. This was
the same for Arg1448Cys and Arg1448His variations. Unlike when comparing PMC and
SCM, there were significant differences seen between the four genotypes as shown in Table
5.8 and distinctive characteristics associated with particular variations.
Firstly, all patients with Arg1448 position variations or Thr1313Met variations were
diagnosed with PMC by their clinician whereas there was a mixture of PMC and SCM
diagnoses for those with Val1589Met and Gly1306 variations. The age of onset of myotonia
in patients with Gly1306 and Val1589Met variations tended to be older (6 years and 5 years
respectively) than Arg1448 and Thr1313Met variations (1 year and 3 years respectively)
although there was not sufficient data to demonstrate a significant difference (p=0.084)
(Figure 5.11a). Warm-up was more common in Gly1306 and Arg1448 variations (67%
in both cases) but again the difference fell short of significance (p=0.051) (Figure 5.12).
Although the majority of patients were sensitive to cold, unusually Gly1306 variations were
also more likely to be sensitive to warmth as well (33%, p=0.042). There were differences
in the factors that relieved myotonia although once corrected for multiple comparisons they
may not be significant (Figure 5.12). No patients reported relief with warmth or exercise
with Val1589Met variations whereas the majority of patients reported this with Gly1306 and
Arg1448 variations. All patients with Thr1313Met improved with warmth but none noticed
an improvement with exercise. There was no significant difference in potassium sensitivity or
in delayed myotonia after exercise. However, those with Gly1306 variations were more likely
to have delayed myotonia than the other genotypes (67% Gly1306 versus 40% Arg1448, 25%
Thr1313Met, 21% Val1589Met) (Figure 5.12, Table 5.8).
The phenotypic analysis showed no significant difference in paramyotonia, pain or
severity of pain between any of the genotypes, although all patients with Gly1306 mutations
had pain and higher pain scores (2.6/3 versus 2.0, 1.8 and 2.1 in Arg1448, Thr1313Met
and Val1589Met) (Figure 5.12, Figure 5.11e). Myotonia was very common in the face in
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Table 5.8: Characteristics of patients with common SCN4A variations. Percentages are in
brackets unless otherwise indicated.(* Indicates significant p-values after Bonferroni correction.
p-values <0.05 in bold. Continuous data have standard deviation in brackets as indicated)
 G1306A/V R1448C/H T1313M V1589M P value 
Number of Cases 9 20 27 18  
Clinician Diagnosis 
- PMC 
- SCM 
 
7 
2 
 
20 
0 
 
27 
0 
 
10 
8 
 
Characteristics of myotonia 
Age of onset of myotonia 
[median] (range) 
6 (0-50) 1 (0-10) 3 (0-9) 5 (0.33 -
14) 
0.084 
Severity of myotonia (1-4) (SD) 2.0 (1) 2.3 (0.9) 2.4 (1.2) 2.3 (0.7) 0.762 
Painful myotonia 7 (100) 5 (71) 10 (77) 7 (64) 0.355 
Severity of pain (1-3) (SD) 2.6 (0.5) 2.0 (0.8) 1.8 (0.6) 2.1 (0.9) 0.195 
Warm-up 4 (67) 4 (67) 3 (21) 2 (18) 0.051 
Location of myotonia 
- Eyes 5 (63) 11 (92) 16 (73) 14 (82) 0.397 
- Hands 7 (88) 14 (82) 18 (78) 14 (88) 0.871 
- limbs -­‐ arms & legs -­‐ legs only -­‐ arms only 
 
4 (50) 
4 (50) 
0 (0) 
 
1 (10) 
5 (50) 
3 (30) 
 
10 (46) 
8 (37) 
2 (9) 
 
10 (67) 
4 (27) 
1 (7) 
0.203 
- trunk 4 (67) 0 (0) 3 (18) 4 (33) 0.023 
Precipitants of myotonia 
- cold 9 (100) 20 (100)  25 (96) 16 (84) 0.122 
- hot 3 (33) 0 (0) 0 (0) 3 (18) 0.042 
- exertion 7 (78) 5(71) 18 (100) 14 (82) 0.177 
Delayed myotonia after exercise 6 (67) 2 (40) 4 (25) 3 (21) 0.116 
Relievers of myotonia 
- warmth 2 (100) 3 (75) 8 (100) 0 (0) 0.037 
- exercise 2 (100) 3 (100) 0 (0) 0 (0) 0.029 
Characteristics of attacks of weakness 
Attacks of weakness 4 (50) 9 (69) 15 (68) 8 (47) 0.458 
Frequency of attacks of paralysis 
per week (SD) 
2.4 (4.0) 3.3 (3.4) 5.9 (6.5) -  0.353 
Duration of attacks of weakness 
in hours (SD) 
0.8 (1.0) 4.9 (8.5) 9.3 (9.7) - 0.107 
Precipitants of weakness 
- strenuous exercise 3 (100) 3 (43) 8 (73) 4 (100) 0.129 
- rest after exercise 1 (33) 3 (50) 3 (33)  -  0.792 
- immobility 0 (0) 3 (75) 1 (14) -  0.047 
- cold 2 (67) 7 (100) 9 (100) -  0.060 
Progressive weakness 2 (33) 2 (33) 5 (50) 0 (0) 0.253 
Improved with mexiletine 5 (100) 4 (100) 9 (90) 8 (100) 0.622 
Examination 
Clinical myotonia 9 (100) 14 (100) 23 (100) 18 (100) - 
Eyelid myotonia 6 (75) 10 (77) 21 (88) 17 (100) 0.190 
Handgrip myotonia 7 (88) 9 (69) 18 (82) 16 (94) 0.331 
Paramyotonia 4 (67) 6 (86) 17 (94) 9 (75) 0.322 
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Table 5.8: Characteristics of patients with common SCN4A variations (cont.)
 G1306A/V R1448C/H T1313M V1589M P value 
Limb weakness 0 (0) 0 (0) 2 (20) 1 (6) 0.435 
Limb hypertrophy 3 (43) 0 (0) 12 (75) 8 (89) 0.001* 
Investigations 
CK, IU/L (SD) 213 (95) 134 (50) 374 (534) 771 (1044) 0.033 
Interictal potassium, mmol/L 
(SD) 
4.2 (0.3) 3.8 (0.5) 4.3 (0.4) 4.2 (0.3) 0.315 
Neurophysiology pattern 
Type I 
Type III 
 
2 (29) 
5 (71) 
 
5 (83) 
1 (17) 
 
12 (86) 
2 (14) 
 
4 (33) 
8 (67) 
0.009 
EMG myotonia 7 (100) 9 (100) 17 (100) 17 (100) - 
Change in myotonia in cold -­‐ Increased -­‐ Reduced  1 (33) 0 (0)  5 (100) 0 (0)  2 (29) 5 (71)  -  0.002* 
Positive short exercise test at 
room temperature 
 
2 (29) 
 
0 (0) 
 
8 (57) 
 
1 (9) 
 
0.019 
Positive short exercise test 
with cooling 
2 (50) 
 
5 (100) 
 
11 (92) 
 
3 (43) 
 
0.035 
 
Abnormal long exercise test 1 (17) 1 (17) 10 (71) 1 (13) 0.011 
Abnormal MRI 3 (100) - 2 (100) 2 (100) - 
 
Figure 5.11: Graphs comparing attacks of weakness and myotonia in the common SCN4A
genotypes. a) Age of onset of myotonia b) Frequency of attacks of weakness c) Duration of
attacks of weakness d) Severity of myotonia (score 1-4) e) Severity of pain (score 1-3)
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Figure 5.12: Graph of key phenotypic comparisons between common SCN4A genotypes (*
indicates significant difference after Bonferroni correction, ° indicates p<0.05 before correction)
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all groups but also frequently seen in the hands. Truncal myotonia was more common in
Gly1306 variation carriers compared with the other variations (p=0.023)(Figure 5.12).
Weakness was reported by patients with all types of variation with a frequency from 47%
to 69% and therefore did not help differentiate between the variations (Figure 5.12). Attacks
of weakness tended to be more frequent and longer in Thr1313Met patients compared with
Arg1448 and Gly1306 variations (Figure 5.11b & c). Strenuous exercise was a common
precipitant in all groups but immobility triggering attacks was most commonly reported in
Arg1448 patients (p=0.047) (Table 5.8).
On examination, limb hypertrophy was more common in Val1589Met and Thr1313Met
patients (p=0.001), which was significant after Bonferroni correction (Figure 5.12). There
were differences in neurophysiology patterns between the mutations. Arg1448 and
Thr1313Met variations had primarily Fournier type I patterns (83% and 86% respectively)
and Gly1306 and Val1589Met variations had primarily type III patterns (71% and 67%
respectively, p=0.009) (Figure 5.12). All patients with Arg1448 variations had increased
electrical myotonia in the cold whereas 71% of Thr1313Met had reduced myotonia in
the cold (p=0.002). Almost all patients with Arg1448 and Thr1313Met had positive short
exercise tests after cooling compared to only half of patients with Gly1306 and Val1589Met
(Figure 5.12). The long exercise test was commonly positive for Thr1313Met patients (71%)
compared with 13-17% of other variations (p=0.011) (Figure 5.12). All MRI scans were
abnormal (Table 5.8).
5.2.1.5 Comparing HyperPP and PMC/SCM patients
Finally to confirm the finding in other studies that there is a significant difference between
HyperPP patients and those with SCM or PMC, I directly compared these two groups. PMC
and SCM groups were combined for this analysis as there was no significant difference
between them. This revealed marked differences between the two groups that were significant
after correction for multiple comparisons (Table 5.9). All patients with PMC/SCM had
myotonia compared with 72% of HyperPP (p<0.0001) (Figure 5.13a). Age of onset was
younger in PMC/SCM patients (5 years versus 8 years) (Figure 5.13b). Severity of myotonia,
presence of paramyotonia and warm-up were all the same in both groups (Figure 5.13c &
d). Patients with PMC/SCM had myotonia sensitive to exertion (88% versus 56%, p=0.004)
and were more likely to have painful myotonia than those with HyperPP (78% versus 30%,
p<0.0001) (Figure 5.13d).
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Table 5.9: Characteristics of patients with PMC/SCM and HyperPP. Percentages are in
brackets unless otherwise indicated. (* Indicates significant p-values after Bonferroni correction.
Continuous data have standard deviation in brackets as indicated)
 n PMC/SCM HyperPP p-value 
Number of cases 137 98 39  
Characteristics of myotonia 
Symptomatic myotonia 130 98 (100) 23 (72) <0.0001* 
Age of onset of myotonia (median & range) 83 5 (0-58) 8 (3-18) 0.087 
Severity of myotonia (1-4) (SD) 76 2.4 (1.0) 2.4 (1.1) 0.796 
Distribution of myotonia 
- eyes 93 63 (82) 11 (69) 0.238 
- hands 98 68 (83) 11 (69) 0.189 
- limbs -­‐ arms & legs -­‐ legs only -­‐ arms only -­‐ none 
78  
32 (47) 
26 (38) 
7 (10) 
3 (5) 
 
6 (60) 
1 (10) 
0 (0) 
3 (30) 
0.024 
Precipitants of myotonia 
- cold 111 88 (93) 15 (94) 0.873 
- exertion 81 57 (88) 9 (56) 0.004 
- rest after exercise 71 21 (38) 3 (20) 0.189 
Painful myotonia 70 39 (78) 6 (30) <0.0001* 
Characteristics of attacks of weakness 
Attacks of weakness 116 49 (66) 39 (100) <0.0001* 
Frequency of attacks per week (SD) 41 3.9 (4.8) 1.0 (2.1) 0.001* 
Duration of attacks of weakness in hours 
(SD) 
49 8.3 (13) 63.4 (89) <0.0001* 
Severity of attacks of weakness (1-4) (SD) 60 1.8 (1.0) 2.4 (0.9) 0.015 
Time of attacks -­‐ on waking -­‐ morning -­‐ night -­‐ anytime 
34  
2 (9) 
3 (13) 
4 (18) 
13 (59) 
 
3 (25) 
5 (42) 
3 (25) 
1 (8) 
0.030 
Distribution of weakness in limbs -­‐ arms & legs -­‐ legs only -­‐ arms only 
61  
12 (50) 
7 (29) 
4 (17) 
 
30 (81) 
7 (19) 
0 (0) 
0.030 
Precipitants 
- strenuous exercise 64 23 (77) 16 (47) 0.015 
- rest after exercise 56 8 (37) 22 (65) 0.038 
- cold 56 22 (92) 14 (44) <0.0001* 
- potassium 49 0 (0) 3 (9) 0.193 
Progressive fixed weakness 62 11 (31) 14 (54) 0.065 
Improvement with mexiletine 44 34 (92) 6 (86) 0.639 
Improvement with acetazolamide 28 3 (43) 16 (77) 0.145 
Examination 
Clinical myotonia 109 82 (100) 21 (78) <0.0001* 
Eyelid myotonia 97 68 (90) 18 (86) 0.631 
Handgrip myotonia 95 63 (85) 6 (29) <0.0001* 
Fixed Proximal Limb Weakness 77 6 (13) 18 (56) <0.0001* 
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Table 5.9: Characteristics of patients with PMC/SCM and HyperPP (cont.)
 n PMC/SCM HyperPP p-value 
Limb appearance -­‐ hypertrophy -­‐ atrophy 67  27 (52) 1 (2)  4 (27) 7 (47) <0.0001* 
Investigations 
CK IU/L (SD) 64 370 (572) 735 (998) 0.026 
Interictal potassium mmol/L (SD) 65 4.1 (0.4) 4.0 (0.5) 0.068 
EMG myotonia 86 67 (100) 16 (84) 0.001* 
Myopathic EMG 46 3 (10) 7 (41) 0.014 
Short exercise test positive 61 13 (27) 1 (8) 0.061 
Short exercise test positive following cooling 47 25 (68) 3 (30) 0.065 
Long exercise test abnormal 59 15 (33) 11 (79) 0.003 
MRI abnormal 13 10 (100) 3 (100) - 
 
Figure 5.13: Graph of comparisons of characteristics of myotonia in HyperPP versus
PMC and SCM a) Presence of myotonia b) Age of onset of myotonia c) Severity of myotonia
(score 1-4) d) Key phenotypic comparisons of characteristics of myotonia (* indicates significant
difference after Bonferroni correction)
As expected, attacks of weakness were present in all HyperPP patients compared with
only 62% PMC/SCM patients (p<0.0001)(Figure 5.14e). The nature of attacks between the
two groups was markedly different, with PMC/SCM patients having more frequent attacks
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Figure 5.14: Graph of comparisons of characteristics of attacks of weakness in HyperPP
versus PMC/SCM a) Frequency of attacks of weakness b) Duration of attacks of weakness
c) Severity of attacks of weakness (score 1-4) d) Creatine kinase levels e) Key phenotypic
comparisons of characteristics of attacks of weakness (* indicates significant difference after
Bonferroni correction)
of weakness (3.9 per week versus 1.0 per week, p=0.001) and much shorter attacks (8.3
hours versus 63.4 hours, p<0.0001) (Figure 5.14a & b). The severity of attacks in HyperPP
was also worse (2.4/3 versus 1.8/3, p=0.015) although not significant after correction (Figure
5.14c). Attacks of weakness in HyperPP tended to occur primarily at night or early morning
whereas with PMC/SCM they could occur at anytime of day (p=0.030). Patients with
PMC/SCM also had focal weakness more commonly than complete weakness of arms and
legs. Interestingly, patients with PMC/SCM were more sensitive to strenuous exercise
(77% versus 47%, p=0.015) whereas patients with HyperPP were more sensitive to rest
after exercise (65% versus 37%, p=0.038) (Figure 5.14e). Although both groups had a
high frequency of sensitivity of myotonia to cold (93% and 94%), patients with PMC/SCM
had more cold-sensitive attacks of weakness compared with HyperPP (92% versus 44%,
p<0.0001) (Figure 5.14e).
On examination hand grip myotonia was much more frequent in PMC/SCM than
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HyperPP (85% versus 29%, p<0.0001) (Figure 5.13d). Fixed proximal limb weakness
was more common in HyperPP patients compared with PMC/SCM (56% versus 13%,
p<0.0001)(Figure 5.14e). Hypertrophy was more common in PMC/SCM whereas atrophy
was more common in HyperPP (Figure 5.14e, Figure 5.13d). On neurophysiology, electrical
myotonia was present in all patients with PMC/SCM but in only 84% of HyperPP (p=0.001).
41% of patients with HyperPP had a myopathic EMG compared with only 10% of PMC/SCM
(Figure 5.13d). The long exercise test was more commonly abnormal in HyperPP (79%) than
in PMC/SCM (33%) but the percentage decrement was not significantly different between
the two groups (Figure 5.14e). All MRIs were abnormal.
5.2.2 Distinguishing Clinical Phenotypes in Periodic Paralysis
5.2.2.1 Demographics
119 patients were identified with PP of which 50 had HypoPP, 36 HyperPP and 33 ATS
(Figure 5.7, Table 5.10). There was a gender bias with approximately two thirds males to
females (81:38). The median age of patients at the time of the study was 43 years with a
range of 8-64 years.
As with other studies, there were significant differences identified between HypoPP,
HyperPP and ATS. Age of onset in HyperPP was noticeably lower than HypoPP (5 years
versus 11.5 years) (p=0.005) but ATS was more intermediate at 8 years (Figure 5.15b). In
all groups there was a male predominance and this was greater in HypoPP with a 3:1 ratio of
males to females (Figure 5.15a). Family history was positive in 90-94% of patients suggesting
an incidence of less than 10% of sporadic cases amongst genetically confirmed individuals.
5.2.2.2 Comparing HypoPP, HyperPP and ATS
There was a difference in the number of patients with HypoPP (98%) compared to HyperPP
(76%) that had documented attacks of complete paralysis from the neck down (p=0.004)
(Figure 5.16). The frequency of all types of attacks were similar between the conditions.
It was greatest for HypoPP (9.9 per month), intermediate for HyperPP (8.8 per month) and
least frequent for ATS (6.9 per month) (Figure 5.15d). There was a significant difference
between maximum attack duration in HypoPP and HyperPP (109 hours versus 88 hours,
p<0.001) and an even greater difference between HyperPP and ATS (163 hours) (Figure
5.15e). During attacks there was a significant difference in ictal serum potassium, with
HyperPP associated with abnormally high potassium (5.16mmol/L), HypoPP associated
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Table 5.10: Characteristics of patients with HypoPP, HyperPP and ATS.Percentages are in
brackets unless otherwise indicated. (* Indicates significant p values after Bonferroni correction.
P-values <0.05 in bold. Continuous data have standard deviation in brackets as indicated)
	   HypoPP	   HyperPP	   ATS	   p-­‐	  value	  Cases	   50	   36	   33	   	  Gender:	  Male	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Female	   38	  (76)	  12	  (24)	   23	  (64)	  11	  (36)	   20	  (61)	  13	  (39)	   	  Age	  of	  onset	  (median,yrs)	   11.5	   5	   8	   0.005	  Attacks	  of	  complete	  paralysis	   48	  (98)	   25	  (76)	   -­‐	   0.004	  Time	  of	  attacks	  (main	  attacks	  at	  night)	   23	  (72)	   6	  (55)	   9	  (56)	   0.425	  Generalised	  episodes	  of	  weakness	   46	  (94)	   28	  (82)	   26	  (93)	   0.191	  
Ictal	  serum	  potassium,	  mmol/L	  (SD)	  	   2.39	  (0.79)	   5.16	  (1.20)	   3.63	  (0.95)	   <0.001*	  
Precipitants	  Strenuous	  exercise	   19	  (54)	   14	  (45)	   21	  (75)	   0.061	  Rest	  after	  exercise	   16	  (46)	   21	  (68)	   15	  (54)	   0.194	  Immobility	   6	  (18)	   15	  (52)	   12	  (43)	   0.013	  Cold	   10	  (29)	   12	  (41)	   9	  (33)	   0.558	  
Carbohydrate	   29	  (81)	   5	  (17)	   12	  (43)	   <0.001*	  High	  potassium	   0	  (0)	   2	  (7)	   2	  (7)	   0.279	  
Relievers	  
Mild	  exercise	   1	  (6)	   7	  (70)	   2	  (40)	   0.002*	  
Potassium	  supplement	   24	  (89)	   0	  (0)	   2	  (67)	   <0.001*	  Glucose	   0	  (0)	   3	  (30)	   0	  (0)	   0.049	  Hospitalisation	  for	  attacks	   18	  (82)	   4	  (33)	   -­‐	   0.037	  Pain	  in	  attacks	   2	  (9)	   5	  (28)	   2	  (15)	   0.289	  
Co-­‐existing	  	  conditions	  
Cardiac	   6	  (18)	   3	  (14)	   19	  (66)	   <0.001*	  Respiratory	   2	  (6)	   3	  (14)	   3	  (19)	   0.384	  Diabetes	   2	  (6)	   2	  (9)	   2	  (13)	   0.743	  Musculoskeletal	   4	  (12)	   9	  (41)	   1	  (7)	   0.011	  
Depression	   0	  (0)	   3	  (16)	   8	  (45)	   0.002*	  
Treatment	  Acetazolamide:	  	  -­‐	  improved	  	  -­‐	  worsened	   	  21	  (72)	  0	  (0)	   	  16	  (84)	  0	  (0)	   	  20	  (91)	  0	  (0)	   	  0.227	  	  Dichlorphenamide:	  	  -­‐	  improved	  -­‐	  worsened	   	  8	  (80)	  2	  (20)	   	  4	  (67)	  1	  (17)	   	  4	  (67)	  0	  (0)	   	  0.355	  	  SandoK:	  	  -­‐	  improved	   	  19	  (95)	   	  -­‐	   	  3	  (100)	   	  0.901	  Potassium-­‐sparing	  agent:	  	  -­‐	  improved	  -­‐	  worsened	   	  5	  (83)	  1	  (17)	   	  -­‐	  	  	  -­‐	   	  3	  (100)	  0	  (0)	   	  0.690	  	  Thiazide	  diuretic:	  	  -­‐ improved	   	  -­‐	   	  6	  (86)	   	  1	  (100)	   	  1.00	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Table 5.10: Characteristics of patients with HypoPP, HyperPP and ATS (cont.)
	   HypoPP	   HyperPP	   ATS	   p-­‐value	  Salbutamol	  -­‐	  improved	   	  -­‐	   	  4	  (80)	   	  -­‐	  	   	  -­‐	  	  Mexiletine	  -­‐	  improved	   	  -­‐	   	  4	  (80)	   	  -­‐	   	  -­‐	  
Examination	  Fixed	  Proximal	  weakness	   	   	   	   	  -­‐ Upper	  limb	   12	  (28)	   10	  (36)	   13	  (46)	   0.280	  -­‐ Lower	  limb	   25	  (58)	   17	  (59)	   19	  (68)	   0.680	  Limb	  appearance	   	   	   	   	  -­‐ Atrophy	   5	  (29)	   7	  (47)	   3	  (14)	   0.025	  -­‐ Hypertrophy	   0	  (0)	   4	  (27)	   6	  (27)	   	  
Clinical	  myotonia	   0	  (0)	   17	  (71)	   0	  (0)	   <0.001*	  
Investigations	  EMG	   	   	   	   	  -­‐ myopathic	   9	  (43)	   6	  (40)	   7	  (32)	   0.743	  -­‐ myotonia	   0	  (0)	   13	  (81)	   0	  (0)	   <0.001*	  Short	  exercise	  test	   	   	   	   	  -­‐ abnormal	  at	  room	  temperature	   0	  (0)	  	   0(0)	  	   0(0)	  	   1.00	  	  -­‐ abnormal	  with	  cooling	   0	  (0)	   3	  (33)	   0	  (0)	   0.068	  Long	  exercise	  test	  -­‐	  abnormal	   	  10	  (67)	   	  10	  (77)	   	  18	  (90)	   	  0.236	  Biopsy	   	   	   	   	  -­‐ abnormal	   9	  (100)	   4	  (80)	   6	  (75)	   0.291	  -­‐ vacuoles	  present	   8	  (89)	   3	  (60)	   1	  (17)	   0.020	  -­‐ tubular	  aggregates	  present	   1	  (13)	   0	  (0)	   2	  (33)	   0.302	  -­‐ “myopathic”	   6	  (67)	   3	  (60)	   1	  (20)	   0.228	  MRI	  legs	  abnormal	   12	  (86)	   3	  (100)	   3	  (100)	   0.621	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Figure 5.15: Graphs of key aspects of attacks of weakness in patients with HypoPP,
HyperPP and ATS. a) Male/female ratios b) Age of onset of attacks of weakness c) Functional
status of patients (mRS) d) Frequency of attacks per month e) Maximum attack duration in hours
f) Severity of attacks (1-4) (* indicates significant difference)
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Figure 5.16: Graph of key phenotypic comparisons between types of periodic paralysis (*
indicates significant difference after Bonferroni correction)
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with abnormally low potassium (2.39mmol/L) and ATS associated with normal potassium
(3.63mmol/L) (p<0.001). There was no difference in the number of patients with generalised
versus focal attacks of weakness between the diseases. Severity of attacks were also similar
(Figure 5.15e)f, Table 5.10).
A number of attack precipitants were investigated. The most significant difference was
seen with carbohydrate loading. Carbohydrate was more likely to precipitate an attack in
HypoPP than in HyperPP or ATS (81% versus 17% versus 43%, p<0.001). Strenuous
exercise was more likely to precipitate attacks in ATS than in HypoPP or HyperPP but this
was not significant (75% versus 54% and 45%, p=0.061) and immobility was more likely to
trigger an attack in HyperPP than HypoPP (52% versus 18%, p=0.013) (Figure 5.16, Table
5.10).
There were significant differences between groups in what factors relieved each disease.
Mild exercise much more frequently improved attacks in HyperPP compared with HypoPP
and ATS (70% versus 40% and 6%, p=0.002). Potassium was more likely to improve attacks
in HypoPP compared to ATS and never improved attacks in HyperPP (89% versus 67%
versus 0%, p<0.001). Glucose only improved attacks in HyperPP but the numbers were
small (p=0.049) (Figure 5.16).
As would fit with the triad of disease in ATS, patients were significantly more likely
to have cardiac disease (p<0.001). They were also more likely to have depression with
45% of patients affected (p<0.002). HyperPP patients, however, were more likely to have
musculoskeletal disease (41%, p<0.011) (Table 5.10).
When response to treatment was analysed, a large proportion of patients reported
improvement with acetazolamide, especially amongst those with ATS (91%) (Figure
5.16). Fewer patients had tried dichlorphenamide but the numbers that noted improvement
were similar. Oral potassium improved 95-100% of patients with HypoPP or ATS. A
potassium-sparing diuretic also improved symptoms in 5 out of the 6 patients with HypoPP
who tried it (Table 5.10).
Examination findings only revealed a small number of differences. Functional status,
measured by mRS score, was similar through the groups with most scoring close to 1 (no
significant disability, able to carry out all usual activities despite some symptoms) (Figure
5.15c). Presence of fixed proximal weakness was similar in all groups although marginally
more common in ATS. MRC scoring of power was also very similar. The biggest difference
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was in clinical myotonia which was only seen in HyperPP (p<0.001). There was also a
difference in numbers with atrophy and hypertrophy of muscles. Surprisingly, not only
patients with HyperPP but also ATS had hypertrophy. As expected patients with HypoPP
had atrophy but more patients with HyperPP had atrophy (29% versus 47%) and few patients
with ATS had atrophy (14%) (p=0.025) (Figure 5.16, Table 5.10).
On neurophysiology there was, as expected, a marked difference in myotonia with it
present in 81% of patients with HyperPP and no patients with HypoPP or ATS (Figure 5.16).
There was no significant difference between the number of patients with myopathy on EMG
and no difference in short or long exercise testing results although they were more likely to
be positive in ATS (90%) than in HypoPP (67%) and HyperPP (77%) (Figure 5.16). There
was no significant difference in the percentage decrement either although again in ATS there
was more likely to be a greater decrement. Biopsy results were abnormal in the majority of
patients (100% HypoPP, 80% HyperPP and 75% ATS). The only notable difference was in
the presence of vacuoles which were commoner in HypoPP and ATS than HyperPP (89%
& 60% versus 17%, p=0.02) (Figure 5.16). MRI scans were also abnormal in the majority
of patients (86% HypoPP and 100% HyperPP and ATS) although numbers were very small
(Table 5.10).
5.2.2.3 HypoPP1 versus HypoPP2
I compared the phenotypes of HypoPP1 and HypoPP2 but there were only 9 cases of
HypoPP2 allowing for only a trend analysis rather than true statistical comparison (Table
5.11). Age of onset for HypoPP2 was younger (8.6 versus 12.4 years) (Figure 5.17a).
Frequency of attacks was similar but maximum attack length was more variable and tended to
be longer in HypoPP2 (Figure 5.17b & c). However the severity of actual attacks were similar
(ictal potassium was similarly low in both groups) (Figure 5.17f). Common precipitants were
similar between the groups but potassium was more likely to improve episodes of weakness
in HypoPP1 than HypoPP2 (96% versus 60%, p=0.023) (Figure 5.18). Proximal weakness
was equally common in the two diseases but age of onset of proximal weakness was earlier
in HypoPP2 than HypoPP1 (26 years versus 41 years) (Figure 5.17d, Figure 5.18).
There was a notable difference in response to treatment. Acetazolamide was much less
likely to improve attacks in HypoPP2 than HypoPP1 (33% versus 83%, p=0.016) (Figure
5.18). The response to dichlorphenamide was better although two patients did worsen with
treatment (Table 5.11). There was also a difference in functional status with, on average,
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Table 5.11: Characteristics of patients with HypoPP1 and HypoPP2. (Percentages are in
brackets unless otherwise indicated. Continuous data have standard deviation in brackets as
indicated)
	   HypoPP1	   HypoPP2	   p-­‐value	  Number	   41	   9	   	  
Characteristics	  of	  Attacks	  Age	  of	  onset	  in	  yrs	  (SD)	   12.4	  (9.8)	   8.6	  (8.8)	   0.189	  Frequency	  of	  major	  attacks	  per	  year	  (SD)	   12.3	  (25)	   10.5	  (20)	   0.910	  Maximum	  attack	  length	  in	  hours	  (SD)	   28.7	  (24)	   153	  (218)	   0.455	  Generalised	  (vs	  focal)	  weakness	  during	  attacks	   37	  (93)	   9	  (100)	   0.396	  Ictal	  potassium	  level,	  mmol/L	  (SD)	   2.37	  (0.67)	   2.50	  (1.25)	   0.810	  
Precipitants:	  Cold	   8	  (29)	   2	  (29)	   1.00	  Immobility	   6	  (21)	   0	  (0)	   0.211	  Rest	  after	  exercise	   14	  (50)	   2	  (29)	   0.309	  Strenuous	  exercise	   15	  (54)	   4	  (57)	   0.865	  
Relievers:	  Potassium	   21	  (96)	   3	  (60)	   0.023	  Hospitalisations	  with	  attacks	   15	  (68)	   3	  (75)	   0.786	  Pain	  during	  attacks	   2	  (12)	   0	  (0)	   0.421	  Severity	  of	  attacks	  (1-­‐4)	  (SD)	   2.7	  (1.1)	   3.2	  (0.7)	   0.229	  Proximal	  weakness	   15	  (47)	   5	  (63)	   0.429	  Age	  of	  onset	  of	  proximal	  weakness	  in	  yrs	  (SD)	   41	  (17)	   26	  (12)	   0.165	  	  
Treatment	  Improvement	  with	  acetazolamide	   19	  (83)	   2	  (33)	   0.016	  Dichlorphenamide	  -­‐ improved	   	  5	  (100)	   	  3	  (60)	   	  0.114	  -­‐ worsened	   0	  (0)	   2	  (40)	   	  
Examination	  Functional	  status	  mRS	  (0-­‐6)	   0.5	  (1.0)	   1.7	  (1.7)	   0.037	  Muscle	  atrophy	   2	  (17)	   3	  (60)	   0.074	  Proximal	  weakness	   	   	   	  -­‐	  upper	  limb	   8	  (24%)	   4	  (44%)	   0.214	  -­‐	  lower	  limb	   19	  (56%)	   6	  (67%)	   0.560	  
Investigations	  
Bloods	  CK,	  IU/L	  (SD)	  	   200	  (105)	   420	  (293)	   0.126	  Interictal	  potassium,	  mmol/L	  (SD)	  	   4.32	  (0.41)	   4.20	  (0.37)	   0.531	  
Neurophysiology	  Myopathic	  EMG	   5	  (31)	   4	  (80)	   0.055	  Long	  exercise	  test	  abnormal	   7	  (70)	   3	  (60)	   0.699	  Long	  exercise	  test	  percentage	  decrement	  (SD)	   	  48	  (20)	   	  40	  (16)	   	  0.441	  Abnormal	  biopsy	   6	  (100)	   3	  (100)	   -­‐	  Abnormal	  MRI	   8	  (80)	   4	  (100)	   0.334	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patients with HypoPP2 having some disability and those with HypoPP1 being normal or
having no significant disability (Figure 5.17e). This was not however reflected in MRC
scores.
Figure 5.17: Graph of comparisons of attacks of weakness in HypoPP1 versus HypoPP2 a)
Age of onset b) Maximum attack length in hours c) Frequency of major attacks per year d) Age
of onset of proximal weakness e) Functional status, mRS (0-6) f) Severity of attacks (0-4)
HypoPP2 patients were more likely to have myopathic EMGs (80% versus 31%). Long
exercise tests and the percentage decrement were very similar and all patients that had
biopsies had abnormalities noted (Figure 5.18).
5.2.2.4 Genotype-Phenotype Correlations in HypoPP
The commonest variants identified in patients with HypoPP were Arg1239His and
Arg528His. I therefore compared the data for these two variations to identify any
distinguishing features. Overall, the variations had very similar phenotypes (Table 5.12).
The key difference was in age of onset, with Arg1239His begin associated with a younger
age of onset (11.4 years) when compared with Arg528His (13.4 years) patients (p=0.006)
(Figure 5.19a). Although the frequency of severe attacks was greater in Arg1239His the
duration and frequency of minor attacks were similar (Figure 5.19b & c). Similar to the
variation in age of onset between the two groups, the age of onset of proximal weakness
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Figure 5.18: Graph of key phenotypic comparisons between HypoPP1 and HypoPP2
was earlier in Arg1239His (28.3 years versus 44.7 years, p=0.05) (Figure 5.19e). Severity of
attacks was similar between the two groups (Figure 5.19f).
Sensitivity to different precipitants was similar in the two groups. The only differences
were in sensitivity to carbohydrates and stress (Figure 5.20). All patients with Arg1239His
were sensitive to carbohydrates, compared with 69% of patients with Arg528His (p=0.036).
64% of Arg1239His patients were sensitive to stress compared with 8% of Arg528His.
Arg1239His patients were also more sensitive to rest after exercise (73% versus 33%) (Figure
5.20). Investigation results between the two groups were very similar, however those with
Arg1239His were more likely to have a myopathy on EMG (80% versus 14%, p=0.023)
(Figure 5.20).
5.2.2.5 Genotype-Phenotype Correlations in HyperPP
The main variants identified in patients with HyperPP were Thr704Met and Met1592Val
(Table 5.13). The age of onset of attacks was younger for Thr704Met (4.2 years) than
Met1592Val (9.5 years) (p=0.027) (Figure 5.21a). Although severity of attacks was similar,
the duration of attacks in Met1592Val was notably longer (147.4 hours versus 38.7 hours,
p=0.032) (Figure5.21c). The most marked difference in precipitants was in strenuous
exercise, which was more commonly a precipitant in Met1592Val (86% versus 28%,
p=0.009); and illness which was also more likely to precipitate attacks in this group of
patients (Figure 5.21d). Progressive weakness was more common in Thr704Met patients
although not significantly different (Figure 5.21d, Table 5.13).
Stiffness was more common in patients with Met1592Val mutations and tended to be
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Table 5.12: Characteristics of patients with HypoPP variations Arg528His and Arg1239His
(Percentages are in brackets unless otherwise indicated. Continuous data have standard deviation
in brackets as indicated. p-values<0.05 in bold, * indicates significant difference after Bonferroni
correction)
	   Arg528His	   Arg1239His	   p-­‐value	  Number	   19	   17	   	  
Age	  of	  onset,	  yrs	  (SD)	   13.4	  (4.7)	   11.4	  (14.7)	   0.006	  Frequency	  of	  severe	  attacks	  per	  year	  (SD)	   2.6	  (3.6)	   22.4	  (34.0)	   0.203	  Frequency	  of	  minor	  attacks	  per	  month	  (SD)	   8.4	  (9.7)	   10.4	  (11.5)	   1.000	  Maximum	  attack	  length	  in	  hours	  (SD)	  	   28.8	  (24.8)	   32.5	  (25.2)	   0.718	  Generalised	  (vs	  focal)	  weakness	  during	  attacks	   19	  (100%)	   14	  (93%)	   0.253	  Ictal	  potassium	  level,	  mmol/L	  (SD)	   2.50	  (0.63)	   2.17	  (0.86)	   0.331	  
Precipitants:	  Cold	   3	  (25%)	   5	  (46%)	   0.304	  Immobility	   2	  (17%)	   3	  (27%)	   0.538	  Rest	  after	  exercise	   4	  (33%)	   8	  (73%)	   0.059	  Strenuous	  exercise	   7	  (58%)	   6	  (55%)	   0.855	  
Carbohydrates	   9	  (69%)	   12	  (100%)	   0.036	  
Stress	   1	  (8%)	   7	  (64%)	   0.005	  
Relievers:	  Potassium	   11	  (100%)	   9	  (100%)	   -­‐	  Hospitalisations	  with	  attacks	   8	  (89%)	   7	  (64%)	   0.194	  Pain	  during	  attacks	   1	  (14%)	   1	  (14%)	   1.000	  Severity	  of	  attacks	  (1-­‐4)	  (SD)	   2.8	  (0.9)	   2.7	  (1.2)	   0.693	  Proximal	  weakness	   4	  (31%)	   9	  (60%)	   0.122	  
Age	  of	  onset	  of	  proximal	  weakness,	  yrs	  
(SD)	  
44.7	  (5.7)	   28.3	  (12.7)	   0.050	  
Treatment	  Improvement	  with	  acetazolamide	   11	  (92%)	   7	  (78%)	   0.368	  Improved	  with	  Daranide	   1	  (100%)	   4	  (100%)	   -­‐	  Functional	  status	  (0-­‐4)	   0.4	  (1.1)	   0.7	  (0.9)	   0.135	  Muscle	  atrophy	   2	  (40%)	   0	  (0%)	   0.067	  Proximal	  weakness	   	   	   	  -­‐	  upper	  limb	   3	  (20%)	   3	  (20%)	   1.000	  -­‐	  lower	  limb	   7	  (47%)	   9	  (60%)	   0.464	  Bloods	   	   	   	  CK,	  IU/L	  (SD)	  	   208	  (123)	   234	  (64)	   0.573	  Interictal	  potassium,	  mmol/L	  (SD)	   4.30	  (0.44)	   4.25	  (0.36)	   0.640	  
Neurophysiology	   	   	   	  
Myopathic	  EMG	   1	  (14%)	   4	  (80%)	   0.023	  Long	  exercise	  test	  abnormal	   2	  (67%)	   4	  (80%)	   0.673	  Long	  exercise	  test	  percentage	  decrement	  (SD)	  	   56%	  (22%)	   48%	  (21%)	   0.655	  Abnormal	  MRI	   2	  (67%)	   3	  (75%)	   0.809	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Figure 5.19: Graph of comparisons of attacks of weakness in patients with HypoPP with
mutations Arg528His and Arg1239His a) Age of onset b) Frequency of severe attacks per year
c) Maximum attack length in hours d) Ictal serum potassium level e) Age of onset of proximal
weakness f) Severity of attacks (0-4)
Figure 5.20: Graph of key phenotypic comparisons between Arg528His and Arg1239His
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Table 5.13: Characteristics of patients with HyperPP variations Thr704Met and
Met1592Val (Percentages are in brackets unless otherwise indicated. Continuous data have
standard deviation in brackets as indicated. P-values<0.05 in bold, * indicates significant
difference after Bonferroni correction)
	   Thr704Met	   Met1592Val	   p-­‐value	  Number	  of	  cases	   22	   8	   	  Age	  of	  onset	  of	  attacks,	  yrs	   4.2	  (4.2)	   9.5	  (5.6)	   0.027	  Attacks	  of	  complete	  paralysis	   16	  (76%)	   8	  (100%)	   0.129	  Frequency	  of	  major	  attacks	  per	  year	  (SD)	   48.5	  (103)	   27.2	  (32)	   0.864	  Maximum	  duration	  of	  attacks	  in	  hours	  (SD)	   38.7	  (40)	   147.4	  (137)	   0.032	  Severity	  of	  attacks	  (1-­‐4)	  (SD)	   2.4	  (0.8)	   2.3	  (1.1)	   0.511	  Focal	  attacks	  of	  weakness	  in	  limbs	   4	  (20%)	   1	  (12.5%)	   0.707	  
Precipitants	  -­‐	  strenuous	  exercise	   5	  (28%)	   6	  (86%)	   0.009	  -­‐	  rest	  after	  exercise	   14	  (78%)	   4	  (57%)	   0.302	  -­‐	  cold	   4	  (25%)	   4	  (57%)	   0.136	  -­‐	  potassium	   2	  (12.5%)	   0	  (0%)	   0.328	  Progressive	  weakness	   9	  (64%)	   2	  (29%)	   0.122	  Hospitalisations	  for	  attacks	   2	  (40%)	   1	  (33%)	   0.850	  Myotonia	   8	  (50%)	   7	  (88%)	   0.074	  Severity	  of	  myotonia	  (1-­‐4)	  (SD)	   1.6	  (0.9)	   2.2	  (1.1)	   0.356	  Distribution	  of	  myotonia	  -­‐	  eyes	   5	  (100%)	   1	  (20%)	   0.010	  -­‐	  hands	   3	  (60%)	   4	  (80%)	   0.490	  Precipitants	  of	  myotonia	  -­‐	  cold	   4	  (100%)	   5	  (83%)	   0.389	  -­‐	  hot	   0	  (0%)	   1	  (20%)	   0.343	  -­‐	  exertion	   2	  (50%)	   4	  (67%)	   0.598	  -­‐	  rest	  after	  exercise	   0	  (0%)	   2	  (33%)	   0.197	  Abnormal	  early	  milestones	   1	  (33%)	   0	  (0%)	   0.273	  Improvement	  with	  acetazolamide	   10	  (77%)	   4	  (100%)	   0.290	  
Examination	  Clinical	  myotonia	   9	  (64%)	   4	  (67%)	   0.919	  Eyelid	  myotonia	   8	  (89%)	   4	  (80%)	   0.649	  Handgrip	  myotonia	   1	  (11%)	   2	  (40%)	   0.207	  Functional	  status	  (0-­‐4)	  (SD)	   1.0	  (1.3)	   0.3	  (0.6)	   0.386	  Limb	  Weakness	   13	  (72%)	   2	  (33%)	   0.088	  
Limb	  appearance:	  -­‐ hypertrophy	   4	  (44%)	   0	  (0%)	   0.002*	  -­‐ atrophy	   5	  (56%)	   0	  (0%)	  Reduced	  or	  absent	  reflexes	   5	  (38.5%)	   0	  (0%)	   0.264	  
Investigations	  CK,	  IU/L	  (SD)	   597	  (492)	   1307	  (1778)	   0.739	  Interictal	  potassium,	  mmol/L	  (SD)	   4.01	  (0.57)	   3.95	  (0.41)	   0.826	  EMG	  myotonia	   4	  (57%)	   4	  (100%)	   0.125	  Myopathic	  EMG	   4	  (57%)	   1	  (33%)	   0.490	  Short	  exercise	  test	  positive	   0	   0	   -­‐	  Short	  exercise	  test	  positive	  with	  cooling	   1	  (33%)	   2	  (100%)	   0.136	  Long	  exercise	  test	  abnormal	  -­‐	  %	  decrement	  (SD)	   4	  (80%)	  61%	  (23%)	   2	  (50%)	  48%	  (11%)	   0.343	  0.439	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Figure 5.21: Graph of comparisons of attacks of weakness in patients with HyperPP with
mutations in Thr704Met and Met1592Val a) Age of onset b) Maximum attack length in hours c)
Severity of attacks (0-4) d) Key phenotypic comparisons of characteristics of attacks of weakness
(* indicates significant difference after Bonferroni correction, ° indicates p<0.05)
more symptomatic in the hands than the eyes compared with Thr704Met (p=0.010) (Figure
5.22b). However, on examination, eyelid myotonia was equally present in both groups
and an equal proportion of patients had myotonia on examination. Warm-up was noted
in some patients with Met1592Val but not in those with Thr704Met where paramyotonia
predominated. Precipitants of myotonia were similar between the two groups (Figure 5.22b).
Limb weakness was more common in Thr704Met and as a result these patients tended to
have a poorer functional status. They had a significant number of patients with hypertrophy
and atrophy (p=0.002), compared with none of the patients with Met1592Val (Figure 5.22b,
Table 5.13).
5.2.2.6 ATS Phenotypes
Data from 33 ATS patients was analysed. All patients had episodes of paralysis, 61% had
cardiac symptoms related to ATS and all patients had skeletal abnormalities. Amongst this
group, the commonest presenting system was paralysis (88%). Age of onset of paralysis
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Figure 5.22: Graph of comparisons of characteristics of myotonia in patients with HyperPP
with mutations in Thr704Met and Met1592Val a) Severity of myotonia (0-3) b) Key phenotypic
comparisons of characteristics of myotonia (* indicates significant difference after Bonferroni
correction, ° indicates p<0.05)
was younger than onset of cardiac symptoms (9.9 years versus 12.9 years) (Table 5.14). The
phenotype of attacks of paralysis are described in Section 5.2.2.2.
The commonest cardiac symptoms were palpitations (94%), with almost half having
syncopal events (43%) but only one reporting a cardiac arrest. Two patients had severe
enough arrhythmias to require a pacemaker and implantable cardioverter defibrillator. 50%
of patients were on at least one cardiac treatment, of which a quarter were on more than
one treatment. The commonest treatment was beta blockers, which was prescribed in 83% of
those on medication. Despite only 61% of patients having cardiac symptoms, 85% of patients
had an abnormal electrocardiogram (ECG). The commonest abnormality was an abnormal U
wave although a third of patients also had frequent ventricular ectopics. The average QTc
interval was at the upper limit of normal for both men and women. A third of patients had
abnormal 24 hour ECGs and 23% had abnormal echocardiograms (Table 5.14).
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Table 5.14: Characteristics of patients with ATS. (Percentages are in brackets unless otherwise
indicated. Continuous data have standard deviation in brackets as indicated)
	  	   N	  (%)	  Number	   33	  Episodes	  of	  paralysis	   33	  (100)	  Cardiac	  symptoms	   17	  (61)	  Dysmorphism	   27	  (100)	  Presenting	  Symptom	   	  -­‐ Paralysis	   29	  (88)	  -­‐ Cardiac	   4	  (12)	  Age	  of	  onset	  	  of	  paralysis,	  yrs	  (SD)	   9.9	  (5.7)	  Age	  of	  onset	  of	  cardiac	  symptoms,	  yrs	  (SD)	   12.9	  (8.9)	  Palpitations	   16	  (94)	  Syncope	   6	  (43)	  Cardiac	  arrest	   1	  (7)	  PPM/ICD	   2	  (14)	  Severity	  of	  cardiac	  symptoms	   	  -­‐ mild	   4	  -­‐ mild-­‐moderate	   4	  -­‐ moderate	   2	  -­‐ severe	   2	  Learning	  difficulties	   4	  (27)	  Memory	  impairment	   5	  (36)	  Depression	   8	  (45)	  Dysmorphisms	   	  -­‐ low	  set	  ears	   17	  (71)	  -­‐ hypertelorism	   13	  (57)	  -­‐ micrognathia	   20	  (83)	  -­‐ cleft	  palate	   2	  (8)	  -­‐ high	  arched	  palate	   3	  (13)	  -­‐ micromelia	   15	  (63)	  -­‐ clinodactyly	   18	  (75)	  -­‐ syndactyly	  -­‐ short	  stature	   5	  (22)	  9	  (36)	  Number	  on	  cardiac	  treatment	   12	  (50)	  Abnormal	  ECG	   23	  (85)	  ECG	  abnormalities	  -­‐	  U	  waves	  -­‐	  Premature	  ventricular	  contractions	  -­‐	  Abnormal	  QTc	  -­‐	  Borderline	  QTc	  -­‐	  QTc	  interval,	  ms	  (SD)	  	  	  -­‐	  male	  	  	  -­‐	  female	  
	  17	  (81)	  7	  (32)	  1	  (5)	  8	  (38)	  	  425	  (20)	  447	  (6)	  Abnormal	  24hr	  ECG	   7	  (32)	  Abnormal	  Echocardiogram	   3	  (23)	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The incidence of cognitive and psychiatric problems in this group was high. 27% had
learning difficulties of varying severity, 36% reported memory impairment and almost half
had a history of depression. The pattern of skeletal abnormalities were variable but the
majority had micrognathia, low set ears, clinodactyly, micromelia and hypertelorism. All
patients who had abnormal features had a minimum of two features identified although on
average four different features were noted (Table 5.14).
5.2.3 Anaesthetics & Pregnancy in Channelopathy Patients
109 patients with genetically confirmed channelopathies responded to the survey. 51% were
female and 48% were male. 25 patients had MC, 37 had PMC, 13 HypoPP, 23 HyperPP and
12 ATS (Figure 5.23a). The median age of respondents was 47.5 years (Table 5.15).
5.2.3.1 Anaesthetics in Channelopathy Patients
Overall, 70 patients had been given local anaesthetic, either via direct injection or through
a spinal or epidural injection. Of the 70 who had received local anaesthetic, 15 (21%)
expressed having a problem with either or both direct injection or spinal/epidural injection.
The most common problem being that the local anaesthetic was ineffective (10 patients). Four
patients described the effect of the local anaesthetic as being prolonged. Two suggested that
it worsened their symptoms, one of whom felt it triggered a prolonged attack of weakness
and the other felt it worsened their myotonia (Figure 5.23b). Of those patients who had
problems with local anaesthetic, two patients who had not had a problem with direct injection,
experienced a problem with spinal/epidural injection, one reporting a prolonged effect of
spinal anaesthetic after back surgery and the other reporting ineffective epidural during
childbirth. One patient who had received both epidural and local anaesthetic injection
reported a prolonged effect of the anaesthetic after both procedures (Table 5.15). When
dividing patients up according to disease type there was a very similar percentage of those
with NDM and those with PP who found local anaesthetic was ineffective. All patients who
found the effect of anaesthetic was prolonged had NDM (Figure 5.23d, Table 5.16).
71 patients received general anaesthetic at some point in their life. Of these, 22
(31%) reported a problem with general anaesthetic, either with prolonged recovery (41%)
or worsening symptoms (45%). None reported MH-like reactions. The remaining three
patients had respiratory arrest, cardiac complications and a reaction to propofol (Figure 5.23c,
Table 5.15). When dividing up the data by disease group, problems with general anaesthetic
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Table 5.15: Table of problems encountered by patients following local and general
anaesthetics 	   Number	  (%)	  Total	  respondents	   109	  Diagnosis	  -­‐ Myotonia	  congenita	   25	  -­‐ PMC/SCM	   37	  -­‐ HyperPP	   13	  -­‐ HypoPP	   23	  -­‐ ATS	   12	  Gender	  -­‐ Male	   43	  (48%)	  -­‐ Female	   57	  (51%)	  Median	  age	  (range)	   47.5	  (18-­‐80)	  
Local	  Anaesthetic	  Exposed	  to	  local	  anaesthetic	  	  (via	  direct	  injection	  or	  spinal/epidural)	   70	  Problems	  with	  injection	  of	  local	  anaesthetic	   13	  (19%)	  Local	  anaesthetic	  ineffective	   9	  (69%)	  Local	  anaesthetic	  prolonged	   3	  (23%)	  Worsened	  symptoms	   2	  (15%)	  Number	  had	  spinal/epidural	   16	  	  Problems	  with	  spinal/epidural	   3	  (19%)	  Spinal	  ineffective	   1	  Spinal	  prolonged	   2	  
General	  Anaesthetic	  Exposed	  to	  General	  Anaesthetic	   71	  Problems	  with	  General	  Anaesthetic	   22	  (31)	  GA	  ineffective	   0	  GA	  prolonged	   9	  	  GA	  worsened	  symptoms	   10	  Malignant	  Hyperthermia-­‐like	  reaction	   0	  	  
Table 5.16: Table of problems reported by muscle channelopathies patients following local
and general anaesthetics in individual channelopathy disease groups
	   MC	   PMC/SCM	   HyperPP	   HypoPP	   ATS	  
Local	  Anaesthetic	  Problems	  with	  LA	   4	  (19%)	   6	  (35%)	   1	  (14%)	   2	  (13%)	   0	  (0%)	  Ineffective	  LA	   3	   4	   1	   1	   	  Prolonged	  LA	   1	   2	   0	   0	   	  
General	  Anaesthetic	  Problems	  with	  GA	   5	  (31%)	   6	  (30%)	   3	  (38%)	   5	  (31%)	   3	  (27%)	  Prolonged	  GA	   3	  (19%)	   4	  (21%)	   0	  (0%)	   1	  (7%)	   1	  (9%)	  GA	  worsened	  symptoms	   3	  (19%)	   1	  (6%)	   2	  (29%)	   3	  (20%)	   1	  (9%)	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Figure 5.23: Graphs of problems reported by patients following anaesthetics. a) Distribution
of channelopathy patients within the survey b) Problems reported with local anaesthetics c)
Problems reported with general anaesthetics d) Problems with local and general anaesthetic split
according to disease group
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were more common in those who had NDM. Results for worsening symptoms were similar
between the two groups (Figure 5.23d, Table 5.16).
5.2.3.2 Pregnancy in Channelopathy Patients
Overall 35 women responded to questions about pregnancy, of which 25 had at least 1
pregnancy. 29 men also supplied information about conception and numbers of children
conceived. 30 patients also gave information regarding the effect of menstruation on their
channelopathy (Table 5.17).
In total 42 patients had tried to conceive, of which 25 were women and 17 were men.
Of these, 8 (22%) patients had problems trying to conceive. A similar proportion of men and
women had difficulty conceiving, 3/15 men and 5/21 women. The average time to conceive
for those with difficulties was 28 months compared to 3 months for those with no difficulties.
Patients did not qualify why they had difficulties conceiving (Table 5.17). There was no
significant difference in difficulty conceiving between patients with NDM and PP (Figure
5.24a).
In total, 87 children were born to patients with channelopathies of which 57 were born
to female patients with channelopathies. There were 114 pregnancies overall of which 84
were in females with channelopathies. Of the 27 pregnancies that were not viable, three
were elective terminations of pregnancy and 24 were miscarriages from nine women. Of the
miscarriages that patients gave information about, only three were after the first trimester. No
information was given about the possible causes of miscarriages. There was no significant
difference between miscarriage rates in any of the diseases (Figure 5.24b, Table 5.18).
Overall 12 patients reported problems in pregnancy and 12 reported problems during
delivery. The commonest complication in pregnancy was urinary tract infection (four
patients). Two patients had gestational hypertension, one pre-eclampsia and one gestational
diabetes (Figure 5.25a). One patient had a stillbirth. Problems during delivery included
six emergency caesarean-sections, six deliveries requiring forceps or ventouse, and seven
premature births. There were three postpartum haemorrhages and one placental abruption
(Figure 5.25c). Four babies were reported to have neonatal problems, three of which had
PMC or SCM and were reported to have either been floppy or have breathing problems
(Figure 5.25b, Table 5.18).
Pregnancy worsened channelopathy symptoms in a significant number of patients with
MC, PMC and HyperPP (Figure 5.24d). It affected 50% of patients with HypoPP and
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Table 5.17: Table of pregnancy and births in channelopathy patients
	  
	   Number	  (%)	  Number	  of	  pregnancies	  overall	   110	  Number	  of	  children	  overall	   87	  Average	  number	  of	  children	   2.0	  Average	  number	  of	  pregnancies	   2.5	  Problems	  trying	  to	  conceive	   8	  (22%)	  Time	  taken	  to	  conceive	  (SD)	   7.7	  months	  (13.4)	  Number	  of	  patients	  with	  miscarriages	   9	  (35%)	  Total	  number	  of	  miscarriages	  	   24	  
Stage	  of	  miscarriage	  -­‐ 1st	  trimester	   10	  -­‐ 2nd	  trimester	   3	  -­‐ 3rd	  trimester	   0	  
Problems	  in	  pregnancy	   12	  	  Pre-­‐eclampsia	   1	  Hypertension	   2	  Gestational	  diabetes	   1	  UTI	   4	  
Problems	  in	  delivery	   12	  Emergency	  C-­‐section	   6	  Forceps	   5	  Ventouse	   1	  Post-­‐partum	  Haemorrhage	   3	  Placental	  abruption	   1	  Stillbirth	   1	  Uterine	  rupture	   1	  Premature	  births	  (<38wks)	   7	  Post-­‐natal	  problems	   4	  Floppy	  baby	   1	  Breathing	  difficulties	   3	  
Change	  in	  channelopathy	  -­‐ better	   3	  (8%)	  -­‐ worse	   29	  (76%)	  -­‐ unchanged	   6	  (16%)	  
When	  symptoms	  changed	  -­‐1st	  trimester	   1	  -­‐2nd	  trimester	   1	  -­‐3rd	  trimester	   3	  
Symptoms	  changed	  in	  pregnancy	  -­‐ myotonia	   15	  (79%)	  -­‐ weakness	   7	  (39%)	  -­‐ pain	   6	  (38%)	  Symptoms	  settled	  after	  birth	   17	  (90%)	  
Time	  to	  settle	  symptoms	  -­‐ immediately	   7	  (54%)	  -­‐ <1	  month	   4	  (31%)	  -­‐ 1-­‐3	  months	   1	  -­‐ >3	  months	   1	  Worsening	  in	  symptoms	  with	  menses	   15	  (50%)	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Figure 5.24: Graphs of problems in pregnancy and birth in individual channelopathies a)
Difficulties with conception b)Miscarriages c)Problems during delivery d)Proportion of patients
in whom pregnancy worsened symptoms e) Specific symptoms that worsened in pregnancy
improved symptoms in three patients with PP. It did not improve symptoms in any patients
with NDM (Figure 5.25d). Only one patient with PMC did not improve symptoms after
delivery. 54% of patients improved immediately after delivery (Figure 5.25e). In MC and
PMC, pregnancy primarily worsened stiffness (Figure 5.24e). Menstruation worsened the
channelopathy symptoms in over half of MC, PMC and ATS patients. It was less likely
to affect HyperPP and HypoPP patients. None of the patients felt that it improved their
symptoms (Table 5.18).
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Figure 5.25: Graphs of problems in pregnancy and birth in all channelopathy patients
a) Problems encountered during pregnancy b) Problems with babies at birth c) Problems
encountered at delivery d) Change in channelopathy symptoms during pregnancy e) Timescale
for improvement of worsening symptoms after childbirth.
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Table 5.18: Table of pregnancy and births in individual channelopathy disease groups
	   MC	   PMC/SCM	   HyperPP	   HypoPP	   ATS	  Number	  of	  respondants	   15	  	   12	   4	   10	   4	  Number	  of	  female	  respondants	  who	  have	  been	  pregnant	   5	   9	   4	   6	   1	  Number	  of	  pregnancies	   42	   28	   6	   42	   3	  Number	  of	  children	   33	   23	   6	   19	   3	  Problems	  trying	  to	  conceive	   2	  (14%)	   3	  (33%)	   1	  (25%)	   1	  (17%)	   1	  (22%)	  >	  1	  year	  to	  conceive	  	   1	   2	   0	   0	   1	  Number	  of	  patients	  with	  miscarriages	   3	  (60%)	   3	  (33%)	   0	  (0%)	   3	  (43%)	   0	  (0%)	  Miscarriages	  after	  1st	  trimester	   1	   1	   0	   1	   0	  Problems	  in	  pregnancy	   2	  (40%)	   4	  (44%)	   2	  (67%)	   3	  (50%)	   1	  (100%)	  Problems	  during	  delivery	   3	  (60%)	   5	  (56%)	   2	  (67%)	   1	  (17%)	   1	  (100%)	  Assisted	  delivery	   1	   4	   0	   2	   -­‐	  Premature	  birth	   0	   4	   1	   1	   1	  Postnatal	  problems	   1	   3	   0	   0	   0	  Floppy	  baby	   0	   1	   0	   0	   0	  Neonatal	  Breathing	  difficulties	   0	   3	   0	   0	   0	  
Pregnancy	  worsen	  
channelopathy	  (p=0.022)	  
3	  (80%)	   19	  (95%)	   4	  (80%)	   3	  (50%)	   	  0	  (0%)	  Stiffness	  worsened	   3	  	   9	  	   2	   1	   -­‐	  Weakness	  worsened	   0	   2	   2	   3	   -­‐	  Pain	  worsened	   1	   4	   0	   1	   -­‐	  Menses	  worsened	  channelopathy	   3	  (50%)	   8	  (67%)	   2	  (40%)	   1	  (20%)	   1	  (50%)	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5.3 Genetic Diagnosis in Skeletal Muscle Channelopathy
Patients
As described in the methods section, three distinct groups of patients were analysed (Figure
4.1, p 77). The targeted sequencing group consisted of nine patients from four pedigrees seen
in the channelopathy service who had an unusual phenotype. These patients had strategic
sequencing of relevant genes.
The second group, the MLPA group, consisted of 60 patients with either a single loss of
function mutation or no mutations with a recessive MC phenotype. They had MLPA analysis
to look for large scale deletions and duplications.
The final next generation sequencing group, consisted of 10 patients with no mutations
but clinical and electrical evidence of a skeletal muscle channelopathy. They went on to have
whole exome sequencing, and if sufficient DNA remained, aCGH.
5.3.1 Targeted Sequencing in Patients with Unusual Phenotypes
Nine patients from four pedigrees were identified as having unusual phenotypes. Two of
these families had a pathogenic variation already identified but when assessed clinically had
a severe atypical phenotype. Following further strategic gene analysis further variations were
found in all patients.
5.3.1.1 Case 1
Case 1 was a family with marked variation in phenotypes between two branches of the same
family. One branch having a particularly severe presentation and unusual neurophysiology
findings.
Phenotype of the Family
The proband was female and initially presented with marked stiffness from the age of 4
years, primarily of the hands and eyes. It later progressed to affect the throat, arms and legs.
It was markedly exacerbated by cold but there was never any accompanying weakness. It
partially responded to treatment with mexiletine and was severely exacerbated during the
second trimester of pregnancy. There was a strong dominant family history as shown in the
pedigree (Figure 5.27). On examination she had generalised muscle hypertrophy and grip,
eyelid and percussion myotonia.
Her investigations demonstrated a mildly elevated CK of 391IU/L. Her neurophysiology
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Figure 5.26: Graph of short exercise test results of Case 1 and relative V.7
testing demonstrated profuse myotonia but had an atypical pattern on short exercise testing.
At room temperature, she had very little decrement with initial exercise but with repeated
exercise in the third and fourth trials demonstrated mild worsening. However in the fifth
and sixth trials of exercise she then showed warm-up (not shown in the figure). However,
after cooling, there was a marked decrement, especially after fourth and fifth trials of
exercise (Figure 5.26). Paradoxically this improved with repeated exercise after rewarming
although, despite rewarming, the limb did not recover back to normal. MRI of the calves and
thighs demonstrated moderate fatty infiltration in the tibialis anterior and the gastrocnemius
bilaterally. Short tau inversion recovery (STIR) sequences demonstrated oedema of the
medial head of the gastrocnemius (Figure 5.28).
The proband’s mother (IV.6) was affected in early childhood. She also had primarily leg
stiffness, worse in the cold. She, like her daughter, had a severe exacerbation in pregnancy
and again later in life when she took hormone replacement therapy. On examination she
had generalised muscle hypertrophy and hand grip myotonia. She was noted to also have
moderate myotonia on EMG when assessed previously (Table 5.19).
The proband’s daughter (VI.1) was severely affected from 6 months old. She had eye
and hand stiffness which was improved with mexiletine treatment. On examination she had
generalised muscle hypertrophy, a stiff gait and eyelid and hand grip myotonia. Her CK was
slightly elevated at 376IU/L and had profuse myotonia on EMG (Table 5.19).
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Figure 5.27: Pedigree of Case 1. (Black arrow indicates the proband. Green indicates
those carrying the Gly1306Val variation in SCN4A. Red indicates those carrying the Ala313Val
variation in CLCN1. Black band indicates patients thought to be affected but not genetically
analysed)
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Figure 5.28: MRI of calves of proband in Case 1 a) T1 MRI of calves demonstrating muscle
hypertrophy b) STIR MRI of calves demonstrating oedema primarily in the medial gastrocnemius
(indicated by red arrows)
The proband’s cousin (V.7) was also found to be affected but with much milder
symptoms. We were able to assess her after she had marked worsening in the third trimester
of pregnancy. She had onset in late childhood with mild cramping and stiffness primarily
after running. She would most frequently develop stiffness after exercise, affecting her eyes,
hands, legs and face. They were significantly worsened by cold. Her mother (IV.7) and
brother (V.8) were also mildly affected. When examined during pregnancy she had moderate
grip and eyelid myotonia with no proximal weakness or hypertrophy. Her EMG demonstrated
profuse myotonia in all tested muscles. Her short exercise test demonstrated an increment
with subsequent trials of exercise rather than a decrement with less of an increment following
cooling (Figure 5.26). Her mother (IV.7) also had a history of stiffness in late childhood with
mild eye stiffness which was worsened by cold (Table 5.19).
Genotype of Case 1
Initial genetic analysis of the proband revealed a known pathogenic variation in CLCN1,
c.938C>T; p.Ala313Val in exon 8 which is commonly associated with dominant MC.
However, given the marked severity of symptoms, which is unusual in dominant MC,
and the predominance of eyelid myotonia and cold-sensitivity, we also sequenced SCN4A.
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   Gender	   Age	   Onset	  of	  
symptoms	  
Symptoms	   Signs	  
Family	  branch	  1	  
V.5	  
Proband	  	  (Case	  1)	  
♀	   52yrs	   4yrs	  old,	  	  
Hand	  stiffness	  
Stiffness	  worst	  in	  cold.	  
No	  weakness	  
Severe	  exacerbation	  in	  
pregnancy	  (2nd	  trimester)	  
Now	  unable	  to	  work.	  
Generalised	  muscle	  
hypertrophy	  
Hand	  grip,	  eyelid	  &	  
percussion	  myotonia	  
VI.1	  
Daughter	  of	  
proband	  
♀	   27yrs	   6	  months	  old,	  
Eye	  &	  hand	  stiffness	  
Severe	  myotonia,	  
improved	  with	  mexiletine	  
Generalised	  muscle	  
hypertrophy,	  	  
Stiff	  gait	  
Eyelid	  &	  hand	  grip	  
myotonia	  
IV.6	  
Mother	  of	  
proband	  
♀	   73yrs	   Early	  childhood,	  
Leg	  stiffness	  
	  
Moderate	  myotonia,	  
Severe	  exacerbation	  in	  
pregnancy	  &	  after	  HRT	  
	  
Proximal	  muscle	  
hypertrophy	  	  
Hand	  grip	  myotonia	  
Family	  branch	  2	  
V.7	  
Cousin	  of	  proband	  
♀	   40yrs	   Late	  childhood,	  
Eye	  and	  hand	  
stiffness	  
Mild	  myotonia	  
Exacerbated	  by	  cold	  
Worsened	  in	  pregnancy	  
Hand	  grip	  &	  eyelid	  
myotonia	  
IV.7	  
Aunt	  of	  proband	  
♀	   67yrs	   Late	  childhood,	  
Eye	  stiffness	  
Mild	  myotonia	  
Exacerbated	  by	  cold	  
Eyelid	  myotonia	  
Founders	  
III.3	  
Grandfather	  of	  
proband	  
♂ Died	   	   Severe	  myotonia	   Grip	  myotonia	  
EMG	  myotonia	  
III.4	  
Grandmother	  of	  
proband	  
♀ Died	   	   Mild	  myotonia	   Eyelid	  myotonia	  
EMG	  myotonia	  
	  
Table 5.19: Clinical details of the family members in Case 1
We discovered a second known pathogenic variation, c.3917G>T; p.Gly1306Val which is
associated with PMC, suggesting that the combination of variations are responsible for the
unusual phenotype. When the proband’s mildly affected cousin and aunt were tested they
were found to only carry the c.3917G>T; p.Gly1306Val variation. It was later established
that both the proband’s grandparents were thought to be affected, not just the grandfather
(III.3), although the grandmother (III.4) was only mildly affected (Figure 5.27).
5.3.1.2 Case 2
Case 2 was a consanguineous family with evidence of myotonia but also unusual features of
proximal weakness and arrhythmias in some family members.
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Phenotype of the Family
Proband: was a 36 year old Pakistani male, who first noticed symptoms at the age of 15
when he had an episode of muscle stiffness after a prolonged fever. His stiffness was present
in the hands, limbs and axial muscles and warmed-up with repetitive movement. Prior to
this he reached normal developmental milestones and was able to function normally but had
always noticed that his muscles were bulky. At the age of 19 years he started to notice
difficulty climbing stairs which gradually progressed. Over time he developed difficulty
lifting heavy objects. He did not have a history of palpitations but did develop excessive
daytime somnolence and memory loss in the 5 years prior to presentation. He came from a
large consanguineous family with first cousin marriages over many generations (Figure 5.29).
He and his wife (IV.6) were second cousins both through his paternal and maternal lines. Four
of his five children were symptomatic with muscle stiffness and weakness as described below.
His youngest child (VI.5) was unaffected. His father (IV.1) had a history of palpitations and
type 2 diabetes mellitus and his mother (III.1) had cataracts and daytime somnolence. His
paternal grandfather (III.5) had increased muscle bulk but no history of stiffness.
On examination he had generalised muscle hypertrophy and significant grip and limb
myotonia with warm-up. He had mild neck flexion weakness and shoulder abduction
weakness (grade 4 MRC). He had severe proximal leg weakness (hip extension grade 3 MRC,
hip flexion and knee flexion grade 4- MRC). Deep tendon reflexes were normal. He did not
have cataracts or frontal balding and his ECG was normal. EMG showed profuse myotonic
discharges with a normal long exercise test and cold immersion exercise testing.
Proband’s daughter (VI.1): The proband’s 16 year old daughter (VI.1) had a normal
neonatal period but was a late walker, walking at two years. At four years she had difficulty
climbing stairs. At five years she noticed mild stiffness, especially in the legs and hands. In
the few years prior to presentation, she developed progressive leg weakness and difficulty
running. At the age of 14 she began to have episodes of palpitations with dizziness, nausea
and chest pain. She was subsequently diagnosed with a supraventricular tachycardia on
Holter 24 hour ECG monitoring. She had also noted increased daytime somnolence. As
described above she came from a large consanguineous family (Figure 5.29). Her parents
were second cousins but her mother (IV.6) was unaffected. All her mother’s siblings had
a history of early cataracts in their 40s. Her mother’s brother (IV.7) was married to her
father’s paternal first cousin (V.7) and one of their four children (VI.7) also had stiffness
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Figure 5.29: Pedigree of Case 2 Green represents Ala566Thr variation in CLCN1 (quarter-filled
= heterozygous, half-filled = homozygous). Red represents pathological expansion in ZNF9
consistent with DM2.
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with no weakness. On examination she had increased muscle bulk with both eyelid and
grip myotonia with warm-up. She had mild proximal muscle weakness with grade 4 MRC
shoulder abduction weakness and grade 4- MRC hip flexion weakness. She had profuse
myotonic discharges on EMG. Her standard 12 lead ECG was normal.
Proband’s eldest son (VI.2): The proband’s 14 year old son (VI.2) had a normal
neonatal period but had congenital dislocation of the left hip at 18 months which was
surgically reduced at two years. He walked late, after 2 years, as a result of the hip problems
but was always able to run and jump. He had difficulty with handwriting due to stiffness but
never had weakness. On examination he had grip myotonia with warm-up. He had normal
tone, power and deep tendon reflexes. He had a normal ECG and echocardiogram. EMG
demonstrated occasional myotonic discharges.
Proband’s second son (VI.3): The proband’s 10 year old son (VI.3) was also a late
walker at two years. He noticed stiffness and falls at seven years. He later developed pain
on chewing. He was always able to run and jump. On examination he had calf hypertrophy
and vitiligo. He had very mild grip and eyelid myotonia with warm-up and was the least
severely affected of the proband’s affected children. EMG demonstrated occasional myotonic
discharges.
Proband’s third son (VI.4): The proband’s eight year old son (VI.4) walked at one
year but had a mild speech delay. He noted stiffness of grip and limbs in early childhood with
frequent falls and clumsiness. He always had problems at school with poor attention and
disruptive behaviour. He had one episode of palpitations at five years old but had a normal
ECG and echocardiogram. On examination he had significantly increased muscle bulk and
grip and eyelid myotonia. Tone, power and reflexes were normal. EMG showed occasional
myotonic discharges.
Genotype of case 2
Given the phenotypes suggestive of recessive MC the service laboratory sequenced all exons
of CLCN1 revealing a homozygous mutation in exon 15, c.1696G>A;p.Ala566Thr in the
proband. This homozygous mutation was also found in the proband’s children (VI.1, VI.2,
VI.3 and VI.4). The reportedly affected wife’s nephew (VI.7) also carried this homozygous
mutation. The unaffected wife (IV.6) and unaffected youngest child (VI.5) were heterozygous
for this mutation (Figure 5.29).
Given the unusual phenotype with proximal weakness and cardiac arrhythmias, and
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the variability in phenotype between the children, DNA was sent for sequencing of DM1
and DM2. The proband and two of his children, VI.1 and VI.4 (the more severely affected
children) were all found to have relatively small DM2 expansions of approximately 81 CCTG
repeats. Children VI.2, VI.3 and unaffected child VI.5 did not have abnormal expansions,
consistent with their milder MC phenotypes.
Expression of the Variation
As Ala566Thr has not been previously described as causing MC it was expressed in Xenopus
oocytes by R.Mannikko to assess its pathogenicity. In contrast to WT CLC-1 channels,
homomeric Ala566Thr channels (homA566T) displayed no or very small voltage dependent
currents when expressed in Xenopus oocytes (Figure 5.30). Only 2 of 12 cells displayed
voltage dependent currents. Mean maximal amplitude of these currents was -1.3±0.1A
compared to mean maximal amplitude of WT currents -8.7±0.6A (n=13). When WT
and Ala566Thr RNA was injected in 1:1 ratio to simulate the heterozygous state found
in the unaffected family members, the resulting currents were significantly smaller than
the WT currents with a mean maximal amplitude of -5.9 ±0.6A, n=10 (p<0.005). The
voltage dependence of the WT and heterozygous Ala566Thr were similar (WT: -33.2
±3.0mV, heterozygous Ala566Thr: -28.2±2.6mV, p=0.23). The findings that homomeric
Ala566Thr channels display no or tiny measurable currents, the fact that current amplitude
of heterozygous Ala566Thr is greater than half of the WT currents, and that coexpression of
A566T with WT had no effect on voltage dependence of the channel activation are all typical
for a recessive ClC-1 mutation (Wollnik et al., 1997). These results fit with the clinical picture
seen in this family of unaffected heterozygous carriers and affected homozygous carriers.
5.3.1.3 Case 3
Case 3 was of two brothers with symptoms suggestive of a sodium channelopathy with an
alternative final diagnosis.
Phenotype of Case 3
The proband was a 25 year old male who was the product of a normal pregnancy and delivery.
He was not floppy at birth. He walked late at 3 years, and had multiple falls, difficulty rising
from seated and was slower at running than peers at school. At age 3.5 years he had a
muscle biopsy which was reported to have non-specific findings. He then improved and
developed normally until 10 years when he began to have progressive gait difficulties, and
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Figure 5.30: Functional expression of wild-type ClC-1 and Ala566Thr mutation by
whole-cell patch clamp of Xenopus Oocytes a-c) Representative whole-cell two-electrode
currents recorded from intact Xenopus oocytes heterologously expressing wild-type, homA566T
or hetA566T channels. Voltage steps from -150 to + 90 mV are shown. The first 2ms of the
capacitative current peaks of each voltage step are not shown. d) Current-voltage relationship
of WT (solid circles, n=13), hetA566T (open circles, n=10) and homA566T channels (open
squares, n=12). The data were fitted to Boltzmann equation with values, WT: I0= -0.8µA, Imax=
-8.6µA, V1
2
= -35.8mV, dV=27.1mV, hetA566T I0=-0.6µA, Imax=-5.9µA, V1
2
=-32.2mV, dV=25.5
mV, homA566T curve was drawn by eye. e) Same as in (d) but the data was normalized to Imax for
WT and hetA566T channels to illustrate similar voltage dependence and similar minimal offset
current. (figure courtesy of R.Manniko)
could only walk short distances with a stick and needed a wheelchair for long distances.
His repeat muscle biopsy, however, was unchanged. Again at 18 years his symptoms settled
and he began to steadily improve, he no longer needed a stick to mobilise. At presentation
his primary complaints were of stiffness and pain especially with prolonged sitting or cold,
and improved with walking. He had occasional episodes of legs giving way and suddenly
becoming weak in the cold. He had tiredness & lethargy with exertion but no association
with carbohydrate meals or bananas. He had no diplopia or dysarthria. His was one of four
siblings and his younger brother was also severely affected (Figure 5.31).
His examination was normal with no proximal weakness or myotonia. His investigations
demonstrated a raised CK at 647IU/L. Electrophysiology demonstrated a positive McManis
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Figure 5.31: Pedigree for Case 3 Black squares indicate affected individuals, arrow indicates
proband.
with 44% decrement from the peak amplitude (although there was only a 12% decrement
from the baseline) (Figure 5.32a). On short exercise testing there was a drop in CMAPs with
exercise, however there was an increase in area suggesting an alteration in the morphology
of the curves with cooling rather than a true decrement. There was no myotonia or myopathy
on EMG. MRI of the lower limbs demonstrated mild fatty infiltration in the thighs and
calf. There was high signal on STIR suggesting oedema present mainly in the soleus in
the calves, subtly in the anterior compartment of the thighs and more significantly in the
posterior compartment of the thighs (Figure 5.33).
The proband’s brother was a 16 year old boy who was also the product of a normal
pregnancy but with a delivery complicated by meconium aspiration with foetal distress.
He was in special care intensive baby unit for 8 days requiring nasogastric feeding but no
ventilation. He also had significantly delayed milestones with delayed standing at 1 year and
walking at 20 months with a waddling gait. At 2 years he started to have multiple falls and
difficulty rising from a seated position and was unable to climb stairs. He had a biopsy at
3 years which demonstrated non-specific abnormalities with type 1 fibre predominance and
normal immunohistochemistry. Initially he was less affected than the proband. As he grew up
he was noted to have mild learning and communication difficulties and then slowly became
more progressively weak and by age 10 he was predominantly using a wheelchair but with
some variability from day to day. He was always able to swim unaided. He would have
attacks of weakness precipitated by cold and these would last for minutes. He had no cardiac
abnormalities but 78% predicted FVC on spirometry. On examination he had a thoracolumbar
scoliosis and proximal limb weakness to MRC grade 3 in the upper and lower limbs.
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Figure 5.32: Case 3 Neurophysiology a) Long exercise test demonstrating significant decrement.
b) Single fibre EMG of trapezius demonstrating jitter
Genotype of Case 3
Given the electrophysiology findings and the periodic nature of the symptoms, the proband
had sequencing of SCN4A, CLCN1, DM1 and 2 and RYR1. No pathogenic mutations
were identified. Given the unusual phenotype he had further EMG with repetitive
stimulation and single fibre studies which demonstrated an abnormal decrement and jitter
in the trapezius muscle (Figure 5.32b). Both subjects went on to have screening of
the congenital myasthenia genes which revealed compound heterozygous variations in
DOK7. The c.1124 1127dupTGCC;p.Leu375fs, which is a known pathogenic mutation
and c.533-37 c.533-11del27 which encompasses a consensus branch point and therefore
may lead to aberrant splicing (Alamut v1.5). This was carried by both the proband and his
brother and given their phenotypes, is likely to account for their disease. Both individuals
were therefore started on salbutamol treatment, which significantly improved their symptoms,
adding weight to the theory that the DOK7 variations were causative.
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ai)
bi)
ii)
ii)
R L
R L
Figure 5.33: MRI of proband in Case 3 ai) T1 MRI of calves demonstrated mild fatty infiltration
primarily in soleus (indicated by red arrow) aii) STIR MRI of calves demonstrating high signal
suggestive of oedema primarily in soleus (indicated by yellow arrow), bi) T1 MRI of thighs
demonstrating very subtle fatty infiltration of the posterior compartment, bii) STIR MRI of thighs
with oedema in the posterior compartment and subtle oedema in the anterior compartment
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5.3.1.4 Case 4
Case 4 was a patient with a complex mixed phenotype with features of periodic paralysis and
congenital myasthenia.
Phenotype of Case 4
The 55 year old proband was born 7 weeks premature and required special schooling. In
childhood he had difficulty rising from the floor and climbing up stairs. He also had difficulty
with running and was poor at sports at school and had always noted fatiguability. In his
second decade he began to have episodes of paralysis, usually with no precipitant. These
would consist of myalgia and then marked leg weakness and respiratory compromise lasting
usually two to seven days. He had a number of occasions when he was so severely affected
that he required intubation and ventilation. He often lost his ability to swallow during
these attacks. He also had more frequent minor episodes of weakness of his neck or arm.
He would have episodes of pharyngeal weakness that required use of a gastrostomy tube
when prolonged. He had a history of hyperthermia reactions to anaesthetic in the past
often accompanied by an episode of paralysis. His other medical history included an atrial
septal defect that was closed, mild mitral valve prolapse, type II diabetes mellitus and atrial
flutter which resolved following DC cardioversion. His parents were unaffected, he had
three siblings, his older sister developed scoliosis at 5 years requiring surgery and had been
diagnosed with fibromyalgia but she had otherwise normal development and her examination
was normal. His sister’s two children were unaffected.
On examination he was mildly dysmorphic and had pes cavus. He had a convergent
strabismus and complex ophthalmoplegia on examination. He had poor eye abduction
bilaterally, limited upgaze and partially limited downgaze. He had mild facial weakness
and neck flexion and extension weakness. He had proximal muscle atrophy and weakness
of shoulder abduction with MRC grade 4 and hip flexors of MRC grade 3 but had
calf hypertrophy. He was areflexic and sensation was preserved. His FVC was 1.85L
(approximately 50% predicted).
His investigations revealed normal routine bloods with a CK just above normal at
247IU/L. His ECG demonstrated first degree heart block. His 24 hour ECG revealed
intermittent Wenckebach and a broad complex tachycardia. An echocardiogram showed mild
bi-atrial dilatation with normal left ventricular diastolic and systolic function, mild bi-leaflet
mitral valve prolapse with mild to moderate mitral regurgitation.
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Figure 5.34: Case 4 Long exercise test
His electrophysiology was very interesting. The EMG was myopathic but with no
myotonia. He had a markedly abnormal long exercise test with a decrement of 59% (Figure
5.34) but normal short exercise tests both at room temperature and cooling. Repetitive
stimulation was normal and single fibre EMG revealed some mild abnormalities in orbicularis
oculi which was in keeping with the severity of the ophthalmoplegia making it less likely to
be a primary neuromuscular junction disorder. However, as a result he had antibody testing
for anti-acetylcholine receptor antibodies, anti-MuSK antibodies and anti-voltage-gated
calcium channel antibodies, all of which were negative. The muscle biopsy showed a
myopathy with core-like structures and Type I fibre predominance (Figure 5.35). MRI of
the calves demonstrated moderate fatty infiltration of tibialis anterior and soleus bilaterally
and hypertrophy of the lateral head of the gastrocnemius (Figure 5.36). He had trialled a
number of treatments including pyridostigmine and mexiletine, neither of which improved
symptoms and acetazolamide which had improved his attacks of weakness.
Genotype of Case 4
The patient therefore had testing of all exons in SCN4A, S4 segments of CACNA1S and
all exons of KCNJ2 which were all normal. Given the decrement seen on single fibre he
was also screened for CHRNE, DOK7, RAPSN, CHRNA1, CHRNB1, CHRND, COLQ and
CHAT none of which revealed pathogenic variations. Given his malignant hyperthermia
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a b
c d
Figure 5.35: Case 4 Biopsy a) Haematoxylin and eosin stain demonstrating variation in fibre size
and shape and internalised central nuclei b) NADH stain demonstrating type 1 fibre predominance
and presence of core-like structures (indicated by red arrow) c) SDH stain demonstrating the
core-like structures (indicated by red arrow) d) ATPase stain demonstrating core-like structures
visible in the type 1 fibres corresponding to areas of myofibrillar disruption within the type 1
fibres (indicated by red arrow)(images supplied by F.Jaffer)
reaction he was then screened for RYR1 variations and found to have three variations: a
heterozygous variation in exon 3, c.208C>T;p.Gln70X, the c.325C>T;Arg109Trp in exon 4
and the c.1453A>G;p.Met485Val variation. The Gln70X variation results in a premature stop
codon and therefore is likely to be pathogenic. The Arg109Trp variation has been previously
reported in a patient with a core myopathy and has been shown to affect the function of
the RYR1 protein making it also highly likely to be pathogenic (Zhou et al., 2006). The
Met485Val variation, has been reported as being in cis with the Arg109Trp mutation with
unknown significance. Given the patient’s phenotype these variations are highly likely to
represent the underlying cause of his symptoms.
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a)
b)
c)
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Figure 5.36: Case 4 MRI of calves a) T1 MRI of calves showing fatty infiltration primarily of
the soleus (indicated by red arrows), b) STIR MRI of calves, c) T1 MRI coronal section of calves
demonstrating hypertrophy of the calves.
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5.3.2 Diagnosing Patients with Single Mutations in CLCN1 using
MLPA
Overall MLPA was performed on 60 patients from the UK and Sicilian cohorts. 4 out of
the 60 (6.7%) displayed altered peak ratios consistent with whole or partial exon deletion or
duplication (Figure 5.37). The clinical details of each of these patients are described in Table
5.20.
Overall in the group of recessive patients with a single mutation, I identified exon
deletions in two patients (6%). No large scale rearrangements were detected in the 12
mutation negative patients. In the group of patients with apparently homozygous mutations,
two out of 16 had abnormal peak ratios on MLPA. I also identified one false positive result
in a patient who was apparently homozygous for a previously described 14 base pair deletion
in exon 13, c.1437 1450del;p.[Pro480fs] (Meyer-Kleine et al., 1994). MLPA identified
a relative peak ratio of 0 for exon 13, indicating a homozygous deletion of this exon.
However, as the 14 base pair deletion mutation encompasses part of the MLPA exon 13 probe
recognition site this most likely results in the loss of probe binding, rather than representing
a true exon deletion.
No rearrangements were detected in CLCN1 by MLPA in the 124 control chromosomes
analysed suggesting that exon deletions and duplications are not common in the normal
population.
5.3.2.1 Patient 5
Phenotype of Patient 5
Patient 5 was an Italian male with muscle stiffness and difficulty walking from age 12
that progressed to marked disability by late teenage years. He experienced the warm-up
phenomenon and had a significant improvement in stiffness with mexiletine. The pedigree
was consistent with recessive inheritance, with his parents and sibling unaffected. On
examination there was marked calf hypertrophy and generalised limb percussion myotonia
but no weakness.
His investigations demonstrated a CK of 576IU/L. EMG showed frequent myotonic
potentials and short exercise testing was consistent with a Fournier type II pattern (Figure
5.38a). MRI of the patient’s calf showed high signal on the STIR images bilaterally in the
lower part of the medial head of the gastrocnemius with normal signal on T1-weighted images
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a)
c)
Control Exon 8 Exon 9 Exon 10
Exon 8 Exon 9 Exon 10 Exon 11 Exon 12 Exon 13 Exon 14
Exon 17 Exon 18 Exon 19 Exon 20 Exon 21 Exon 22
Exon 7
Exon 16
Exon 7
d)
b)
Exon 15
Exon 23
Figure 5.37: Relative MLPA probe heights in patients with large scale alterations (Red peaks
represent average peak height of target probes from reference samples; blue peaks represent peak
height of target probes in patient samples) (a) Control sample MLPA: both peaks are of equal
height, representing normal copy number for that exon. (b) Patient 5: exons 8-10 have probe ratios
of approximately 0.5 representing a heterozygous deletion. (c) Patients 7 & 8: exons 8-14 have
probe ratios of >1.8, representing a homozygous duplication (4 copies of each exon). (d) Patient
6: exons 17-22 have probe ratios of approximately 0.5 representing a heterozygous deletion.
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Table 5.20: Clinical details and genetic results of patients with confirmed exon deletions
or duplications in the MLPA study (* sequence variant - non-pathogenic mutation based on
expression studies)
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indicating the presence of oedema in that muscle (Figure 5.39).
Genotype of Patient 5
Altogether the clinical picture and pedigree were consistent with recessive MC, DNA
sequencing of CLCN1 identified a heterozygous intronic point mutation, c.1167-10T>C; p.?,
which has previously been described in recessive pedigrees (Trip et al., 2008). This mutation
did not lie within the MLPA probe binding region for exon 11. MLPA identified peak ratios
of approximately 0.5 in exons 8, 9 and 10 (Figure 5.37b). Exons 7 and 11 had normal peak
ratios. This data is consistent with a contiguous deletion of exons 8-10. Break point analysis
performed by the lab confirmed the deletion as c.854-363 1077del;p.?
5.3.2.2 Patient 6
Phenotype of Patient 6
Patient 6 was a 13 year old Polish boy with generalised stiffness from childhood and warm-up
phenomenon. His paternal grandfather was reported to have grip stiffness, but a clinical
examination report from Poland of the asymptomatic father was negative for both clinical and
electrical myotonia. The mother was also asymptomatic by her own history and on clinical
examination. A half-sister and half-brother on the maternal side were clinically unaffected.
On examination there was calf hypertrophy and generalised percussion myotonia but no
weakness. Investigations demonstrated a normal CK and the EMG demonstrated myotonia.
Genotype of Patient 6
The patient’s pedigree and clinical phenotype were consistent with recessive MC.
CLCN1 sequencing of the patient’s DNA identified the previously published mutation
c.2680C>T;p.Arg894X (George et al., 1994). The unaffected mother carried the Arg894X
mutation only. The father was not resident in the UK and therefore it was not possible to test
him. MLPA in the patient identified a contiguous deletion of exons 17-22 with a minimum
size of 4901-9268 base pairs (Figure 5.37d).
5.3.2.3 Patient 7
Phenotype of Patient 7
Patient 7 was a female patient from Northern Iraq with muscle stiffness and warm-up from
infancy. She had also developed mild proximal weakness in childhood. Her three siblings
and father were similarly affected. In addition, four out of seven of her father’s siblings
had similar symptoms. She was from a consanguineous pedigree, her parents were second
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Figure 5.38: Short exercise test results of patients 5 & 8 from MLPA study a) Patient 5 b)
Patient 8. (Both graphs illustrate significant transient decrement (>20%) post-exercise which
rapidly normalises and shows a less significant decrement with subsequent trials of isometric
exercise)
a)
b)
5.3. Genetic Diagnosis in Skeletal Muscle Channelopathy Patients 169
a)
b)
Right Left
Figure 5.39: MRI scan of calves of Patient 5 (a) T1 weighted image of calves (b) STIR
sequence, shows high signal in the medial head of the gastrocnemius bilaterally suggesting the
presence of oedema (indidcated by red arrows)
cousins and paternal grandparents were first cousins consistent with a recessive pedigree.
On examination she had severe generalised myotonia demonstrable on percussion and grip.
There was mild proximal muscle weakness (MRC score 4/5). EMG showed myotonia and
the short exercise test revealed a Fournier type II pattern.
Genotype of Patient 7
CLCN1 exon sequencing identified the homozygous sequence variant, c.2230C>A;
p.Pro744Thr, not previously described in the literature. This variation was not found in
the UK control samples but was predicted by PolyPhen2 and SIFT to be non-pathogenic.
Expression studies were therefore performed by J.Burge in HEK293T cells to assess
pathogenicity. Both WT and mutant Pro744Thr yielded fast deactivating inward currents
in HEK cells (Figure 5.40a & b). Current magnitude varied depending on the amount
of vector taken up by the cell being studied (as indicated by brightness of fluorescence).
Brightly fluorescing cells produced currents in the 1020nA range. In contrast to published
studies of dominant mutations, which strongly reduce or eradicate channel activity, there
was no systematic difference when comparing Pro744Thr with WT CLCN1 (Figure 5.40c),
suggesting that this variation was non-pathogenic and did not cause the patient’s phenotype.
MLPA identified relative peak ratios of approximately 1.8 in exons 8 to 14 consistent
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Figure 5.40: Functional expression of wild-type ClC-1 and Pro744Thr mutation by
whole-cell patch clamp of transfected HEK293T cells (a) Representative wild-type recording
(2mOhm series resistance, 70% series resistance compensation). (b) Representative mutant
recording (3mOhm series resistance, 70% series compensation) (c) Boltzmann fits of the
normalized tail currents from 6 wildtype (squares) and 4 mutant (triangles) recordings to show
the similar voltage dependence of activation (figure supplied by J.Burge)
with either a homozygous duplication or a heterozygous triplication (Figure 5.37c).
5.3.2.4 Patient 8
Phenotype of Patient 8
Patient 8 was an Iraqi female with stiffness affecting the arms and legs at one years old. She
had warm-up phenomenon and was resistant to anti-myotonic treatment including mexiletine.
She also developed mild proximal muscle weakness. There was a strong family history with
two out of six siblings affected. Her parents were distant cousins. Neither of the patient’s
two children were affected. A nephew from a consanguineous kindred was also reported
to be affected suggesting a recessive pedigree. On examination she had generalised muscle
hypertrophy and grip and percussion myotonia. There was mild proximal muscle weakness
(MRC score 4/5). Her investigations included a normal CK. EMG studies demonstrated
myotonic discharges and the short exercise test demonstrated a Fournier type II pattern
(Figure 5.38b).
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Genotype of Patient 8
CLCN1 sequencing identified the same homozygous sequence variant c.2230C>A;
p.Pro744Thr as identified in patient 7. The patients were not known to be related but
both originated from Iraq. The six intragenic SNPs in both patients 7 and 8 were
consistent with the mutation being on a shared haplotype but heterozygosity of the SNPs
studied was high. MLPA analysis of patient 8 also demonstrated the same homozygous
duplication/heterozygous triplication of exons 8-14 as detected in patient 7 with relative peak
ratios of approximately 1.9 (Figure 5.37c).
5.3.3 Diagnosing Genetically Unconfirmed Cases using aCGH and
Whole Exome Sequencing
Overall DNA from 10 patients were analysed using whole exome sequencing. All patients
had no mutations identified but objective evidence of a skeletal muscle channelopathy.
Of the 10 patients, seven (70%) had likely causative pathogenic variations identified.
Two had variations identified in the known channelopathy genes and the others had variations
in unusual genes which were likely to underlie their phenotype.
5.3.3.1 Case 9
Phenotype of Case 9
The first case I analysed was a 65 year old man with stiffness primarily of the hands, arms and
legs but also in the face since he was 5 years old. The stiffness was severe with only mild pain.
He had warm-up phenomenon but no sensitivity to cold or particular foods. He had a good
response to mexiletine. He also had hypertension, hypercholesterolaemia and type II diabetes
mellitus. His family history included one affected older brother and an unaffected sister and
brother. His parents and grandparents were unaffected. His daughter and her four sons were
unaffected as were their children. His parents were not known to be consanguineous although
they were from the same community. On examination he had generalised calf hypertrophy
and hand grip myotonia. He did not have any eyelid myotonia and had normal strength.
He had a normal ECG and his CK was elevated at 485IU/L. His electrophysiology
demonstrated prominent myotonic discharges in all limb muscles. The short exercise
test showed a marked decrement on initial exercise which improved over time and with
subsequent exercise. There was less decrement seen on rewarming than cooling (Figure
5.41). The long exercise test was normal. This pattern is most suggestive of MC. His MRI
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Table 5.21: Table of total number of variants identified in whole exome sequencing cases
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scan demonstrated a mild degree of diffuse symmetrical fatty infiltration of the thigh and calf
muscles. The distal part of the medial head of the gastrocnemius muscle was completely
replaced by fatty tissue. The was no evidence of oedema (Figure 5.42).
Figure 5.41: Graph of short exercise test for Case 9 Red diamonds represent CMAP percentage
at room temperature, blue squares represent CMAP percentage after cooling and green triangles
represent CMAP percentage after rewarming
Given the pattern of stiffness, neurophysiology and MRI it was consistent with recessive
MC. However, full sequencing of CLCN1, SCN4A and MLPA of CLCN1 did not reveal any
pathogenic variants. Testing for DM1 and DM2 expansions was also normal. This patient
was therefore selected for next generation sequencing.
aCGH for Case 9
This patient had aCGH using the 720K array. 112 anomalies were detected of which six were
novel and located within the exome (Table 5.22). None of these six anomalies were in ion
channel genes expressed in skeletal muscle. The patient therefore did not have any relevant
CNVs that could explain his phenotype.
Whole Exome Results for Case 9
The whole exome sequencing identified 203,331 SNVs in the exome and surrounding parts
of the genome. Of these, 863 were found in the exome and not identified in dbSNP or
1000 Genomes (Table 5.21). These variations were then filtered for those located in the
known channelopathy genes. One homozygous variation was identified in the 5’UTR region
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a i)
a ii)
b i)
b ii)
*
*
*
*
*
*
R L
R L
Figure 5.42: MRI scan of thighs and calves of Case 9 ai) T1 weighted image of thighs with
mild fatty infiltration primarily in posterior compartment (most affected muscles indicated by red
?) aii) STIR sequence of thighs, bi) T1 weighted image of calves with complete fatty replacement
of medial gastrocnemius (indicated by red arrows) bii) STIR sequence of calves.
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Chr	   Size	  of	  copy	  number	  
variation	  
Loss/	  
Gain	  
Average	  
ratio	   Genes	   Gene	  function	  1	   1q41(218,155,426-­‐218,179,977)	   Gain	   1.42	   RNU5F-­‐1,	  SLC30A10	   manganese	  transporter	  
5	   5q31.1(131,567,703-­‐131,572,738)	   Loss	   0.74	   P4HA2	   catalyses	  posttranslational	  formation	  of	  4-­‐hydroxyproline	  in	  collagens	  8	   8q12.1(56,177,665-­‐56,178,359)	   Loss	   0.75	   XKR4	   unknown	  10	   10q25.2(114,700,599-­‐114,701,271)	   Loss	   0.56	   TCF7L2	   diabetes	  mellitus	  susceptibility	  17	   17q12(34,352,565-­‐34,364,646)	   Gain	   1.40	   FBXO47	   associated	  with	  papillary	  cell	  carcinoma	  18	   18q21.2(50,004,390-­‐50,004,848)	   Loss	   0.65	   MBD2	   T	  helper	  cells	  and	  IL4	  induction	  
Table 5.22: Table of novel copy number variations identified by aCGH for Case 9
of CLCN1 that has not been previously reported, c.1-59C>A (g.143013247C>A) (Table
5.23). Its presence was confirmed by Sanger sequencing of exon 1 by the genetics unit at
NHNN. It was not identified in the most current versions of exome variation server, dbSNP
or 1000 Genomes. It was also absent in 504 control chromosomes. It was not identified in
the original sequencing of CLCN1 for this patient as it was located under the forward primer
for exon 1. Although this region is conserved in primates it is not highly conserved in other
groups.
Gene	   Type	  of	  
variation	  
Variation	   Hetero/	  
homozygous	  
Associated	  disease	   Expression	  
in	  skeletal	  
muscle	  
in	  silico	  
prediction	  
Muscle	  Disease	  Genes	  
CLCN1	   Nonsyn	   c.1-­‐59C>A	  (g.143013247C>A)	   Homo	   Myotonia	  congenita	   High	   	  DYSF	   NFmS	  insertion	   c.3139_3140insAGGCGG:	  p.Q1047delinsQAE	   Hetero   LGMD2B,  AR	   High     BAG3	   Nonsyn	   c.418G>A:p.G140S	   Hetero	   Myofibrillar	  Myopathy,	  AD	   High	   Tolerated	  TTN	   Nonsyn	   c.16707T>A:p.H5569Q	   Hetero	   LGMD2J,	  AR	   High	   Tolerated	  TTN	   Nonsyn	   c.12997A>G:p.K4333E	   Hetero	   LGMD2J,	  AR	   High	   Tolerated	  
Ion	  channel	  genes	  GRIN2A	   Nonsyn	   c.3482G>C:p.G1161A	   Hetero	   Epilepsy	   None	   	  ALG10	   Nonsyn	   c.887C>T:p.S296L	   Hetero	   Reduced	  susceptibility	  to	  LQTS	   Medium	   Tolerated	  ANO10	   Nonsyn	   c.647A>G:p.Y216C	   Hetero	   SCA10,	  AR	   Medium	   Tolerated	  ANO7	   Nonsyn	   c.2234G>T:p.R745L	   Hetero	   	   Low	   Tolerated	  SCN9A	   Nonsyn	   c.1741A>G:p.N581D	   Hetero	   	   None	   Damaging	  KCNH6	   Stop	  gain	   c.2176C>T:p.R726X	   Hetero	   	   None	   	  	  
Table 5.23: Table of novel variations identified by whole exome sequencing in Case 9
The remainder of the exome data was analysed to ensure no other likely variations
were identified. When data was filtered for muscle disease causing genes, four variations
in three different genes were identified (Table 5.23). Variations in DYSF are associated
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with LGMD type 2B but both alleles need to be affected to cause disease and only one was
identified in this case. Two variations were identified in TTN which is associated with LGMD
type 2J. Both of these are predicted to be benign or tolerated by PolyPhen2 and SIFT. The
phenotype of LGMD2J is also very different from this patient, as it is normally associated
with cardiomyopthy and a tibial muscular dystrophy. I did however, identify a variation
in BAG3, c.418G>A;p.Gly140Ser (Table 5.23). There have been reports of patients with
autosomal dominant myofibrillar myopathy type 6 with variations in BAG3 having electrical
myotonia but this variation is predicted by PolyPhen2, SIFT and mutation taster as having
a very high probability of being a polymorphism. This makes it likely that the causative
variation is the 5’UTR homozygous variation in CLCN1.
5.3.3.2 Case 10
Phenotype of Case 10
The second case was a 66 year old man who was well until he was 17 years old when he began
to notice occasional episodes of shoulder abduction weakness. His legs were unaffected at
that stage. 14 years later, at 31 years old, he had his first significant episode of weakness when
his legs gave way after getting up from a chair. This was associated with significant pain and
lasted four days. From this point on he continued to have attacks approximately once a month.
Attacks primarily occurred in the evenings or night-time. Severe attacks would involve arms,
legs and neck usually lasting approximately eight hours. His speech, swallow, breathing
and eye movements were all normal during attacks. There were no obvious precipitants.
Unfortunately a potassium level was never recorded during an attack. The attacks were at
their worst in his mid to late 40s but tailed off in the last 10 years and reverted to progressive
weakness with a significant painful component. He did not find any improvement with
treatment with acetazolamide. At the point of review he could only mobilise to 50 yards
without stopping.
His past medical history includes three myocardial infarctions, the last eight years ago.
He had hypertension diagnosed 20 years ago and type 2 diabetes mellitus diagnosed around
the same time. He also had a history of migraine. He was on metformin, insulin, carvedilol,
felodipine, prednisolone, omeprazole, aspirin and ezetamibe. His parents were unaffected,
his sister had hypertension and was diagnosed with fibromyalgia, his brother was unaffected.
He had two daughters, the older daughter was diagnosed with fibromyalgia. His younger
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daughter had hypertension and in her 30s had episodes of weakness after the delivery of each
of her children but has refused all medical investigations.
On examination he had marked proximal wasting and weakness of arms and legs with
shoulder abduction MRC grade 4+ and hip flexion MRC grade 4. He was unable to rise
from a chair unaided and needed a stick to mobilise. His reflexes were absent at the knees
but were otherwise normal. Investigations demonstrated a mildly elevated CK of 270IU/L.
His mitochondrial respiratory chain enzymes were also normal. Electrophysiology done
elsewhere demonstrated a normal short exercise test but an abnormal long exercise test with a
45% decrement . There was no myotonia on EMG but some myopathic changes. Single fibre
EMG was normal. MRI demonstrated complete fatty replacement of circumscribed areas
of the vastus muscles, many of which had a ring of oedema around them. There was also
some fatty infiltration of the tibialis anterior and soleus bilaterally and mild oedema of the
gastrocnemius bilaterally (Figure 5.43).
His biopsy demonstrated variation of fibre size and and scattered atrophic fibres (Figure
5.45a). There was a mild focal increase in endomysial connective tissue. A high proportion
of fibres had multiple basophilic inclusions of varying size (Figure 5.45b). These inclusions
stained strongly for NADH (Figure 5.45c) and electron microscopy confirmed these were
tubular aggregates (Figure 5.45i & j). Two rimmed vacuoles of unclear significance were
also identified but did not contain any protein aggregation (Figure 5.45e, f, g & h).
I was also able to fully assess the patient’s eldest daughter. She was 35 years old with
a history of two episodes at night in her early twenties of waking unable to move her right
arm. She had weakness of the arm for two days with full recovery of strength afterwards.
Following that she had a number of mild episodes of weakness in the arms and legs but was
still able to mobilise independently and these recovered fully. She also had longstanding
problems with lower back and neck pain. She was not known to have hypertension and was
on gabapentin, meloxicam and citalopram. She had one unaffected child. On examination
she had very subtle proximal weakness in the upper and lower limbs. Her CK was normal at
54IU/L. Her EMG and long exercise test were normal with a decrement of 24% from peak.
Her MRI demonstrated mild fatty infiltration of the adductors of the thigh and atrophy of the
lateral head of gastrocnemius in the calf. There was no evidence of oedema (Figure 5.44).
Given the episodic weakness and positive long exercise test, S4 segments of CACNA1S,
all exons of SCN4A and KCNJ2 were tested but no pathogenic variations were found.
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Figure 5.43: MRI scan of thighs and calves of Case 10 ai) T1 weighted image of thighs with
fatty infiltration in areas of vastus muscle (indicated by yellow arrows) aii) STIR sequence of
thighs with ring of oedema around vastus muscle (indicated by red arrows), bi) T1 weighted
image of calves with mild fatty infiltration of tibialis anterior and soleus (indicated by yellow
arrows) bii) STIR sequence of calves with mild oedema of the gastrocnemeii (indicated by red
arrows).
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Figure 5.44: MRI scan of thighs and calves of daughter of Case 10 ai) T1 weighted image
of thighs showing mild fatty infiltration of adductors (indicated by yellow arrows) aii) STIR
sequence of thighs, bi) T1 weighted image of calves with atrophy of lateral head of gastrocnemius
(indicated by yellow arrows) bii) STIR sequence of calves
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Figure 5.45: Muscle biopsy of vastus lateralis of Case 10 a) Haematoxylin and eosin stain
showing variation in fibre size b) Haematoxylin and eosin stain at higher power demonstrating
tubular aggregates c) NADH staining of tubular aggregates d) COX stain showing no staining
of tubular aggregates e) Haematoxylin and eosin stain at higher power demonstrating rimmed
vacuoles f) Gomori trichrome stain demonstrating rimmed vacuoles g) SDH stain showing no
staining of rimmed vacuoles, h) Desmin stain showing no staining of rimmed vacuoles, i) Electron
microscopy of tubular aggregates j) High power electron microscopy of tubular aggregates
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Mitochondrial DNA analysis was also normal. He was therefore selected for next generation
sequencing. Although aCGH was performed the quality of DNA was too poor to use.
Whole Exome Results for Case 10
Overall 207,646 SNVs were identified in the exome and surrounding parts of the genome.
Of these, 671 were novel and located within the exome (Table 5.21). No novel variations
were identified in the known channelopathy genes. I then looked at variations in known
muscle channel genes and identified 2 novel variations (Table 5.24). The first variation
was located in CRYAB, the gene for αB-crystallin, at location c.460G>A;p.Gly154Ser.
Pathogenic variations in this gene have been associated with myofibrillar myopathy. This
particular variation was previously reported in the literature in a patient with a late-onset
distal myopathy (Reilich et al., 2010). The reported case had no history of episodes
of weakness and had a much later onset of a primarily distal myopathy, different from
Case 10. However, this variation has also been reported in dbSNP as having uncertain
significance (rs150516929). SIFT and PolyPhen2 both predict that the variation is benign
but Mutation taster suggests it is pathogenic, possibly because it has been published as
pathogenic. The second variation identified was in TTN which is associated with LGMD
type 2J causing an autosomal dominant late-onset distal myopathy. Again the phenotype of
Case 10 was different from the cardiomyopathy and tibial muscular dystrophy that is seen in
TTN mutations. This variation was predicted in silico to be a polymorphism.
Gene	   Type	  of	  
variation	  
Variation	   Hetero/	  
homozygous	  
Associated	  disease	   Expression	  in	  
skeletal	  muscle	  
in	  silico	  
prediction	  
Muscle	  Disease	  Genes	  
CRYAB	   Nonsyn	   c.460G>A:p.G154S	   Hetero	   Myofibrillar	  Myopathy	  	   High	   ?tolerated	  
(published	  as	  
pathogenic)	  TTN	   Nonsyn	   c.13948C>T:p.P4650S	   Hetero   LGMD2J,	  AR	  Late	  onset	  distal	  myopathy,	  AD	   High   Tolerated  
Ion	  channel	  genes	  
SCNN1B	   Deletion	   c.1307_1310del:	  
p.436_437del	  
Hetero	   Liddles	  Disease	   None	   Pathogenic	  	  
Table 5.24: Table of novel variations identified by whole exome sequencing in Case 10
As there was some question as to the pathogenicity of the variation in CRYAB,
I also looked at the variations located in ion channel genes. Only one variation was
identified that was not seen in other patients from my exome panel or in the updated
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version of dbSNP (Table 5.24). This variation was a frameshift deletion in SCNN1B,
c.1307 1310delAGAG;p.Arg438PfsX17 which would prematurely terminate the transcript.
SCNN1B encodes an amiloride-sensitive sodium channel β subunit that is specifically
expressed in the kidney, acting as a distal renal sodium channel. The β subunit augments
the channel activity of the α subunit which is responsible for conductance of sodium ions
(Canessa et al., 1994). Variations in this gene are associated with Liddle’s syndrome
(Shimkets et al., 1994). This syndrome is characterised by hypertension, metabolic alkalosis
and hypokalaemia due to excessive sodium reabsorption in the distal nephron and therefore
could potentially cause secondary HypoPP (Liddle et al., 1963).
I confirmed the presence of both the CRYAB and SCNN1B variations with Sanger
sequencing in both the patient and his eldest daughter (Figure 5.46). His youngest daughter
declined genetic testing. Given the possible diagnosis of Liddle’s syndrome I also tested
plasma aldosterone which was low at 122pmol/L (600-1200) and renin which was normal
2.67nmol/h/l (1.2-4.4). Bicarbonate was normal 22mmol/L. Urine aldosterone was also
normal at 19 nmol/24hr (10-50). Plasma aldosterone and renin levels in the proband’s
daughter however, were normal at 954pmol/L and 2.23nmol/h/l respectively. There are
therefore two possible pathogenic variations that may be responsible for the patient’s disease.
5.3.3.3 Case 11
Phenotype of Case 11
Case 11 was a 27 year old right handed female. She developed recurrent attacks of weakness
from 24 years old. Her first episode was of bilateral leg weakness one evening after a 45
minute period of sitting whilst at a bar. Her weakness recovered the next day although she
continued to have mild heaviness of her left leg. Her next episode was a year later when,
after an asthma attack and using her salbutamol inhaler several times, she developed marked
bilateral weakness which resolved after two hours. Her potassium was recorded as normal
during this attack. Following that episode she continued to have minor attacks every couple
of months which were always during the day and usually after a period of exertion. She
had never awoken with weakness or had night-time attacks. Her attacks improved with
acetazolamide. She also has a history of palpitations from 24 years old but no associated
syncope or chest pain. She was the product of a normal pregnancy and delivery and reached
all her developmental milestones at the appropriate age. She was, however, very clumsy at
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of Case 10
c.460G>A;p.Gly154Ser
b) SCNN1B
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Case 10
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of Case 10
c.1307_1310delAGAG;p.Arg438PfsX17
c) RYR1
control
Case 12
c.3128G>A;p.Arg1043His
Figure 5.46: Electropherogram for variants that were Sanger sequenced to confirm
the findings from whole exome sequencing a) CRYAB sequencing demonstrating variant
c.460G>A;p.Gly154Ser present in case 10 and his daughter, b) SCNN1B sequencing
demonstrating frameshift deletion c.1307 1310delAGAG;p.Arg438PfsX17 in case 10 and his
daughter, c) RYR1 sequencing demonstrating variant c.3128G>A;p.Arg1043His identified in
case 12.
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school and poor at sports. Her past medical history was of asthma and migraine.
Her family history included a 32 year old sister who also had palpitations and was found
to have a prolonged QT interval of 580ms. She never had any attacks of weakness, no skeletal
abnormalities and had a normal long exercise test. The proband’s mother and two of her
mother’s 11 siblings all had epilepsy. Her father and her grandparents were unaffected.
On examination the proband was of small stature and had low set ears. She had subtle
clinodactyly and syndactyly of the second and third toes and looked very different from her
sister. She had mild proximal weakness, although there was some functional overlay to her
weakness. Her reflexes were normal. Her blood tests were normal including potassium during
attacks. Her CK was 58IU/L. Her ECG demonstrated U waves and a QTc of 460ms, the
upper limit of normal for a woman, although in the past it had been recorded as 500ms. Her
24 hour tape was normal, as was her echocardiogram. Electrophysiology testing was initially
abnormal with a CMAP decrement of 51% of the amplitude and a corresponding decrement
of area of 59%, however repeated testing at our centre was normal. MRI of thighs and calves
were normal (Figure 5.47).
a i)
a ii)
b i)
b ii)
R L R L
Figure 5.47: MRI scan of thighs and calves of Case 11 ai) T1 weighted image of thighs aii)
STIR sequence of thighs, bi) T1 weighted image of calves bii) STIR sequence of calves.
The positive long exercise test, episodes of weakness, subtle dysmorphic features and
borderline QT interval suggested a diagnosis of ATS. However, sequencing and MLPA of
KCNJ2 was negative as was sequencing of SCN4A exons and S4 segments of CACNA1S.
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She was therefore selected for next generation sequencing.
aCGH in Case 11
Array CGH was performed using the 1.4M array. 106 anomalies were identified of which
28 were novel anomalies. Of these, seven were located within the exome and not detected
in other samples from the same analysis set (Table 5.25). The only CNV located in a
relevant gene was a gain of copy number of the MRPL44 gene. This was a single gain of
approximately 16,052 base pairs long and included the entire MRPL44 gene (Figure 5.48).
This gene is a large subunit of the mitochondria ribosome. Homozygous variations and
compound heterozygous variations in the gene have been documented as causing childhood
hypertrophic cardiomyopathy (Carroll et al., 2013). However, as this is a heterozygous
CNV it would only cause disruption to expression of the MRPL44 gene from one allele and
therefore would be unlikely to be responsible for the patient’s phenotype.
	  
Chr	   Position	  of	  copy	  
number	  variation	  
Width	   Loss/	  
Gain	  
Average	  
ratio	   Genes	   Gene	  function	  
2	   2q36.1(224,818,710-­‐224,834,762)	   16,052	   Gain	   1.31	   MRPL44,	  SERPINE2,	  WDFY1	   large	  subunit	  of	  the	  mitochondrial	  ribosome	  
7	   7p14.3(29,594,671-­‐29,605,644)	   10,972	   Loss	   0.74	   PRR15	   	  
8	   8q13.2(68,132,759-­‐68,143,371)	   10,612	   Gain	   1.30	   ARFGEF1	   regulate	  vesicular	  traffic	  
11	   11p15.1(17,896,787-­‐17,917,301)	   20,513	   Loss	   0.75	   SERGEF	   	  
18	   18q12.1(28,883,480-­‐28,916,303)	   32,823	   Gain	   1.33	   DSG1	   	  
19	   19q12(31,791,099-­‐31,807,952)	   16,853	   Loss	   0.80	   TSHZ3	   neuronal	  and	  smooth	  muscle	  differentiation	  
X	   Xq13.1(71,349,754-­‐71,357,559)	   7,804	   Loss	   0.69	   FLJ44635,	  NHSL2,	  RGAG4	   	  
Table 5.25: Table of novel copy number variations identified by aCGH for Case 11
Whole Exome Results in Case 11
Overall 205,731 SNVs were identified. Of these 616 were not in dbSNP (Table 5.21). No
novel variations were identified in the known channelopathy genes. I then looked at the
variations identified in known muscle disease causing genes and genes associated with long
QT syndrome, given the family history of long QT and the patient’s borderline prolonged
QT. Only two novel variations were identified in muscle disease genes, one in PLEC and one
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Figure 5.48: ArrayCGH ratio plot with gain in copy number of gene MRPL44 and
surrounding region.
in CHRNE (Table 5.26). Both genes are only associated with autosomal recessive diseases,
LGMD2Q and congenital myasthenia respectively, and were therefore unlikely to be relevant.
However, looking at the long QT genes, two variations were identified including one that
has been reported in the literature as pathogenic (Table 5.26). I identified the variation
c.805G>A;p.Gly269Ser in KCNQ1. Variations in this gene are associated with LQT1 and
this variation has been reported in a number of families with syncope and sudden cardiac
death both heterozygously and homozygously expressed (Donger et al., 1997; Ackerman
et al., 1999; Murray et al., 2002). The presence of this variation was confirmed by the service
laboratory in the patient, her sister and her father by Sanger sequencing. Her father remained
unaffected with a normal QTc and cardiac investigations.
Gene	   Type	  of	  
variation	  
Variation	   Hetero/	  
homozygous	  
Associated	  disease	   Expression	  in	  
skeletal	  muscle	  
in	  silico	  prediction	  
Muscle	  Disease	  Genes	  PLEC	   Nonsyn	   c.7550G>A:p.R2517H	   Hetero	   LGMD2Q,	  AR	   High	   Tolerated	  CHRNE	   Nonsyn	   c.1036C>G:p.L346V	   Hetero   Congenital	  Myasthenia,	  AR	   High   Possibly  damaging  
Long	  QT	  genes	  
KCNQ1	   Nonsyn	   c.805G>A:p.G269S	   Hetero	   LQTS	   Low	   Known	  Pathogenic	  	  
Table 5.26: Table of novel variations identified by whole exome sequencing in Case 11
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This variation, however does not explain the patient’s episodes of weakness as none of
the reported cases and the proband’s sister and father who carry the variation did not have
symptoms of recurrent weakness. I therefore looked at the variations in other ion channels
but did not find any other plausible variations.
5.3.3.4 Case 12
Phenotype of Case 12
Case 12 was a 45 year old right handed man who was fit and well until the age of 14. At that
point he started having episodes of weakness of the hands, arms and legs following activity,
which would last a couple of hours. It would frequently occur after weight training, although
he did have a few spontaneous attacks. These episodes were never accompanied by a change
in urine colour. He had a number of episodes of waking in the middle of the night feeling
that his arms and legs were weak but would recover by the morning. At this point he was
having episodes a couple of times per year. In his early twenties however, these became more
frequent, with clusters a couple of times a week but with long periods attack free. His first
major attack was at 29 years when he awoke at 7am unable to move from the neck down. His
potassium level was checked and was 2.31mmol/L and he was given potassium replacement.
He returned to normal strength in 10 hours. After this he began to have very frequent attacks
of at least one a week where he would wake unable to lift his arms and legs. In the last
few years his attacks began to last longer, sometimes taking up to 48 hours to return back to
normal strength. His attacks were precipitated by heat, strenuous exercise, eating after 8pm,
fasting and alcohol. He was started on regular Sando-K but felt it worsened attacks and on
stopping his attack frequency did improve. At 42 years he was started on dichlorphenamide
which improved his attack frequency and exercise tolerance considerably. He had been given
two general anaesthetics, one at 9 years old when he had no problems and the second at
18 years which did not bring on an attack but he was told he had problems due to volatile
anaesthetics which may have been MH. No further details of this were available.
His only relevant family history was of hypertension and vitamin D deficiency. He had
a positive family history, with his father also affected although not as severe. He would
get weakness after strenuous exercise but never had attacks of complete paralysis. It was
not known if his father had problems with general anaesthetic as his father died in his
60s with a heart condition. The proband had one older brother who was unaffected. His
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father’s siblings and parents were thought to be unaffected. His mother was adopted and
therefore had no knowledge of her family history. He has one daughter who was 20 years and
currently unaffected. His examination was completely normal with no fixed weakness, facial
dysmorphisms or ECG abnormalities.
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Figure 5.49: Case 12 long exercise test (Positive with 68% decrement from peak)
His blood results between episodes were normal with a CK of 92IU/L and normal
electrolytes including interictal potassium level. He had endocrine investigations at his local
hospital to try and identify a secondary cause of his episodes of hypokalaemia but they were
all negative. His EMG was normal but his long exercise test was markedly abnormal with a
decrement of 68% from peak and 62% from baseline (Figure 5.49). His MRI showed mild
fatty infiltration in the posterior compartment of the thighs and the calves, more evident
in the soleus (Figure 5.50). His needle muscle biopsy demonstrated increased fibre size
variation, occasional ring fibres and regenerating fibres and a single cytochrome oxidase
(COX)-deficient ragged red fibre (Figure 5.51).
Given the typical pattern of episodes of weakness and positive long exercise test, full
exon sequencing of KCNJ2 and SCN4A and sequencing of S4 segments of CACNA1S was
done, all of which were negative. He was therefore selected for next-generation sequencing.
There was insufficient DNA for aCGH as well.
5.3. Genetic Diagnosis in Skeletal Muscle Channelopathy Patients 189
a i)
a ii)
b i)
b ii)
R L
R L
Figure 5.50: MRI scan of thighs and calves of Case 12 ai) T1 weighted image of thighs showing
mild fatty infiltration in the posterior compartment (indicated by red arrows) aii) STIR sequence
of thighs, bi) T1 weighted image of calves with mild fatty infiltration in the soleus (indicated by
red arrows) bii) STIR sequence of calves.
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Figure 5.51: Muscle biopsy of vastus lateralis of Case 12 a) Haematoxylin and eosin stain
showing variation in fibre size, internal nuclei and fibre hypertrophy b) Haematoxylin and eosin
stain demonstrating a regenerating fibre c) Haematoxylin and eosin stain demonstrating a ring
fibre d) Haematoxylin and eosin stain demonstrating a necrotic fibre e) Gomori trichrome stain
demonstrating a ragged red fibre f) COX-SDH stain with a ragged red fibre stained blue g) NADH
staining of a ring fibre h) NADH stain showing type 1 fibre predominance
Whole exome results of Case 12
Overall 190,372 SNVs were identified, 10,491 of which were novel (Table 5.21). No novel
variations were identified in the channelopathy genes. I looked at variations in the known
muscle disease genes and identified four novel variations (Table 5.27). The first was in RYR1
c.3128G>A;p.Arg1043His. This gene is known to be associated with a case of atypical
PP and multi-minicore disease and so could be relevant (Zhou et al., 2010). This particular
variation lies in a highly conserved region and was predicted to be pathogenic by SIFT (0.01),
PolyPhen2 (1.000) and Mutation Taster (0.99989) as it lies at a splice site as well as altering
the protein. This would be expected to considerably disrupt the protein downstream.
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Gene	   Type	  of	  
variation	  
Variation	   Hetero/	  
homozygous	  
Associated	  disease	   Expression	  in	  
skeletal	  muscle	  
in	  silico	  
prediction	  
Muscle	  Disease	  Genes	  
RYR1	   Nonsyn	   c.3128G>A:p.R1043
H	  
Hetero	   Multi-­‐minicore	  disease	  
Central	  core	  disease	  
Malignnat	  hyperthermia	  
High	   Pathogenic	  
AR	   Non	  FM	  ins	   c.170_171insGCA:	  p.L57delinsLQ	   Hetero	   Spinal	  muscular	  atrophy	  (with	  CAG	  expansion)	   Low	   	  ATXN1	   Non	  FM	  del	   c.624_626del:	  p.208_209del	   Hetero	   Spinocerebellar	  ataxia	  1	  (with	  CAG	  expansion)	   High	   	  SNRPN	   Splicing	   g.	  25131738T>C	   Hetero	   Prader-­‐Willi	  (with	  deletion)	   Low	   	  
Ion	  channel	  genes	  BEST3	   FM	  del	   c.177delA:p.K59fs	   Hetero	   Anion	  channel	   Medium	   Pathogenic	  KCNMA1	   Nonsyn	   c.1499C>T:p.A500V	   Hetero	   Paroxysmal	  dyskinesia	   None	   Pathogenic	  LYN	   Nonsyn	   c.170A>C:p.H57P	   Hetero	   Regulation	  of	  mast	  cell	  degranulation	   None	   Pathogenic	  	  
Table 5.27: Table of novel variations identified by whole exome sequencing in Case 12
Two of the other three variations identified were in genes that are only associated with
disease in the presence of CAG expansions (AR and ATXN1) (Table 5.27) and the final
variation was in a splice site for SNRPN which is associated with Prader-Willi syndrome but
only in the presence of deletions. These are therefore unlikely to be relevant.
Given the presence of the single ragged red fibre on biopsy, I checked for possible
variations in known nuclear mitochondrial disease genes but no novel variations were
identified.
Three variations were identified in ion channel genes, two of which were in genes not
expressed or expressed in very low levels in skeletal muscle (Table 5.27). The other variation
was a frameshift deletion identified in BEST3, c.177delA;p.K59fs. This gene encodes an
anion channel and is expressed in skeletal muscle. Its role in skeletal muscle is unknown but
as it is a frameshift mutation it would be expected to produce a non-functioning protein.
Given the patient’s phenotype, however, the likeliest relevant variation is the one
identified in RYR1.
5.3.3.5 Case 13
Phenotype of Case 13
Case 13 was of a 16 year old female with problems since birth. She was the product
of a normal pregnancy with normal foetal movements. She was born at 38 weeks and
was admitted to the Specialist Care Baby Unit for feeding difficulties and temperature
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instability and was noted to have a cleft palate which was repaired at one year. Her initial
developmental milestones were normal, sitting without support at 6 months, standing at 10
months, walking independently at one year and running at 15 months. However, she was
always slower than her peers and had speech delay requiring speech therapy for phonation
and articulation difficulties. At the age of 5 she had difficulty rising and walking after a
long period of sitting which would improve over a couple of hours. Over the next few
years this progressed to distinct episodes of weakness after illness or after she had done
exercise. Her episodes of weakness primarily occurred on waking and were associated
with arm weakness and then leg weakness, resulting in difficulties walking. She had no
abnormalities of swallowing, breathing or ocular muscles. At the time of assessment her
episodes were occurring approximately once a month, lasting for 48 to 72 hours.
Her other problems included bilateral conductive hearing loss, short stature (for which
she was on growth hormone), special educational needs, recurrent chest infections, a small
right kidney and scoliosis. At the age of nine she had an episode of cardiac syncope which
was found to be secondary to ventricular tachycardias. She had another episode two years
later and, as a result, had an implantable cardioverter defibrillator inserted. She had a negative
family history with an unaffected sister and parents, although her father had similar facial
features.
On examination she was 30.4 kg weight and 137.7cm in height, two blocks below the
0.4th centile. Her VC was 1.27L. She had microcephaly, micrognathia, broad nasal bridge,
low hanging columella, low set ears, syndactyly, clinodactyly, short toes and dysplastic nails
(Figure 5.52). She had asymmetrical scoliosis with a thoracic convexity to the right and a
waddling gait. She had a positive Gowers’ manoeuvre on rising from the floor. She had neck
flexion weakness, MRC score 3-/5, trunk flexion weakness (4-/5) and extensor weakness
(4+/5). Proximal upper arm strength was 3-/5 but distally she had full power. Her proximal
lower limb strength was only mildly impaired at 4+/5 with normal distal strength. She had
a mildly impaired vibration sense in the lower limbs but otherwise sensory examination was
normal.
Her blood tests were normal with a CK of 99 IU/L. Her echocardiogram demonstrated
normal biventricular size and function with mild mitral regurgitation and tricuspid
regurgitation. Due to her defibrillator she was only able to have needle EMG which
demonstrated myopathic changes. Her sleep study demonstrated occasional desaturations
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Figure 5.52: Photos of distinctive facial features and skeletal abnormalities in Case 13 a)
Face demonstrating microcephaly, micrognathia, broad nasal bridge and low hanging columella,
b) Hand demonstrating syndactyly and clinodatyly, c) Foot demonstrating short toes, syndactyly
and dysplastic nails. (Images reproduced with permission from the patient)
suggestive of mild obstructive sleep apnoea. She was unable to have an MRI of the lower
limbs because of her defibrillator. She had a muscle biopsy which demonstrated variation in
fibre size, primarily of type I fibres, with occasional round or angular atrophic fibres and rare
nuclear bag fibres (Figure 5.53a). Occasional fibres contained internal nuclei. There were
at least six COX deficient fibres seen and several fibres with intermediate staining (Figure
5.53c). Given the presence of COX negative fibres she had mitochondrial respiratory chain
enzyme analysis which were all normal, although complex IV activity was at the lower limit
of normal.
Given the combination of arrhythmias, skeletal abnormalities and episodes of weakness,
DNA was sequenced for variations in KCNJ2. This was negative as was MLPA of KCNJ2,
excluding deletions or duplications within the gene. Analysis of S4 segments of SCN4A
and CACNA1S were also negative. Given the presence of COX negative fibres she had full
sequencing of the mitochondrial genome and analysis for rearrangements which were all
negative. She therefore went on to have aCGH and whole exome sequencing.
aCGH in Case 13
Array CGH was performed using the 1.4M array. 119 CNVs were detected of which 27 were
novel. Of these 18 were identified within the exome (Table 5.28). One CNV with possible
relevance was identified in this group, a gain of one copy of 9,826 base pairs in SYNE1 based
on the reading from 3 probes (Figure 5.54). The extra copy was located from exons 112 to
117. Missense mutations in this gene are associated with Emery-Dreifuss muscular dystrophy
type 4 and autosomal recessive spinocerebellar ataxia (SCA) type 1 (Gros-Louis et al., 2007).
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Figure 5.53: Muscle biopsy of vastus lateralis of Case 13 a) Haematoxylin and eosin stain
showing variation in fibre size b) Gomori trichrome stain c) COX-SDH stain with COX negative
fibre stained blue
The phenotype in SCA1 is associated with adult-onset ataxia, dysarthria and oculomotor
abnormalities. This is distinct from the phenotype in this case. Emery-Dreifuss muscular
dystrophy caused by variations in SYNE1 is an autosomal dominant condition associated with
contractures, slowly progressive skeletal muscle wasting and weakness and cardiomyopathy
(Zhang et al., 2007). This phenotype was similar to this patient’s presentation, however the
call was based on the presence of only 3 probes questioning the validity of the result.
Whole Exome Results in Case 13
Overall 188,725 SNVs were identified, 10,679 of which were not in dbSNP (Table 5.21). No
novel variations were identified in the channelopathy genes. There were only two variations
identified in known muscle disease genes (Table 5.29). Both variations were in the nebulin
gene, c.5567G>A;p.Arg1856Glu and c.10383G>C;p.Met3461Ile. However both variations
have now been reported in single cases in the most recent release of dbSNP making them
less likely to be pathogenic. The Arg1856Glu variation is predicted to be pathogenic but
the Met3461Ile variation is predicted by SIFT and PolyPhen2 to be tolerated making it less
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Chr	   Position	  of	  copy	  
number	  variation	  
Width	   Loss/	  
Gain	  
Average	  
ratio	   Genes	   Gene	  function	  
1	   1q24.2(170,125,366-­‐170,127,166)	   1,800	   Loss	   0.55	   METTL11B,	  MIR3119-­‐1,	  MIR3119-­‐2	   	  
1	   1q25.3(185,099,060-­‐185,130,966)	   31,906	   Gain	   1.46	   SWT1,	  TRMT1L	   	  
1	   1q42.13(229,760,620-­‐229,762,527)	   1,907	   Loss	   0.54	   TAF5L,	  URB2	   Type	  1	  Diabetes	  
3	   3p26.1(4,622,159-­‐4,637,074)	   14,914	   Loss	   0.77	   ITPR1	   deep	  in	  intron	  
3	   3q21.2(124,909,065-­‐124,921,424)	   12,359	   Loss	   0.76	   SLC12A8	   Psoriasis	  vulgaris	  
6	   6q22.31(125,384,574-­‐125,394,752)	   10,177	   Loss	   0.75	   RNF217	   	  
6	  
6q25.2(152,544,036-­‐
152,553,863)	   9,826	   Gain	   1.76	   SYNE1	   ED	  type	  4,	  SCA8	  
7	   7p14.3(32,930,248-­‐32,933,067)	   2,819	   Loss	   0.71	   KBTBD2	   	  
8	   8q23.1(108,325,294-­‐108,334,609)	   9,315	   Gain	   1.45	   ANGPT1	   microvascular	  leakage	  
9	   9q21.11(71,937,583-­‐71,942,207)	   4,623	   Loss	   0.66	   FAM189A2	   	  
14	   14q13.2(35,653,392-­‐35,689,422)	   36,029	   Gain	   1.33	   KIAA0391	   sbunit	  of	  mitochondrial	  RNAse	  P	  
15	   15q25.2(84,576,950-­‐84,585,731)	   8,781	   Gain	   1.46	   ADAMTSL3	   	  
17	   17p12(11,143,638-­‐11,145,026)	   1,387	   Loss	   0.46	   SHISA6	   	  
17	   17q24.2(64,801,841-­‐64,806,678)	   4,837	   Loss	   0.62	   PRKCA	   processing	  self	  motion	  signals	  
20	   20p13(4,980,741-­‐5,001,791)	   21,049	   Loss	   0.75	   SLC23A2	   sodium	  coupled	  vit	  c	  transporter	  
22	   22q13.1(40,439,815-­‐40,445,411)	   5,596	   Loss	   0.71	   TNRC6B	   	  
X	   Xp22.31(6,983,859-­‐6,996,188)	   12,329	   Gain	   1.44	   HDHD1	   	  
X	   Xp22.12(21,751,932-­‐21,754,047)	   2,115	   Gain	   1.60	   SMPX	   Deafness	  x-­‐linked	  
Table 5.28: Table of novel copy number variations identified on aCGH for Case 13
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Figure 5.54: ArrayCGH ratio plot showing gain in copy number of part of the SYNE1 gene
likely to be the responsible pathogenic variations. Variations in nebulin are associated with
autosomal recessive nemaline myopathy 2.
Gene	   Type	  of	  
variation	  
Variation	   Hetero/	  
homozygous	  
Associated	  disease	   Expression	  in	  
skeletal	  muscle	  
in	  silico	  
prediction	  
Muscle	  Disease	  Genes	  NEB	   Nonsyn	   c.5567G>A:p.R1856Q	   Hetero	   Nemaline	  myopathy	   High	   Pathogenic	  In	  dbSNP	  144	  NEB	   Nonsyn	   c.10383G>C:p.M3461I	   Hetero   Nemaline	  myopathy	   High   Tolerated  
In  dbSNP  144  
Mitochondrial	  disease	  genes	  NUBPL	   Nonsyn	   c.125G>A:p.G42D	   Hetero	   Complex	  I	  deficiency	  ,	  AR	   Low	   Pathogenic	  
Ion	  channel	  genes	  PKD1L2	   Stop	  loss	   c.2974T>A:p.X992R	   Hetero	   	   Unknown	   Tolerated	  	  
Table 5.29: Table of novel variations identified with whole exome sequencing in Case 13
Given the COX negative fibres, I looked at variations in known nuclear mitochondrial
genes. I first looked at genes associated with complex IV deficiency and no novel variations
were found. I then expanded to all other nuclear mitochondrial genes. This only revealed one
novel variation (Table 5.29), a heterozygous variation in NUBPL which is associated with
complex 1 deficiency with autosomal recessive inheritance. As there was only a heterozygous
variation in this patient, it is unlikely that it is responsible for the patient’s phenotype. I also
checked for variations in genes associated with arrhythmias but no novel variations were
identified. Finally I looked at the variations in ion channels. Four novel variations were
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identified. Only one of the genes was expressed in skeletal muscle, PKD1L2. This was a stop
loss variation, c.2974T>A;p.X992Arg which results in an extra 25 amino acids added on to
the end of the transcript. It is however predicted to be a polymorphism by Mutation taster
(>0.999).
Given the presence of facial dysmorphism, I input her distinctive facial features and
symptom cluster into Face2Gene, a facial dysmorphology package that analyses facial
features and compares them to a database of other patients with dysmoprhic features
and confirmed diagnoses (www.fdna.com/face2gene). The patient did not have any novel
variations in genes associated with the diagnoses suggested based on her profile. It therefore
seems likely that the only variations that may have relevance are those in the nebulin gene or,
less likely, the extra copy of exons 112-117 of SYNE1.
5.3.3.6 Case 14
Phenotype of Case 14
Case 14 was a 23 year old man with a history of episodes of severe calf pain accompanied
by weakness from the age of 7. The episodes lasted five days to a few weeks and were
always associated with significant pain. Episodes primarily occurred in the evening or at
night. As he grew older the episodes of weakness improved but he continued to have painful
episodes. These episodes were also associated with blurring of vision. His past medical
history was of migraine but also of postural syncope and palpitations. There was no family
history. On examination he had mild proximal weakness of MRC score 4+/5 but the rest of
the examination was normal.
His investigations demonstrated an abnormal long exercise test with a 52% decrement
but normal short exercise test and EMG (Figure 5.55). His nerve conduction studies did
demonstrate a reduced left sural sensory nerve action potential (SNAP) of 7µV but the rest of
the study was otherwise normal. His CK during one attack in childhood was 10,000IU/L but
in recent attacks was normal. The MRI demonstrated a mild degree of fatty infiltration in the
semimembranosus and the long head of the biceps bilaterally. There was also a mild increase
of STIR signal in the gastrocnemius bilaterally (Figure 5.56).
aCGH in Case 14
Array CGH was performed using the 720K array. 109 anomalies were identified of which 28
were novel. 12 of these were not seen in other samples and were located within the exome
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Figure 5.55: Case 14 long exercise test (Positive with 52% decrement from peak)
(Table 5.30). None of the CNVs were in ion channel genes expressed in skeletal muscle.
Whole Exome Results in Case 14
Case 14 had 199,977 variations identified of which 663 were novel exome variations (Table
5.21). There were no novel variations in muscle disease genes but one variation was found
in the ion channel gene SCN11A, c.2776G>A;p.Val926Ile (Table 5.31). This is predicted
by Mutation taster, PolyPhen2 and SIFT to be a polymorphism (p>0.999). This channel is
primarily expressed in the dorsal root ganglion and variations are associated with hereditary
sensory and autonomic neuropathy type VII (Leipold et al., 2013) and more recently in
painful peripheral neuropathies (Huang et al., 2014). Given that this patient has a pain
syndrome with autonomic features and an abnormal sural SNAP it is possible that this
mutation may account for some of his symptoms, although it does not explain his episodes
of weakness.
5.3.3.7 Cases 15-18
The remaining cases did not reveal any plausible explanations on whole exome sequencing.
A brief summary of the cases is therefore given.
Case 15 was a 50 year old man with episodes of weakness of the arms and legs with an
associated potassium of 1.9mmol/L. His power returned to normal after his potassium level
returned to normal. His long exercise test, done at another centre, was positive.
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Figure 5.56: MRI scan of thighs and calves of Case 14 ai) T1 weighted image of thighs showing
mild fatty infiltration of semimembranosus and the long head of the biceps (indicated by red
arrows) aii) STIR sequence of thighs, bi) T1 weighted image of calves bii) STIR sequence of
calves demonstrating subtle oedema in gastrocnemeii (indicated by yellow arrows)
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Chr	   Position	  of	  copy	  
number	  variation	  
Width	   Loss/	  
Gain	  
Average	  
ratio	   Genes	   Gene	  function	  
1	   1p36.32(4,671,850-­‐4,671,870)	   20	   Loss	   0.72	   AJAP1	   	  
1	   1p34.2(41,022,552-­‐41,022,567)	   15	   Loss	   0.72	   KCNQ4	   AD	  hearing	  loss	  
2	   2p11.2(85,214,454-­‐85,215,011)	   556	   Loss	   0.66	   TCF7L1	   transcription	  factor,	  skin	  and	  hair	  formation	  
5	   5q35.3(179,430,648-­‐179,431,182)	   534	   Loss	   0.66	   RNF130	   	  
7	   7q32.1(127,457,366-­‐127,457,901)	   534	   Loss	   0.74	   LRRC4,	  SND1	   	  
11	   11p15.4(7,066,989-­‐7,067,876)	   886	   Loss	   0.72	   RBMXL2	   spermatogenesis	  
11	   11q13.1(65,567,077-­‐65,568,214)	   1136	   Loss	   0.67	   GAL3ST3	   	  
13	   13q12.13(26,231,483-­‐26,231,889)	   406	   Loss	   0.76	   GPR12	   	  
13	   13q13.1(32,489,212-­‐32,489,768)	   556	   Loss	   0.76	   KL	  
assoc	  tumour	  
calcinosis	  and	  
coronary	  artery	  
disease	  
16	   16q13(56,120,006-­‐56,120,494)	   488	   Loss	   0.73	   CCDC102A	   	  
17	   17q11.2(27,838,830-­‐27,839,332)	   501	   Loss	   0.69	   CDK5R1	   pain	  hypersensitivity	  
X	   Xp21.3(26,122,068-­‐26,122,278)	   209	   Loss	   0.72	   MAGEB6	   	  
Table 5.30: Table of novel copy number variations identified by aCGH for Case 14
Gene	   Type	  of	  
variation	  
Variation	   Hetero/	  
homozygous	  
Associated	  disease	   Expression	  in	  
skeletal	  muscle	  
in	  silico	  
prediction	  
Ion	  channel	  genes	  
SCN11A	   Nonsyn	   c.2776G>A:p.V926I	   Hetero	   Neuropathy,	  hereditary	  
sensory	  and	  autonomic,	  
type	  VII	  
Low	  	  (mainly	  in	  DRG)	   Tolerated	  	  
Table 5.31: Table of novel variations identified with whole exome sequencing in Case 14
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Case 16 was a 68 year old female with a history of episodes of weakness in the context
of low potassium. She had a positive glucose provocation test, with a low potassium and
weakness after glucose loading and a family history of episodes of weakness.
Case 17 was a 19 year old man with onset of symptoms at 8 years old. His primary
problem was his legs locking up whilst playing football with stiffness and transient weakness.
In his mid teens this progressed to stiffness of the upper arms. The stiffness would improve
with warm-up and there were no discrete episodes of weakness. His symptoms were
improved by mexiletine. There was no family history of stiffness and his parents were
thought to be unrelated. On examination he had generalised muscle hypertrophy and grip and
percussion myotonia. The blood tests demonstrated a CK 537IU/L. His EMG demonstrated
profuse myotonia. The short exercise test demonstrated immediate decrement of the CMAP
after exercise which improved with subsequent trials. There was no significant difference
following cooling or rewarming (Figure 5.57). The long exercise test was normal. These
findings and the clinical phenotype were suggestive of recessive MC.
Figure 5.57: Graph of short exercise test for Case 17 (Red diamonds represent CMAP
percentage at room temperature, blue squares represent CMAP percentage after cooling and green
triangles represent CMAP percentage after rewarming)
Case 18 was a 41 year old with onset of attacks of weakness from his early twenties.
Initially these episodes only affected his legs but over time progressed to involve the arms
and legs. At the start of the attacks he developed redness of the eyes progressing to slurring
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of speech. Following this his limbs would become weak and he would be unable to move
for several hours. It would often take up to a week before his function completely returned
to normal. Attacks were worsened by activity and were often precipitated by changes in
temperature or heavy carbohydrate meals. He had no cardiac or respiratory problems. There
was no family history and his parents were unrelated, his mother being from the Western Isles
and his father from Southern Ireland. His examination was normal.
His CK was normal at 93IU/L, as was his interictal potassium. His electrophysiology
demonstrated a positive long exercise test with a decrement of 76% (Figure 5.58). There was
no decrement on short exercise testing and no myotonia on EMG. MRI demonstrated mild
fatty infiltration of the medial and posterior compartment of the thighs and the superficial
posterior compartment muscles in the calves. There was no evidence of water deposition
(Figure 5.59).
Figure 5.58: Case 18 long exercise test (Positive with 76% decrement from peak.)
Whole Exome Results for Cases 15-18
The overall numbers of SNVs for each case are described in the Table 5.21.
Case 15 had 416,148 SNVs, 348 of which were in the exome and not in dbSNP
(Table 5.21). There were no novel variations in known muscle disease genes and only one
variation in an ion channel gene expressed in skeletal muscle (Table 5.32a). This was in
CACNA2D3, c.1156C>G;p.Pro386Ala. It was predicted by Mutation taster and PolyPhen2
to be pathogenic (>0.999) although predicted to be tolerated by SIFT (0.27). The gene
is highly expressed in skeletal muscle. It is associated with problems with impaired pain
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Figure 5.59: MRI scan of thighs and calves of Case 18 ai) T1 weighted image of thighs showing
mild fatty infiltration in the medial and posterior compartment (indicated by red arrows), bi) T1
weighted image of calves with mild fatty infiltration in the superficial posterior compartment
(indicated by red arrows) bii) STIR sequence of calves.
perception but has not been associated with weakness. It is therefore unlikely to be causative
variation. Array CGH of this case was performed using the 720K array. 101 anomalies were
identified of which 21 were novel. 4 of these were not seen in other samples and were located
within the exome (Table 5.32b). None of the CNVs were in ion channel genes expressed in
skeletal muscle.
Case 16 had 194,199 SNVs, of which 692 were exonic and not in dbSNP (Table
5.21). Only one novel variant was identified in muscle channel genes in CLCN1,
c.412G>A;p.Val138Ile (Table 5.33). However, as there was no of myotonia, the phenotype in
this patient was not consistent with this being a pathogenic variation. All the novel variations
in ion channels were in genes that did not have significant expression in skeletal muscle and
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a)	  Whole	  exome	  sequencing	   	  	  	  	  	  	  	  	  	  	  
b)	  aCGH	  	  
Gene	   Type	  of	  
variation	  
Variation	   Hetero/	  
homozygous	  
Associated	  disease	   Expression	  in	  
skeletal	  muscle	  
in	  silico	  
prediction	  
Ion	  channel	  genes	  CACNA2D3	   Nonsyn	   c.1156C>G:p.P386A	   Hetero	   von	  Hippel	  Lindau	  (deletions)	  Knockout	  mice	  have	  impaired	  pain	  	   High	   Pathogenic	  (PolyPhen)	  Tolerated	  (SIFT)	  
Chr	   Position	  of	  copy	  
number	  variation	  
Width	   Loss/	  
Gain	  
Average	  
ratio	   Genes	   Gene	  function	  
2	   2p25.1(9,263,829-­‐9,264,756)	   926	   Loss	   0.53	   ASAP2	   	  
2	   2p11.2(85,214,454-­‐85,215,011)	   556	   Loss	   0.69	   TCF7L1	   difficulty	  wound	  healing	  
4	   4q24(106,683,227-­‐106,704,025)	   20797	   Loss	   0.51	   ARHGEF38	   	  
5	   5q31.3(140,031,158-­‐140,032,577)	   1419	   Loss	   1.46	   DND1	   congenital	  teratoma	  risk	  in	  mice	  
Table 5.32: Table of novel variations identified in Case 15 a) Novel variations idenitifed in
whole exome sequencing, b) Novel copy number variations identified in aCGH.
therefore were not likely to be causative. There was insufficient DNA for aCGH analysis.
Gene	   Type	  of	  
variation	  
Variation	   Hetero/	  
homozygous	  
Associated	  disease	   Expression	  in	  
skeletal	  muscle	  
in	  silico	  
prediction	  
Muscle	  Disease	  Genes	  CLCN1	   Nonsyn	   c.412G>A:p.V138I	   Hetero	   Myotonia	  congenita	   High	   Tolerated	  
Ion	  channel	  genes	  GABRA4	   Nonsyn	   c.1102C>T:p.R368C	   Hetero	   	   Very	  low	   Tolerated	  GRID2	   Nonsyn	   c.2110A>C:p.M704L	   Hetero	   	   Very	  low	   Pathogenic	  GLRA1	   Nonsyn	   c.74A>C:p.E25A	   Hetero	   Hyperekplexia,  
hereditary  1,  AD	   Very	  Low	   Tolerated	  	  
Table 5.33: Table of novel variations identified with whole exome sequencing in Case 16
Case 17 had 250,363 variations identified of which 352 were novel exome variations
(Table 5.21). There were no novel variations identified in muscle disease genes or ion channel
genes. DM1 and DM2 testing were both normal. He was, however homozygous for the
intronic variant c.1930+6T>G in CLCN1 and given that the remainder of his sequencing
was normal it seems likely that this variation is responsible for his phenotype. There was
insufficient DNA for aCGH analysis.
Case 18 had 344,866 variations of which 313 were novel exome variations (Table
5.21). The only variation identified in muscle or ion channel genes was in TTN,
c.76381G>C;p.Glu25461Gln (Table 5.34a). This was, however, predicted by Mutation
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Taster and PolyPhen2 to be a polymorphism (p>0.999). Mutations in TTN are not known
to cause the phenotype seen in this patient and it is therefore unlikely to be the causative
variation. Array CGH was performed using the 1.4M array. 137 CNVs were detected of
which 15 were novel exome CNVs (Table 5.34b). None of the CNVs were in ion channel
genes expressed in skeletal muscle.
a)	  Whole	  exome	  sequencing	  	   	  	  	  	  	  	  	  
b)	  aCGH	  
Gene	   Type	  of	  
variation	  
Variation	   Hetero/	  
homozygous	  
Associated	  disease	   Expression	  in	  
skeletal	  muscle	  
in	  silico	  
prediction	  
Muscle	  disease	  genes	  TTN	   Nonsyn	   c.76381G>C:p.E25461Q	   Hetero	   LGMD2J,	  AR	   High	   Polymorphism	  
Chr	   Position	  of	  copy	  number	  
variation	  
Width	   Loss/	  
Gain	  
Average	  
ratio	   Genes	   Gene	  function	  
2	   2p23.3(24,172,948-­‐24,226,142)	   53,194	   Loss	   0.61	   MFSD2B,	  UBXN2A	   	  
2	   2q24.1(158,973,419-­‐158,977,935)	   4,516	   Loss	   0.60	   UPP2	   	  
3	   3p13(72,936,126-­‐72,942,214)	   6,088	   Loss	   0.73	   GXYLT2	   	  
3	   3q26.33(179,673,767-­‐179,676,437)	   2,670	   Gain	   1.45	   PEX5L	   	  
6	   6q22.1(117,738,906-­‐117,741,851)	   2,944	   Loss	   0.66	   ROS1	   tyrosine	  kinase	  
7	   7p22.2(2,881,402-­‐2,884,784)	   3,381	   Loss	   0.57	   GNA12	   autophagy	  +	  cilia	  
7	   7q36.1(151,121,398-­‐151,132,934)	   11,535	   Loss	   0.70	   CRYGN,	  MIR3907	   	  
9	   9q22.33(101,868,408-­‐101,870,269)	   1,861	   Loss	   0.60	   TGFBR1	   Loeys-­‐Dietz	  Syndrome	  
12	   12p13.1(14,104,394-­‐14,109,484)	   5,089	   Loss	   0.68	   GRIN2B	  
NMDA	  receptor	  subunit	  2b,	  
epileptic	  enecephalopathy	  
12	   12q13.11(46,653,133-­‐46,657,444)	   4,310	   Loss	   0.61	   SLC38A1	   glutamate	  transporter	  
13	   13q12.13(27,740,968-­‐27,744,739)	   3,770	   Loss	   0.58	   USP12	  
deubiquinating	  of	  androgen	  
receptor	  
17	   17p12(11,137,471-­‐11,145,786)	   8,315	   Loss	   0.67	   SHISA6	   	  
19	   19p13.11(16,471,925-­‐16,473,249)	   1,323	   Loss	   0.44	   EPS15L1	   	  
19	   19p13.11(17,749,656-­‐17,769,491)	   19,834	   Loss	   0.70	   UNC13A	   APP	  processing	  
21	   21q22.3(43,932,365-­‐43,933,471)	   1,106	   Loss	   0.54	   SLC37A1	   sugar	  phosphate	  transporter	  
Table 5.34: Table of novel variations identified in Case 18 a) Novel variations idenitifed in
whole exome sequencing, b) Novel copy number variations identified in aCGH.
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5.4 Efficacy of Mexiletine in Treating Non-dystrophic
Myotonia
5.4.1 Study Population
Overall, 62 patients were recruited across all sites between December 2008 and January 2011.
Three patients were ineligible at screening due to prolonged QTc interval, elevated alanine
transaminase or no myotonia seen on clinical examination. 59 patients were randomised,
29 patients received mexiletine and then placebo and 30 patients received placebo then
mexiletine. Two patients data were not usable as they did not call into the IVR system
enough times during weeks three and four of either period. There were three dropouts, one
for gastric discomfort, one with exacerbation of migraine and one with failure to attend study
visits (Figure 5.60). 57 patients were included in the modified intention to treat analysis (two
were excluded as they did not call the IVR during either period of treatment). In the UK
group, 14 patients were recruited and randomised, seven to mexiletine and then placebo and
seven to placebo and then mexiletine. One of the drop outs was from the UK cohort due to
exacerbation of migraines.
Enrolled
n = 62
Randomised
n = 59
Placebo
n = 30
Mexiletine
n = 29
Placebo
n = 30
Mexiletine
n = 29
Analysed
n = 55
Excluded
n = 3
Withdrawn
n = 2
Withdrawn
n = 2
Figure 5.60: CONSORT flow diagram of patients assessed in the study of the efficacy of
mexiletine in NDM
5.4.1.1 Demographics
In the whole cohort there were 33 men (56%) and 26 women (44%). The median age was 42
years and mean age 43 years. Patients were predominantly Caucasian (57/59). 34 patients
had chloride channel mutations of which 20 had dominant MC and 14 had recessive MC. 21
patients had a sodium channel mutation, 12 of which had PMC and 9 of which had SCM
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(Figure 5.61). 4 patients had no mutations identified. 17 patients were on drug treatment for
myotonia prior to starting the study of which 13 (76%) were taking mexiletine. All patients
had the appropriate washout period (equivalent of 5 times the half life of drug) prior to starting
the study. The groups in the different treatment sequences (those who received mexiletine
then placebo versus placebo then mexiletine) were well balanced (Table 5.35).
Figure 5.61: Distribution of patient diagnoses in the mexiletine study.
5.4.2 Primary Outcome Measure
There was a significant improvement in stiffness as recorded by IVR when patients were on
mexiletine (Figure 5.62). In period 1 the mean stiffness score was 2.53 on mexiletine and
4.21 on placebo and for period 2 it was 1.60 for mexiletine and 5.27 for placebo. When
group scores were compared in treatment period 1 this gave a difference of 1.68 (95% CI
2.66 to 0.706; p<0.001) and in period 2 a difference of 3.68 (95% CI 3.85 to 0.139 p=0.04).
The Wald test comparing the difference in scores from period 1 to period 2 was significant
(estimate 0.997, p=0.04) and therefore the p-value for the analysis of period 2 was corrected
based on the Wald estimate to account for the carry-over effect.
5.4.3 Secondary Outcome Measures
Mexiletine improved the majority of secondary outcome measures (Table 5.37). There was a
significant improvement in patient-reported pain, weakness and tiredness (p<0.001). There
were also significant improvements in both eye closure myotonia (mexiletine 0.161s vs
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Figure 5.62: Stiffness severity by treatment group in the mexiletine study a) Individual
treatment severity scores by treatment group in second two weeks of treatment, b) Average
stiffness severity by treatment group in all four weeks of treatment (supplied by J. Statland)
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 Mexiletine then 
Placebo group  
(n=29) 
Placebo then 
mexiletine group 
(n=30) 
Age, mean (range), yrs 41.1 (16-66)	   44.7 (22-68)	  
Male sex  13 (44.8)	   20 (66.7)	  
Caucasian  28 (96.6)	   29 (100.0)	  
Medication prior to study 	   	  
Mexiletine  7 (24.1)	   6 (20.0)	  
Other  3 (10.3)	   1 (3.3)	  
IVR diary–stiffness, mean (SD) 3.89 (2.39)	   4.63 (2.99)	  
SF-36, mean (SD) 	   	  
Physical, norm-based  38.7 (9.65)	   40.8 (11.0)	  
Mental component  44.5 (13.3)	   47.6 (9.8)	  
INQOL–QOL score, mean (SD) 14.0 (9.03)	   15.9 (12.5)	  
Geometric-like mean (pseudo SD), secs 	   	  
Clinical hand-opening time  1.11 (0.898-3.48)	   0.605 (0.510-1.84)	  
Clinical eye-opening time   0.507 (0.486-2.42)	   0.466 (0.455-2.31)	  
Quantitative handgrip myotonia  0.651 (0.288-0.518)	   0.507 (0.211-0.361)	  
Electromyographic grade = 3  
Abductor digiti minimi   
 
18 (62.1)	    18 (62.1)	  
Short exercise test (% of baseline), mean (SD) 78.7 (24.5)	   80.8 (28.7)	  
Mutation 	   	  
Chloride  17 (58.6)	   17 (56.7)	  
Sodium  10 (34.5)	   11 (36.7)	  
None identified 	   2 (6.9)	   2 (6.7)	  	  
Table 5.35: Screening baseline characteristics of the 2 treatment sequence groups
placebo 0.474s; p<0.001) and hand grip myotonia (mexiletine 0.164s vs placebo 0.494s;
p<0.001). Quantitative hand grip assessment, measuring the relaxation time to drop from
90% to 5% of isometric contraction also showed a significant improvement (mexiletine,
0.321s versus placebo, 0.429s; p<0.001). There was no difference between results in the
long (p=0.50) or short exercise tests (p=0.09). However, there was a marked improvement
in severity of EMG myotonia when on mexiletine compared to placebo (p<0.001) (Figure
5.63d, Table 5.37).
Quality of life measures showed significant improvements in the majority of physical
aspects with mexiletine treatment (Table 5.37). INQoL had a significant improvement in
the summary quality of life (QOL) score (mexiletine 14.0 vs placebo 16.7; p<0.001) with
improvement in all aspects apart from weakness (Figure 5.63b). Of note muscle locking,
pain and fatigue were all improved. SF-36 showed improvement of overall physical function
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(mexiletine 42.8 vs placebo 37.8; p<0.001) and bodily pain (mexiletine 49.8 vs placebo 42.0;
p<0.001) (Figure 5.63a).
Figure 5.63: Graphs of change in secondary outcome measures in the mexiletine study a)
SF-36 scales in mexiletine versus placebo groups, b) INQoL scales in mexiletine versus placebo
groups, c) Hand grip opening time in mexiletine versus placebo groups, d) EMG myotonia grade
in placebo versus mexiletine groups (Graphs supplied by J.Statland)
5.4.4 Subgroup Analysis
Subgroup analysis of the effect of mexiletine in chloride channel patients versus sodium
channel patients was performed. It demonstrated a more marked decrease in hand grip
myotonia in chloride channel patients compared with sodium channel patients (chloride
channel, -1.24s versus sodium channel, -0.355s; p=0.04). The reduction in stiffness severity
was greater for patients with chloride channel mutations in treatment period 2, however,
patients with sodium channel mutations showed a greater reduction in stiffness severity
during treatment period 1. There was no significant difference between chloride and sodium
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channel patients in the reduction in eye closure myotonia or patient-reported weakness. This
was despite there being a significant difference between the proportion of patients who had
eye closure myotonia with sodium channel mutations compared to chloride channel mutations
(91% vs 46%, p=0.002) and a significant difference in the maximum duration of stiffness
between the two groups (8.5s vs 0.89, p=0.008). In comparison, although there was a
significant difference between those who had hand grip myotonia with chloride channel
mutations versus those with sodium channel mutations (97% vs 68%, p=0.012), there was
no significant difference in the maximum duration of stiffness between the two groups (3.3s
vs 3.4s, p=0.94). Subgroup analysis of neurophysiology testing was not practical giving the
large variation in response between subgroups.
5.4.5 Drug Safety and Tolerability
Mexiletine was well tolerated and safe. There was one serious adverse event that was deemed
to be unrelated to the study (due to narcotics withdrawal) (Table 5.36). The commonest side
effect was gastrointestinal, affecting nine subjects in the mexiletine group and one subject in
the placebo group. The majority of symptoms were relieved with over the counter medication
or a reduction of mexiletine to twice daily dosing. One patient did not continue with the
second phase of the study due to gastric discomfort. There were two reported cardiac events,
both incidentally identified on ECG at the end of the treatment phase. One patient had
bradycardia whilst on mexiletine, which resolved on follow-up and the other had premature
ventricular complexes whilst on placebo. Both patients were asymptomatic and did not
require termination of study participation.
5.4.6 Compliance and Blinding
Compliance with treatment was 90.2% for mexiletine and 92.7% for placebo for period 1 and
93% for mexiletine and 92.7% for placebo in period 2. Mexiletine levels in all patients at
baseline and following washout periods were undetectable. The mean (SD) mexiletine level
at the end of the treatment period was 0.54(0.35)µg/ml (therapeutic anti-arrhythmic level,
0.5-2.0µg/ml).
Compliance with calling into the IVR diary during the primary outcome time period
(weeks 3 to 4) was 74.3% (78.6% in period 1 and 70.0% in period 2).
Patients were surveyed to determine if they were fully blinded to treatment allocations
given the side effect profile of mexiletine. In treatment period 1, 64% (18/28) correctly
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Category	   Mexiletine	   Placebo	  
Cardiac	   1	   1	  
Constitutional	   3	   0	  
Dermatology/Skin	   1	   2	  
Gastrointestinal	   9	   1	  
Infection	   1	   3	  
Lymphatics	   0	   1	  
Musculoskeletal/Soft	  Tissue	   0	   2	  
Neurologic	   5	   1	  
Pain	   4	   0	  
Total	   24	   11	  	  
Table 5.36: Adverse events in the mexiletine study
identified that they were on mexiletine and 69% (20/29) correctly identified that they were on
placebo. In period 2, 79% (23/29) correctly identified being on mexiletine and 80% (20/28)
on placebo.
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Table 5.37: Table of secondary outcome measures for the mexiletine study
Endpoint	  –	  Period	  (No.	  of	  
Participants)	  
Mean	  
Mexiletine	  
Treatment	  
(95%	  CI)	  
Mean	  
Placebo	  
Treatment	  
(95%	  CI)	  
Treatment	  
Effect	  Estimate	  
(95%	  CI)	  
Effect	  
Size	  
p-­‐
value	  
IVR:	  Stiffness	  –	  First	  (57)	  	   2.53	  (1.80,	  3.17)	   4.21	  (3.40,	  5.20)	   -­‐1.68	  (-­‐2.66,	  -­‐0.706)	   -­‐1.36	   <0.001	  
IVR:	  Stiffness	  -­‐	  Second	  (57)	   1.60	  (1.04,	  2.20)	   5.27	  (4.44,	  6.27)	   -­‐3.68	  (-­‐3.85,	  -­‐0.139)	   -­‐2.97	   0.04	  
IVR:	  Pain	  –	  Overall	  (48)	   1.54	  (0.924,	  2.13)	   3.17	  (2.43,	  3.93)	   -­‐1.63	  (-­‐2.00,	  -­‐1.26)	   -­‐1.36	   <0.001	  
IVR:	  Weakness	  –	  Overall	  
(44)	  	  
1.96	  (1.42,	  2.63)	   3.22	  (2.52,	  3.98)	   -­‐1.26	  (-­‐1.67,	  -­‐0.861)	   -­‐0.994	   <0.001	  
IVR:	  Tiredness	  –	  Overall	  (49)	  	   2.9	  (2.12,	  3.68)	   3.82	  (3.03,	  4.53)	   -­‐0.918	  (-­‐1.30,	  -­‐0.532)	   -­‐0.709	   <0.001	  	  
Short	  Exercise	  –	  Overall	  (%	  
baseline;	  56)	  
83.1	  (77.5,	  88.4)	   78.6	  (71.9,	  84.7)	   4.54	  (-­‐0.680,	  9.75)	   0.347	   0.09	  
Prolonged	  Exercise	  –	  Overall	  
(%	  baseline;	  56)	  
81.8	  (76.8,	  87.0)	   80.1	  (74.7,	  86.4)	   1.69	  (-­‐3.34,	  6.73)	   0.134	   0.50	  
Needle	  EMG:	  ADM	  –	  Overall	  
(56)	  
2.05	  (1.75,	  2.33)	   2.62	  (2.39,	  2.86)	   -­‐0.568	  (-­‐0.812,	  -­‐0.325)	   -­‐0.947	   <0.001	  
Needle	  EMG:	  TA	  –	  Overall	  
(56)	  
2.07	  (1.73,	  2.37)	   2.54	  (2.28,	  2.76)	   -­‐0.464	  (-­‐0.675,	  -­‐0.254)	   -­‐0.900	   <0.001	  	  
Clinical	  Assessment:	  Eye	  
Closure	  	  –	  Overall	  (seconds;	  
57)	  
0.161	  (0.0704,	  0.314)	   0.474	  (0.261,	  0.871)	   -­‐0.313	  (-­‐0.602,	  -­‐0.149)	   -­‐0.888	   <0.001	  
Clinical	  Assessment:	  Hand	  
Grip	  –	  Overall	  (seconds;	  57)	  	   0.164	  (0.0858,	  0.294)	   0.494	  (0.281,	  0.872)	   -­‐0.330	  -­‐0.633,	  -­‐0.142)	   -­‐0.748	   <0.001	  
QMA	  Hand	  Grip	  –	  	  Overall	  
(seconds;	  54)	  	   0.321	  (0.274,	  0.370)	  	   0.429	  (0.365,	  0.517)	   -­‐0.109	  (-­‐0.177,	  -­‐0.0560)	  	   -­‐0.518	   <0.001	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Table 5.37: Table of secondary outcome measures for the mexiletine study (cont.)
Endpoint	  –	  Period	  (No.	  of	  
Participants)	  
Mean	  
Mexiletine	  
Treatment	  
(95%	  CI)	  
Mean	  
Placebo	  
Treatment	  
(95%	  CI)	  
Treatment	  
Effect	  
Estimate	  	  
(95%	  CI)	  
Effect	  
Size	  
p-­‐
value	  
SF36:	  	  Physical	  Function	  –	  
Overall	  (57)	  
42.8	  (40.1,	  46.1)	   37.8	  (34.9,	  41.3)	   5.00	  (2.81,	  7.20)	   .904	   <0.001	  
SF36:	  	  Role	  Physical	  –	  
Overall	  (57)	  
46.5	  (43.6,	  49.2)	   39.2	  (35.7,	  42.6)	   7.23	  (4.55,	  9.92)	   1.07	   <0.001	  
SF36:	  	  Bodily	  Pain	  –	  Overall	  
(57)	  
49.8	  (46.4,	  52.6)	   42.0	  (38.6,	  45.5)	   7.78	  (5.08,	  10.5)	   1.14	   <0.001	  
SF36:	  	  General	  Health	  –	  
Overall	  (57)	  
45.5	  (41.9,	  48.7)	   44.5	  (41,	  47.7)	   0.977	  (-­‐0.659,	  2.61)	   0.240	   0.24	  
SF36:	  	  Vitality	  -­‐	  First	  (57)	   45.5	  (41.1,	  49.6)	   43.7	  (39.7,48.1)	   1.76	  (-­‐4.34,	  7.85)	   0.211	   0.57	  
SF36:	  	  Vitality	  –	  Second	  (57)	   51.9	  (48.1,	  55.5)	   40.0	  (35.1,	  45.0)	   11.9	  (-­‐0.307,	  20.5)	   1.43	   0.06	  
SF36:	  	  Social	  Function	  –	  
Overall	  (57)	  
47.1	  (44.4,	  49.8)	   41.9	  (38.5,	  44.9)	   5.27	  (2.69,	  7.85)	   0.809	   <0.001	  
SF36:	  	  Role	  Emotional	  -­‐	  First	  
(57)	  
46.2	  (42.0,	  50.3)	   45.5	  (41.2,	  49.4)	   0.764	  (-­‐5.68,	  7.21)	   0.102	   0.81	  
SF36:	  	  Role	  Emotional	  -­‐	  
Second	  (57)	  
49.9	  (46.2,	  53.1)	   39.1	  (33.5,	  45.0)	   10.8	  (-­‐1.51,	  21.6)	   1.45	   0.09	  
SF36:	  	  Mental	  Health	  -­‐	  First	  
(57)	  
47.3	  (43.6,	  51.0)	   47.3	  (43.7,	  50.6)	   0.016	  (-­‐5.24,5.27)	   0.00258	   0.99	  
SF36:	  	  Mental	  Health	  –	  
Second	  (57)	  
53.3	  (50.2,	  56.2)	   44.4	  (39.8,	  48.7)	   8.84	  (-­‐0.572,	  18.2)	   1.42	   0.07	  
SF36:	  	  Physical	  Composite	  –	  
Overall	  (57)	  
44.8	  (41.9,	  47.4)	   39.2	  (35.9,	  41.9)	   5.58	  (3.44,	  7.72)	   1.04	   <0.001	  
SF36:	  	  Mental	  Composite	  -­‐	  
First	  (57)	  
47.4	  (44.0,	  50.2)	   47.7	  (44.2,	  51.3)	   -­‐0.351	  (-­‐5.87,	  5.17)	   -­‐0.0539	   0.90	  
SF36:	  	  Mental	  Composite	  –	  
Second	  (57)	  
53.1	  (50.3,	  55.8)	   42.7	  (36.8,	  48.3)	   10.4	  (0.941,	  20.6)	   1.60	   0.03	  	   	  
5.4. Efficacy of Mexiletine in Treating Non-dystrophic Myotonia 215
Table 5.37: Table of secondary outcome measures for the mexiletine study (cont.)
Endpoint	  –	  Period	  (No.	  of	  
Participants)	  
Mean	  
Mexiletine	  
Treatment	  
(95%	  CI)	  
Mean	  
Placebo	  
Treatment	  
(95%	  CI)	  
Treatment	  
Effect	  
Estimate	  	  
(95%	  CI)	  
Effect	  
Size	  
p-­‐
value	  
INQoL:	  	  Weakness	  –	  Overall	  
(35)	  
45.7	  (37.7,	  52.6)	   49.3	  (41.7,	  57.3)	   -­‐3.56	  (-­‐9.54,	  2.43)	   -­‐0.290	   0.24	  
INQoL:	  	  Muscle	  Locking	  –	  
Overall	  (43)	  
40.0	  (33.1,	  46.7)	   53.8	  (46.4,	  61.1)	   -­‐13.7	  (-­‐20.4,	  -­‐7.03)	   -­‐0.888	   <0.001	  
INQoL:	  	  Pain	  –	  Overall	  (32)	   39.9	  (30.6,	  49.0)	   48.2	  (39.2,	  57.1)	   -­‐8.32	  (-­‐13.8,	  -­‐2.87)	   -­‐0.782	   0.004	  
INQoL:	  	  Fatigue	  –	  Overall	  
(35)	  
48.4	  (40.9,	  56.6)	   58.3	  (50.6,	  66.0)	   -­‐9.96	  (-­‐17.0,	  -­‐2.93)	   -­‐0.678	   0.007	  
INQoL:	  	  Activity	  –	  Overall	  
(51)	  
34.2	  (26.7,	  43.0)	   47.1	  (40.1,	  55.5)	   -­‐12.9	  (-­‐18.3,	  -­‐7.43)	   -­‐0.950	   <0.001	  
INQoL:	  	  Independence	  –	  
Overall	  (51)	  
17.8	  (12.3,	  23.3)	   22.5	  (17.2,	  28.1)	   -­‐4.74	  (-­‐8.14,	  -­‐1.35)	   -­‐0.561	   0.007	  
INQoL:	  	  Social	  Relations	  –	  
Overall	  (51)	  
18.9	  (13.5,	  24.5)	   25.9	  (18.0,	  35.2)	   -­‐7.02	  (-­‐13.4,	  -­‐0.671)	   -­‐0.440	   0.03	  
INQoL	  -­‐	  Emotions	  –	  Overall	  
(51)	  
27.7	  (22.0,	  34.4)	   33.8	  (27.1,	  41.5)	   -­‐6.13	  (-­‐10.1,	  -­‐2.15)	   -­‐0.619	   0.003	  
INQoL:	  	  Body	  Image	  –	  Overall	  
(51)	  
24.2	  (17.3,	  31.0)	   29.4	  (22.0,	  36.5)	   -­‐5.27	  (-­‐10.4,	  -­‐0.105)	   -­‐0.408	   0.05	  
INQoL:	  QOL	  –	  Overall	  (51)	   14.0	  (11.6,	  16.5)	   16.7	  (14.0,	  19.4)	   -­‐2.69	  (-­‐4.07,	  -­‐1.30)	   -­‐0.780	   <0.001	  
INQoL:	  	  Perceived	  Treatment	  
Effect	  –	  Overall	  (51)	  
36.6	  (27.1,	  45.8)	   21.7	  (12.7,	  31.1)	   14.9	  (7.43,	  22.3)	   0.797	   <0.001	  
INQoL:	  	  Expected	  Treatment	  
Effect	  –	  Overall	  (51)	  
36.1	  (26.9,	  47.0)	   23.1	  (14.5,	  33.6)	   13.0	  (4.18,	  21.8)	   0.585	   0.005	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Chapter 6
DISCUSSION
6.1 Prevalence Study of the Skeletal Muscle Channelopathies
in England
6.1.1 Key Findings of the Prevalence Study
This prevalence study identifies the overall prevalence of skeletal muscle channelopathies in
England. It estimates the minimum prevalence at 1.12/100,000, suggesting it is comparable to
other rare neuromuscular disorders such as Pompe Disease (1.1/100,000) and Lambert-Eaton
myasthenic syndrome (1.0/100,000) (www.orpha.net). The prevalence of the commonest
channelopathy, MC was estimated at 0.52/100,000 and PP at 0.37/100,000.
6.1.2 Novel Findings Identified in the Prevalence Study
This is the first documented study investigating the prevalence of all of the skeletal muscle
channelopathies as there are no other studies documenting the prevalence of HyperPP, ATS
or SCM in any country. It is also the only study to estimate channelopathy prevalence
for the whole of England. The only previous study identified prevalence for a part of
northern England (Walton and Nattrass, 1954). This is the largest series of patients with
genetically-defined skeletal muscle channelopathies reported to date and one of very few
conducted since genetic testing has become widely available (Darin and Tulinius, 2000; Sun
et al., 2001). It is also one of the only studies to use only genetically confirmed cases to try
to accurately determine the minimum point prevalence (Sun et al., 2001).
218 6. DISCUSSION
6.1.3 Comparison with Previous Prevalence Studies
As this is the first study of prevalence of all skeletal muscle channelopathies it is difficult
to compare the overall results, however the individual prevalences can be compared. The
majority of literature available discusses the prevalence of MC. When all the previous
literature is combined it estimates the prevalence of MC worldwide at approximately
0.67/100,000 with a range from 0.3-9.0/100,000 (Table 2.2, p 36). The prevalence of MC
in this study is comparable to the lower end of the average and this is likely to be related
to the fact that I have only used genetically confirmed cases. The prevalence for England is
significantly lower when compared to the Scandinavian countries, which report prevalences
between 7-9/100,000 (Baumann et al., 1998; Sun et al., 2001) but this is likely to be related
to the founder effect and geographical restrictions of that region causing higher prevalences
than is seen in other areas of the world (Baumann et al., 1998; Papponen et al., 1999; Sun
et al., 2001).
In keeping with other reports of MC prevalence, the male to female ratio was 1.97
(Papponen et al., 1999) with a higher ratio in recessive MC than dominant MC (Becker et al.,
1977) (Table 5.1, p 97). This may be due to the fact that females are more mildly affected than
males and therefore there may be a selection bias towards male patients (Becker et al., 1977;
Colding-Jorgensen, 2005). A possible explanation for the ratio being higher in recessive MC
is that there have been reports of male patients with single recessive mutations being more
likely to have myotonia on EMG, suggesting that there may be male manifesting carriers
(Deymeer et al., 1999; Mailander et al., 1996). However, when the cases in this study were
analysed there were only two heterozygous patients with recessive MC and although they
were both male they would not be enough to account for the large difference here in the male
to female ratio seen between dominant and recessive cases in this cohort. This suggests that
there may be a hormone-related explanation for this (Fialho et al., 2008; Burge et al., 2013).
The prevalence of PMC from other studies ranges from 0.2-1.1/100,000 (Table 2.2).
These studies do not make a distinction between SCM and PMC and therefore it is likely that
the term PMC was used to encompass both diseases. This study estimates the prevalence of
PMC and SCM together at 0.22/100,000 and therefore matches the lower end of other studies.
The prevalence of HypoPP from other studies ranges from 0.4-1.7/100,000 but all
studies pre-date genetic testing (Table 2.2). The overall estimate for PP from this study is
0.37/100,000 with HypoPP specifically at 0.17/100,000. This difference is likely to be related
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to the clinical overlap between the different types of periodic paralysis as well as the overlap
between HypoPP and other neuromuscular disorders causing an overestimate and possible
misclassification of cases if genetic testing is not done. This problem is more common in the
diagnosis of PP than in NDM as the main objective clinical test, the long exercise test, is only
positive in approximately 60% of cases. This is unlike in NDM, when myotonia on EMG can
provide an objective marker of disease with a high negative predictive value as only a handful
of cases do not have myotonia.
There is likely to be an underestimate in cases in this study as only genetically confirmed
cases were counted. This is especially problematic in PP as it is known that approximately
20% of cases remain genetically unconfirmed despite full sequencing of known channel genes
(Sternberg et al., 1993; Jurkat-Rott and Lehmann-Horn, 1993). If this is corrected for in the
prevalence estimate then the prevalence for PP in England would be closer to 0.46/100,000
which is in keeping with other studies but still at the lower end of other estimates. The
male to female ratio for PP in this study was strikingly high at 3.52 (Figure 5.2, p 98). It
has been noted in many other studies that the ratio is high in HypoPP and this is thought to
be related to reduced penetrance in women but other studies have only reported a ratio of
between 1.23-1.63 (Elbaz et al., 1995; Miller et al., 2004). The high ratio was primarily in
patients with the Arg528His mutation, at 5.8 and it is unclear why the ratio overall is still
much higher. It may be related to a greater selection bias due to under-reporting in milder
females as this study follows an epidemiological design rather than a genetic study design in
which all family members would be sequenced.
6.1.4 Genetic Mutations Identified in the Prevalence Study
The spectrum and frequency of genetic alterations observed in patients with NDM and PP
were similar to those reported in the literature (Feero et al., 1993; Fouad et al., 1997; Miller
et al., 2004; Donaldson et al., 2004; Vicart et al., 2005; Lossin and George, 2008). A large
number of private mutations were found in patients with MC and ATS. However, only a
limited number of mutations accounted for most cases: 15 CLCN1 mutations accounted for
disease in 83% of all patients with MC, 11 SCN4A mutations in 86% of PMC and SCM
pedigrees (Figure 5.4, p 101) and three KCNJ2 mutations in 42% of ATS pedigrees.
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6.1.4.1 Myotonia Congenita
Whilst previous surveys have suggested a predominance of recessive over dominant MC, I
found similar percentages of dominant and recessive pedigrees (Baumann et al., 1998; Sun
et al., 2001; Becker et al., 1977). Studies in areas with high prevalence of MC have shown
that more than 85% of affected individuals were compound heterozygous or homozygous
for CLCN1 mutations, suggesting recessive inheritance in most cases, even in families with
apparent dominant transmission (Papponen et al., 1999; Sun et al., 2001). This may be
explained by a high carrier frequency of certain mutations in those areas, probably resulting
from a founder effect and geographical isolation (Papponen et al., 1999; Sun et al., 2001). In
this study, most patients with a dominant family history were heterozygous, with variations
that are known to exhibit a dominant-negative effect, supporting a true dominant inheritance
(Figure 5.5, p 103). One possible bias in this study data could be that there is more likely
to be accurate family history data in dominant MC pedigrees therefore making it easier to
classify these patients compared with recessive MC giving the appearance of higher numbers
of dominant versus recessive cases. Also, patients with a dominant family history may exhibit
a reporting bias as they know what signs are associated with the disease. When family history
was excluded the total proportion of heterozygous patients (59%) was higher than that of
patients with two or more mutated alleles (41%) suggesting that this may be a true difference
in the British population.
In this study, the breakdown of mutations in MC patients and the frequency with
which they are associated with second mutations was assessed. It is thought that certain
mutations cause dominant-negative inhibition of the ClC-1 homodimer resulting in dominant
MC and dominantly inherited disease. However, it has been observed that some mutations in
CLCN1 can cause both dominantly and recessively inherited disease (George et al., 1994;
Meyer-Kleine et al., 1995; Zhang et al., 1996; Sun et al., 2001) although the mechanism for
this is not understood. This study allowed a closer look at the inheritance of a large number of
mutations. It demonstrates that the majority of heterozygous mutations were associated with
dominant MC (95%). Of the two patients with recessive MC and a single mutation, one had
a novel mutation, Val321Leu, and the other carried Phe413Cys which, although is commonly
associated with recessive MC, has been identified heterozygously in another study (and is
seen here heterozygously in two other cases with unknown family histories) (Sun et al.,
2001). The makes it more likely that in these cases there may be a second mutation that has
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yet to be identified.
When a mutation-specific analysis is done, however, the the issue of variable inheritance
is more evident. For instance the Gly285Glu mutation is expressed with a second mutation
in only 65% (20) of cases. In the remaining 11 cases the family history could not be fully
identified so it is not clear if in those cases it is associated with the dominant MC. A similar
case is seen for Phe167Leu and Val327Ile when 63%(5) and 57%(4) of cases were associated
with a second mutation. However in all the single mutation cases, again the inheritance
was unknown. So although the data here supports the possibility of variable inheritance for
particular mutations it must be interpreted with caution as the family data was not available.
The other mutation which is commonly discussed in the literature as being associated
with dominant and recessive MC is Arg894X. It is commonly associated with recessive
MC (George et al., 1994) but cellular electrophysiology studies for this mutation have
been inconclusive, demonstrating both a large reduction in chloride currents and a weak
dominant-negative effect in co-expression studies consistent with both recessive or dominant
inheritance (Meyer-Kleine et al., 1995). In this study 14 (78%) patients had a second
mutation expressed with it but three of these patients came from dominant pedigrees. The
family history was unknown for the four patients who only carried Arg894X. When the data
is critically assessed there is insufficient evidence for true duality in MC mutations.
6.1.4.2 PMC & SCM
This study demonstrates an interesting pattern for mutations causing PMC and SCM. As
has been found by others, all the cases with Thr1313Met and mutations at the Arg1448
locus clinically had PMC (McClatchey et al., 1992b; Ptacek et al., 1993; Hayward et al.,
1996; Yang et al., 1994) (Table 5.4b, p 104). However, although previously mutations at
the Gly1306 locus have traditionally been thought to only cause SCM (Mitrovic´ et al.,
1995; Ricker et al., 1994; Lerche et al., 1993; Colding-Jorgensen et al., 2006) this study
demonstrates that they can also be associated with PMC, especially Gly1306Val which was
associated with PMC in 6/8 patients (Table 5.4b). Some of this data was initially published by
our group suggesting that there were 3 atypical cases but since then we have found numerous
others (Matthews et al., 2008b).
The Val1589Met mutation is well documented as being associated with both PMC and
with SCM (Mitrovic´ et al., 1994; Ferriby et al., 2006; Heine et al., 1993); and there were
almost equal numbers of patients in this study (14:13) with each type of disease (Table 5.4b).
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Another 2 mutations which have previously been documented as being associated with only
PMC, Ile693Thr (Plassart-Schiess et al., 1998; Plassart et al., 1996; Hayward et al., 1999) or
only SCM, Val1293Ile (Green et al., 1998; Koch et al., 1995) were found to be associated
with both forms of the disease (Table 5.4b). This evidence demonstrates that there is more
phenotypic variability within different SCN4A genotypes than previously described and how
difficult it is to direct genetic testing based on current disease classification alone. This
suggests that further work may be needed to better differentiate between these two diseases.
6.1.4.3 Periodic Paralysis
Amongst patients with HypoPP, 82%(78) had HypoPP1 and 18%(17) HypoPP2. This is
higher than the 10-12% that has been previously documented in other studies (Sternberg
et al., 2001; Matthews et al., 2009) which may be related to the fact that previous studies did
not look for mutations in the whole of SCN4A and only sequenced specific exons. In this
study 6/17 of mutations in SCN4A were found outside of exons 12 and 18 and therefore
would have been missed by routine sequencing (Sternberg et al., 1993). In HypoPP1
the majority of patients had either Arg1239His (50%) or Arg528His (44%) mutations. In
HypoPP2 there was a more even spread of mutations although they did cluster around exons
12 and 18 (65%).
Amongst HyperPP patients, 75% (53) had mutations at Thr704Met and 20%(14) had
mutations at Met1592Val which is consistent with the numbers found in the large series by
Miller et al (Miller et al., 2004).
In ATS, I observed that the majority of mutations were personal to specific pedigrees as
described elsewhere (Donaldson et al., 2004) although the Arg218Trp and Arg67Trp were
each observed in four different UK families.
6.1.5 Limitations of the Prevalence Study
Due to the study design there are some limitations in the data. To ensure that only definite
cases were counted, only genetically-confirmed, clinically affected patients were included.
Whilst this gives a more accurate calculation of the minimum prevalence it makes it more
likely that this may be an underestimate of the true prevalence. There are other aspects of the
study design which increase the possibility of incomplete case ascertainment. The study had a
service-based, epidemiological design, so only affected individuals seeking medical attention
who were referred to our centre were identified. However, as the genetic diagnostic service
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for skeletal muscle channelopathies in England is centralised, this means all genetically
confirmed cases in England should have been captured. There are however, a small number
of patients who have been sending DNA samples to Germany as part of their free research
service and therefore they may not be captured unless they then seek intervention in England
following diagnosis. The common difficulty with these types of studies is that those who are
mildly affected and do not seek medical advice and those that may be part of large affected
families with a well established diagnosis, may choose not to have a formal genetic diagnosis
and therefore are not captured.
6.1.6 Further Work to Determine Prevalence
To take this work further it would be useful to repeat this study with a survey-based design
to see if a similar prevalence rate is identified, including approaching many of the charities
to distribute information and advertising on social media. This would reduce the problem
of incomplete ascertainment especially in mildly affected patients who are genetically
unconfirmed. It would also be useful to repeat the study including looking for patients with
mutations in the recently identified KCNJ18 gene (Ryan et al., 2010).
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6.2 Clinical Phenotype Study of Patients with PP and NDM
To date the only large phenotype studies in muscle chanelopathies in the UK cohort have been
in MC (Fialho et al., 2007). There have been some studies of HypoPP and HyperPP patients
in other countries (Miller et al., 2004; Charles et al., 2013) but no phenotype studies of these
diseases in the UK cohort. Again in ATS there have not been any large phenotype studies
in the UK cohort. Most strikingly, however, there have been no large studies internationally
comparing PMC and SCM patients. As part of this thesis, I therefore attempted to carefully
phenotype the UK cohort of patients with PMC, SCM, HypoPP, HyperPP and ATS to
establish the key features of these diseases in those with genetically confirmed disease.
There have also been no studies investigating the effect of anaesthetics and pregnancy
in NDM and PP patients and therefore I have attempted to ascertain key aspects of these two
conditions in patients compared with the general population.
6.2.1 Clinical Phenotypes of PMC & SCM
Traditionally patients with sodium channel mutations and prominent myotonia have been
divided into PMC and SCM (or PAMs). Patients with PMC have been described as
having myotonia with episodes of weakness. They typically have paramyotonia, worsening
myotonia with exercise, and are usually markedly cold-sensitive (Eulenburg, 1886). Patients
with SCM have been described as being potassium-sensitive with no episodes of weakness.
They may have warm-up, are not always cold-sensitive and may have delayed myotonia
following exercise (Trudell et al., 1987; Ricker et al., 1990; Lerche et al., 1993; Matthews
et al., 2010). As demonstrated in the prevalence study in the previous chapter, individual
mutations were associated with both diseases and some patients have a mixed presentation
making clinical diagnosis difficult. There are no large studies comparing the phenotypes of
these two diseases and little information published on the general phenotype of patients with
SCM. This study aimed to be the first to carefully phenotype patients with PMC and SCM and
identify key differentiating aspects between the two groups and improve diagnostic clarity.
However, when I analysed the data from a large cohort of genetically confirmed patients it
did not illustrate two clinically distinct groups. This suggests that these two conditions are
part of a spectrum of a single disease rather than two distinct diseases and it would be more
accurate to consider them as one disease.
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6.2.1.1 Key Differences between PMC and SCM
PMC and SCM are traditionally clinically differentiated by the presence or absence of
weakness. They are also thought to be distinguished by neurophysiology type, with PMC
associated with a Fournier type I pattern and SCM associated with a Fournier type III pattern.
I therefore first looked at how many patients, diagnosed by the assessing clinician with PMC
and SCM, had weakness and discovered that despite the traditional classification, not all
patients with PMC had weakness and some patients with SCM had episodes of weakness
(Figure 5.8, p 109). This suggested that there were flaws in the classification. This led
me to split the cohort according to the presence and absence of weakness rather than by
clinician diagnosis to see if this distinction produced two clinically distinct groups. As
illustrated in Table 5.6 (p 110), the only difference between these groups of over 80 patients,
was the severity of myotonia and that was not significant once multiple corrections were
accounted for. Surprisingly, none of the patients without episodes of weakness reported
potassium sensitivity as would be expected in SCM, which is traditionally composed of the
“potassium-aggravated” myotonias. This may either be because the incidence of potassium
sensitivity is lower than first thought or more likely because, since the advent of genetic
testing, we no longer perform potassium loading tests and so have no objective measure of
potassium sensitivity.
To investigate if neurophysiology classification was a better differentiator of patients
with PMC and SCM, I analysed the data according to Fournier type. This again did not
show any significant differences apart from in interictal potassium which was high in patients
with type III pattern of neurophysiology (associated with SCM). As type III is commonly
associated with PAM, the marginally higher interictal potassium may explain the increased
sensitivity to potassium in those patients. As previously reported it is however still within the
normal range for potassium in both groups (Miller et al., 2004) and the difference seen was
not significant once corrected for multiple comparisons.
6.2.1.2 Key Genotype-Phenotype Correlations in PMC and SCM
I then looked at the phenotypes of specific variations to see if specific genotypes were
associated with distinct phenotypes. This analysis was limited due to the relatively small
numbers but despite this, a number of interesting trends were revealed. Although all patients
with variations at position Arg1448 and those with the Thr1313Met variation were diagnosed
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as PMC, there was a mix of SCM and PMC diagnoses in patients with variations at position
Gly1306 and Val1589Met variations which may be why an arbitrary comparison of PMC and
SCM may lead to two similar phenotypic groups.
Overall this study found that Gly1306 variations were associated with older onset,
warm-up and more severe pain, which correlates with other publications (Ricker et al., 1994).
Patients tended to be both heat and cold-sensitive, which may be why others have reported
patients not being as cold-sensitive as seen in other variations (McClatchey et al., 1992b).
Patients were less likely than in other variations to have attacks of weakness but weakness
was still seen in 50% of the UK cohort, contrary to previous reports that this mutation was
primarily associated with SCM and no attacks of weakness (McClatchey et al., 1992b; Ricker
et al., 1994). Attacks, however, tended to be shorter in duration and these patients frequently
had type III neurophysiology as previously reported (Fournier et al., 2006).
Arg1448 variations tended to have a younger age of onset also with warm-up. The
eyes were the most severely affected part and patients were more likely to have episodes of
weakness as described in the literature for classical PMC. In this cohort, patients had type
I neurophysiology, but this was only apparent after cooling. Electrical myotonia commonly
increased with cooling, suggesting electrical cold sensitivity. This is in contrast to previous
reports that suggest that Arg1448 variations are associated with a type I pattern without the
need for cooling (Fournier et al., 2004, 2006).
Thr1313Met patients had a younger onset of symptoms and were more sensitive to
exertion than the other mutations. They also more commonly had episodes of weakness
consistent with reports that they were commonly associated with a PMC phenotype
(McClatchey et al., 1992b; Ptacek et al., 1993). Attacks were more frequent and longer
duration than the other mutations. In keeping with this they had type I neurophysiology,
abnormal long exercise testing and myotonia reduced by cold.
The Val1589Met mutations had an older age of onset with eyes markedly affected. They
were often heat as well as cold sensitive and had limb hypertrophy on examination. They
were also noted to have a high CK and type III pattern of neurophysiology.
6.2.1.3 Suggestions for a Change in Nomenclature
Analysing the data from a large number of patients with sodium channel mutations, it
appears that the traditional distinction of patients as having PMC or SCM according to
presence or absence of weakness is arbitrary and there is no significant phenotypic difference
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between these two groups. This also holds true when dividing patients according to their
neurophysiology pattern. Overall, cold sensitivity was very common amongst all patients,
being seen in 93% and therefore not restricted to the PMC phenotype. Warm-up was also
more common than previously thought and reported in 35% of all patients. Painful myotonia
was also common amongst patients, reported in 78% but not particularly associated with
SCM or patients with no weakness as has been previously suggested (Trudell et al., 1987). As
originally observed by Eulenburg, I also found face and eyelid myotonia were very common.
The similarity of the phenotypes of PMC and SCM may explain why there have been
many reports of patients with the same mutation, both from different pedigrees and even
occasionally within the same pedigree, that may present with either PMC or SCM (Plassart
et al., 1996; Matthews et al., 2008b). This finding would be better explained by these
conditions being part of the same disease. I did however, find specific genotype-phenotype
correlations in this cohort suggesting that particular variations predispose an individual to
being at a particular end of the sodium channel disease spectrum. I therefore propose that it
may be more clinically useful to diagnose patients as having “Sodium channel disease” with
further clinical advice being given according to the specific genotype identified on genetic
testing.
6.2.2 Phenotypic Differences in HyperPP versus PMC & SCM
Since dividing PMC and SCM patients did not yield any differences, I set out to confirm
that the UK cohort of PMC and SCM patients was still phenotypically different from those
with HyperPP. The data showed significant differences between these two groups, especially
related to painful myotonia and the nature of the attacks of weakness (Figure 5.13, p 121).
Those with PMC/SCM tended to have shorter more frequent attacks of milder severity. These
were more likely to be focal and occur at any time of day compared with the primarily
night-time, generalised attacks seen in HyperPP.
The nature of the myotonia in these two groups, however was very similar although,
as with the episodes of weakness it tended to be more generalised in HyperPP and focal in
PMC/SCM with greater cold sensitivity. These results are in keeping with those published in
the large comparative study conducted by Miller et al (Miller et al., 2004), validating these
results.
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6.2.3 Clinical Phenotype of Periodic Paralysis
There is one large comparative phenotype study of patients with HypoPP and HyperPP
conducted in 2004 (Miller et al., 2004) that included genetically unconfirmed cases, but
since then no further studies have been published. There are no published studies that
compare ATS and the other types of PP and individual studies in ATS have looked at
fewer than 25 patients. I therefore attempted to phenotype a large number of genetically
confirmed PP patients referred to our centre to identify key phenotypic patterns, identify
genotype-phenotype correlations and further understand these diseases in the UK cohort.
The age of onset in HyperPP and HypoPP was similar to what has previously been
reported, with HyperPP cases having a significantly lower age of onset than HypoPP patients
(Miller et al., 2004) (Figure 5.15, p 126). The ratio of males to females was high as has been
suggested in other studies although this cohort had a higher ratio than was previously reported
in both HypoPP and HyperPP patients. This may suggest a lower penetrance in females in
this cohort than has previously been documented or may be related to ascertainment bias
as mildly affected females are less likely to be referred for genetic testing and assessment
(Sternberg et al., 2001; Charles et al., 2013). Others have also suggested that there is a
difference in age of onset between males and females (Sternberg et al., 1993), finding that
females tended to have two to three years earlier age of onset. I found an even more striking
difference with the median age of onset for women, 6.5 years younger than that for men (12
years versus 5.5 years) in HypoPP. In HyperPP and ATS however, the age of onset was much
more similar between genders (HyperPP, 5 versus 4 years and ATS, 10 versus 7.5 years). The
incidence of sporadic cases in this cohort was similar to that recently reported in HyperPP
of less than 10% (Charles et al., 2013) although previously it was thought that the incidence
was higher (Venance et al., 2006). This is likely to be because genetically unconfirmed cases
were included in previous estimates.
6.2.3.1 Key Phenotypic Features in HypoPP
To improve the knowledge of the HypoPP phenotype and identify key features present in the
UK cohort, I investigated key elements of the attacks of weakness (Table 5.10, p 124). I
found that almost all patients (48/49) had attacks of complete paralysis involving arms, legs
and neck which is similar to what has been reported previously (Sternberg et al., 1993).
To investigate attack frequency and duration, I split them into major and minor attacks to
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encompass the significant differences in types of attack commonly reported by patients. This
aimed to improve accuracy of reporting, as patients find it easier to report the worst ever attack
length than try to estimate an average length of their very variable attacks. Severe attacks of
complete paralysis occurred, on average, once a month whereas minor attacks, either focal
attacks or attacks with only partial paralysis, were on average 9.9 times per month. Severe
attacks lasted on average, 109 hours compared to 52 hours for minor attacks. Previous papers
have not made this distinction in types of attacks but I felt it was important to do so as, after
talking to patients, there is extensive variability in attack length in each individual. Previous
estimates of attack frequency range from 7 to 9 attacks per month (Miller et al., 2004) which
matches my estimate for minor attacks.
The average duration of attacks in many studies are poorly defined and suggest it may
be hours to days. The only papers to fully quantify it suggested it was on average 20 hours
(Miller et al., 2004; Venance et al., 2006; Sternberg et al., 1993). I found the average attack
duration, even of minor attacks to be much higher suggesting under-reporting of average
attack length previously although it could alternatively represent over-reporting in this cohort
(Table 5.10). However, given that this higher attack duration is seen across all the UK patients
it may be an accurate representation. As a marker of severity I also looked at the number of
patients who required hospitalisation during severe attacks and in HypoPP this was as high as
82%. This has not been previously reported but gives an important insight into the associated
morbidity of the disease. Attacks primarily occurred at night or on waking (72%). Ictal
potassium was noted to be low in 93% of patients with a mean of 2.39mmol/L.
I investigated key precipitants and relievers of attacks in HypoPP and, as has been
reported throughout the literature, carbohydrates and strenuous exercise were the two
commonest precipitants (Miller et al., 2004; Venance et al., 2006; Sternberg et al., 1993;
Kantola and Tarssanen, 1992) (Table 5.10). Potassium supplementation helped relieve attacks
in the majority of cases (89%). Acetazolamide, dichlorphenamide and potassium sparing
diuretics were all effective in improving symptoms in the majority of patients who tried them.
Two patients reported worsening with dichlorphenamide, both of whom had HypoPP2 and
one reported worsening with a potassium-sparing diuretic.
Progressive weakness was noted in half of participants with an average age of onset of
36.7 years. There has been no systematic study investigating this but Links et al suggested
that it commonly occurs in the fourth to fifth decades independent of the attack frequency
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and severity (Links et al., 1990). This study therefore suggests that the age of onset may
be earlier than initially thought. There was also no correlation between attack frequency,
duration or age of onset of weakness and the age of onset of progressive weakness. Despite
only 20 patients reporting proximal weakness, 25 patients were found to have some proximal
weakness on examination suggesting that it may be under-reported by patients (Table 5.10).
The EMG was myopathic in 43%, with normal short exercise tests in all patients and
abnormal long exercise tests in only 67% of patients suggesting that it cannot be relied on to
identify all patients who are likely to be mutation positive. There was no correlation between
percentage decrement on long exercise testing and severity of attacks (p=0.634). 9 patients
had biopsies, all of which were abnormal, most commonly with vacuoles although one had
tubular aggregates similar to previous reports (Links et al., 1990) (Table 5.10).
There has only been one study of MRI in HypoPP in 6 patients which demonstrated a
difference in oedema compared with controls (Nagel et al., 2011). I found the MRI was
abnormal in 12 out of 14 patients with primarily fatty infiltration seen in the thighs. Those
without fatty infiltration in the thighs had oedema either in the calves or the thighs. 4 out of
the 12 patients had severe changes on MRI and all reported: progressive weakness, severe
to moderately severe attacks of weakness, fixed upper limb and lower limb weakness and
elevated CK. No patients with only mildly abnormal or normal MRI scans had fixed weakness
and all had normal or only mildly elevated CK (maximum 363IU/L). Two patients had mild
arm or leg weakness on examination and there was significant variation in attack severity
between the patients. Not only did MRI severity correlate with progressive weakness but
there was also a difference in the average age between those with severe to moderate changes
(43 years) and those with mild or normal changes (32 years). These findings suggest that
MRI findings may be a good marker of clinical severity and may be useful in prognosticating
for patients.
Phenotypic Differences in HypoPP1 versus HypoPP2
I investigated the key differences in phenotypes between HypoPP caused by mutations in
sodium versus calcium channels. There is conflicting evidence in previous studies as to
differences between these two groups. The two main studies only had a small number of
patients with HypoPP2, as was also the case in this study, making it difficult to make strong
conclusions about these two phenotypes (Miller et al., 2004; Sternberg et al., 2001).
Miller et al suggested that those with HypoPP1 had an earlier age of onset and longer
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duration of attacks compared to HypoPP2 (Miller et al., 2004). However the original study
in which the HypoPP2 mutation, Arg672Gly was identified suggests that the age of onset
is lower than Arg528His mutations and similar to Arg1239His mutations (Sternberg et al.,
2001). This study had marginally more patients sampled (n=11) compared to the Miller et al
paper (n=7) but also found that the age of onset for HypoPP2 cases was younger (although
not significantly so), especially compared to the Arg528His patients. The Miller et al study
suggested that the duration of attacks in HypoPP2 were significantly shorter (1 hour versus
20 hours) (Miller et al., 2004), however I found attack length was much longer (153 hours
versus 29 hours) but the UK data is skewed by two patients with very prolonged attacks of
two to three weeks long and so is questionable. Both groups had 43% of patients with attacks
lasting less than 24 hours suggesting that when the outliers are removed the attack duration
may be similar to other studies.
As was found in the Miller et al paper, common precipitants were very similar between
the two groups. There was a marked difference in age of onset of progressive weakness,
with HypoPP2 patients in this cohort having an earlier age of onset of weakness, greater than
could be accounted for by their earlier age of onset of disease alone. This is also reflected by
the markedly poorer functional status of these patients with almost half needing to mobilise
with a stick or worse compared with only 7% of patients with HypoPP1. More HypoPP2
patients also had myopathic EMGs which would correlate with this. There was however,
no significant difference in power grading or presence of muscle atrophy possibly because
these measures may not be sensitive enough to determine a difference and further quantitative
measures of muscle strength are needed. It does seem from this evidence that, in the UK
cohort, HypoPP2 patients were more severely physically affected.
There have been a number of publications suggesting that patients with HypoPP2 have
poorer response to acetazolamide and in some cases a deleterious effect (Sternberg et al.,
2001; Bendahhou et al., 2001; Miller et al., 2004; Kim et al., 2007). One study reviewing
all the case literature found that only 3 out of 19 patients had a response to acetazolamide
and 11 had a deleterious effect (Matthews et al., 2011a). This is compared to 31 out of 55
patients with HypoPP1. I also found a significant difference in response to acetazolamide
with only 2 out of 6 patients responding. Interestingly none of the patients reported a
deleterious effect. The UK cohort however, did have a much higher percentage of patients
with HypoPP1 that had improvement with acetazolamide, 83% compared to the reported
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56% in other studies (Matthews et al., 2011a). The results for dichlorphenamide were also
contrasting, in HypoPP1 all patients reported an improvement and in other studies it has been
demonstrated to have a significant effect compared to placebo (Tawil et al., 2000). However,
only three UK patients with HypoPP2 found it improved symptoms and two patients found
that it worsened their symptoms, something which has not been reported in the literature
previously. In this cohort, potassium was beneficial in 96% of HypoPP1 but only 60% of
patients with HypoPP2. This has not been investigated in other studies.
Overall the evidence from this cohort suggests that HypoPP2 patients were more
severely physically affected than HypoPP1 patients, supported objectively by myopathy
on EMG. However, these results should be interpreted with some caution given the small
numbers. I also found that HypoPP2 patients were not as responsive to acetazolamide, may
be worsened by dichlorphenamide and may not be as responsive to potassium, a finding which
has not been previously reported.
Genotype-Phenotype Correlations in HypoPP Mutations
Previous studies have looked at the differences between specific genotypes. They found
that patients with Arg1239His mutations have a younger age of onset than Arg528His and
were more sensitive to exercise (Miller et al., 2004; Sternberg et al., 2001; Jurkat-Rott
et al., 2009). Arg528His patients also tended to be more sensitive to carbohydrates, have
more severe weakness and have a more myopathic EMG (Miller et al., 2004). The data
from this cohort concurs with existing evidence, demonstrating a significantly lower age of
onset of disease with Arg1239His patients. The duration and frequency of attacks were not
significantly different as found by Miller et al (Miller et al., 2004). Contrary to Miller et al
however, I found that all patients with Arg1239His were sensitive to carbohydrates and rates
of sensitivity to exercise were similar between the two groups. I also found that Arg1239His
patients were more sensitive to stress and illness than Arg528His patients. Age of onset
of proximal weakness was also markedly lower in Arg1239His and associated with a more
myopathic EMG which is contrary to what was found by Miller et al but their study had
smaller numbers for comparison suggesting they may not be representative.
Previous studies have suggested that the response to acetazolamide was similar in both
groups (Sternberg et al., 2001; Jurkat-Rott et al., 2009; Matthews et al., 2011a) and this study
had similar findings, although I found overall there was a greater response rate noted amongst
these patients. Ictal potassium level has been variably reported with some groups suggesting
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that levels are higher in Arg1239His (Sternberg et al., 2001; Jurkat-Rott et al., 2009) and
others reporting it higher in Arg528His (Miller et al., 2004). This study supports a lower
ictal potassium level in Arg1239His mutations but it is difficult to ascertain the accuracy of
this as the data was not taken in a controlled way and the time it was taken during an attack
varied between patients and may account for the variability between different studies.
Overall I found that Arg528His and Arg1239His mutations were very similar. The key
differences were that patients with Arg1239His appeared to be more severely affected with
an earlier age of onset, earlier age of progressive weakness and myopathic EMG.
6.2.3.2 Key Phenotypic Features in HyperPP
As part of this comparative study, I looked at the phenotype data for HyperPP patients.
During this data analysis period a large scale phenotype study of HyperPP was also published
(Charles et al., 2013), but prior to this the only comparative study published was in 2004
(Miller et al., 2004).
Other reports suggested that onset of HyperPP is in the first decade of life, which is
consistent with the findings in this study. There is some variability between other studies,
with Miller et al suggesting an age of onset of 2 years ± 4 (Miller et al., 2004) and Charles
et al finding that 25% of patients had their first attacks in the second decade of life (Charles
et al., 2013). This study’s findings correlate to some extent with these papers. The mean age
of onset was 7 years ± 5 years but I found that a third of patients had onset in the second
decade of life agreeing with the recent suggestion that many patients do have a later onset
than previously thought.
Patients with HyperPP are traditionally described as having relatively mild attacks
of paralysis, tending to have more focal attacks with high frequency and duration of
approximately 24 hours (Amato and Russell, 2008; Miller et al., 2004). The types of attack
have not been quantified previously but in this cohort a surprisingly large number of HyperPP
patients (76%) had severe attacks of paralysis from the neck down. I found that 42% had 1-3
attacks per month which is a much higher proportion than described (Charles et al., 2013).
The duration of HyperPP attacks were longer than the 24 hours suggested in early reports
(Miller et al., 2004; Venance et al., 2006). The Charles et al study also suggested that 22%
of their subjects had attacks lasting over 2 days (Charles et al., 2013). I found that 56% of
patients had major attacks lasting over 2 days and only 14% had minor attacks lasting over
2 days. 43% of patients in the study had minor attacks lasting less than 2 hours consistent
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with the earlier literature. The time of attacks clustered around night-time and early morning
with 27% of patients having attacks at night, 27% on waking and 36% in the morning which
is similar to the ratios reported previously (Charles et al., 2013). During attacks the ictal
potassium was thought to be normal or high and I found that the mean ictal potassium was
mildly elevated at 5.16mmol/L (upper limit of normal 5.0) with four out of seven cases having
a high potassium and three having a normal potassium. This value is marginally lower than
5.4mmol/L previously reported (Miller et al., 2004).
Put together this data suggests that patients with HyperPP may have two distinct types
of attack, the minor more focal attacks which are short and frequent in duration and major
attacks which are infrequent but much more prolonged.
In HyperPP, rest after exercise, immobility and exercise were the commonest
precipitants. Exercise only precipitated events in 45% compared to the 80% previously
reported but in that study they did not separate it with rest after exercise and so may have
encompassed both groups (Miller et al., 2004). Rest after exercise in this group was a
precipitant in 68%, very similar to the 67% reported by Charles et al (Charles et al., 2013).
Surprisingly, in this study, high potassium only triggered attacks in 7% of patients in contrast
to the previously reported 20-35% (Miller et al., 2004; Charles et al., 2013). This may be
explained by the fact that many patients avoid potassium and so do not report it as a common
trigger and the fact we no longer perform potassium provocation testing.
Proximal weakness was reported commonly in this group of patients with estimates
varying from 37–60%, tending to occur in the fifth decade (Miller et al., 2004; Charles
et al., 2013). I identified it in 54% of patients, with a mean age of onset of 41.6 years and two
thirds of those over 40 years reporting some progressive weakness, compared to 85% reported
elsewhere (Charles et al., 2013). It has been noted to be unrelated to attack frequency which
is what was found in this study. I did, however, find a strong correlation with age, both
with patient-reported weakness (p=0.010) and weakness on examination (p<0.001) and all
patients over 52 years had fixed weakness (Bradley et al., 1990; Plassart et al., 1994; Miller
et al., 2004).
Myotonia was previously thought to be uncommon in HyperPP with initial reports
suggesting less than 20% were affected clinically (Plassart et al., 1994). More recent studies,
however, have reported myotonia in approximately 55-74% of cases and I detected it in 71%
of cases. Electrical myotonia has been reported in 50-75% of individuals (Plassart et al.,
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1994; Miller et al., 2004), and I identified it in 81% of patients.
Traditionally acetazolamide or dichlorphenamide have been used for treatment. One
report suggested that just under three quarters of patients notice an improvement with
acetazolamide but there are no randomised controlled studies investigating its efficacy (Miller
et al., 2004; Sansone et al., 2008). The results in this study suggest that acetazolamide was
effective in 84% of patients and did not worsen any patients but, given the study design,
this improvement was not quantifiable. Dichlorphenamide has been shown to reduce attack
frequency in a RCT in HyperPP (Tawil et al., 2000), and I found that 67% of patients
had improved with the medication and one out of six patients worsened. Patients also
trialled thiazide diuretics and salbutamol following evidence of efficacy in some case reports
(Ricker et al., 1983; Hanna et al., 1998) and these were effective in 86% and 80% of patients
respectively. A small number of patients were also on mexiletine for the treatment of their
myotonia which was effective in 80% of cases.
Investigation results were in keeping with the current literature. However in this cohort
the CK was markedly high with a mean of 776IU/L. This did not correlate with attack
duration or frequency but inversely correlated with age (p=0.010) which may be related to the
observation that patients with frequent attacks often have a high CK and are younger whereas
older patients have less frequent attacks and more proximal weakness. However, there was
no correlation with attack frequency but this may be because of the small sample sizes and
the fact that the maximum attack frequency is recorded rather than current average attack
frequency.
Neurophysiology testing has been reported as having either a normal or mild increase
in CMAP on short exercise testing and a significant decrement on long exercise testing
(Fournier et al., 2004). Only one out of ten of the patients had an increment during short
exercise testing. Interestingly three of the patients developed a significant decrement on
cooling, all three of which also had electrical myotonia more suggestive of a cross-over
with PMC. 77% of patients had an abnormal long exercise test and 40% of patients had a
myopathic EMG, all of whom were over the age of 50 years. The numbers of patients with
biopsies and MRI of the lower limbs were too small to draw any meaningful conclusions.
Genotype-Phenotype Correlations in HyperPP Mutations
To investigate the phenotype-genotype correlations in HyperPP I looked at the two common
mutations, Thr704Met and Met1592Val. There is only one large study comparing genotype
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and phenotype in HyperPP by Miller et al and they had larger numbers of patients in their
cohort than in this study. They identified a marked difference in age of onset between
Thr704Met and Met1592Val patients which was also noted in this cohort (Miller et al., 2004)
The frequency of attacks reported by Miller et al were higher for Thr704Met compared
to Met1592Val, however I did not note such a significant difference (Miller et al., 2004).
This data for Thr704Met patients was skewed by one very high result and when excluded
the frequency of attacks was similar to other reports, with Thr704Met patients having 1.5
attacks per month and Met1592Val patients having just over two attacks per month. Data
from both Miller’s study and this one had very small numbers which may account for the
differences reported. Duration of attacks, however were significantly different in both this
study (p=0.032) and the previous study. Both studies demonstrated much longer attacks for
Met1592Val patients, although in this study there were even longer attacks than found by
Miller (Miller et al., 2004). Attack severity and distribution of weakness were very similar
between the two genotypes.
Looking at attack triggers the most marked difference was in strenuous exercise with
Met1592Val patients being very sensitive to it (p=0.009), they were also more sensitive to
illness than Thr704Met patients but the numbers were very small. Miller et al noted the
largest differences to be between sensitivity to cold, finding that Thr704Met mutations were
more cold-sensitive. However I did not note a significant difference in this cohort.
Patients with Thr704Met were more likely to have progressive weakness although
the numbers were not sufficient to reach significance and this was mirrored by a higher
proportion of those with reduced power proximally on examination, poorer functional status,
significantly more limb atrophy and more patients with myopathic EMG.
Both studies noted a higher incidence of myotonia both electrically and clinically in
patients with Met1592Val mutations although not statistically significant (p=0.074) (Miller
et al., 2004). In Thr704Met the myotonia was more prominent in the eyes than in
Met1592Val.
Response to acetazolamide was previously thought to be poorer in Thr704Met, with only
50% of patients with that mutation responding compared to 75% overall (Miller et al., 2004).
Although response in this study was poorer (77% versus 100%), it was not significantly
different.
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6.2.3.3 Key Phenotypic Features in ATS
ATS is characterised by the presence of three key features: episodes of paralysis, ventricular
arrhythmias and skeletal abnormalities. The reported prevalence of episodes of paralysis in
other studies in patients varies from 57-83% (Tristani-Firouzi et al., 2002; Donaldson et al.,
2003; Haruna et al., 2007; Kimura et al., 2012). The prevalence in this UK cohort was much
higher at 100% which probably demonstrates ascertainment bias as patients have all been
seen in a specialist periodic paralysis clinic which therefore selects for those with episodes of
paralysis. Cardiac abnormalities have been reported in 67-84% of patients (Tristani-Firouzi
et al., 2002; Haruna et al., 2007; Kimura et al., 2012). In this study it was in a slightly lower
proportion, 61%, but again this is likely to be due to ascertainment bias with the majority
of the published cases being reported by cardiologists making it likely that they see a higher
proportion of cardiac abnormalities. Finally skeletal abnormalities have been reported with a
huge variation in incidence from 36-78%. I identified two or more dysmorphic features in all
of the UK patients, many of which were subtle but this suggests that features may have been
under-reported in other studies.
The features of attacks of paralysis in ATS have been poorly documented in previous
publications, often because the studies have concentrated on the cardiac aspects of the
disease. The one study that includes some data is a UK study and does contain some of the
patients described in this cohort (Davies et al., 2005). I found paralysis to be the presenting
symptom in 88% of patients with onset between the first and second decades (mean 9.9 years)
which corresponds with reports in the literature (Davies et al., 2005; Venance et al., 2006).
Patients reported an average attack frequency of just under seven per month, with attacks
lasting, on average, almost a week (163 hours). There has been no systematic survey of
attack duration in ATS but most papers have suggested attacks normally last one to two days
(Donaldson et al., 2003; Venance et al., 2006; Sansone and Tawil, 2007; Davies et al., 2005).
I did not find any correlation between age and attack frequency.
Ictal potassium ranged between hypokalaemic, normokalaemia and hyperkalaemic
(2.5-5.12mmol/L) with 67% of patients having low potassium during attacks but not to the
level commonly seen in HypoPP. This is very similar to what was reported by Tristani-Firouzi
et al where they found 55% of patients had hypokalaemic attacks with an overall average
potassium of 3.6mmol/L (Tristani-Firouzi et al., 2002). The commonest precipitants for
attacks were strenuous exercise and rest after exercise with immobility and carbohydrates
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being the next most common which is similar to what others have reported (Haruna et al.,
2007; Tristani-Firouzi et al., 2002; Venance et al., 2006).
Proximal weakness is thought to be a common feature (Donaldson et al., 2003; Venance
et al., 2006) and it was identified in 62% of this cohort. Age of onset for fixed weakness
was younger than expected at 31 years and did not correlate with attack severity, frequency
or duration. Despite having such a young age of onset, unlike in HyperPP, being an older
age did not determine the presence of fixed weakness, with the oldest patient (63 years) not
having any fixed weakness. This may be partly related to the marked variation of phenotype
between patients.
Treatment with acetazolamide was effective in 91% of patients with none reporting
any worsening. Dichlorphenamide was effective in 67%, but fewer patients had tried it (6
patients). Both drugs have been reported as having benefit in ATS patients (Tawil et al., 1994;
Sansone et al., 1997). Some patients with hypokalaemic attacks also improved with oral
potassium or potassium-sparing diuretics and one patient also noted benefit with a thiazide
diuretic. These were, however, always used with caution to avoid precipitating hyperkalaemic
attacks or cardiac arrhythmias.
Neurophysiology testing in this ATS cohort demonstrated myopathic EMG in only 32%
but all apart from one had fixed proximal weakness. Short exercise testing was normal in
all patients and long exercise testing was positive in 18 out of 20 cases which is similar to
previous reports (Katz et al., 1999; Davies et al., 2005). Biopsies were performed in eight
patients, six of which were abnormal. Tubular aggregates were seen in two patients which
have been reported in other ATS patients, the rest having myopathic changes or vacuoles
(Tristani-Firouzi et al., 2002; Davies et al., 2005; Haruna et al., 2007). MRI was performed
in three severely affected patients, all of which were abnormal with fatty infiltration in the
thighs.
Cardiac symptoms are often the most concerning in ATS as they are associated with a
risk of cardiac arrest and sudden death and therefore many published studies on ATS have
focused on that. In this study, cardiac symptoms tended to follow the onset of episodes of
paralysis with an average age of onset of under 13 years. Whilst it is acknowledged that
cardiac symptoms are noted after episodes of paralysis (Donaldson et al., 2003), few studies
have mentioned age of onset of cardiac symptoms, possibly because patients may often be
asymptomatic despite having cardiac abnormalities. I found the commonest symptoms to
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be palpitations (94%) with only one patient having had a cardiac arrest and two requiring
an implantable cardioverter defibrillator. This matches the observation by others that the
arrhythmias associated with ATS are less commonly malignant than other long QT syndromes
(Tristani-Firouzi et al., 2002).
Although only 61% of patients were symptomatic, 85% had abnormalities on ECG. This
included the presence of abnormal U waves (81%) and premature ventricular contractions
(32%). Surprisingly only one patient had a prolonged QTc although the average QTc was
at the upper limit of normal for both male and female patients. Although these values
appear much lower than some of the original reports (Tristani-Firouzi et al., 2002), they
do correlate with more recent papers which encompass some of the less severely affected
cases (Haruna et al., 2007; Kimura et al., 2012). The incidence of premature ventricular
contractions in this cohort was still considerably lower and this may be a reflection on
having a paralysis-predominant phenotype rather than cardiac-predominant phenotype. Three
patients had abnormalities on echocardiogram but all were valvular abnormalities, unlikely
to be related to ATS. None had a dilated cardiomyopathy that has been reported in one family
(Schoonderwoerd et al., 2006). 50% of patients were on cardiac treatment, of which 83%
were on a beta blocker. A quarter required dual therapy.
Skeletal abnormalities were very common in this cohort. The commonest findings being
micrognathia and low set ears which is similar to findings in other centres (Tristani-Firouzi
et al., 2002; Donaldson et al., 2003). Scoliosis and cleft palate were relatively rare. There
has been debate as to whether short stature should be included in the selection of associated
features (Canu´n et al., 1999) but it was noted in over a third of patients suggesting it is a
relative common finding.
Aside from the skeletal abnormalities, this study highlighted a number of other
interesting observations. There was a higher incidence of learning difficulties (27%), memory
impairment (36%) and depression (45%) amongst this cohort than would be expected for the
normal population. Learning difficulties have only been reported in a couple of studies and
were not previously thought to be common but there has been anecdotal evidence of a higher
incidence (Sansone et al., 1997; Davies et al., 2005). It was more formally investigated along
with memory impairment in a group of 10 patients matched with their normal siblings (Yoon
et al., 2006). The study found no overall difference in scoring but some reduction in executive
function and on tests of general ability. This, combined with evidence from the phenotype
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study, suggests that further testing needs to be done to investigate the cognitive problems
in ATS. Memory impairment in this cohort was not related to age with the mean age of
those with memory impairment being 31 years. It occurred in a range of different genotypes
and could potentially be related to the expression of KCNJ2 in the hippocampus (Karschin
et al., 1996). Depression tended to occur in older patients (p=0.051) but was not related to
attack severity. It is unclear if it is related to the disease itself or the impact of the disease
on the individual’s life. The rates were much higher than seen in patients with HyperPP
and HypoPP which may suggest it is related to the underlying disease rather than solely the
impact of the disease on lifestyle alone. It would be useful to systematically perform SF-36
and INQoL questionnaires in patients to further determine the relevance of these findings.
Higher incidence of memory impairment and depression have not been recorded previously
in the literature and so is a novel finding.
Previous studies have suggested a high incidence of de novo mutations with 30-37% of
kindreds having sporadic mutations (Donaldson et al., 2003; Haruna et al., 2007). Only 3 out
of 20 sporadic cases (15%) were present suggesting it may not be as common as previously
suggested.
Genotype-Phenotype Correlation in ATS
Due to the small numbers of patients, I was unable to perform a meaningful analysis
of genotype-phenotype correlations in ATS. I therefore looked at a small number of
key factors and split genotype according to whether mutations were known to affect
phosphatidylinositol-3,4-bisphosphate (PIP2) binding or known to cause disease by another
mechanism. I also looked at the two commonest mutations in this cohort (Arg82Gln and
Arg218Trp) to see if there were any phenotype-genotype trends. As ATS is commonly caused
by personal mutations there was not a large enough number of patients with other mutations
to draw conclusions.
A number of mutations affect PIP2 binding and therefore it is thought to be one of
the key pathomechanisms in inhibiting functioning of Kir2.1 (Tristani-Firouzi et al., 2002;
Donaldson et al., 2003). Other mechanisms include alterations in membrane trafficking
and effects on the pore forming region of the channel. As found by others, there was no
significant difference in the phenotype between those with PIP2 binding altering mutations
and other mutations (Donaldson et al., 2003). When I looked at the phenotypes of the
two commonest mutations, the only difference was in proximal weakness, with Arg218Trp
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being more likely to have proximal weakness (83% versus 20%, p=0.036) and abnormal early
milestones (p=0.025) but these findings need confirmation in a larger study. There was no
difference in age of onset, severity of symptoms or ECG findings.
6.2.3.4 Phenotypic Differences between HypoPP, HyperPP and ATS
Although in the past HypoPP and HyperPP have been compared there has never been a
comparison including ATS patients. I set out to identify any key distinguishing features
between these diseases as some cases do not present with the typical triad of signs and
understanding more about the nature of attacks relative to the more common types of PP
may inform management. The first marked difference in type of attack was in age of onset,
with HyperPP patients having the youngest age of onset and HypoPP having the oldest, with
a significant difference between the two (p=0.004). This was also reported by Miller et al
(Miller et al., 2004). ATS had a more intermediate age of onset, possibly matching with
the fact that patients may have hypokalaemic, hyperkalaemic or normokalaemic attacks. As
previously documented, patients with HyperPP were less likely to have severe attacks of
complete paralysis, tending to have more focal attacks (Amato and Russell, 2008). This has
not been quantified previously but a surprisingly large number of HyperPP patients (76%)
had severe attacks of paralysis from the neck down. Consistent with other groups, almost
all patients with HypoPP had episodes of complete paralysis (Sternberg et al., 1993). When
comparing the frequency of all types of attacks the three diseases were very similar which
is contrary to previous comparisons of HyperPP and HypoPP. However, when specifically
comparing frequency of major attacks there were significantly more attacks in HyperPP than
HypoPP which does correspond to what has previously been reported (Miller et al., 2004). It
is also striking that ATS patients have much fewer attacks compared to HyperPP and HypoPP.
There is no published data to compare with but this may be related to the prolonged duration
of attacks experienced by ATS patients. Attack duration was longer in HypoPP than HyperPP
as has been previously reported (Miller et al., 2004). Attacks in ATS were of significantly
longer duration than HypoPP and HyperPP attacks which may explain why patients develop
proximal weakness at a younger age, however there was no significant correlation between
duration and age of onset of progressive weakness in these patients as the numbers were too
small.
As reported extensively in the literature there was a significant difference between ictal
potassium in HypoPP and HyperPP, with ATS patients again having an intermediate result at
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the lower limit of normal values (Miller et al., 2004; Tristani-Firouzi et al., 2002). Severity of
attacks did not demonstrate any significant differences but severity scores are naturally graded
relative to other patients with the same disease and therefore is not suited to comparison
between diagnoses. The number of patients who were hospitalised during attacks however,
was 82% in HypoPP compared with only 33% in HyperPP suggesting that major attacks may
be more severe in these patients.
I investigated key precipitants and relievers for each of the three diseases. Exercise
was a key precipitant in all three as has been commonly reported (Miller et al., 2004;
Tristani-Firouzi et al., 2002; Venance et al., 2006). The most significant difference however,
was in carbohydrates which again were a very common trigger in HypoPP, a rare trigger
in HyperPP and an intermediate trigger in ATS. Immobility was a much more frequent
trigger in HyperPP and ATS although this was not significant after Bonferroni correction.
Acetazolamide and dichlorphenamide had similar efficacy in all three groups contrary to
previous reports that acetazolamide is less effective in HyperPP cases (Miller et al., 2004).
Interestingly, there was no significant difference between proximal weakness in each of
the diseases, however it was more common and occurred at a lower age of onset in patients
with ATS which may account for the disability that is associated with this condition. This
was also illustrated by differences in functional status. Although functional status was similar
between groups, a larger proportion of patients with ATS had difficulty with stairs compared
to a very small proportion of HypoPP and HyperPP cases who had impaired function which
corresponds to the higher incidence of proximal weakness in ATS patients.
On examination there was no significant difference in proximal limb strength between
the diseases, probably because MRC scoring is not sensitive to subtle differences in power.
Limb appearance however was different, especially the rate of atrophy seen in HyperPP.
Interestingly, 27% of patients with ATS had hypertrophy which is striking since these patients
do not have myotonia and the mechanism for this is unclear. These patients do however, often
complain of stiffness and it would be interesting to investigate if they have increased muscle
membrane excitability during episodes of high potassium that may account for it. CK was
higher in patients with HyperPP than HypoPP and ATS patients had intermediate levels.
Interictal potassium levels were similar throughout. There was no significant difference in
short or long exercise testing, biopsy or MRI results.
Overall when comparing the three diseases, HyperPP and HypoPP lie at either end
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of the spectrum of periodic paralysis with ATS patients having an intermediate phenotype.
This is somewhat expected given that ATS patients can have hypokalaemic, hyperkalaemic
and normokalaemic attacks. When treating ATS patients it may therefore be useful to
identify whether they have predominantly hyperkalaemic or hypokalaemic attacks and treat
accordingly.
6.2.3.5 Overall Findings and Limitations of the Clinical Phenotypes
Study
This large phenotype study was done retrospectively, utilising data collected from patients
over many years and is therefore subject to recall bias. It may not fully capture all the
data as it is reliant on accurate documentation at the time of assessment and means that
some data collection was incomplete. It does, however, set the groundwork for a larger,
prospective study which would be very valuable if done in a systematic way with clearly
defined questionnaires. If coupled as part of a natural history study over 10 years it would
aid in determining patient prognosis more fully. The other key problem was the number of
patients recruited. Despite this being one of the largest studies to date, numbers for analysis
of genotype-phenotype correlations were small and meant that, after correction for multiple
comparisons, the number of statistically significant findings was diminished. It did however
still allow for trend analysis. Despite these limitations in the study a number of novel findings
were identified.
Overall I identified that in a large group of patients with PMC and SCM there is little
phenotypic difference between the two groups suggesting that this is actually a spectrum of
clinical phenotypes within one disease. HyperPP continues to be a distinct phenotypic entity
with marked differences compared to patients with PMC and SCM.
My findings when investigating HyperPP patients was similar to the two previously
published studies. I did however note that HyperPP patients tended to have two types of
attacks, not only the focal attacks that are traditionally described but also longer generalised
attacks. These are important findings as previously we have always advised patients that
HyperPP is associated primarily with short, focal, less disabling attacks and so are often
treated less aggressively. It may be that more aggressive treatment may lead to better
outcomes in these patients in the long term and it is therefore important to investigate this
further.
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My findings when investigating HypoPP patients was also similar to the published
literature, although the age of onset of proximal weakness in this cohort appears to be earlier
than previously reported. I also noted that MRI severity correlated with progressive weakness
and CK and therefore may be a promising objective marker of severity for clinical trials. A
systematic study with quantitative measures of strength and MRI changes would be useful to
further evaluate this as a clinical tool and is currently underway.
The ATS study gave similar results to previous studies, although this cohort had a
higher rate of episodes of paralysis than other cohorts. This is the first study comparing
the phenotype of ATS with HypoPP and HyperPP and I found that the nature of attacks was
in the intermediate range between the types of attacks seen in HyperPP and HypoPP. This is
unsurprising as patients often have a mixture of types of attacks and will be useful for guiding
treatment in these patients.
In all diseases I found interesting genotype-phenotype correlations despite the small
numbers of patients, highlighting the importance of genetic diagnosis in directing patient
treatment and advice. It also suggests the importance of large specific genotype-phenotype
studies to inform clinical practice.
6.2.4 Pregnancy and Anaesthetics in Channelopathy Patients
6.2.4.1 Anaesthetics in Channelopathy Patients
Very little data exists on the effect of anaesthetics in patients with channelopathies, with all
the published data consisting mainly of case studies. I surveyed patients to try and assess the
incidence of problems with anaesthetics in this population.
General Anaesthetics in Channelopathy Patients
There were two main forms of complications associated with general anaesthesia. Firstly
exacerbation of symptoms and secondly MH-like reactions. The evidence for MH-like
reactions in NDM is sparse and based on case studies that pre-date genetic testing and
therefore may not be indicative of a problem directly related to the disease. It has also been
suggested that the previously reported reactions represent generalised muscle spasms with
increased temperature rather than true MH and have been misdiagnosed (Lehmann-Horn
and Iaizzo, 1990; Gronert, 1995). The data from this study concurs with this with none of
the patients with NDM having MH-like reactions. The other group of patients in which MH
has been reported are in HypoPP where one patient with an RYR1 mutation and episodes of
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paralysis had MH (Marchant et al., 2004). Others have been from patient-reported studies.
However, given that a CACNA1S mutation has been associated with MH, and RYR1 (the
gene commonly associated with MH susceptibility) is coupled to CACNA1S it is possible
that there is a true association with HypoPP. We, however, did not have any patients with MH
reactions.
The most significant problem reported with general anaesthetics in this cohort has been
the exacerbation of symptoms. In MC there have been reports of depolarising agents causing
severe stiffness and masseter spasm affecting intubation and ventilation (Thiel, 1967). In
PMC and HyperPP there are reports of patients developing paralysis for several hours after an
anaesthetic, related to hypothermia and respiratory depression associated with the anaesthetic
(Egan and Klein, 1959; Klingler et al., 2005). Specifically in HyperPP there have been reports
of potassium-releasing drugs such as succinylcholine inducing weakness (Weller et al., 2002)
or spasm (Paterson, 1962; Cody, 1968). In HypoPP there have also been reports of attacks
following anaesthesia related to hypokalaemia and hyperglycaemia (Lema et al., 1991).
In this cohort overall 17% (10 out of 59) of patients reported a worsening of symptoms
following general anaesthetic which was unrelated to duration of procedure. It was most
common in HyperPP (29%) and least common in PMC/SCM (6%), however the difference
was not significant between the groups possibly because of the small numbers. The higher
frequency in HyperPP patients does match the literature, which has several reports of
patients with attacks of weakness following anaesthetic and may be related to the use
of potassium-releasing agents. However, because patients are not given details of what
anaesthetics were used the exact details of this could not be collected. Interestingly, nine
patients also reported a prolonged recovery after general anaesthetic, the majority of whom
had NDM. It is unclear what the mechanism for this is. It has not been previously reported
in the literature as a specific problem related to channelopathies. One possibility is that
some of the cases of prolonged recovery may indicate a worsening of symptoms. The
designation of a ‘prolonged’ recovery is based on a judgement by the patient as to what
is considered prolonged. At baseline each individual will have differing recovery rates
depending on the anaesthetic agent used, length of surgery and other comorbidities so
it is difficult to draw extensive conclusions from this information without more clinical
information. There was no relationship between those with prolonged recovery and a longer
length of surgery. Those with prolonged recovery had a variety of procedures from tooth
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extractions to cholecystectomies and none had extensive surgery.
Local Anaesthetics in Channelopathy Patients
There are no reports in the literature of problems with local anaesthetics, although the use
of adrenaline (which may be mixed with lidocaine) is contraindicated as it can exacerbate
myotonia (Klingler et al., 2005). Although local anaesthetics are known to improve myotonia
when given systemically this is via their effect on the NaV1.4 channel not the other sodium
channels (NaV1.8 and 1.9) or the potassium channels that are blocked in the skin on injection
so problems with local anaesthetic injection would not be expected. Interestingly however,
over 20% of patients reported that local anaesthetic was ineffective. Again this is difficult
to quantify as it would vary for a number of different reasons from patient to patient. How
much was given to each patient is not known, if they had any local factors which would
reduce efficacy and whether it was correctly injected to provide an effective blockade. There
was no difference between NDM and PP patients or those with SCN4A mutations compared
to other mutations suggesting that this is unlikely to be a specific problem related to channel
excitability. In the normal population local anaesthetic for dental procedures is effective in
75-90% of patients and this is much lower in infected or inflamed tissue suggesting that
the incidence in this population is likely to be similar to the normal population (Meechan,
2002). Only two patients reported worsening of symptoms and therefore it is more likely
to be unrelated to the local anaesthetic per se although it could be related to the stress
of the procedure precipitating an attack. Four patients reported prolonged effects of local
anaesthetic and again it is difficult to know whether this is a true effect or confounded by
other factors such as quantity injected and location.
Overall findings of Anaesthetics in Channelopathy Patients
This study on anaesthetics was a patient survey and therefore information collected was
limited by the patients’ knowledge of the procedure and any anaesthetic complications. It
is also subject to recall bias by the patient and without a control arm it is difficult to know
the normal occurrence rate of these problems. To fully investigate these differences a further
prospective study looking at the full anaesthetic notes is needed. This was not possible for this
study as all the procedures done were performed at other hospitals where I did not have access
to the notes. Investigating these aspects in a rare disease is complex as although patients are
all seen at one centre for disease management, management of any other problems are at
multiple different sites across the country.
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Overall, local anaesthetic is unlikely to cause any significant problems in channel
patients. It is possible that it is associated with reduced efficacy but it is not possible to
be certain if this is confounded by other factors. The data collected on general anaesthetics
suggests that around a sixth of patients have worsening of symptoms with general anaesthetics
but patients may also notice a prolonged recovery time.
6.2.4.2 Pregnancy in Channelopathy Patients
There is no extensive published information on pregnancy in muscle channelopathy patients.
The little data available suggests that symptoms can be exacerbated in pregnancy, most often
in HyperPP and less frequently in PMC and MC (Charles et al., 2013; Trivedi et al., 2013).
In some cases of HyperPP, however, patients did report improvement of symptoms (Charles
et al., 2013).
The average completed family size (in females aged 45 years and over) for this
population was 1.89, very similar to the national average of 1.91 (Office for National
Statistics, 2012). The rate of childlessness of those at the end of their childbearing years (45
years) was only 11%, lower than the national average of 19% (Office for National Statistics,
2012). This suggests that the fertility amongst channelopathy patients is similar to the general
population. The incidence of miscarriages in this population was 21%, similar to the 17-22%
miscarriage rate reported in the normal population (Garcı´a-Enguı´danos et al., 2002).
21% of pregnancies had complications during the pregnancy and 21% had complications
during delivery of which 42% of patients had problems in both pregnancy and delivery. 8%
of patients had gestational hypertension, compared to approximately 10% of the population
(Duley, 2009). 4% of patients developed pre-eclampsia during pregnancy compared to 2–8%
of the normal population (Duley, 2009). 11% of patients required emergency caesarean
sections which is lower than the average rate of 14.8% in England (Health & Social Care
Information Centre, 2013). Assisted vaginal delivery was necessary in 11% of patients which
is lower than the average in England of 12.8% (Health & Social Care Information Centre,
2013). Overall complication rates in this population appear to be lower than the normal
population in England. Unfortunately I do not have data for the rate of elective caesarean
section rate and it would be interesting to identify if this rate is higher amongst channelopathy
patients, taken as a precaution because of their condition.
Postnatal problems were noted in four patients overall, three of whom had PMC/SCM.
This correlates with reports of paediatric phenotypes of neonatal hypotonia, neonatal stridor
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and laryngospasm which have been documented in patients, often with de novo mutations
in Gly1306Glu (Lion-Francois et al., 2010; Caietta et al., 2013) but also with Ile693Thr
(Matthews et al., 2008a), Thr1313Met (Matthews et al., 2011b), Asn1297Lys (Gay et al.,
2008) and Arg799Ser (Lion-Francois et al., 2010). The patients with children with neonatal
problems had Gly1306Glu, Thr1313Met and Ile693Thr variations which were then identified
in those children. This highlights the importance of genetic counselling of neonatal risks in
patients with these variations but also in all those who have SCN4A mutations.
The most interesting data is that for the change in symptoms during pregnancy. I noted
a much higher percentage worsened in pregnancy than the previously reported figures of
25 to 44% in NDM (Trivedi et al., 2013), with over 75% worsening and only 16% noting
some improvement. This was most evident in patients with PMC/SCM where 19 patients
noted worsening, most commonly of the stiffness. HypoPP patients least commonly reported
worsening with only 50% (3 patients) noting a difference. The one patient who had ATS was
not worsened by pregnancy but the numbers were too small to draw any conclusions. The
percentages for worsening of symptoms during menstruation had a similar distribution with
PMC/SCM patients being most commonly affected but overall worsening was less frequent
than in pregnancy.
Although this is the first study of a significant number of patients with muscle
channelopathies, this data has to be treated with caution as the numbers were still small
as this is such a rare disease. The data also relied on patients recall of events as well
as the patients’ understanding of any problems in pregnancy or delivery which may lead
to some inaccuracies. Unfortunately there was insufficient data to draw any conclusions
regarding patients with ATS. This not only related to the rarity of the condition but also to the
observation that only a small number of female patients tried to conceive. This may be partly
related to the severity of symptoms but also to the cognitive implications of this disease. To
draw more concrete conclusions it would be useful to repeat a prospective study with a larger
multi-centre design to collect a larger data set. It would also be more informative to correlate
this data with patients’ obstetric notes. This was not possible in this study as I did not have
access to patient records from other hospitals.
Overall the data suggests that patients with channelopathies do not have a higher
complication rate or infertility rate than the normal population. There is however, a high
proportion of patients who experience worsening during pregnancy which has not been
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previously reported. The most interesting aspect is that this worsening in pregnancy is present
in almost all patients with PMC or SCM and therefore it is important to make these patients
aware of this possibility.
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6.3 Genetic Diagnosis in Skeletal Muscle Channelopathies
To try and improve the genetic diagnosis rate in patients with skeletal muscle channelopathies,
I utilised a number of approaches to identify the “missing” causative variations in
undiagnosed channelopathy patients. I selected three main cohorts of patients: those with
unusual phenotypes, some of whom may have had a variation identified but had an unusual
presentation; those with a single CLCN1 loss of function variation from a recessive pedigree
and those with no pathogenic variations identified despite full sequencing of the known
channelopathy genes.
Overall 182 patients were carefully phenotyped. Of these, 85 were selected for more
detailed testing. All patients identified for targeted sequencing had likely causative variations
identified. 7% of patients selected for MLPA analysis had large scale rearrangements
identified. 7 patients selected for next generation sequencing and aCGH had likely causative
variations identified, suggesting a hit rate of 70% for carefully selected patients. Overall,
25% of unconfirmed cases were genetically diagnosed, improving the genetic diagnosis rate
(Figure 4.1, p 77).
6.3.1 Targeted Sequencing of Unusual Cases
6.3.1.1 Case 1
Case 1 demonstrates that one possible explanation for phenotypic variability can be the
presence of “double trouble”, 2 pathogenic variations in different related genes. This family
is a very interesting example as there was marked phenotypic variability between the two
branches of a family which was independent of their gender. I showed that the more severe
phenotype in one branch of the family was associated with the presence of dominant-acting
mutations in both the sodium and chloride channels whereas the mildly affected branch only
had a single dominant sodium channel variation
Clinically, the presence of two variations is likely to account for the earlier age of onset,
the generalised muscle hypertrophy and the unusual pattern on neurophysiology seen in the
proband. The short exercise test for the proband did not demonstrate a pattern that fits either
dominant MC or PMC but a mixture of both. She had both paramyotonia after trials three
and four of exercise (as seen in PMC) but then warm-up following the fifth and sixth trials (as
seen in MC) (Fournier et al., 2004) (Figure 5.26, p 148). She was sensitive to cold, as would
be expected in PMC but following rewarming, rather than demonstrating paramyotonia with
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subsequent trials she showed warm-up as would be seen in MC. However, unlike what is seen
in MC, she did not fully recover her decrement in CMAP after rewarming (Fournier et al.,
2006). This results in a mixed Fourner type I and II pattern. So it appears that the interplay
of these two variations gives rise to a cold-sensitive myotonia that initially worsens with
exercise but may improve with further exercise giving a more delayed warm-up. In distinct
contrast, the proband’s cousin, who only had the Gly1306Val variation, had neurophysiology
consistent with an SCM phenotype with increment rather than decrement on exercise.
The branch of the family with the milder phenotype only carried the sodium channel
mutation which manifests as a pure myotonic phenotype with marked worsening in pregnancy
and a characteristic Fournier type III pattern on testing. The striking features in both branches
of the family was the marked exacerbation in pregnancy which is likely related to the
Gly1306Val variation and correlates with the findings of the pregnancy survey, suggesting
that patients with sodium channel mutations commonly worsen during pregnancy.
It is interesting to speculate about the pathophysiology of disease in the individuals with
the two variations. It was thought that two variations in SCN4A would be lethal given the
importance of the role of the channel in muscle excitability. However, there have been a few
cases of homozygosity of dominant mutations in SCN4A not being lethal but causing a severe
phenotype with marked weakness in the homozygous, compared to heterozygous carriers.
This is thought to be due to reduced penetrance of those particular variants (Arzel-he´zode
et al., 2010). Although the patients in Case 1 with two variations did not have marked
weakness as in that case, they did demonstrate a marked drop in CMAP following cooling and
subsequent exercise compared to the individuals with a single variation, as was seen when
comparing homozygotes and heterozygotes in the reported case (Arzel-he´zode et al., 2010).
In this particular case, as dominant MC variations would only be expected to cause a
maximum of 75% reduction of chloride current and because chloride current only contributes
to 85% of the resting membrane potential (Bryant and Morales-Aguilera, 1971), the
combination of a dominant chloride variation and a sodium channel variation may be
expected to give the phenotype of a recessive MC. They would not have the lethality of
two SCN4A mutations as 50% of the sodium channels are still able to function. The variation
in the sodium channel, however, does confer the susceptibility to cold and a predominance
of symptoms in the eyes and face. It would be interesting to see electrically if the warm-up
and paramyotonia in the eyes compared to the hands differ as PMC and MC have different
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predispositions to each of these areas.
This case illustrates the value of neurophysiology in guiding diagnosis and the
importance of investigating cases of marked phenotypic variability further.
6.3.1.2 Case 2
Case 2 illustrates again how the variation in clinical phenotype within a family may be due to
the presence of a second variation. In this case there was a marked change in clinical severity
and phenotype seen with the combination of a ZNF9 expansion and homozygous CLCN1
mutations compared with family members with only CLCN1 mutations.
DM2 is a multi-system disorder, typically presenting in the third decade with myotonia
and proximal weakness. Patients may also develop cardiac conduction defects, cataracts,
insulin sensitivity and cognitive problems (Turner and Hilton-Jones, 2010). Although
patients may present with a similar myotonic phenotype to MC the mechanism behind the
disease is markedly different. It is caused by an expansion of between 75 and 11,000 of the
micro-satellite repeat CCTG in intron 1 of the ZNF9 gene (Udd et al., 2003). This leads to
abnormal splicing of a number of genes including CLCN1, resulting in myotonia, and RYR1
possibly causing muscle weakness.
A number of studies have identified heterozygous CLCN1 mutations co-segregating in
patients with DM2 (Sun et al., 2001; Suominen et al., 2008; Lamont, 2004). This includes
a large study looking at 200 DM2 patients that identified a higher frequency of patients with
specific heterozygous CLCN1 mutations than in the normal population (Suominen et al.,
2008). This was thought to be due to ascertainment bias as patients were thought to be more
likely to have myotonia and therefore more likely to have disease. However, a worsening in
clinical severity of these patients has not been described.
In this case the father and two of his children both had DM2 expansions and were
homozygous for the Ala566Thr mutation. The children who carried both the DM2 and
MC variations had a severe phenotype with a younger age of onset than is characteristically
seen in DM2, with not only severe grip myotonia, but also significant proximal weakness,
cardiac arrhythmias and daytime somnolence. It appears in this case that the presence of
both variations modifies the onset of DM2 symptoms as well as the myotonic symptoms.
Commonly in DM2, the average age of onset is the third decade. The earliest sign is often
myotonia with the youngest report being at 13 years but other symptoms such as weakness
and arrhythmias occurred later, with none reporting it before 18 years (Day et al., 2003).
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The age of onset of myotonia in this family was much younger than reported in DM2 alone,
occurring within the first decade but this is often seen in recessive MC. However, the daughter
of the proband (VI.I) also noted a very early onset of arrhythmias and weakness which is hard
to explain pathophysiologically as the CLCN1 variation would not be expected to modify
abnormal splicing of genes outside of CLCN1. One possible explanation is the presence of
observer bias, because the father is affected the symptoms are looked for more carefully in
affected children at an earlier age. This bias has been reported in other family groups with
DM2 (Day et al., 2003).
The children who were only homozygous for the CLCN1 mutation have less severe
myotonia and no other significant symptoms supporting the suggestion that the combination
of the two variations worsens the severity of symptoms. This is interesting because the
homozygous variation would be expected to cause a loss of function of both copies of
the ClC-1 protein, supported by the fact that expression studies show no current when the
variation is expressed homozygously (Figure 5.30, p 156). This means that problems with
splicing would not be expected to have any further effect on the severity as the protein is
already non-functional. It suggests that there may either be some low level function of
the ClC-1 and so once splicing defects occur no protein is produced, or that the splicing
abnormalities of RYR1 may contribute to the exacerbated symptoms. Without analysis of
biopsy samples, which the family declined, it will be difficult to ascertain the true reason.
This family illustrates how dual variations modify severity and again highlight the
importance of assessing other genes in cases of atypical severity and presentation.
6.3.1.3 Case 3
Case 3 is an example of a family with symptoms consistent with a sodium channelopathy
including stiffness and episodes of weakness but with atypical features. These included
developmental delay and severe weakness which resolved over time. The electrophysiology
demonstrated an abnormal long exercise test and abnormalities in short exercise testing
suggestive of abnormal muscle membrane excitability. However, sequencing of the skeletal
muscle channel genes was normal. Repeated EMG identified abnormal decrement and
jitter and so the search was focused on variations in channels associated with congenital
myasthenic syndromes and compound heterozygous variations were found in DOK7. The
c.1124 1127dupTGCC;p.Leu375fs variation was a known pathogenic mutation, and the
c.533-37 c.533-11del27 variation encompassed a consensus branch point and is predicted
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to lead to aberrant splicing.
DOK7 encodes docking protein 7, which is essential for neuromuscular synaptogenesis
through interaction with MuSK. Pathogenic variations were found to be associated with a
limb girdle-type phenotype (Beeson et al., 2006). It is associated with delayed milestones,
although most children are walking by 4 years with frequent falls and difficulty rising from
the floor as is seen in these two patients. If weakness is present it is primarily proximal
and, unlike in this case, often associated with ptosis and restricted eye movements. There
are reports of patients having variability and prolonged periods of worsening as was seen in
this family. Feeding difficulties and respiratory problems are also common, especially early
in life (Klein et al., 2013). The phenotype of DOK7 mutations is very variable and the
phenotype of this family does fit with it. It is interesting that it causes alterations in muscle
membrane excitability despite being a neuromuscular junction phenomenon and suggests it
is important to investigate for possible neuromuscular junction impairment in patients with
atypical muscle channelopathy phenotypes.
6.3.1.4 Case 4
Case 4 was a patient with a very severe phenotype with onset in childhood of impaired
mobility and later developing episodes of paralysis with supportive electrophysiology. He
also had additional problems with respiratory muscle weakness, swallowing compromise and
ophthalmoplegia which is not usually seen in typical periodic paralysis. There was also
fatiguability with an associated mild decrement on repetitive stimulation suggestive of a
neuromuscular junction defect, however this was not felt to be significant given the extent
of ocular weakness.
The likely causative pathogenic variations were found in RYR1. RYR1 mutations
are associated with a number of different congenital myopathies with both dominant and
recessive inheritance. This includes the dominantly-inherited central core disease and
MH susceptibility and the recessive diseases, multi-minicore disease, congenital fibre-type
disproportion, centronuclear myopathy and King Denborough syndrome (Klein et al., 2012).
Central core disease is typically associated with hip girdle weakness and scoliosis and not
usually bulbar or respiratory weakness whereas multi-minicore disease can be associated
with severe rigidity and respiratory involvement. Histopathological analysis shows central
‘cores’, which are devoid of oxidative enzyme activity (Zhou et al., 2007).
The resulting phenotype is related to the location of variations in RYR1, with those
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in the N-terminal or central regions (amino acids 35-614 and 2163-2458 respectively)
being associated with a MH susceptibility phenotype, compared to those with C-terminal
variations being associated with a central core disease phenotype (amino acids 4550-4940)
(Zhou et al., 2007). Recessive-acting mutations however appear to be more distributed
throughout the gene (Zhou et al., 2007). This patient had multiple variations including
the c.208C>T;p.Gln70X variation which is predicted to cause loss of function of
one of the RYR1 alleles. The c.325C>T;Arg109Trp variation in combination with
c.1453A>G;p.Met485Val, has been previously reported in two different families and
associated with minicore disease either in isolation (Jungbluth et al., 2005), or with another
loss of function mutation (Zhou et al., 2006; Klein et al., 2012). The combination of these
pathogenic variations is likely to be the underlying cause of the patient’s unusual phenotype.
The reports of the Arg109Trp mutation with Met485Val in isolation were in a family
with minicore myopathy (Jungbluth et al., 2005). The affected siblings had the characteristic
proximal muscle weakness and wasting affecting the shoulder girdle more than the hip
girdle, external ophthalmoplegia predominantly affecting the upward and lateral gaze and
worsening of weakness in the cold, all similar to this case. Their neonatal history, however
was more fraught with reduced fetal movements, hydrops, hypotonia, feeding and respiratory
difficulties. They also had a reduced FVC of 58% & 80% and needed a gastrostomy tube. The
patient in Case 4 had a similarly low FVC but only required his gastrostomy during attacks
of weakness. The biopsy in the published case demonstrated variable fibre size and increased
central nucleation with isolated nemaline rods and had both multiple and single core lesions.
The MRI findings were consistent as well with marked involvement of the soleus and sparing
of the gastrocnemius and relative involvement of the tibialis anterior. However, this group
of patients had some involvement of the peroneal group of muscles which is spared in the
proband (Jungbluth et al., 2005). In the published case, despite analysing the whole RYR1
coding sequence, variations were only identified in one allele, the Arg109Trp in cis with
Met485Val but they were homozygous in cDNA, suggesting that the second allele was either
not expressed or deleted (Jungbluth et al., 2005).
The other report was a family with the c.325C>T;Arg109Trp and c.1453A>G;
p.Met485Val that was later found to have a premature stop codon, c.4485G>A;p.Tyr1495X
on the other allele (Zhou et al., 2006; Klein et al., 2012). This patient also had onset before
10 years with delayed motor milestones, with difficulty with stairs and rising from the floor,
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similar to this case. However, he presented with muscle weakness, hypotonia and feeding
difficulties at birth, which the proband did not have. He also had ophthalmoplegia, as in
this case and marked axial weakness and needed gastrostomies in childhood due to poor
feeding, something the proband had only required during his attacks of paralysis in later life.
Respiratory muscle weakness was also present although mild, as in this patient, although
his was most significant during attacks (Zhou et al., 2006). The published case did not
have episodes of MH and the biopsy demonstrated type 1 fibre predominance, cores and
minicores. Functional studies were done which demonstrated that there was only expression
of the allele with the Arg109Trp and Met485Val variations and not the allele carrying
the stop codon (Jungbluth et al., 2005). When they expressed the Arg109Trp variation
homozygously it affected calcium transport and ryanodine binding causing dysregulation of
calcium (Jungbluth et al., 2005). Given that the patient in this case has a non-functional
second allele due to the premature stop codon (c.208C>T;p.Gln70X), only the allele
with Arg109Trp would be expected to be expressed and would therefore act as if it were
homozygously expressed as well.
This case had some marked differences compared to the reported cases. The key
differences being the episodic paralysis and the MH episodes. MH reactions have been
reported in a few cases of multi-minicore disease (Koch et al., 1985; Osada et al., 2004)
and minicores have been seen in families with MH susceptibility (Guis et al., 2004). It is
also more commonly associated with variations in the N-terminal hotspot which correlates
with the location of the patient’s variations. Therefore in this case it is likely to be related
to the patient’s multi-minicore disease. There has been one previous report of a patient with
multi-minicore disease and atypical episodes of PP (Zhou et al., 2010). This patient had
a very similar presentation to Case 4 with some motor developmental delay and difficulties
rising from supine and climbing stairs. She also experienced exercise-induced myalgia and
cold-induced stiffness and had distinct episodes of paralysis, starting in the legs and ascending
to the arms for several days from 18 years of age. She did not however, have respiratory or
bulbar compromise and tended to have episodes triggered by cold. She had no MH reactions.
On examination she did have facial weakness and ophthalmoplegia, affecting primarily
up-gaze and abduction. She had axial and neck flexion weakness with more pronounced
shoulder girdle than hip girdle weakness. She had normal FVC and cardiac function and
her MRI demonstrated diffuse involvement of primarily the vasti, the gastrocnemius and the
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soleus. She had myopathic changes on EMG and cold immersion testing which triggered
profound weakness of the hands with normally preserved CMAP responses both pre- and
post-cooling, suggesting cold-induced electron-contraction uncoupling. Her long exercise
test was negative but demonstrated an increase in CMAP amplitude and area post-exercise
and oral potassium loading triggered profound paralysis with a normal ictal potassium
level. She was found to have a heterozygous missense variation in exon 57 in RYR1
c.8816G>A;p.Arg2939Lys and a premature stop mutation, c.6721C>T;p.Arg2241X on the
other allele which resulted in only the first allele being expressed in muscle. However
functional studies did not demonstrate abnormal functioning of RYR1 with the Arg2939Lys
variation and the exact mechanism is not yet fully understood for that case.
The phenotype in Case 4 is very similar to the reported patient with a proximal
weakness and ophthalmoplegia phenotype, later developing episodes of paralysis. However,
the patient in Case 4 did not demonstrate uncoupling of excitation and contraction and had
electrophysiological features more typical of classic PP. It suggests that there may be a further
mechanism at work that may be causing the unusual mixed phenotype which needs further
investigation. It may be, as many of the multi-minicore disease patients are children, they
have not yet developed the episodes of paralysis and as more survive into adulthood we may
begin to see this phenotype more commonly. It may also be that other patients have such
severe weakness and respiratory compromise that the episodes of paralysis are not noted as
distinct episodes and instead attributed to natural variation of the disease day to day. It would
be useful to look at this patient’s muscle protein expression and further determine the possible
pathomechanisms involved.
6.3.2 Diagnosing Patients with Single Mutations in CLCN1 using
MLPA
I utilised MLPA to demonstrate that exonic deletions and duplications were present in
approximately 6% of this MC patient cohort with a single identifiable recessive mutation
(Figure 4.2, p 79). The deletions and duplications found are likely to be pathogenic. Although
it was not possible to do detailed break point mapping in all cases, it is probable that the
alterations are contiguous and cause disruption of the reading frame resulting in nonsense
mediated decay of the resultant mRNA. It is possible, though unlikely, that the alterations
are in-frame causing production of either a severely truncated or elongated protein which
258 6. DISCUSSION
may alter insertion of the protein into the membrane or impair channel function. I did not
identify any deletions or duplications in 124 control chromosomes and none were identified
in CLCN1 in the Database of Genomic Variants (Zhang et al., 2006).
6.3.2.1 Large Scale Rearrangements Identified
Patient 5 had a contiguous heterozygous deletion of exons 8 to 10. If in-frame it would disrupt
3 of the 18 α helices and eliminate a number of highly conserved domains (Fialho et al.,
2007) making it likely to be pathogenic. The patient was also heterozygous for the previously
described recessive intronic point mutation, c.1167-10T>C;p.? This has been reported as a
predicted splice-site acceptor (Trip et al., 2008) but according to prediction software it has a
low probability of affecting splicing. Muscle was not available from this patient to confirm
the effect of this mutation on splicing empirically. However, it has been reported to segregate
with disease in multiple families and we have observed it in homozygous form in two other
unrelated patients making it likely to be pathogenic.
Patient 6 had a large contiguous deletion of exons 17 to 22. If in-frame this would
affect both of the channel’s CBS domains, which are highly conserved regions essential for
channel opening and chloride channel subunit interactions (Estevez et al., 2004; Scott et al.,
2004). The patient was also heterozygous for the common mutation, Arg894X, in the final
exon of the gene, which has previously been described in many recessive pedigrees (George
et al., 1994) and is predicted to cause a 95 amino acid truncation of the carboxyl-terminus
of the protein (George et al., 1994). Previous cellular electrophysiology cell studies
have been inconclusive, demonstrating both a large reduction in chloride currents and a
weak dominant-negative effect in co-expression studies consistent with both recessive and
dominant inheritance (Meyer-Kleine et al., 1995). However, the observation that the patient’s
clinically unaffected mother carried the Arg894X mutation, is consistent with recessive
inheritance in this family.
Patients 7 and 8 exhibited a similar very severe myotonic phenotype with onset in
infancy. These patients both harboured the novel homozygous sequence variant Pro744Thr.
Our detailed expression studies in HEK293T cells showed no difference in cell currents
compared to the WT channel suggesting it was non-pathogenic and therefore not responsible
for the patients’ phenotype. MLPA studies in these patients showed peak ratios greater
than 1.8 encompassing exons 8 to 14, indicating the presence of four copies of these
exons. Parental DNA was unobtainable to confirm if this was the result of a homozygous
6.3. Genetic Diagnosis in Skeletal Muscle Channelopathies 259
duplication (two copies on each allele) or a heterozygous triplication (three copies on one
allele and one copy on the other). However, as both individuals were severely affected
and came from consanguineous pedigrees it is most likely that the rearrangement detected
represents a contiguous homozygous duplication of exons 8-14. If this was the case and these
duplications caused a frameshift, they would render the downstream homozygous variation,
Pro744Thr, redundant. As both patients were of the same ethnic origin, have the same
apparent homozygous duplication, sequence variant and intragenic SNPs, it suggests that
the duplication is a founder mutation. However, this could not be confirmed as additional
family members were not available for haplotype analysis.
6.3.2.2 Limitations of MLPA and Further Work
MLPA is a commonly used method for identifying genomic deletions and duplications.
Although it has been very useful in identifying copy number changes in this cohort it has
limitations. It cannot detect inversions and translocations that do not result in relative copy
number changes. Also, as the MLPA probes cover a small region of each exon it will not
detect small deletions and duplications within an intron, or 5’ and 3’ UTRs. The probability
of a normal sample incorrectly having an abnormal peak ratio is statistically small but if the
MLPA probe sequence lies over a polymorphism, point mutation, small deletion or insertion
in the sample DNA this can influence the ligation or destabilise the binding of the probe
oligonucleotides giving a false positive. This is illustrated by my finding in the patient with
a homozygous 14 base pair deletion and apparent probe ratio of zero in the same exon. This
occurrence can be minimised by cross-checking the sample DNA sequence with the probe
sequence. False positives are however extremely unlikely in cases with multiple contiguous
exon copy number changes as was seen in these four cases but caution must always be taken
when interpreting such results.
Useful further work would include confirming the effects of these changes on chloride
channel function and expression by analysing patient muscle mRNA and performing
functional studies of mutated channels. This would give a more extensive understanding
of the consequences of these changes and confirm the findings identified by MLPA.
6.3.2.3 Key findings of MLPA
This study demonstrates that CLCN1 exon deletions or duplications are an important genetic
mechanism in patients with recessive MC. In particular it shows that large scale alterations
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may explain some apparent recessive pedigrees with single loss of function mutations.
Genetic counselling in this group of patients is difficult and causes uncertainty, so MLPA
analysis may be a relatively quick and cost-effective way of improving diagnostic accuracy in
these cases. There remains a significant number of cases that cannot be not explained by such
rearrangements indicating that there are additional, as yet unidentified genetic mechanisms.
6.3.3 Whole exome sequencing and aCGH
6.3.3.1 Case 9
Case 9 was a patient with symptoms and signs consistent with MC from a recessive pedigree.
He had the characteristic generalised hypertrophy, onset of stiffness in the first decade of
life and primarily hand and limb myotonia (Fialho et al., 2007; Trivedi et al., 2013).
His electrophysiology showed unequivocal evidence of myotonia and short exercise testing
was characteristic of recessive MC (Figure 5.41, p 173) (Fournier et al., 2004). His
MRI demonstrated marked fatty infiltration in the gastrocnemii and milder fatty infiltration
elsewhere. The gastrocnemii involvement was more severe than typically seen in recessive
MC patients, although he was 65 years old and we have seen a marked correlation with age
and severity of MRI changes in recessive MC patients (Figure 5.42, p 174) (Morrow et al.,
2013). The rest of his MRI pattern was consistent with our findings in other MC patients.
Sanger sequencing did not identify any pathogenic variations in CLCN1 or SCN4A
or expansions in DMPK or ZNF9. aCGH did not reveal any related CNVs. I did,
however, identify a novel homozygous variation, c.1-59C > A;p?, in the 5’UTR region of
CLCN1, that may be responsible for the patient’s phenotype. This variation has not been
documented in dbSNP, 1000 Genomes or the Exome Variant Server. It was also not present
in 504 chromosomes from a mixture of ethnically matched and unmatched samples. This
homozygous variant would fit with the autosomal recessive inheritance.
The 5’UTR region of genes are important in the translation of the gene and therefore
variations in that region may be responsible for causing disease. In this particular case the
variation in the 5’UTR region is at a base which is not highly conserved making it harder to be
certain of its relevance. Splicing prediction software, NetGen2 and RegRNA (A Regulatory
RNA Motifs and Elements Finder), was used to identify if this region was at a predicted splice
site or other regulatory motif but none were identified. These did not reveal any predicted role
for this location. We are therefore in the process of establishing a minigene assay to try and
6.3. Genetic Diagnosis in Skeletal Muscle Channelopathies 261
determine the pathogenicity of this variation. Unfortunately we were unable to get DNA from
the affected and unaffected siblings to confirm segregation of the homozygous variation.
As the variation in CLCN1 did not have definitive evidence in favour of its pathogenicity,
I went on to look at other variations found in known muscle channel genes to ensure there
were no more likely pathogenic variations. Although variations in three different genes
were identified, the variation in the dysferlin gene was discounted as two affected alleles
are required to cause the autosomal recessive LGMD2B. I did identify two variations in
TTN, a protein which is associated with autosomal dominant tibial muscular dystrophy (with
mutations in the final exon), cardiomyopathy and with autosomal recessive LGMD2J. These
variations were novel and since the patient had an autosomal recessive pedigree, I looked
further into the possibility him having LGMD2J. The two variations identified were predicted
to be polymorphisms making them less likely to be pathogenic. The phenotype for LGMD2J
is also quite different from the phenotype in Case 9. At its most severe, it is associated with
severe childhood onset of proximal muscle disease that progresses to wheelchair confinement
in 20 years (Udd et al., 2005). In the more recently described less severe form, it is still
associated with early onset of proximal weakness that gradually progresses through life
(Evila¨ et al., 2014) making it very unlikely that it is the underlying cause of this patient’s
phenotype. Most importantly it is not associated with myotonia which is the predominant
feature in this case.
The final possible variant I investigated was the heterozygous variant in BAG3. BAG3
is associated with autosomal dominant myofibrillar myopathy type 6 (Selcen et al., 2009).
Myofibrillar myopathies have been associated with myotonic discharges on EMG (Selcen
et al., 2004; Hanisch et al., 2013), however these myotonic discharges were not associated
with clinical myotonia. Myotonia has also not been specifically reported in BAG3 mutations.
Although electrical myotonia is present in this patient, the other aspects of BAG3-associated
disease, with early onset of severe and progressive muscle weakness with cardiomyopathy
and respiratory insufficiency, were not present. MFM type 6 is seen specifically with
the c.626C>T;p.Pro209Leu variation which was not the variation identified in this patient.
Pathogenicity prediction software also predicted this to be a polymorphism making less likely
that this variation is responsible for the patient’s disease phenotype.
It therefore seems likely, given the patient’s very characteristic recessive MC phenotype,
that the variation in the 5’UTR region is responsible for his disease although we are
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currently undertaking further studies to investigate this further (Table 6.1). This illustrates
the importance of looking at the 5’UTR and 3’UTR regions when sequencing CLCN1.
6.3.3.2 Case 10
Case 10 is of a patient with initially rare episodes of weakness in his late teens, which
progressed significantly to regular episodes in his 30s. These attacks were characteristic of
PP although they were not improved by acetazolamide. In his 50s however, attacks started to
tail off and he began to have fixed weakness which slowly progressed. His electrophysiology
confirmed changes consistent with PP with a positive long exercise test. His MRI had features
similar to other patients with HypoPP of the same age in the phenotype study with marked
fatty infiltration. His biopsy was also consistent with other HypoPP cases with tubular
aggregates, although this is not a specific finding and is seen in many other types of myopathy
(Rosenberg et al., 1985; Miller et al., 2004). He had a dominant family history with at least
one affected daughter.
I identified two possible causative variations. The first was previously reported as a
pathogenic variation, c.406G > A;p.Gly154Ser, in αB-crystallin and causing a myofibrillar
myopathy (Reilich et al., 2010). The published patient had late onset distal leg weakness and
finger flexor weakness. His MRI demonstrated symmetrical fatty degeneration and atrophy
of the vastus, rectus femoris, tensor fascia lata and sartorius. There was also marked fatty
replacement of the medial gastrocnemius and tibialis anterior. The pattern of MRI changes
was similar to those seen in Case 10 although the pattern in the calf from the published
case was much more severe (Figure 6.1). The published case, however, had anti-desmin and
anti-αB-crystallin positive aggregates whereas Case 10 only had tubular aggregates. There
were therefore a number of distinct findings from Case 10. This coupled with the fact that
the variation has also been reported in dbSNP as uncertain significance makes it unclear if
this variation is causative. Given that there were some similarities it does suggest that this
variation may show reduced penetrance and be responsible for the later onset fixed myopathy
that the patient developed. It is, however, unlikely to account for his episodes of paralysis.
The second variation was in SCNN1B, c.1307 1310delAGAG;p.Arg438PfsX17. This
gene encodes an amiloride-sensitive sodium channel. Autosomal dominant mutations in
this gene are known to cause Liddle’s syndrome. All the described mutations have been
frameshifts, stop codons or missense variations affecting the PY motif in the gene. This
proline-rich region is important for binding Nedd4-2, which regulates the turnover and
6.3. Genetic Diagnosis in Skeletal Muscle Channelopathies 263
Figure 6.1: MRI images of case 10 and corresponding images from Reilich et al study from
patient with the same variation Gly154Ser in CRYAB gene a) T1 weighted MRI of thigh and
calf from patient with Gly154Ser in CRYAB from (Reilich et al., 2010). b) T1 weighted MRI of
thigh and calf from Case 10 who also carries the Gly154Ser
internalisation of the sodium channel. If Nedd4-2 is unable to bind it leads to reduced
internalisation and an increase in the number of sodium channels resulting in a gain of
function. This is associated with a syndrome of young onset hypertension, usually in the
third or fourth decade, with hypokalaemia and metabolic alkalosis (Shimkets et al., 1994).
The previously reported frameshift mutations all lie from codon 579 onwards (Yang et al.,
2014). The frameshift mutation I identified was located from codon 438 creating a truncation
in the protein 17 codons downstream. This is earlier in the protein than has been previously
described in cases of Liddle’s syndrome but would be expected to have the same effect as
it removes the PY motif and therefore would prevent binding of Nedd4-2. What is unclear,
however, is if this would give rise to a functional protein or if the mRNA would be subject to
nonsense mediated decay due to the premature termination. The location of the termination
would truncate the channel before the second helical region and therefore would be expected
to lead to a non-functioning protein. If the transcript did not translate to a functional protein
then it would be unlikely to cause Liddle’s syndrome as it is a gain of function disease.
Looking at the patient’s analysis, he had a young onset of hypertension with poor control
despite anti-hypertensives. He did have a very low aldosterone which is in keeping with
the disorder. His renin however was normal. This may be because he was on a calcium
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channel blocker for treatment of his blood pressure which is documented to cause a selective
rise in renin levels without affecting aldosterone. At the point I tested him he did not have
hypokalaemia or metabolic alkalosis but at that stage his episodes of paralysis had burnt
out which may be related to the treatment of hypertension managing his Liddle’s syndrome.
There have been a handful of case reports from Asian journals of patients with Liddle’s
syndrome with episodes of HypoPP. None of these reports however, had genetic confirmation
of the condition (Kayal et al., 2013; Kang et al., 1998; Boorugu et al., 2009). It does however
suggest that there is evidence of Liddle’s causing secondary PP. As this is secondary HypoPP
it would be expected that the symptoms would settle when the Liddle’s syndrome was treated.
Interestingly, the patient’s possibly affected 35 year old daughter had both the CRYAB
and SCNN1B variations. She had some early signs on MRI of fatty infiltration in a similar
pattern to her father although no evidence of Liddle’s syndrome. The patient’s other daughter,
who declined testing, was known to have early hypertension in her 30s and episodes of
paralysis. These findings combined do suggest that it is possible that Case 10 has a
combination of the consequences of both Liddle’s disease leading to secondary HypoPP prior
to treatment and as he has become older has developed a proximal myopathy related to the
CRYAB mutation (Table 6.1).
To try and verify this further we are currently trying to establish the pathogenicity of
the SCNN1B frameshift mutation by expressing it in HEK293T cells. The pathogenicity of
the CRYAB variation will be harder to establish and it will be interesting to see how the
patient’s phenotype develops over time since the previously reported case had a late onset of
his marked symptoms.
6.3.3.3 Case 11
Case 11 was a patient with a phenotype suggestive of ATS. She had prolongation of QTc, mild
dysmorphic features and episodes of paralysis supported by an initially positive long exercise
test. Her sequencing of KCNJ2 and MLPA of the gene were normal which led me to perform
whole exome sequencing. There were a number of atypical features in her phenotype. Firstly,
she had onset of attacks in the third decade, which is extremely unusual in ATS as attacks
most commonly occur in the first decade or early teens. Her attacks were also atypical, as it is
very unusual to see PP attacks that only occur in the day and never at night. Her dysmorphic
features were subtle and could be unrelated. Interestingly, her MRI was normal which again
is unusual compared to the other ATS cases in the phenotype study who all had, at the very
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least, fatty infiltration of the calves. However objectively, she had a prolonged QT interval
and a positive long exercise test at presentation done at another centre.
Array CGH revealed only one possibly relevant CNV encompassing an extra copy of
the gene MRPL44. This is a nuclear gene that encodes the large subunit of the mitochondrial
ribosome. Homozygous variations have been documented as causing a childhood onset
hypertrophic cardiomyopathy (Carroll et al., 2013). More recently there has also been
evidence of a case with hemiplegic migraine, Leigh-like lesions on MRI, renal insufficiency
and hepatopathy (Distelmaier et al., 2015). A single gain of copy number may disrupt the
open reading frame for the MRPL44 gene on one allele, assuming it is out of frame and
close to the start codon for the gene. If it were in-frame or was distant enough from the
beginning of the gene it would not be expected to cause disruption as the extra copy includes
the entire gene. Even if the CNV did disrupt production of the protein as there is still one
functioning allele it would be unlikely to cause disease without a pathogenic variation on the
second allele. The phenotype of affected patients is also different as Case 11 did not have
hypertrophic cardiomyopathy making it unlikely that this variation is causative.
The whole exome sequencing did identify a known pathogenic variation in a Long QT
gene, KCNQ1 (previously KvLQT1). This variation has been reported in a number of cases
(Donger et al., 1997; Ackerman et al., 1999; Murray et al., 2002). It is primarily associated
with a mildly prolonged QT interval, can be associated with asymptomatic carriers and does
not commonly lead to sudden death except in homozygous carriers. Expression analysis
suggests it only prevents channel function in the homozygous state and does not cause a
dominant negative effect in the heterozygous state (Murray et al., 2002). Given that it has
been reported in many patients with Long QT and is present in the affected sister it is very
likely that it is responsible for the prolongation of the QT interval in this case. It does not
however, explain the episodes of weakness in this patient. As none of the reported cases or the
affected sister have reported episodes of weakness and because KCNQ1 is not significantly
expressed in skeletal muscle (Uhle´n et al., 2015), it makes it unlikely that it is also the cause
of the episodes of weakness.
As no other likely variations were identified, it seems in this particular case that I can
only explain the long QT in this patient and her sister with a genetic cause but not the episodes
of weakness.
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6.3.3.4 Case 12
Case 12 was a patient with typical episodes of paralysis associated with hypokalaemia starting
in his teens and an affected father. He also had a reaction to volatile anaesthetics. He had
an abnormal long exercise test but only subtle abnormalities on MRI of the lower limbs.
Unusually he also had a single ragged red fibre on muscle biopsy.
The most notable novel variation identified on sequencing was in RYR1. The
c.3128G>A;p.Arg1043His has been previously described in the literature in one study as
being possibly pathogenic (Brandom et al., 2013). This case was a patient with MH,
a family history of the condition and positive caffeine and halothane contracture tests,
which are used to identify MH susceptibility. A variation affecting the same codon,
c.3127C>T;p.Arg1043Cys has also been described in two cases of MH (Robinson et al.,
2006; Levano et al., 2009). In one of these cases it was expressed with Arg2336His
on the same chromosome and this variation was shown to significantly alter intracellular
calcium levels in the presence of 4-chloro-m-cresol or caffeine which is thought to indicate
susceptibility to MH (Levano et al., 2009). In that particular case it was concluded that the
Arg2336His was the pathogenic variation and they did not do further functional analysis on
Arg1043Cys. None of the reported cases, however, had documented episodes of weakness
and as the patient’s affected father was deceased I was unable to demonstrate if the variation
segregated with disease.
Codon 1043 lies in a highly conserved region and is predicted by SIFT, PolyPhen2
and Mutation taster to be pathogenic. It lies in the the recently described P1 domain of
RYR1, a phosphorylation hotspot that is intertwined with the SPRY domains (Yan et al.,
2015). The SPRY domains have been postulated to be important in coupling to CaV1.1 (Lau
and Van Petegem, 2014). However, the interaction between the two channels is still poorly
understood and the role of the P1 region is not established. Interestingly other pathogenic
malignant hyperthermia variations are located in this region. Even more interestingly the only
other reported periodic paralysis variation in RYR1 lies in the P2 region which is functionally
similar to P1 (Zhou et al., 2010). In that particular case however, there was decoupling of
CaV1.1 and RYR1 as the episodes of paralysis were associated with a normal CMAP on long
exercise testing rather than a decrement. The other case of a patient with an RYR1 mutation
with episodes of paralysis (Case 4), however, also demonstrated a lack of electron-contraction
uncoupling with a positive McManis test suggesting that it may not be necessary to cause a
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PP phenotype in RYR1 mutations.
The other variations identified in muscle disease-causing genes were all point variations
in genes only associated with disease in the presence of deletions or triplet repeat expansions.
The one variation found in an ion channel gene, although highly likely to produce an
abnormal protein, encoded a chloride permeable channel and therefore would be unlikely
to cause attacks of weakness.
Another possible explanation for this case is that he has a secondary cause of periodic
paralysis, given the low potassium recorded during attacks, however, this was investigated
fully suggesting that it is unlikely to be the underlying cause. This suggests that the the
variation in RYR1 could be underlying his disease and at the very least may be responsible
for his reaction to volatile anaesthetics (Table 6.1). It is unclear, however, why it would
cause a PP phenotype in him but not in other reported cases. One possibility is reduced
penetrance. Another alternative is that he carries a polymorphism that, in combination with
the RYR1 variation, leads to susceptibility to episodes of paralysis. One way of investigating
this further would be to get DNA from affected and unaffected family members which was
not possible in this case. Another option would be to perform functional studies with RYR1
and its interaction with CACNA1S but given the size of the gene and the current lack of
understanding of exactly how the two channels couple this is currently a complex task.
6.3.3.5 Case 13
Case 13 was of a young girl with problems since birth with cleft palate, scoliosis, conductive
hearing loss, short stature, ventricular tachycardias, reduced ventilatory function, lower than
normal IQ and episodes of weakness. She also had distinctive facial abnormalities including
micrognathia, syndactyly, clinodactyly and nail dysplasia. Her muscle biopsy revealed a
number of COX negative fibres which suggested a mitochondrial disease process but with
normal mitochondrial respiratory chain enzyme analysis. Despite this collection of symptoms
her KCNJ2 and mitochondrial genome and rearrangement analysis were all negative.
Array CGH suggested the presence of an extra copy of exons 112 to 117 with
flanking intronic regions in SYNE1. This encodes the spectrin nuclear envelope protein 1.
Homozygous variations in this gene are related to SCA1 with a late onset ataxia phenotype
which was not present in this case. However heterozygous missense mutations in this have
been associated with Emery-Dreifuss muscular dystrophy type 4 (Zhang et al., 2007). The
published phenotype of these cases is of onset of progressive muscle weakness in childhood,
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cardiac arrhythmias, cardiomyopathy and early contractures which is similar to the phenotype
in this case although there have not been significant contractures noted. Muscle biopsy in the
reported cases confirmed a muscular dystrophy with normal immunohistochemistry, although
there have not been reports of COX negative fibres as was found in Case 13. Some caution
has to taken with these results. The SYNE1 gene consists of 536117 bases and 146 exons
and the 1.4M assay covers it with 330 probes. (The coverage of this region is similar in the
720K array). The call of the presence of an extra copy was based only on the presence of 3
probes with an average ratio of 1.77. Given the sparse coverage of this region it is difficult to
be certain whether this is a true CNV. Repeating the test with the 720K exon focused array
would not improve coverage of this particular region and therefore has not been done. There
is currently no MLPA kit designed for this gene, therefore further verification will be sought
using Sanger sequencing and PCR of exons 111 to 118 to try and confirm the presence of an
extra copy.
Whole exome sequencing did not reveal any variations in known channelopathy or
nuclear mitochondrial genes. However, two novel variations were identified in the nebulin
gene, c.5567G > A;p.Arg1856Glu and c.10383G > C;p.Met3461Ile. Variations in the
nebulin gene are associated with nemaline myopathy 2 which is an autosomal recessive
condition associated with proximal weakness, occasionally respiratory muscle weakness and
dysmorphic features including micrognathia and scoliosis. However, these patients do not
typically have cardiac abnormalities and commonly have nemaline rods on muscle biopsy
which was not noted in this patient. Both of the variations identified are present in isolation in
dbSNP in two separate cases, however this in itself does not confirm they are polymorphisms
as they would only be expected to cause disease when expressed with a second pathogenic
variation. It therefore appears to be the most likely explanation (Table 6.1). The other
alternative explanation is that, given the presence of COX negative fibres on biopsy, that
this is a mitochondrial disease and the variation has been missed on initial sequencing. We
are therefore in the process of resequencing the mitochondrial genome to ensure this is not
the case.
6.3.3.6 Case 14
Case 14 was of a 23 year old man with marked painful episodes, which also involved episodes
of weakness. He had some history of autonomic symptoms with a positive tilt table test
suggestive of postural tachycardia syndrome. He had abnormal long exercise testing, a
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reduced left sural SNAP and one episode of raised CK during an attack.
Array CGH was not informative. Exome sequencing identified one variation of note
which was located in SCN11A, c.2776G>A;p.Val926Ile. In silico analysis suggested that
this was likely to be a polymorphism, however variations in this gene have been associated
with a number of neuropathic phenotypes. The first is a gain of function mutation which
results in congenital inability to perceive pain with marked autonomic dysfunction. These
patients had self-mutilation, slow healing wounds and multiple painless fractures (Leipold
et al., 2013). The second phenotype is a gain of function which is associated with a painful
neuropathy (Huang et al., 2014). The phenotype of those with SCN11A variations included
cramping of the legs, orthostatic dizziness, palpitations and hyperhydrosis. This is a very
similar presentation to this patient. The only difference is the initial episodes of weakness
and positive long exercise test which could not be easily explained by a variation in SCN11A.
To further confirm this we intend to perform voltage clamp analysis of the mutated SCN11A
channel to assess its impact on channel function and determine if it may underlie the patient’s
phenotype (Table 6.1).
6.3.3.7 Cases 15-18
The remaining four cases analysed with next generation sequencing did not have any likely
causative variations found in whole exome or aCGH testing. There are a number of possible
explanations for this. This includes the possibility that the causative variation has been missed
by whole exome sequencing, that it lies in a gene which was not identified in my targeted
analysis approach or that the patient has a non-organic or secondary cause of disease that is
not genetic.
Cases 15 and 16 only had very limited clinical information from the clinicians and
patients were not contactable for further information. They were included in the study
because both had documented evidence of low potassium in the context of weakness which
suggested there was some objective evidence of disease. However, in these cases it was not
possible to rule out secondary causes of hypokalaemia and both patients had a significantly
older age of onset than would be expected in primary HypoPP, which commonly presents in
the teenage years to the early twenties.
In case 15 the only novel variation in an ion channel gene was in CACNA2D3. This
gene encodes the α2δ3 calcium channel subunit. When knocked out of Drosophila and
mice it alters thermal sensitivity to pain and SNPs within this gene are thought to modify
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human thermal pain sensitivity (Neely et al., 2010). More recently a role for α2δ1 and
α2δ2 have been identified in synaptic transmission in the control of the abundance of
presynaptic calcium channels and the probability of exocytosis (Hoppa et al., 2012). Neither
of these characteristics would be expected to lead to episodes of paralysis in the presence of
hypokalaemia making the variation identified unlikely to be related to the clinical picture.
Case 16 only had a novel variation identified in CLCN1. Variations in CLCN1 have
never been documented as causing episodes of profound weakness and are unlikely to cause
disease in the absence of myotonia. This patient did not complain of stiffness and did not
have clinical or electrical myotonia suggesting that this variation is unrelated to the clinical
picture.
Case 17 was already known to have the homozygous intronic variant c.1930+6T>G in
CLCN1. He had a typical recessive MC phenotype with onset at 8 years, profuse myotonia
on EMG and short exercise testing suggestive of recessive MC. However, the variation does
not appear to lie at a predicted splice site and therefore its pathogenicity was uncertain. I
therefore performed whole exome sequencing. This did not reveal any possible causative
variants suggesting that the homozygous intronic variant was likely to be pathogenic in this
case (Table 6.1), however, further expression studies with a minigene assay are needed to
confirm this.
Finally case 18 had atypical attacks of weakness with an abnormal CK but objective
evidence of altered muscle membrane excitability from a positive long exercise test and
fatty infiltration in thighs and calf on MRI. Despite having a distinctive phenotype, the
only variation identified was a heterozygous variation in TTN which is predicted to be a
polymorphism. Variations in TTN are associated with autosomal dominant tibial muscular
dystrophy. However, this is associated with variations in the final exon (191) and this variation
is in exon 186. The common phenotype is of progressive distal weakness in later life, very
different to this patient’s presentation. It therefore seems very unlikely to be related. In this
particular case I have excluded secondary causes of HypoPP and this therefore suggests that
the correct gene responsible for this patient’s phenotype has not been identified. As there
were no other affected family members and the patient has lost contact with his father this
makes trio sequencing to identify the likely pathogenic variant more difficult. However, it
would be the next step to identify the underlying cause in this case.
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6.3.3.8 Limitations of Whole Exome Sequencing and aCGH
Whole exome sequencing and aCGH is a useful technique for sequencing a large number of
genes quickly and cost effectively. In this study it has provided a useful method of identifying
possible causative variations in a number of patients. This approach to diagnosing cases does,
however, have limitations. Firstly these techniques have an inherent false negative rate that
is higher than seen in Sanger sequencing. This is because of a combination of, low coverage
in particular areas, missing sequencing in areas that are not covered by the targeted capture
technology (like deep within introns) and poor sequencing of GC-rich areas. These aspects
may partly explain why at least 30% of the cases remain undiagnosed. One way to minimise
these problems would be to repeat the exome sequencing in negative cases using different
capture technology to see if that reveals any other variations missed with the first run of
sequencing.
Secondly variations that are detected may still be missed following filtering. This
technique generates a large number of variations per patient and it is difficult to know which
is the likely causative variation. To narrow down the search, different levels of filtering were
used but this means that causative variations can be missed or ignored, especially if they lie
in novel genes whose function is currently unknown. Another problem arises if variations
detected by other groups are wrongly entered into variation databases such as dbSNP as
non-pathogenic when they actually are pathogenic. It is difficult to manage this aspect as a
balance must be struck between the large volume of sequencing and identifying a meaningful
result. One technique, which we are currently trying in the negative cases is trio sequencing.
This involves sequencing of the patient with both parents (or in some cases with an affected
and closely related unaffected family members). This increases the likelihood of identifying
the causative variation especially in novel genes. This was not possible initially in this study
because of lack of samples from family members. Another useful approach would be to
perform muscle biopsies in undiagnosed patients and perfom mRNA expression profiling to
see if this could direct sequencing further. Trying this approach in this cohort was limited by
difficulties getting patient consent for muscle biopsy.
With the aCGH no likely pathogenic rearrangements were identified. This may be for
a number of reasons. Firstly it may be that, given the nature of these diseases, none of the
patients had rearrangements causing disease. This seems to be a likely explanation but it was
still important to use the technique to exclude these types of variation. Alternatively it may be
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that this technique was not sensitive enough to pick up causative rearrangements. Although
a combination of both 720K and 1.4M arrays were used to try and cover the most likely
affected areas, small rearrangements would be missed. One option to tackle this would be to
create a targeted aCGH array with closer spaced probes covering the ion channels genes.
This study was designed based on the theory that these patients were most likely to have
variations in known ion channel genes or genes expressed in skeletal muscle. Whilst this
remains the most likely answer in most cases, it relies heavily on correct identification of all
genes in the human genome and an understanding of the function of the protein that they code
for. It may be that variations in unexplained cases lie in genes that are unidentified, wrongly
identified or in accessory genes that code for proteins that interact with ion channels. As
our understanding of the genome and gene function develops it will be useful to rescreen the
results to try and identify genes that may have been initially discounted.
Finally, the results of this study were limited by information available about specific
variations. In the cases described I have presented the evidence available for suggesting
that particular variations are responsible for causing disease. In many cases, further proof
of the deleterious nature of these variations is required using minigene assays and channel
expression studies. These are currently being established in our department to provide the
final evidence of the pathogenicity of these variations.
6.3.3.9 Summary of Whole Exome Results
Overall of the 10 cases assessed by whole exome sequencing and in some cases array CGH,
possible explanations have been reached for seven of them (Table 6.1). Two cases had intronic
variations identified in CLCN1 which are likely to be responsible for the disease. One case
is likely to be a genetic cause of secondary periodic paralysis on the background of a late
onset myofibrillar myopathy. The others appear to be atypical presentations of other muscle
diseases, one of an atypical RYR1 disease and other a possible nemaline myopathy. Finally,
the other two cases appear to have a non-muscle pathology, one with a long QT syndrome
mutation to explain their cardiac phenotype and the other a SCN11A phenotype that may
explain their painful neuropathic and autonomic phenotype. This illustrates the variety of
possible explanations for genetic disease in this small cohort.
This genetic study shows the value of next generation sequencing in the diagnosis of
carefully phenotyped patients. These results suggest that RYR1 should be considered as
a muscle channelopathy gene given there are now 3 cases of patients with episodes of
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paralysis and variations in this gene. For patients with myotonia it appears that variations
in unsequenced regions of CLCN1 or large scale rearrangements may underlie the few
undiagnosed cases and so full sequencing of exonic and intronic regions of CLCN1 should
be considered.
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Table 6.1: Summary of likely causative variations and diagnoses in whole exome cases
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6.4 Efficacy of Mexiletine in Treating NDM
6.4.1 Key Findings of the Mexiletine Study
The mexiletine study is the first study in patients with NDM to provide level I evidence for
the efficacy of any drug in the treatment of NDM. The efficacy of mexiletine in this group
was demonstrated, not only in the primary outcome measure of patient-reported stiffness,
but also in the majority of secondary outcome measures. This included patient-reported
weakness, pain and tiredness, quality of life assessments and the more objective measures
of clinical myotonia. It also demonstrated a marked reduction in electrical myotonia which
is an objective electrical correlate to clinical myotonia. The drug was well tolerated and
side effects were mild, with primarily gastrointestinal discomfort which in all cases but one
was not severe enough to require withdrawal from in the study. There were no study-related
serious adverse events.
The majority of effect sizes were greater than 0.5 which, in the literature, corresponds
to a moderate effect but there were a number of outcome measures, including the the primary
outcome measure, that had effect sizes of greater than 0.8 corresponding to a large effect
(de Vet et al., 2006; Husted et al., 2000; Kazis et al., 1989; Liang et al., 1985). This also
included IVR measures of stiffness, weakness and pain; SF-36 physical composite score,
clinical eye closure myotonia and EMG myotonia.
6.4.2 Comparison to other Treatment Studies
Prior studies of mexiletine in NDM have been limited to case studies and a single-blind trial
as described earlier (Pouget and Serratrice, 1983; Leheup et al., 1986; Kwiecinski et al., 1992;
Jackson et al., 1994). These studies included myotonic dystrophy patients and had no washout
period and therefore did not provide objective, good quality evidence of efficacy. The more
recent study from Logigian et al however, demonstrated safety and efficacy for mexiletine in
myotonia in DM1 patients (Logigian et al., 2010) in a randomised-controlled double-blinded
trial, which supports the evidence from this study. That trial however, was specific to DM1
and did not look at any patient-reported outcomes or quality of life measures to demonstrate
whether the improvement to stiffness had any significant impact on patient health. In DM1
patients, the significant problems are rarely due to myotonia but to the systemic effects of
the disease (Turner and Hilton-Jones, 2010), whereas in the NDM population the primary
symptoms are related to myotonia (Statland et al., 2011). Therefore a medication that
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specifically targets this symptom is more likely to have a significant impact on patient health,
as suggested by these results.
6.4.3 Carry-over effect in Cross-over Studies
An important consideration in cross-over studies is the possible carry-over effect of a drug
from one treatment period to another. To identify the presence of this the Wald test was
applied to all data. It was noted in the patient-reported outcomes there was a significant
increase in treatment effect when comparing mexiletine and placebo in treatment period 2. A
significant Wald test would normally be explained by carry-over effect of the drug, however
the result was the inverse of what would be expected if this was the case. Those patients on
mexiletine in period 1 had greater stiffness in period 2 than those that had placebo in period 1.
Conversely those who had mexiletine in period 2 had a greater mean improvement of stiffness
than those who were on mexiletine in period 1. None of the patients had any mexiletine
detected in serum samples following wash-out, making it unlikely that this was due to a
direct chemical drug effect. The groups were well balanced apart from the group of placebo
followed by mexiletine having a larger proportion of males to females (67% compared to
45% in the other group). This could potentially affect the results as men are reported to
be more severely affected than women but the overall mean IVR stiffness between the two
groups was not significantly different suggesting this difference in gender did not impact
on the stiffness scores overall. If gender were to have an effect it would be expected to
worsen the IVR placebo scores in period 1 compared to period 2 when in fact the placebo
scores for period 2 were worse. When the differences between the groups were eliminated
by calculating the treatment effect within each group (by calculating the change for the first
group from when they were on mexiletine to when they were on placebo and the change in
the second group from when they were on placebo to when they were on mexiletine) then
there was no significant difference between the two groups (treatment effect 2.74 vs 2.61).
This again suggests that the groups were balanced.
A possible explanation for this difference between the two treatment periods is that
unblinding has occurred. This could be an unintentional unblinding due to a marked treatment
effect caused by the efficacy of mexiletine or due to the distinctive side effects of mexiletine
making it apparent which medication the patient was on. This means that when patients
entered into period 2 they may have known whether they were on treatment or placebo
therefore biasing their responses on the IVR. It is evident from the patient survey at the
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end of the study that there was some unblinding as over 79% of patients correctly identified
the drug they were on in period 2.
An alternative explanation for this is that patients without medication have some
compensation mechanisms in place to manage their stiffness on a day to day basis, including
avoiding particular tasks and using tricks to warm-up the stiffness. When a patient is on
mexiletine, due to its efficacy, they stop needing to put these compensation processes in
place and therefore when the medication is suddenly stopped the stiffness initially appears
more exaggerated than before starting the medication. Another explanation could be that
prolonged use of mexiletine causes an up-regulation of sodium channel expression in skeletal
muscle myocytes, as this has been demonstrated in rat cardiac myocytes (Duff et al., 1992).
If this is the case, when the patient stops mexiletine in the initial period the myotonia is worse
than if they had been on no drug as there are more abnormal channels expressed with their
persistent inward current. This effect would be expected to settle as the channel expression
down-regulates again. If either of these two explanations were valid then I would expect the
stiffness in the group which was on mexiletine and then placebo, to be significantly worse
in the first two weeks after stopping mexiletine compared to the second two weeks whilst on
placebo but in fact the results were the other way round with worsening of stiffness in the
second set of two weeks when on placebo (4.63 vs 4.97; p=0.02). Average stiffness severity
may also be expected to be worse in those that had placebo second compared to those that
had placebo first but there was no significant difference in stiffness in the first two weeks on
placebo between the two treatment groups (p=0.28).
This analysis suggests that the most likely mechanism for the difference is unblinding
bias. Despite this there was still a significant difference when data was analysed with
adjustments for the carry-over effect. The fairest interpretation may therefore be that the
estimate of treatment effect lies between the 2 values for the 2 treatment periods, 1.68-3.68.
6.4.4 Limitations of the Mexiletine Study
One of the main limitations of this study has been the short duration of treatment. Patients
were only on treatment for four weeks and so it is not known whether the improvement
would have been sustained over a longer period of time. This therefore warrants further
investigation. This short treatment phase, limited the time frame for adverse events and the
small study number also limited the power for detecting adverse events. The inclusion of
both chloride and sodium channel mutation patients for analysis also made data analysis more
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complex and it would have been more robust to investigate these groups separately. However,
given the rarity of these diseases the inclusion of both groups were necessary to power the
study appropriately. This was felt to be a reasonable approach as the final mechanism for
myotonia in both these diseases is the same and mexiletine specifically acts on this final
mechanism.
The unblinding of this study is another limitation which is difficult to prevent given the
side effect profile and efficacy of the drug but does limit some of the interpretation of the
study. It would not, however, be ethical to redesign the study to give patients the same side
effects when on placebo and therefore this needs to be borne in mind when analysing the
data.
6.4.5 Further Work in Treatment Trials
The data from this study should ideally be extended further to include a larger number of
patients and over a longer duration to identify the long term efficacy and tolerability of the
drug. It would be very interesting to extend it with a large enough number of sodium and
chloride channel patients to determine any difference in effect between the two groups. It
would also be useful to compare its efficacy with some of the other available treatments such
as carbamazepine and disopyramide to determine its relative efficacy.
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Chapter 7
CONCLUSIONS
This thesis set out to increase the understanding of skeletal muscle channelopathies. It has
done this by looking at a number of different aspects of the skeletal muscle channelopathies
and identifying a number of novel findings.
I performed a prevalence study of the minimum point prevalence of all the skeletal
muscle channelopathies in England. This is the first study to identify total prevalence in
England and the first study worldwide to identify prevalence estimates for SCM, HyperPP
and ATS. This study also identified the common mutations present in the UK population in
the individual channelopathies.
I performed a comprehensive clinical phenotype study of PMC, SCM and periodic
paralysis. There have been no previous published phenotype studies comparing PMC and
SCM and this is the largest phenotype study of PMC patients documented. This study
indicated that PMC and SCM are actually part of a single disease rather than two separate
entities as traditionally thought, suggesting that a change in nomenclature may be appropriate.
This is also the first comparative study of ATS with HypoPP and HyperPP, showing the
intermediate nature of ATS attacks when compared to these two other diseases. It also
identified correlations between MRI imaging and disease severity suggesting a further role
for work in this area. As part of the clinical phenotype study I also performed the first study
on anaesthetics and pregnancy in skeletal muscle channelopathies. All previous literature has
been based on individual case studies and this is the first patient-based survey. This revealed
that no patients had malignant hyperthermia but worsening of symptoms were seen in 17%
after general anaesthetic. In pregnancy the most significant finding was the marked worsening
in symptoms seen in the majority of patients and in almost all patients with PMC and SCM.
I performed a genetic diagnosis study to improve the genetic diagnosis rate in genetically
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unconfirmed patients. This utilised a combination of targeted Sanger sequencing, MLPA,
arrayCGH and whole exome sequencing with a focused analysis of muscle disease and ion
channel genes. This is the first study to demonstrate large scale rearrangements in CLCN1 in
MC patients. It is also the first study using whole exome and aCGH to identify variations
in channelopathy patients. This study revealed that in atypical or undiagnosed periodic
paralysis, RYR1 should be sequenced as this is associated with episodes of paralysis in two
cases from this cohort and one previously published case. It also revealed that variations
in intronic, 5’UTR and 3’UTR regions may underlie the undiagnosed cases of recessive
MC and should be routinely checked in these patients. I also identified a likely case of
inherited secondary periodic paralysis with a patient with a variation consistent with Liddle’s
syndrome. This suggests that undiagnosed patients should be screened for possible genetic
causes of secondary periodic paralysis when a common cause is not identified.
Finally I recruited and performed the data collection and some of the statistical analysis
for the UK part of an international phase II randomised double-blinded placebo-controlled
trial in the efficacy of mexiletine in NDM. This is the first level I evidence available showing
the efficacy of any drug in the treatment of NDM. This demonstrated efficacy in the primary
outcome of patient-reported stiffness and the majority of the secondary outcomes, including
both quality of life questionnaires and objective electrical and clinical measures of myotonia.
Overall this thesis has identified a number of novel findings. It has given new
perspectives on the prevalence of channelopathies. It has changed our understanding of
clinical phenotypes and increased our knowledge of pregnancy and anaesthetics in this group
of diseases. It has expanded the spectrum of known variations and disease genes associated
with channelopathy phenotypes and provided evidence for the efficacy of treatment with
mexiletine in NDM.
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Table B.1: List of known genes associated with muscle disease phenotype used for filtering
whole exome data (LGMD = Limb girdle muscular dystrophy)
 
Gene	   Name	   Associated	  Muscle	  Disease	  
ACAD9	   Acyl-­‐CoA	  Dehydrogenase	  9	   Mitochondrial	  Complex	  I	  Deficiency	  
ACTA1	   Alpha-­‐Actin	   Nemaline	  Myopathy	  Type	  3,	  Congenital	  Myopathy	  
With	  Cores,	  Congenital	  Myopathy	  With	  Fibre	  Type	  
Disproportion	  
AGL	   Amylo-­‐1,6-­‐Glucosidase	  &	  	  
4-­‐Alpha-­‐Glucanotransferase	  
Glycogen	  Storage	  Disease	  III	  
AGRN	   Agrin	   Congenital	  Myasthenia	  
AMPD1	   Myoadenylate	  Deaminase	   Myopathy	  Due	  To	  Myoadenylate	  Deaminase	  
Deficiency	  
ANO5	   Anoctamin	  5	   LGMD	  2L,	  Miyoshi	  Muscular	  Dystrophy	  3	  
AR	   Androgen	  Receptor	   Spinal	  And	  Bulbar	  Muscular	  Atrophy	  Of	  Kennedy	  
ATP2A1	   Calcium-­‐Transporting	  ATPase	   Brody	  Myopathy	  
ATXN1	   Ataxin	  1	   Spinocerebellar	  Ataxia	  1	  
BAG3	   BCL2-­‐Asociated	  Athanogene	  3	   Myofibrillar	  Myopathy	  6	  
BIN1	   Bridging	  Integrator	  1	   Centronusclear	  Myopathy	  
CACNA1A	   P/Q	  Type	  Voltage	  Gated	  Calcium	  Channel	   Spinocerebellar	  Ataxia	  6,	  Episodic	  Ataxia,	  Type	  2	  
CACNA1S	   L	  Type	  Voltage	  Gated	  Calcium	  Channel	   Hypokalemic	  Periodic	  Paralysis	  
CAPN3	   Calpain-­‐3	   LGMD2A	  
CAV3	   Caveolin-­‐3	   LGMD1C,	  Distal	  Myopathy,	  Rippling	  Muscle	  
Disease	  
CFL2	   Cofilin-­‐2	   Nemaline	  Myopathy	  7	  
CHAT	   Choline	  Acetyltransferase	   Congenital	  Myasthenia	  
CHRNA1	   Nicotinic	  Acetylcholine	  Receptor,	  Alpha	  
Subunit	  
Congenital	  Myasthenia	  
CHRNB1	   Nicotinic	  Acetylcholine	  Receptor,	  Beta	  
Subunit	  
Congenital	  Myasthenia	  
CHRND	   Nicotinic	  Acetylcholine	  Receptor,	  Delta	  
Subunit	  
Congenital	  Myasthenia	  
CHRNE	   Nicotinic	  Acetylcholine	  Receptor,	  Epsilon	  
Subunit	  
Congenital	  Myasthenia	  
CLCN1	   Muscle	  Chloride	  Channel	  1	   Myotonia	  Congenita	  
CNTN1	   Contactin	  1	   Congenital	  Myopathy	  
COL6A1	   Collagen	  Type	  VI,	  Alpha	  1	   Bethlem	  Myopathy,	  Ulrich	  Congenital	  Muscular	  
Dystrophy	  
COL6A2	   Collagen	  Type	  VI,	  Alpha	  2	   Bethlem	  Myopathy,	  Ulrich	  Congenital	  Muscular	  
Dystrophy	  
COL6A3	   Collagen	  Type	  VI,	  Alpha	  3	   Bethlem	  Myopathy,	  Ulrich	  Congenital	  Muscular	  
Dystrophy	  
COLQ	   Collagenic	  Tail	  Of	  Endplate	  
Acteylcholinetserase	  
Congenital	  Myasthenia	  
CRYAB	   Alpha-­‐B-­‐Crystallin	   Myofibrillar	  Myopathy	  
DAG1	   Dystrophin-­‐Associated	  Glycoproteins	   Α-­‐Dystroglycanopathy	  
DES	   Desmin	   LGM1E,	  Scapuloperoneal	  Syndrome	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Table B.1: List of known genes associated with a muscle disease phenotype (cont.)
Gene	   Name	   Associated	  Muscle	  Disease	  
DMD	   Dystrophin	   Duchenne	  Muscular	  Dystrophy,	  Becker	  Muscular	  
Dystrophy	  
DMPK	   Dystrophia	  Myotonica	  Protein	  Kinase	   Myotonic	  Dystrophy	  Type	  1	  
DNAJB6	   DNAJ/HSP40	  Homolog	   LGMD1E	  
DNM2	   Dynamin	  2	   Centronuclea	  Myopathy,	  CMT	  Type	  2M	  
DOK7	   Downstream	  Of	  Tyrosine	  Kinase	  7	   Congenital	  Myasthenia	  
DPM3	   Dolichol-­‐Phosphate-­‐Mannosyltransferase	  
3	  
Congenital	  Disorder	  Of	  Glycosylation	  
DYSF	   Dysferlin	   LGMD2B,	  Distal	  Myopathy,	  Miyoshi	  Muscular	  
Dystrophy	  1	  
EMD	   Emerin	   Emery-­‐Dreifuss	  Muscular	  Dystrophy	  1	  
ENO3	   Enolase	  3	   Glycogen	  Storage	  Disease	  XIII	  
FHL1	   Four	  And	  A	  Half	  LIM	  Domanins	  1	   Emery-­‐Dreifuss	  Muscular	  Dystrophy	  6,	  
Scapuloperoneal	  Myopathy,	  Reducing	  Body	  
Myopathy	  
FKBP14	   FK506-­‐Binding	  14	   Ehlers-­‐Danlos	  Syndrome	  With	  Myopathy	  
FKRP	   Fukutin-­‐Related	  Protein	  Gene	   LGMD1I	  
FKTN	   Fukutin	   LGMD2M	  
FLNC	   Filamin	  C	   Myofibrillar	  Myopathy	  Type	  5,	  Distal	  Myopathy	  
GAA	   Alpha-­‐1,4-­‐Glucosidase	   Glycogen	  Storage	  Disease	  II	  
GBE1	   Glycogen	  Branching	  Enzyme	   Glycogen	  Storage	  Disease	  IV	  
GFPT1	   Glutamine:Fructose-­‐6-­‐Phosphate	  
Amidotransferase	  
Congenital	  Myasthenia	  
GMPPB	   GDP-­‐Mannose	  Pyrophosphorylase	  B	   Muscular	  Dystrophy-­‐Dystroglycanopathy	  
GNE	   UDP-­‐N-­‐Acetylglucosamine	  2-­‐Epimerase/  
N-­‐Acetylmannosamine	  Kinase	  
Inclusion	  Body	  Myositis,	  Nonaka	  Myopathy	  
GYG1	   Glycogenin-­‐1	   Glycogen	  Storage	  Disease	  XV	  
GYS1	   Glycogen	  Synthase	   Glycogen	  Storage	  Disease	  
HMBS	   Porphobilinogen	  Deaminase	   Acute	  Intermittent	  Porphyria	  
HNRNPDL	   Heterogeneous	  Nuclear	  
Ribonucleoproteins	  
LGMD1G	  
HSPB1	   Heat-­‐Shock	  Protein	  27	   Charcot-­‐Marie-­‐Tooth	  Disease	  
HSPG2	   Perlecan	   Schwartz-­‐Jampel	  Syndrome	  
IGHMBP2	   Immunoglobulin	  Mu-­‐Binding	  Protein	  2	   Charcot-­‐Marie-­‐Tooth	  Disease	  
ISPD	   Isoprenoid	  Synthase	  Domain-­‐Containing	  
Protein	  
Muscular	  Dystrophy-­‐Dystroglycanopathy	  
KBTBD13	   Kelch	  Repeat	  And	  BTB/POZ	  Domains-­‐
Containing	  Proteins	  13	  
Nemaline	  Myopathy	  6	  
KCNJ18	   Inward	  Rectifying	  Potassium	  Channel	  18	   Susceptibility	  To	  Thyrotoxic	  Periodic	  Paralysis	  
KCNJ2	   Inward	  Rectifying	  Potassium	  Channel	   Andersen	  Tawil	  Syndrome	  
KIF1B	   Kinesin	  Family	  Member	  1B	   Charcot-­‐Marie-­‐Tooth	  Disease	  
LAMA2	   Laminin	  2	   Congenital	  Merosin-­‐Deficient	  Muscular	  Dystrophy	  	  
LAMP2	   Lysosome-­‐Associated	  Membrane	  Protein	  
B	  
Danon	  Disease	  
LARGE	   Acetylglucosaminyltransferase-­‐Like	  
Protein	  
Muscular	  Dystrophy-­‐Dystroglycanopathy	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Table B.1: List of known genes associated with a muscle disease phenotype (cont.)
Gene	   Name	   Associated	  Muscle	  Disease	  
LDB3	   LIM	  Domain-­‐Binding	  3	   Myofibrillar	  Myopathy	  4	  
LDHA	   Lactate	  Dehydrogenase	  A	   Glycogen	  Storage	  Disease	  XI	  
LIFR	   Leukemia	  Inhibitory	  Factor	  Receptor	   Schwartz-­‐Jampel	  Type	  2	  Syndrome	  
LMNA	   Lamin	  A/C	   Emery-­‐Dreifuss	  Muscular	  Dystrophy,	  LGMD1B	  
MATR3	   Matrin	  3	   Distal	  Myopathy,	  Amyotrophic	  Lateral	  Sclerosis	  
MEGF10	   Multiple	  Epidermal	  Growth	  Factor-­‐Like	  
Domains	  10	  
Myopathy,	  Areflexia,	  Respiratory	  Distress,	  And	  
Dysphagia	  
MFN2	   Mitofusin	  2	   Charcot-­‐Marie-­‐Tooth	  Disease	  
MPZ	   Myelin	  Protein	  Zero	   Charcot-­‐Marie-­‐Tooth	  Disease	  
MSTN	   Myostatin	   Muscle	  Hypertrophy	  
MTM1	   Myotubularin	   Myotubular	  Myopathy	  
MUSK	   Muscle-­‐Specific	  Kinase	   Congenital	  Myasthenia	  
MYF6	   Myogenic	  Factor	  6	   Centronuclear	  Myopathy	  
MYH2	   Myosin	  Heavy	  Chain	  2	   Proximal	  Myopathy	  And	  Ophthalmoplegia	  
MYH3	   Myosin	  Heavy	  Chain	  3	   Arthrogryposis	  
MYH7	   Myosin	  Heavy	  Chain	  7	   Myosin	  Storage	  Myopathy,	  Scapuloperoneal	  
Syndrome,	  Laing	  Distal	  Myopathy	  
MYOT	   Myotilin	   LGMD1A,	  Myofibrillar	  Myopathy	  
NEB	   Nebulin	   Nemaline	  Myopathy	  	  
NEFL	   Neurofilament	  Protein,	  Light	  Polypeptide	   Charcot-­‐Marie-­‐Tooth	  Disease	  
PABPN1	   Pokyadenylate	  –Binding	  Protein,	  Nuclear	  
1	  
Oculopharyngeal	  Muscular	  Dystrophy	  
PGAM2	   Phosphoglycerate	  Mutase	  2	   Glycogen	  Storage	  Disease	  
PGK1	   Phosphoglycerate	  Kinase	  1	  	   Phosphoglycerate	  Kinase	  1	  Deficiency	  
PGM1	   Phosphoglucomutase	  1	   Congenital	  Disorder	  Of	  Glycosylation,	  Type	  It	  
PHKA1	   Alpha	  Subunit	  Phosphorylase	  Kinase	   Muscle	  Glycogenosis	  
PHKB	   Beta	  Subunit	  Phosphorylase	  Kinase	   Phosphorylase	  Kinase	  Deficiency	  Of	  Liver	  And	  
Muscle	  
PLEC1	   Plectin	  1	   LGMB2Q	  
PMP22	   Peripheral	  Myelin	  Protein	  22	   Charcot-­‐Marie-­‐Tooth	  Disease	  
POLG	   DNA	  Polymerase	  Gamma	   Progressive	  External	  Ophthalmoplegia,	  Alpers,	  
MNGIE	  
POMGNT1	   Protein	  O-­‐Mannose	  Beta-­‐1,2-­‐N-­‐
Acetylglucosaminyltransferase	  
Muscular	  Dystrophy-­‐Dystroglycanopathy	  
POMK	   Protein-­‐O-­‐Mannose	  Kinase	   Muscular	  Dystrophy-­‐Dystroglycanopathy	  
POMT1	   Protein	  O-­‐Mannosyltransferase	  1	   Muscular	  Dystrophy-­‐Dystroglycanopathy	  
POMT2	   Protein	  O-­‐Mannosyltransferase	  2	   Muscular	  Dystrophy-­‐Dystroglycanopathy	  
PTRF	   RNA	  Polymerase	  I	  And	  Transcript	  Release	  
Factor	  
Congenital	  Lipodystrophy	  4	  
PYGM	   Muscle	  Glycogen	  Phosphorylase	   Mcardle	  Disease	  
RAPSN	   Receptor-­‐Associated	  Protein	  Of	  The	  
Synapse	  
Congenital	  Myasthenia	  Syndrome	  
RMD1	   Rippling	  Muscle	  Disease	  1	   Rippling	  Muscle	  Disease	  
RYR1	   Ryanodine	  Receptor	  1	   Central	  Core	  Disease,	  Multi-­‐Minicore	  Disease,	  
Malignant	  Hyperthermia	  Susceptibility	  
SCN4A	   Voltage-­‐Gated	  Sodium	  Channel	  Type	  4	   HyperPP,	  PMC,	  SCM,	  HypoPP2	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Table B.1: List of known genes associated with a muscle disease phenotype (cont.)
Gene	   Name	   Associated	  Muscle	  Disease	  
SEPN1	   Selenoprotein	  N1	   Congenital	  Myopathy,	  Rigid	  Spine	  Muscular	  
Dystrophy	  
SGCA	   Alpha	  Sarcoglycan	   LGMD2D	  
SGCB	   Beta	  Sarcoglycan	   LGMD2E	  
SGCD	   Delta	  Sarcoglycan	   LGMD2F	  
SGCG	   Gamma	  Sarcoglycan	   LGMD2C	  
SIL1	   Homolog	  S.Cerevisiae	   Marinesco-­‐Sjogren	  Syndrome	  
SLC25A4	   Solute	  Carrier	  Family	  25,	  Member	  4	   Progressive	  External	  Ophthalmoplegia	  
SMCHD1	   Structural	  Maintenance	  Of	  Chromosomes	  
Hinge	  Domain-­‐Containing	  Protein	  1	  
Fascioscapulohumeral	  Muscular	  Dystrophy	  2	  
SMN1	   Survival	  Of	  Motor	  Neuron	  1	   Spinal	  Muscular	  Atrophy	  
SMN2	   Survival	  Of	  Motor	  Neuron	  2	   Spinal	  Muscular	  Atrophy	  
SOD1	   Superoxide	  Dismutase	  1	   Amyotrophic	  Lateral	  Sclerosis	  
SYNE1	   Spectrin	  Repeat-­‐Containing	  Nuclear	  
Envelope	  Protein	  1	  
Emery-­‐Dreifuss	  Muscular	  Dystrophy,	  
Spinocerebellar	  Ataxia	  
SYNE2	   Spectrin	  Repeat-­‐Containing	  Nuclear	  
Envelope	  Protein	  2	  
Emery-­‐Dreifuss	  Muscular	  Dystrophy	  
TARDBP	   TAR	  DNA	  Binding	  Protein	   Amyotrophic	  Lateral	  Sclerosis	  
TAZ	   Tafazzin	   Barth	  Syndrome	  
TCAP	   Titin-­‐CAP	   LGMD2G	  
TGFB1	   Transforming	  Growth	  Factor,	  Beta-­‐1	   Camurati-­‐Engelmann	  Disease	  
TK2	   Thymidine	  Kinase	  2	   Mitochondrial	  DNA	  Depletion	  Syndrome	  
TNNT1	   Troponin	  T1	  Slow	   Nemaline	  Myopathy	  
TNPO3	   Transportin	  3	   LGMD1F	  
TPM2	   Tropomyosin	  2	   Nemaline	  Myopathy,	  CAP	  Myopathy	  
TPM3	   Tropomyosin	  3	   Nemaline	  Myopathy,	  CAP	  Myopathy,	  Congenital	  
Myopathy	  
TRAPPC11	   Trafficking	  Protein	  Particle	  Complex,	  
Subunit	  11	  
LGMD2S	  
TRIM32	   Tripartite	  Motif-­‐Containing	  Protein	  32	   LGMD2H	  
TTN	   Titin	   LGMD2J,	  Tibial	  Muscular	  Dystrophy	  
VCP	   Valosin-­‐Containing	  Protein	   Inclusion	  Body	  Myositis,	  Amyotrophic	  Lateral	  
Sclerosis	  
WDM	   Welander	  Distal	  Myopathy	   Welander	  Distal	  Myopathy	  
ZC4H2	   Zinc	  Finger	  C4h2	  Domain-­‐Containing	  
Protein	  
Wieacker-­‐Wolff	  Syndrome	  
ZNF9	   Zinc	  Finger	  Protein	  9	   Myotonic	  Dystrophy	  Type	  2	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Table B.2: List of known ion channel genes used for filtering whole exome data with skeletal
muscle expression levels
 
Gene	   Gene	  description	   Skeletal	  
muscle	  
Expression	  	  
CACNA1S	   calcium	  channel,	  voltage-­‐dependent,	  L	  type,	  alpha	  1S	  
subunit	  
High	  
CACNG1	   calcium	  channel,	  voltage-­‐dependent,	  gamma	  subunit	  1	   High	  
CLCN1	   chloride	  channel,	  voltage-­‐sensitive	  1	   High	  
KCNA2	   potassium	  channel,	  voltage	  gated	  shaker	  related	  
subfamily	  A,	  member	  2	  
High	  
KCNJ11	   potassium	  channel,	  inwardly	  rectifying	  subfamily	  J,	  
member	  11	  
High	  
SCN3B	   sodium	  channel,	  voltage	  gated,	  type	  III	  beta	  subunit	   High	  
TRPC6	   transient	  receptor	  potential	  cation	  channel,	  subfamily	  C,	  
member	  6	  
High	  
CACNA1S	   calcium	  channel,	  voltage-­‐dependent,	  L	  type,	  alpha	  1S	  
subunit	  
High	  
ASIC4	   acid	  sensing	  (proton	  gated)	  ion	  channel	  family	  member	  4	   Medium	  
AQP4	   aquaporin	  4	   Medium	  
CACNA1G	   calcium	  channel,	  voltage-­‐dependent,	  T	  type,	  alpha	  1G	  
subunit	  
Medium	  
CACNB4	   calcium	  channel,	  voltage-­‐dependent,	  beta	  4	  subunit	   Medium	  
CACNG3	   calcium	  channel,	  voltage-­‐dependent,	  gamma	  subunit	  3	   Medium	  
CACNG5	   calcium	  channel,	  voltage-­‐dependent,	  gamma	  subunit	  5	   Medium	  
CACNG8	   calcium	  channel,	  voltage-­‐dependent,	  gamma	  subunit	  8	   Medium	  
CLCA2	   chloride	  channel	  accessory	  2	   Medium	  
CLCN5	   chloride	  channel,	  voltage-­‐sensitive	  5	   Medium	  
CLCNKA	   chloride	  channel,	  voltage-­‐sensitive	  Ka	   Medium	  
CLIC5	   chloride	  intracellular	  channel	  5	   Medium	  
CNGA3	   cyclic	  nucleotide	  gated	  channel	  alpha	  3	   Medium	  
HCN2	   hyperpolarization	  activated	  cyclic	  nucleotide	  gated	  
potassium	  channel	  2	  
Medium	  
KCNA7	   potassium	  channel,	  voltage	  gated	  shaker	  related	  
subfamily	  A,	  member	  7	  
Medium	  
KCNC1	   potassium	  channel,	  voltage	  gated	  Shaw	  related	  
subfamily	  C,	  member	  1	  
Medium	  
KCNE1	   potassium	  channel,	  voltage	  gated	  subfamily	  E	  regulatory	  
beta	  subunit	  1	  
Medium	  
KCNE2	   potassium	  channel,	  voltage	  gated	  subfamily	  E	  regulatory	  
beta	  subunit	  2	  
Medium	  
KCNE4	   potassium	  channel,	  voltage	  gated	  subfamily	  E	  regulatory	  
beta	  subunit	  4	  
Medium	  
KCNF1	   potassium	  channel,	  voltage	  gated	  modifier	  subfamily	  F1	   Medium	  
KCNG4	   potassium	  channel,	  voltage	  gated	  modifier	  subfamily	  G,	  
member	  4	  
Medium	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Table B.2: List of known ion channel genes (cont.)
Gene	   Gene	  description	   Expression	  	  
KCNH5	   potassium	  channel,	  voltage	  gated	  eag	  related	  subfamily	  
H,	  member	  5	  
Medium	  
KCNIP4	   Kv	  channel	  interacting	  protein	  4	   Medium	  
KCNJ14	   potassium	  channel,	  two	  pore	  domain	  subfamily	  J,	  
member	  14	  
Medium	  
KCNK13	   potassium	  channel,	  two	  pore	  domain	  subfamily	  K,	  
member	  13	  
Medium	  
KCNK18	   potassium	  channel,	  two	  pore	  domain	  subfamily	  K,	  
member	  18	  
Medium	  
KCNN2	   potassium	  channel,	  calcium	  activated	  intermediate/small	  
conductance	  subfamily	  N	  alpha,	  member	  2	  
Medium	  
KCNQ5	   potassium	  channel,	  voltage	  gated	  KQT-­‐like	  subfamily	  Q,	  
member	  5	  
Medium	  
KCNU1	   potassium	  channel,	  subfamily	  U,	  member	  1	   Medium	  
RYR3	   ryanodine	  receptor	  3	   Medium	  
SCN1A	   sodium	  channel,	  voltage	  gated,	  type	  I	  alpha	  subunit	   Medium	  
SCN7A	   sodium	  channel,	  voltage	  gated,	  type	  VII	  alpha	  subunit	   Medium	  
SCN8A	   sodium	  channel,	  voltage	  gated,	  type	  VIII	  alpha	  subunit	   Medium	  
TRPC3	   transient	  receptor	  potential	  cation	  channel,	  subfamily	  C,	  
member	  3	  
Medium	  
TRPM3	   transient	  receptor	  potential	  cation	  channel,	  subfamily	  M,	  
member	  3	  
Medium	  
TRPM7	   transient	  receptor	  potential	  cation	  channel,	  subfamily	  M,	  
member	  7	  
Medium	  
TRPV3	   transient	  receptor	  potential	  cation	  channel,	  subfamily	  V,	  
member	  3	  
Medium	  
CACNA1C	   calcium	  channel,	  voltage-­‐dependent,	  L	  type,	  alpha	  1C	  
subunit	  
Low	  
CACNA1E	   calcium	  channel,	  voltage-­‐dependent,	  R	  type,	  alpha	  1E	  
subunit	  
Low	  
CACNA2D1	   calcium	  channel,	  voltage-­‐dependent,	  alpha	  2/delta	  
subunit	  1	  
Low	  
CACNA2D2	   calcium	  channel,	  voltage-­‐dependent,	  alpha	  2/delta	  
subunit	  2	  
Low	  
CACNB1	   calcium	  channel,	  voltage-­‐dependent,	  beta	  1	  subunit	   Low	  
CACNB3	   calcium	  channel,	  voltage-­‐dependent,	  beta	  3	  subunit	   Low	  
CLCN4	   chloride	  channel,	  voltage-­‐sensitive	  4	   Low	  
CLCNKB	   chloride	  channel,	  voltage-­‐sensitive	  Kb	   Low	  
CLIC2	   chloride	  intracellular	  channel	  2	   Low	  
CNGA2	   cyclic	  nucleotide	  gated	  channel	  alpha	  2	   Low	  
CNGB3	   cyclic	  nucleotide	  gated	  channel	  beta	  3	   Low	  
KCNA4	   potassium	  channel,	  voltage	  gated	  shaker	  related	  
subfamily	  A,	  member	  4	  
Low	  
KCNA5	   potassium	  channel,	  voltage	  gated	  shaker	  related	  
subfamily	  A,	  member	  5	  
Low	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  description	   Expression	  	  
KCNC3	   potassium	  channel,	  voltage	  gated	  Shaw	  related	  
subfamily	  C,	  member	  3	  
Low	  
KCNC4	   potassium	  channel,	  voltage	  gated	  Shaw	  related	  
subfamily	  C,	  member	  4	  
Low	  
KCND1	   potassium	  channel,	  voltage	  gated	  Shal	  related	  subfamily	  
D,	  member	  1	  
Low	  
KCND3	   potassium	  channel,	  voltage	  gated	  Shal	  related	  subfamily	  
D,	  member	  3	  
Low	  
KCNE3	   potassium	  channel,	  voltage	  gated	  subfamily	  E	  regulatory	  
beta	  subunit	  3	  
Low	  
KCNH1	   potassium	  channel,	  voltage	  gated	  eag	  related	  subfamily	  
H,	  member	  1	  
Low	  
KCNJ13	   potassium	  channel,	  inwardly	  rectifying	  subfamily	  J,	  
member	  13	  
Low	  
KCNJ18	   potassium	  channel,	  two	  pore	  domain	  subfamily	  J,	  
member	  18	  
Low	  
KCNJ2	   potassium	  channel,	  two	  pore	  domain	  subfamily	  J,	  
member	  2	  
Low	  
KCNK10	   potassium	  channel,	  two	  pore	  domain	  subfamily	  K,	  
member	  10	  
Low	  
KCNK12	   potassium	  channel,	  two	  pore	  domain	  subfamily	  K,	  
member	  12	  
Low	  
KCNK15	   potassium	  channel,	  two	  pore	  domain	  subfamily	  K,	  
member	  15	  
Low	  
KCNK4	   potassium	  channel,	  two	  pore	  domain	  subfamily	  K,	  
member	  4	  
Low	  
KCNK6	   potassium	  channel,	  two	  pore	  domain	  subfamily	  K,	  
member	  	  6	  
Low	  
KCNMA1	   potassium	  channel,	  calcium	  activated	  large	  conductance	  
subfamily	  M	  alpha,	  member	  1	  
Low	  
KCNMB1	   potassium	  channel	  subfamily	  M	  regulatory	  beta	  subunit	  
1	  
Low	  
KCNN4	   potassium	  channel,	  calcium	  activated	  intermediate/small	  
conductance	  subfamily	  N	  alpha,	  member	  4	  
Low	  
KCNQ3	   potassium	  channel,	  voltage	  gated	  KQT-­‐like	  subfamily	  Q,	  
member	  3	  
Low	  
KCNS1	   potassium	  voltage-­‐gated	  channel,	  modifier	  subfamily	  S,	  
member	  1	  
Low	  
KCNV1	   potassium	  channel,	  voltage	  gated	  modifier	  subfamily	  V,	  
member	  1	  
Low	  
SCN10A	   sodium	  channel,	  voltage	  gated,	  type	  X	  alpha	  subunit	   Low	  
SCN1B	   sodium	  channel,	  voltage	  gated,	  type	  I	  beta	  subunit	   Low	  
SCN4A	   sodium	  channel,	  voltage	  gated,	  type	  IV	  alpha	  subunit	   Low	  
SCN4B	   sodium	  channel,	  voltage	  gated,	  type	  IV	  beta	  subunit	   Low	  
SCNN1A	   sodium	  channel,	  non	  voltage	  gated	  1	  alpha	  subunit	   Low	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Table B.2: List of known ion channel genes (cont.)
Gene	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  description	   Expression	  	  
TPTE2	   transmembrane	  phosphoinositide	  3-­‐phosphatase	  and	  
tensin	  homolog	  2	  
Low	  
TRPA1	   transient	  receptor	  potential	  cation	  channel,	  subfamily	  A,	  
member	  1	  
Low	  
TRPC7	   transient	  receptor	  potential	  cation	  channel,	  subfamily	  C,	  
member	  7	  
Low	  
TRPM5	   transient	  receptor	  potential	  cation	  channel,	  subfamily	  M,	  
member	  5	  
Low	  
TRPV2	   transient	  receptor	  potential	  cation	  channel,	  subfamily	  V,	  
member	  2	  
Low	  
TRPV4	   transient	  receptor	  potential	  cation	  channel,	  subfamily	  V,	  
member	  4	  
Low	  
ASIC1	   acid	  sensing	  (proton	  gated)	  ion	  channel	  1	   None	  
ASIC2	   acid	  sensing	  (proton	  gated)	  ion	  channel	  2	   None	  
ASIC3	   acid	  sensing	  (proton	  gated)	  ion	  channel	  3	   None	  
ASIC5	   acid	  sensing	  (proton	  gated)	  ion	  channel	  family	  member	  5	   None	  
ALG10	   alpha-­‐1,2-­‐glucosyltransferase	   None	  
ANKRD36C	   ankyrin	  repeat	  domain	  36C	   None	  
ANO1	   anoctamin	  6	   None	  
ANO10	   Anoctamin	  10	   None	  
ANO2	   Anoctamin	  2	   None	  
ANO3	   Anoctamin	  3	   None	  
ANO4	   Anoctamin	  4	   None	  
ANO5	   Anoctamin	  5	   None	  
ANO6	   Anoctamin	  6	   None	  
ANO7	   Anoctamin	  7	   None	  
ANO8	   Anoctamin	  8	   None	  
ANO9	   Anoctamin	  9	   None	  
ANXA9	   annexin	  A9	   None	  
APP	   amyloid	  beta	  (A4)	  precursor	  protein	   None	  
AQP1	   aquaporin	  1	  	   None	  
BEST1	   Bestrophin	  1	   None	  
BEST2	   Bestrophin	  2	   None	  
BEST3	   Bestrophin	  3	   None	  
BEST4	   Bestrophin	  4	   None	  
CACNA1A	   Calcium	  channel,	  voltage-­‐dependent,	  P/Q	  type,	  α1A	  
subunit	  
None	  
CACNA1B	   calcium	  channel,	  voltage-­‐dependent,	  N	  type,	  α1B	  subunit	   None	  
CACNA1D	   calcium	  channel,	  voltage-­‐dependent,	  L	  type,	  α1D	  subunit	   None	  
CACNA1F	   calcium	  channel,	  voltage-­‐dependent,	  L	  type,	  α1F	  subunit	   None	  
CACNA1H	   calcium	  channel,	  voltage-­‐dependent,	  T	  type,	  α1H	  subunit	   None	  
CACNA1I	   calcium	  channel,	  voltage-­‐dependent,	  T	  type,	  α1I	  subunit	   None	  
CACNA2D3	   calcium	  channel,	  voltage-­‐dependent,	  alpha	  2/delta	  
subunit	  3	  
None	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CACNA2D4	   calcium	  channel,	  voltage-­‐dependent,	  alpha	  2/delta	  
subunit	  4	  
None	  
CACNB2	   calcium	  channel,	  voltage-­‐dependent,	  beta	  2	  subunit	   None	  
CACNG2	   calcium	  channel,	  voltage-­‐dependent,	  gamma	  subunit	  2	   None	  
CACNG4	   calcium	  channel,	  voltage-­‐dependent,	  gamma	  subunit	  4	   None	  
CACNG6	   calcium	  channel,	  voltage-­‐dependent,	  gamma	  subunit	  6	   None	  
CACNG7	   calcium	  channel,	  voltage-­‐dependent,	  gamma	  subunit	  7	   None	  
CALHM1	   calcium	  homeostasis	  modulator	  1	   None	  
CAPN2	   calpain	  2,	  (m/II)	  large	  subunit	   None	  
CATSPER1	   cation	  channel,	  sperm	  associated	  1	   None	  
CATSPER2	   cation	  channel,	  sperm	  associated	  2	   None	  
CATSPER3	   cation	  channel,	  sperm	  associated	  3	   None	  
CATSPER4	   cation	  channel,	  sperm	  associated	  4	   None	  
CDH5	   cadherin	  5,	  type	  2	   None	  
CFTR	   cystic	  fibrosis	  transmembrane	  conductance	  regulator	  
(ATP-­‐binding	  cassette	  sub-­‐family	  C,	  member	  7)	  
None	  
CHRFAM7A	   CHRNA7	  (cholinergic	  receptor,	  nicotinic,	  alpha	  7,	  exons	  
5-­‐10)	  and	  FAM7A	  (family	  with	  sequence	  similarity	  7A,	  
exons	  A-­‐E)	  fusion	  
None	  
CHRNA1	   cholinergic	  receptor,	  nicotinic,	  alpha	  1	  (muscle)	   None	  
CHRNA10	   cholinergic	  receptor,	  nicotinic,	  alpha	  10	  (neuronal)	   None	  
CHRNA2	   cholinergic	  receptor,	  nicotinic,	  alpha	  2	  (neuronal)	   None	  
CHRNA3	   cholinergic	  receptor,	  nicotinic,	  alpha	  3	  (neuronal)	   None	  
CHRNA4	   cholinergic	  receptor,	  nicotinic,	  alpha	  4	  (neuronal)	   None	  
CHRNA5	   cholinergic	  receptor,	  nicotinic,	  alpha	  5	  (neuronal)	   None	  
CHRNA6	   cholinergic	  receptor,	  nicotinic,	  alpha	  6	  (neuronal)	   None	  
CHRNA7	   cholinergic	  receptor,	  nicotinic,	  alpha	  7	  (neuronal)	   None	  
CHRNA9	   cholinergic	  receptor,	  nicotinic,	  alpha	  9	  (neuronal)	   None	  
CHRNB1	   cholinergic	  receptor,	  nicotinic,	  beta	  1	  (muscle)	   None	  
CHRNB2	   cholinergic	  receptor,	  nicotinic,	  beta	  2	  (neuronal)	   None	  
CHRNB3	   cholinergic	  receptor,	  nicotinic,	  beta	  3	  (neuronal)	   None	  
CHRNB4	   cholinergic	  receptor,	  nicotinic,	  beta	  4	  (neuronal)	   None	  
CHRND	   cholinergic	  receptor,	  nicotinic,	  delta	  (muscle)	   None	  
CHRNE	   cholinergic	  receptor,	  nicotinic,	  epsilon	  (muscle)	   None	  
CHRNG	   cholinergic	  receptor,	  nicotinic,	  gamma	  (muscle)	   None	  
CLCA3P	   chloride	  channel	  accessory	  3,	  pseudogene	   None	  
CLCN2	   chloride	  channel,	  voltage-­‐sensitive	  2	   None	  
CLCN3	   chloride	  channel,	  voltage-­‐sensitive	  3	   None	  
CLCN6	   chloride	  channel,	  voltage-­‐sensitive	  6	   None	  
CLCN7	   chloride	  channel,	  voltage-­‐sensitive	  7	   None	  
CLIC1	   chloride	  intracellular	  channel	  1	   None	  
CLIC3	   chloride	  intracellular	  channel	  3	   None	  
CLIC4	   chloride	  intracellular	  channel	  4	   None	  
CLIC6	   chloride	  intracellular	  channel	  6	   None	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CNGA1	   cyclic	  nucleotide	  gated	  channel	  alpha	  1	   None	  
CNGA4	   cyclic	  nucleotide	  gated	  channel	  alpha	  4	   None	  
CNGB1	   cyclic	  nucleotide	  gated	  channel	  beta	  1	   None	  
CTNNB1	   catenin	  (cadherin-­‐associated	  protein),	  beta	  1	   None	  
CYBB	   cytochrome	  b-­‐245,	  beta	  polypeptide	   None	  
DLG2	   discs,	  large	  homolog	  2	   None	  
DLG4	   discs,	  large	  homolog	  4	   None	  
ENKUR	   enkurin,	  TRPC	  channel	  interacting	  protein	   None	  
ENSA	   endosulfine	  alpha	   None	  
FKBP1B	   FK506	  binding	  protein	  1B	   None	  
FXYD1	   FXYD	  domain	  containing	  ion	  transport	  regulator	  1	   None	  
FXYD2	   FXYD	  domain	  containing	  ion	  transport	  regulator	  2	   None	  
FXYD3	   FXYD	  domain	  containing	  ion	  transport	  regulator	  5	   None	  
FXYD4	   FXYD	  domain	  containing	  ion	  transport	  regulator	  6	   None	  
FXYD5	   FXYD	  domain	  containing	  ion	  transport	  regulator	  6	  
pseudogene	  3	  
None	  
FXYD6	   FXYD	  domain	  containing	  ion	  transport	  regulator	  7	   None	  
FXYD6P3	   FXYD	  domain	  containing	  ion	  transport	  regulator	  1	   None	  
FXYD7	   FXYD	  domain	  containing	  ion	  transport	  regulator	  2	   None	  
GABRA1	   gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  alpha	  1	   None	  
GABRA2	   gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  alpha	  2	   None	  
GABRA3	   gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  alpha	  3	   None	  
GABRA4	   gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  alpha	  4	   None	  
GABRA5	   gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  alpha	  5	   None	  
GABRA6	   gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  alpha	  6	   None	  
GABRB1	   gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  beta	  1	   None	  
GABRB2	   gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  beta	  2	   None	  
GABRB3	   gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  beta	  3	   None	  
GABRD	   gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  delta	   None	  
GABRE	   gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  epsilon	   None	  
GABRG1	   gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  gamma	  1	   None	  
GABRG2	   gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  gamma	  2	   None	  
GABRG3	   gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  gamma	  3	   None	  
GABRP	   gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  pi	   None	  
GABRQ	   gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  theta	   None	  
GABRR1	   gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  rho	  1	   None	  
GABRR2	   gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  rho	  2	   None	  
GABRR3	   gamma-­‐aminobutyric	  acid	  (GABA)	  A	  receptor,	  rho	  3	  
(gene/pseudogene)	  
None	  
GLRA1	   glycine	  receptor,	  alpha	  1	   None	  
GLRA2	   glycine	  receptor,	  alpha	  2	   None	  
GLRA3	   glycine	  receptor,	  alpha	  3	   None	  
GLRA4	   glycine	  receptor,	  alpha	  4	   None	  
GLRB	   glycine	  receptor,	  beta	   None	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GNB2L1	   guanine	  nucleotide	  binding	  protein	  (G	  protein),	  beta	  
polypeptide	  2-­‐like	  1	  
None	  
GPR89B	   G	  protein-­‐coupled	  receptor	  89B	   None	  
GRIA1	   glutamate	  receptor,	  ionotropic,	  AMPA	  1	   None	  
GRIA2	   glutamate	  receptor,	  ionotropic,	  AMPA	  2	   None	  
GRIA3	   glutamate	  receptor,	  ionotropic,	  AMPA	  3	   None	  
GRIA4	   glutamate	  receptor,	  ionotropic,	  AMPA	  4	   None	  
GRID1	   glutamate	  receptor,	  ionotropic,	  delta	  1	   None	  
GRID2	   glutamate	  receptor,	  ionotropic,	  delta	  2	   None	  
GRIK1	   glutamate	  receptor,	  ionotropic,	  kainate	  1	   None	  
GRIK2	   glutamate	  receptor,	  ionotropic,	  kainate	  2	   None	  
GRIK3	   glutamate	  receptor,	  ionotropic,	  kainate	  3	   None	  
GRIK4	   glutamate	  receptor,	  ionotropic,	  kainate	  4	   None	  
GRIK5	   glutamate	  receptor,	  ionotropic,	  kainate	  5	   None	  
GRIN1	   glutamate	  receptor,	  ionotropic,	  N-­‐methyl	  D-­‐aspartate	  1	   None	  
GRIN2A	   glutamate	  receptor,	  ionotropic,	  N-­‐methyl	  D-­‐aspartate	  2A	   None	  
GRIN2B	   glutamate	  receptor,	  ionotropic,	  N-­‐methyl	  D-­‐aspartate	  2B	   None	  
GRIN2C	   glutamate	  receptor,	  ionotropic,	  N-­‐methyl	  D-­‐aspartate	  2C	   None	  
GRIN2D	   glutamate	  receptor,	  ionotropic,	  N-­‐methyl	  D-­‐aspartate	  2D	   None	  
GRIN3A	   glutamate	  receptor,	  ionotropic,	  N-­‐methyl-­‐D-­‐aspartate	  3A	   None	  
GRIN3B	   glutamate	  receptor,	  ionotropic,	  N-­‐methyl-­‐D-­‐aspartate	  3B	   None	  
HCN1	   hyperpolarization	  activated	  cyclic	  nucleotide	  gated	  
potassium	  channel	  1	  
None	  
HCN3	   hyperpolarization	  activated	  cyclic	  nucleotide	  gated	  
potassium	  channel	  3	  
None	  
HCN4	   hyperpolarization	  activated	  cyclic	  nucleotide	  gated	  
potassium	  channel	  4	  
None	  
HTR3A	   5-­‐hydroxytryptamine	  (serotonin)	  receptor	  3A,	  ionotropic	   None	  
HTR3B	   5-­‐hydroxytryptamine	  (serotonin)	  receptor	  3B,	  ionotropic	   None	  
HTR3C	   5-­‐hydroxytryptamine	  (serotonin)	  receptor	  3C,	  ionotropic	   None	  
HTR3D	   5-­‐hydroxytryptamine	  (serotonin)	  receptor	  3D,	  ionotropic	   None	  
HTR3E	   5-­‐hydroxytryptamine	  (serotonin)	  receptor	  3E,	  ionotropic	   None	  
HVCN1	   hydrogen	  voltage	  gated	  channel	  1	   None	  
IAPP	   islet	  amyloid	  polypeptide	   None	  
ITPR1	   inositol	  1,4,5-­‐trisphosphate	  receptor,	  type	  1	   None	  
ITPR2	   inositol	  1,4,5-­‐trisphosphate	  receptor,	  type	  2	   None	  
ITPR3	   inositol	  1,4,5-­‐trisphosphate	  receptor,	  type	  3	   None	  
KBTBD13	   kelch	  repeat	  and	  BTB	  (POZ)	  domain	  containing	  13	   None	  
KCNA1	   potassium	  channel,	  voltage	  gated	  shaker	  related	  
subfamily	  A,	  member	  1	  
None	  
KCNA10	   potassium	  channel,	  voltage	  gated	  shaker	  related	  
subfamily	  A,	  member	  10	  
None	  
KCNA3	   potassium	  channel,	  voltage	  gated	  shaker	  related	  
subfamily	  A,	  member	  3	  
None	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KCNA6	   potassium	  channel,	  voltage	  gated	  shaker	  related	  
subfamily	  A,	  member	  6	  
None	  
KCNAB1	   potassium	  channel,	  voltage	  gated	  subfamily	  A	  regulatory	  
beta	  subunit	  1	  
None	  
KCNAB2	   potassium	  channel,	  voltage	  gated	  subfamily	  A	  regulatory	  
beta	  subunit	  2	  
None	  
KCNAB3	   potassium	  channel,	  voltage	  gated	  subfamily	  A	  regulatory	  
beta	  subunit	  3	  
None	  
KCNB1	   potassium	  channel,	  voltage	  gated	  Shab	  related	  subfamily	  
B,	  member	  1	  
None	  
KCNB2	   potassium	  channel,	  voltage	  gated	  Shab	  related	  subfamily	  
B,	  member	  2	  
None	  
KCNC2	   potassium	  channel,	  voltage	  gated	  Shaw	  related	  
subfamily	  C,	  member	  2	  
None	  
KCND2	   potassium	  channel,	  voltage	  gated	  Shal	  related	  subfamily	  
D,	  member	  2	  
None	  
KCNG1	   potassium	  channel,	  voltage	  gated	  modifier	  subfamily	  G,	  
member	  1	  
None	  
KCNG2	   potassium	  channel,	  voltage	  gated	  modifier	  subfamily	  G,	  
member	  2	  
None	  
KCNG3	   potassium	  channel,	  voltage	  gated	  modifier	  subfamily	  G,	  
member	  3	  
None	  
KCNH2	   potassium	  channel,	  voltage	  gated	  eag	  related	  subfamily	  
H,	  member	  2	  
None	  
KCNH3	   potassium	  channel,	  voltage	  gated	  eag	  related	  subfamily	  
H,	  member	  3	  
None	  
KCNH4	   potassium	  channel,	  voltage	  gated	  eag	  related	  subfamily	  
H,	  member	  4	  
None	  
KCNH6	   potassium	  channel,	  voltage	  gated	  eag	  related	  subfamily	  
H,	  member	  6	  
None	  
KCNH7	   potassium	  channel,	  voltage	  gated	  eag	  related	  subfamily	  
H,	  member	  7	  
None	  
KCNH8	   potassium	  channel,	  voltage	  gated	  eag	  related	  subfamily	  
H,	  member	  8	  
None	  
KCNIP1	   Kv	  channel	  interacting	  protein	  1	   None	  
KCNIP2	   Kv	  channel	  interacting	  protein	  2	   None	  
KCNIP3	   Kv	  channel	  interacting	  protein	  3,	  calsenilin	   None	  
KCNJ1	   potassium	  channel,	  inwardly	  rectifying	  subfamily	  J,	  
member	  1	  
None	  
KCNJ10	   potassium	  channel,	  inwardly	  rectifying	  subfamily	  J,	  
member	  10	  
None	  
KCNJ12	   potassium	  channel,	  inwardly	  rectifying	  subfamily	  J,	  
member	  12	  
None	  
KCNJ15	   potassium	  channel,	  two	  pore	  domain	  subfamily	  J,	  
member	  15	  
None	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KCNJ16	   potassium	  channel,	  two	  pore	  domain	  subfamily	  J,	  
member	  16	  
None	  
KCNJ3	   potassium	  channel,	  two	  pore	  domain	  subfamily	  J,	  
member	  3	  
None	  
KCNJ4	   potassium	  channel,	  two	  pore	  domain	  subfamily	  J,	  
member	  4	  
None	  
KCNJ5	   potassium	  channel,	  two	  pore	  domain	  subfamily	  J,	  
member	  5	  
None	  
KCNJ6	   potassium	  channel,	  two	  pore	  domain	  subfamily	  J,	  
member	  6	  
None	  
KCNJ8	   potassium	  channel,	  two	  pore	  domain	  subfamily	  J,	  
member	  8	  
None	  
KCNJ9	   potassium	  channel,	  two	  pore	  domain	  subfamily	  J,	  
member	  9	  
None	  
KCNK1	   potassium	  channel,	  two	  pore	  domain	  subfamily	  K,	  
member	  1	  
None	  
KCNK16	   potassium	  channel,	  two	  pore	  domain	  subfamily	  K,	  
member	  16	  
None	  
KCNK17	   potassium	  channel,	  two	  pore	  domain	  subfamily	  K,	  
member	  17	  
None	  
KCNK2	   potassium	  channel,	  two	  pore	  domain	  subfamily	  K,	  
member	  2	  
None	  
KCNK3	   potassium	  channel,	  two	  pore	  domain	  subfamily	  K,	  
member	  3	  
None	  
KCNK5	   potassium	  channel,	  two	  pore	  domain	  subfamily	  K,	  
member	  5	  
None	  
KCNK7	   potassium	  channel,	  two	  pore	  domain	  subfamily	  K,	  
member	  7	  
None	  
KCNK9	   potassium	  channel,	  two	  pore	  domain	  subfamily	  K,	  
member	  9	  
None	  
KCNMB2	   potassium	  channel	  subfamily	  M	  regulatory	  beta	  subunit	  
2	  
None	  
KCNMB3	   potassium	  channel	  subfamily	  M	  regulatory	  beta	  subunit	  
4	  
None	  
KCNMB4	   potassium	  channel,	  calcium	  activated	  large	  conductance	  
subfamily	  M	  alpha,	  member	  1	  
None	  
KCNN1	   potassium	  channel,	  calcium	  activated	  intermediate/small	  
conductance	  subfamily	  N	  alpha,	  member	  1	  
None	  
KCNN3	   potassium	  channel,	  calcium	  activated	  intermediate/small	  
conductance	  subfamily	  N	  alpha,	  member	  3	  
None	  
KCNQ1	   potassium	  channel,	  voltage	  gated	  KQT-­‐like	  subfamily	  Q,	  
member	  1	  
None	  
KCNQ2	   potassium	  channel,	  voltage	  gated	  KQT-­‐like	  subfamily	  Q,	  
member	  2	  
None	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Table B.2: List of known ion channel genes (cont.)
Gene	   Gene	  description	   Expression	  	  
KCNQ4	   potassium	  channel,	  voltage	  gated	  KQT-­‐like	  subfamily	  Q,	  
member	  4	  
None	  
KCNS2	   potassium	  voltage-­‐gated	  channel,	  modifier	  subfamily	  S,	  
member	  2	  
None	  
KCNS3	   potassium	  voltage-­‐gated	  channel,	  modifier	  subfamily	  S,	  
member	  3	  
None	  
KCNT1	   potassium	  channel,	  sodium	  activated	  subfamily	  T,	  
member	  1	  
None	  
KCNT2	   potassium	  channel,	  sodium	  activated	  subfamily	  T,	  
member	  2	  
None	  
KCNV2	   potassium	  channel,	  voltage	  gated	  modifier	  subfamily	  V,	  
member	  2	  
None	  
LIN7B	   lin-­‐7	  homolog	  B	  (C.	  elegans)	   None	  
LRRC26	   leucine	  rich	  repeat	  containing	  26	   None	  
LYN	   LYN	  proto-­‐oncogene,	  Src	  family	  tyrosine	  kinase	   None	  
MCOLN2	   Mucolipin	  2	   None	  
MCOLN3	   Mucolipin	  3	   None	  
MFSD11	   major	  facilitator	  superfamily	  domain	  containing	  11	   None	  
MLC1	   megalencephalic	  leukoencephalopathy	  with	  subcortical	  
cysts	  1	  
None	  
MMD	   monocyte	  to	  macrophage	  differentiation-­‐associated	   None	  
MTCH1	   mitochondrial	  carrier	  1	   None	  
MYOCD	   myocardin	   None	  
NALCN	   sodium	  leak	  channel,	  non	  selective	   None	  
NOX1	   NADPH	  oxidase,	  EF-­‐hand	  calcium	  binding	  domain	  1	   None	  
NOX5	   NADPH	  oxidase,	  EF-­‐hand	  calcium	  binding	  domain	  5	   None	  
OPN4	   opsin	  4	   None	  
ORAI1	   ORAI	  calcium	  release-­‐activated	  calcium	  modulator	  1	   None	  
ORAI3	   ORAI	  calcium	  release-­‐activated	  calcium	  modulator	  3	   None	  
P2RX1	   purinergic	  receptor	  P2X,	  ligand	  gated	  ion	  channel,	  1	   None	  
P2RX2	   purinergic	  receptor	  P2X,	  ligand	  gated	  ion	  channel,	  2	   None	  
P2RX3	   purinergic	  receptor	  P2X,	  ligand	  gated	  ion	  channel,	  3	   None	  
P2RX4	   purinergic	  receptor	  P2X,	  ligand	  gated	  ion	  channel,	  4	   None	  
P2RX5	   purinergic	  receptor	  P2X,	  ligand	  gated	  ion	  channel,	  5	   None	  
P2RX5-­‐
TAX1BP3	   P2RX5-­‐TAX1BP3	  readthrough	  (NMD	  candidate)	  
None	  
P2RX6	   purinergic	  receptor	  P2X,	  ligand	  gated	  ion	  channel,	  6	   None	  
P2RX6P	   purinergic	  receptor	  P2X,	  ligand	  gated	  ion	  channel,	  6	  
pseudogene	  
None	  
P2RX7	   purinergic	  receptor	  P2X,	  ligand	  gated	  ion	  channel,	  7	   None	  
PANX1	   pannexin	  1	   None	  
PANX2	   Pannexin	  2	   None	  
PANX3	   Pannexin	  3	   None	  
PDZD3	   PDZ	  domain	  containing	  3	   None	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Table B.2: List of known ion channel genes (cont.)
Gene	   Gene	  description	   Expression	  
PHPT1	   phosphohistidine	  phosphatase	  1	   None	  
PICK1	   protein	  interacting	  with	  PRKCA	  1	   None	  
PIEZO1	   piezo-­‐type	  mechanosensitive	  ion	  channel	  component	  1	   None	  
PIEZO1P1	   piezo-­‐type	  mechanosensitive	  ion	  channel	  component	  1	  
pseudogene	  1	  
None	  
PIEZO2	   piezo-­‐type	  mechanosensitive	  ion	  channel	  component	  2	   None	  
PKD1L2	   polycystic	  kidney	  disease	  1-­‐like	  2	  (gene/pseudogene)	   None	  
PKD1L3	   polycystic	  kidney	  disease	  1-­‐like	  3	   None	  
PKD2	   polycystic	  kidney	  disease	  2	  (autosomal	  dominant)	   None	  
PKD2L2	   polycystic	  kidney	  disease	  2-­‐like	  2	   None	  
PKDREJ	   polycystin	  (PKD)	  family	  receptor	  for	  egg	  jelly	   None	  
PLLP	   plasmolipin	   None	  
PLP2	   proteolipid	  protein	  2	  (colonic	  epithelium-­‐enriched)	  
	  
None	  
PNPLA8	   patatin-­‐like	  phospholipase	  domain	  containing	  8	   None	  
RAPGEF3	   Rap	  guanine	  nucleotide	  exchange	  factor	  (GEF)	  3	   None	  
RSC1A1	   regulatory	  solute	  carrier	  protein,	  family	  1,	  member	  1	   None	  
RYR1	   ryanodine	  receptor	  1	   None	  
RYR2	   ryanodine	  receptor	  2	  (cardiac)	   None	  
SCN11A	   sodium	  channel,	  voltage	  gated,	  type	  XI	  alpha	  subunit	   None	  
SCN2A	   sodium	  channel,	  voltage	  gated,	  type	  II	  alpha	  subunit	   None	  
SCN2B	   sodium	  channel,	  voltage	  gated,	  type	  II	  beta	  subunit	   None	  
SCN3A	   sodium	  channel,	  voltage	  gated,	  type	  III	  alpha	  subunit	   None	  
SCN5A	   sodium	  channel,	  voltage	  gated,	  type	  V	  alpha	  subunit	   None	  
SCN9A	   sodium	  channel,	  voltage	  gated,	  type	  IX	  alpha	  subunit	   None	  
SCNN1B	   sodium	  channel,	  non	  voltage	  gated	  1	  beta	  subunit	   None	  
SCNN1D	   sodium	  channel,	  non	  voltage	  gated	  1	  delta	  subunit	   None	  
SCNN1G	   sodium	  channel,	  non	  voltage	  gated	  1	  gamma	  subunit	   None	  
SIRT2	   sirtuin	  2	   None	  
SLC26A9	   solute	  carrier	  family	  26	  (anion	  exchanger),	  member	  9	   None	  
SLC4A11	   solute	  carrier	  family	  4,	  sodium	  borate	  transporter,	  
member	  11	  
None	  
SLC9A11	   solute	  carrier	  family	  9,	  sodium	  borate	  transporter,	  
member	  11	  
None	  
SLC9A3R2	   solute	  carrier	  family	  9,	  subfamily	  A	  (NHE3,	  cation	  proton	  
antiporter	  3),	  member	  3	  regulator	  2	  
None	  
SRC	   SRC	  proto-­‐oncogene,	  non-­‐receptor	  tyrosine	  kinase	   None	  
SRF	   serum	  response	  factor	  (c-­‐fos	  serum	  response	  element-­‐
binding	  transcription	  factor)	  
None	  
STX1A	   syntaxin	  1A	  (brain)	   None	  
STX1B	   syntaxin	  1B	  (brain)	   None	  
TMEM37	   transmembrane	  protein	  37	   None	  
TPCN1	   two	  pore	  segment	  channel	  1	   None	  
TPCN2	   two	  pore	  segment	  channel	  2	   None	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Table B.2: List of known ion channel genes (cont.)
Gene	   Gene	  description	   Expression	  
TPTE	   transmembrane	  phosphatase	  with	  tensin	  homology	   None	  
TRPC1	   transient	  receptor	  potential	  cation	  channel,	  subfamily	  C,	  
member	  1	  
None	  
TRPC4	   transient	  receptor	  potential	  cation	  channel,	  subfamily	  C,	  
member	  4	  
None	  
TRPC5	   transient	  receptor	  potential	  cation	  channel,	  subfamily	  C,	  
member	  5	  
None	  
TRPM1	   transient	  receptor	  potential	  cation	  channel,	  subfamily	  M,	  
member	  1	  
None	  
TRPM2	   transient	  receptor	  potential	  cation	  channel,	  subfamily	  M,	  
member	  2	  
None	  
TRPM4	   transient	  receptor	  potential	  cation	  channel,	  subfamily	  M,	  
member	  4	  
None	  
TRPM6	   transient	  receptor	  potential	  cation	  channel,	  subfamily	  M,	  
member	  6	  
None	  
TRPM8	   transient	  receptor	  potential	  cation	  channel,	  subfamily	  M,	  
member	  8	  
None	  
TRPV1	   transient	  receptor	  potential	  cation	  channel,	  subfamily	  V,	  
member	  1	  
None	  
TRPV5	   transient	  receptor	  potential	  cation	  channel,	  subfamily	  V,	  
member	  5	  
None	  
TRPV6	   transient	  receptor	  potential	  cation	  channel,	  subfamily	  V,	  
member	  6	  
None	  
TTYH1	   tweety	  family	  member	  1	   None	  
TTYH2	   tweety	  family	  member	  2	   None	  
TTYH3	   tweety	  family	  member	  3	   None	  
UNC93A	   unc-­‐93	  homolog	  A	  (C.	  elegans)	   None	  
UNC93B1	   unc-­‐93	  homolog	  B1	  (C.	  elegans)	   None	  
YES1	   YES	  proto-­‐oncogene	  1,	  Src	  family	  tyrosine	  kinase	   None	  
ZACN	   zinc	  activated	  ligand-­‐gated	  ion	  channel	   None	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Table B.3: List of known genes associated with long QT with associated phenotype
Gene	   Gene	  Description	   Disease	  
ABCC9	   ATP-­‐Binding	  Cassette,	  Subfamily	  C,	  Member	  9	   Familial	  AF,	  Dilated	  
Cardiomyopathy	  
ACADM	   Acyl-­‐CoA	  dehydrogenase,	  medium	  chain	   Deficiency	  of	  Acyl-­‐CoA	  
dehydrogenase,	  medium	  chain	  
(causing	  longQT)	  
ACE	   Angiotensin	  I-­‐converting	  enzyme	   Long	  QT	  in	  ESRF	  
ADRA2C	   Alpha-­‐2c-­‐Adrenergic	  Receptor	   	  
ADRB1	   Beta-­‐1-­‐Adrenergic	  Receptor	   	  
ADRB2	   Beta-­‐2-­‐Adrenergic	  Receptor	   	  
AKR1B1	   Aldo-­‐Keto	  Reductase	  Family	  1,	  Member	  B1	   	  
ALG10B	   alpha-­‐1,2-­‐glucosyltransferase	   Long	  QT	  
ANK2	   Ankyrin	  2	   Long	  QT	  4	  
AR	   androgen	  receptor	   	  
ATP6	   ATP	  synthase	  6	   Mitochondrial	  complex	  V	  
deficiency	  
ATP8	   ATP	  synthase	  8	   Mitochondrial	  complex	  V	  
deficiency	  
C2	   Complement	  component	  2	   C2	  defieciency	  
CACNA1C	   calcium	  channel,	  voltage-­‐dependent,	  L	  type,	  
alpha	  1C	  subunit	  
Brugada	  syndrome,	  Timothy	  
syndrome	  
CACNA1D	   calcium	  channel,	  voltage-­‐dependent,	  L	  type,	  
alpha	  1D	  subunit	  
Sinoatrial	  node	  dysfunction	  
CACNB3	   calcium	  channel,	  voltage-­‐dependent,	  beta	  3	  
subunit	  
	  
CALM1	   Calmodulin	  1	   Long	  QT	  4,	  polymorphic	  VT	  
CALM2	   Calmodulin	  2	   Long	  QT	  15	  
CALM3	   Calmodulin	  3	   	  
CAV1	   Caveolin	  1	   	  
CAV3	   Caveolin	  3	   Long	  QT	  9	  
CDH15	   Cadherin	  15	   	  
CDKN2B	   Cyclin-­‐Dependent	  Kinase	  Inhibitor	  2b	   	  
EDA	   Ectodysplasin	  A	   	  
ELN	   Elastin	   Supravalvar	  aortic	  stenosis	  
FBN1	   Fibrillin	  1	   Marfan	  Syndrome	  
FBXW4	   F-­‐Box	  And	  Wd40	  Domain	  Protein	  4	   	  
GAS	   Gastrin	   	  
GJA8	   Gap	  Junction	  Protein,	  Alpha-­‐8	   	  
GJB3	   Gap	  Junction	  Protein,	  Beta-­‐3	   Deafness	  
GJB6	   Gap	  Junction	  Protein,	  Beta-­‐6	   Deafness	  
GPR133	   G	  Protein-­‐Coupled	  Receptor	  133	   	  
HAND2	   Heart-­‐	  And	  Neural	  Crest	  Derivatives-­‐Expressed	  2	   	  
HCN4	   Hyperpolarization-­‐Activated	  Cyclic	  Nucleotide-­‐
Gated	  Potassium	  Channel	  4	  
Brugada	  syndrome	  
HFE	   HFE	  gene	   Haemochromatosis	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Table B.3: List of genes associated with Long QT (cont.)
Gene	   Gene	  Description	   Disease	  
HLA-­‐DRB3	   Major	  Histocompatibility	  Complex,	  Class	  Ii,	  Dr	  
Beta-­‐3	  
	  
HMI	   Hypomelanosis	  of	  Ito	   	  
HMOX1	   Heme	  Oxygenase	  1	   Heme	  oxygenase-­‐1	  deficiency	  
HRAS	   V-­‐Ha-­‐Ras	  Harvey	  Rat	  Sarcoma	  Viral	  Oncogene	  
Homolog	  
Congenital	  myopathy	  
IGLV2-­‐18	   Immunoglobulin	  lambda	  variable	  2-­‐18	   	  
IGLV2-­‐8	   immunoglobulin	  lambda	  variable	  2-­‐8	   	  
IKZF1	   Ikaros	  Family	  Zinc	  Finger	  1	   	  
IL10	   Interleukin	  10	   	  
INS	   Insulin	   	  
KCNA4	   potassium	  channel,	  voltage	  gated	  shaker	  
related	  subfamily	  A,	  member	  4	  
	  
KCNA5	   potassium	  channel,	  voltage	  gated	  shaker	  
related	  subfamily	  A,	  member	  5	  
Familial	  Atrial	  fibrillation	  
KCNB1	   potassium	  channel,	  voltage	  gated	  Shab	  
related	  subfamily	  B,	  member	  1	  
	  
KCND2	   potassium	  channel,	  voltage	  gated	  Shal	  
related	  subfamily	  D,	  member	  2	  
	  
KCND3	   potassium	  channel,	  voltage	  gated	  Shal	  
related	  subfamily	  D,	  member	  3	  
Spinocerebellar	  ataxia	  19	  
KCNE1	   potassium	  channel,	  voltage	  gated	  subfamily	  E	  
regulatory	  beta	  subunit	  1	  
Long	  QT	  5	  
KCNE1L	   Potassium	  Channel,	  Voltage-­‐Gated,	  Isk-­‐Related	  
Family,	  Member	  1-­‐Like	  
	  
KCNE2	   potassium	  channel,	  voltage	  gated	  subfamily	  E	  
regulatory	  beta	  subunit	  2	  
Long	  QT	  6	  
KCNE3	   potassium	  channel,	  voltage	  gated	  subfamily	  E	  
regulatory	  beta	  subunit	  3	  
Brugada	  syndrome	  
KCNH2	   potassium	  channel,	  voltage	  gated	  eag	  related	  
subfamily	  H,	  member	  2	  
Long	  QT	  2	  
KCNJ11	   potassium	  channel,	  two	  pore	  domain	  
subfamily	  J,	  member	  11	  
	  
KCNJ2	   potassium	  channel,	  two	  pore	  domain	  
subfamily	  J,	  member	  2	  
Andersen	  Tawil	  Syndrome	  
KCNK3	   potassium	  channel,	  two	  pore	  domain	  
subfamily	  K,	  member	  3	  
	  
KCNN4	   potassium	  channel,	  calcium	  activated	  
intermediate/small	  conductance	  subfamily	  N	  
alpha,	  member	  4	  
	  
KCNQ1	   potassium	  channel,	  voltage	  gated	  KQT-­‐like	  
subfamily	  Q,	  member	  1	  
Long	  QT1	  
KCNQ2	   potassium	  channel,	  voltage	  gated	  KQT-­‐like	  
subfamily	  Q,	  member	  2	  
Epileptic	  encephalopathy,	  
seizures	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Table B.3: List of genes associated with Long QT (cont.)
Gene	   Gene	  Description	   Disease	  
KCNQ4	   potassium	  channel,	  voltage	  gated	  KQT-­‐like	  
subfamily	  Q,	  member	  4	  
Deafness	  
LDLR	   low	  density	  lipoprotein	  receptor	   	  
LQT1	   Long	  QT	  Syndrome	  1	   Long	  QT1	  
MAPK3	   mitogen-­‐activated	  protein	  kinase	  3	   	  
MEA1	   Male-­‐enhanced	  antigen	  1	   	  
MINK1	   Misshapen/Nik-­‐Related	  Kinase	  1	   	  
MMP9	   Matrix	  Metalloproteinase	  9	   Metaphyseal	  anadysplasia	  2	  
MRPL28	   Mitochondrial	  Ribosomal	  Protein	  L28	   	  
MTND1	   Complex	  1,	  Subunit	  ND1	   MELAS,	  Leber	  optic	  atrophy	  
MTND2	   Complex	  1,	  Subunit	  ND2	   Mitochondrial	  Complex	  1	  
Deficiency,	  Leber	  optic	  atrophy	  
MTND4	   Complex	  1,	  Subunit	  ND4	   Leber	  optic	  atrophy	  
MTND5	   Complex	  1,	  Subunit	  ND5	   MELAS,	  Leber	  optic	  atrophy,	  
Mitochondrial	  Complex	  1	  
Deficiency	  
MTND6	   Complex	  1,	  Subunit	  ND6	   Leber	  optic	  atrophy	  
MUC2	   Mucin	  2	   	  
MYBPC3	   Cardiac	  myosin-­‐binding	  protein	  C	   Hypertrophic	  cardiomyopathy,	  
Dilated	  cardiomyopathy	  
MYH7	   Myosin,	  Heavy	  Chain	  7	   Hypertrophic	  cardiomyopathy,	  
Hypertrophic	  cardiomyopathy,	  
Myopathy	  
NOS1AP	   Nitric	  Oxide	  Synthase	  1	  (Neuronal)	  Adaptor	  
Protein	  
	  
NXT1	   NTF2-­‐Like	  Export	  Factor	  1	   	  
OR6K3	   Olfactory	  Receptor,	  Family	  6,	  Subfamily	  K,	  
Member	  3	  
	  
PELI1	   Drosophila	  homolog	  of	  Pellino	  1	   	  
PKP2	   Plakophilin	  2	   Arrhythmogenic	  right	  
ventricular	  dysplasia	  9	  
POMC	   Proopiomelanocortin	   	  
PTEN	   Phosphatase	  And	  Tensin	  Homolog	   	  
PTRF	   RNA	  Polymerase	  I	  And	  Transcript	  Release	  Factor	   Lipodystrophy	  
RYR2	   Ryanodine	  Receptor	  2	   Arrhythmogenic	  right	  
ventricular	  dysplasia	  2	  
SCD	   Stearoyl-­‐CoA	  desaturase	   	  
SCN4B	   Sodium	  Channel,	  Voltage-­‐Gated,	  Type	  Iv,	  Beta	  
Subunit	  
Long	  QT10,	  Atrial	  fibrillation	  
SCN5A	   Sodium	  Channel,	  Voltage-­‐Gated,	  Type	  V,	  Alpha	  
Subunit	  
Long	  QT3,	  Atrial	  Fibrillation,	  
Brugada	  syndrome	  1,	  
Cardiomyopathy	  
SLC18A2	   Solute	  Carrier	  Family	  18	  (Vesicular	  Monoamine),	  
Member	  2	  
	  
SLC22A5	   Solute	  Carrier	  Family	  22	  (Organic	  Cation	  
Transporter),	  Member	  5	  
Carnitine	  deficiency	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Table B.3: List of genes associated with Long QT (cont.)
Gene	   Gene	  Description	   Disease	  
SLN	   Sarcolipin	   	  
SNTA1	   Alpha	  1	  syntrophin	   Long	  QT12	  
SPESP1	   Sperm	  Equatorial	  Segment	  Protein	  1	   	  
SUB1	   S.	  Cerevisiae,	  Homolog	  Of	  SUB1	   	  
TF	   Transferrin	   Atransferrinemia	  
TGFB3	   Transforming	  Growth	  Factor,	  Beta-­‐3	   Arrhythmogenic	  right	  
ventricular	  dysplasia	  1	  
TIMP2	   Tissue	  Inhibitor	  Of	  Metalloproteinase	  2	   	  
TLX1NB	   TLX1	  Divergent	  Gene	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Anaesthetics	  and	  Pregnancy	  in	  Channelopathy	  Patients	  	  There	  is	  very	  little	  information	  available	  about	  the	  effect	  of	  anaesthetics	  and	  pregnancy	  in	  muscle	  channel	  patients.	  We	  are	  therefore	  trying	  to	  gather	  data	  on	  all	  our	  patients	  so	  that	  we	  can	  give	  better	  advice	  and	  support	  in	  the	  future.	  We	  of	  course	  need	  your	  help	  to	  do	  this.	  	  
Please	  fill	  out	  all	  the	  applicable	  sections	  of	  this	  form	  as	  fully	  as	  possible.	  	  	  
Name:	  	   	   	   	   	   	  
Gender:	  	  	  	   Male	  	  /	  	  	  Female	  
Date	  of	  Birth:	  	  
Your	  diagnosis:	  (if	  known)	  	  
Have	  you	  had	  a	  positive	  genetic	  test?	  	  	   	   Yes	  /	  No	  
At	  what	  age	  did	  you	  first	  get	  symptoms?	  	  	  
1.	  Anaesthetics	  
a)	  Have	  you	  ever	  had	  a	  local	  anaesthetic?	   	   	   Yes	  /	  No	  	  	  	  	  	  	  	  (e.g	  dental	  procedures/	  stitches)	  	  	  
If	  yes:	  	  What	  did	  you	  have	  the	  local	  anaesthetic	  for?	  (please	  give	  full	  details)	  	  	  
Did	  you	  have	  any	  problems	  with	  it?	  	  	  	  	   	   	   Yes	  /	  No	  
If	  yes:	  What	  problems	  did	  you	  have?	   	   It	  was	  ineffective	   	   ☐	  	   	   	   	   	   	   Its	  effect	  was	  prolonged	   ☐	  	  	   	   	   	   	   	   Other:	  	  b)	  Have	  you	  ever	  had	  a	  spinal	  anaesthetic	  or	  epidural?	  	   Yes	  /	  No	  
If	  yes:	   What	  did	  you	  have	  it	  for?	  (please	  give	  full	  details)	  	  	  
Did	  you	  have	  any	  problems	  with	  it?	  	  	  	  	   	   	   Yes	  /	  No	  
If	  yes:	  	  What	  problems	  did	  you	  have?	   	   It	  was	  ineffective.	   	   ☐	  	   	   	   	   	   	   Its	  effect	  was	  prolonged	   ☐	  Other:	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c)	  Have	  you	  ever	  had	  a	  general	  anaesthetic?	  	  	   	   	   Yes	  /	  No	  
If	  yes:	  	  What	  procedure/s	  did	  you	  have	  it	  for?	  	  (please	  give	  details	  of	  all	  surgeries	  and	  the	  treating	  hospital)	  	  	  	  
Did	  you	  have	  any	  problems	  with	  the	  anaesthetic?	  	  	  	  	   Yes	  /	  No	  If	  yes,	  what	  problems	  did	  you	  have?	  (please	  give	  full	  details)	  	  	  
	  
2.	  Pregnancy	  	  
Male	  &	  Female	  patients	  please	  complete	  this	  section	  
a)	  Have	  you	  ever	  tried	  to	  conceive?	  	   	   	   	   Yes	  /	  No	  	  
If	  yes:	  	   Have	  you	  ever	  had	  problems	  trying	  to	  conceive?	  	   	   Yes	  /	  No	  	  How	  long	  did	  it	  take	  you	  to	  conceive?	  
	  
b)	  How	  many	  children	  have	  you	  had?	  	  
Female	  patients	  ONLY	  need	  to	  complete	  this	  section	  
	  
d)	  How	  many	  pregnancies	  have	  you	  had?	  	  
c)	  Have	  you	  ever	  had	  a	  termination	  of	  pregnancy?	   	   Yes	  /	  No	  	  
If	  yes:	  How	  many	  terminations	  have	  you	  had?	  	  
d)	  Have	  you	  ever	  had	  a	  miscarriage?	   	   	   	   Yes	  /	  No	  	  
If	  yes:	  	  How	  many	  miscarriages	  have	  you	  had?	  	   At	  what	  stage	  of	  the	  pregnancy	  was	  your	  miscarriage/s?	  	  	   What	  was	  the	  cause	  of	  your	  miscarriage/s?	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e)	  Did	  you	  have	  any	  problems	  during	  your	  pregnancies?	   	   Yes	  /	  No	  
If	  yes:	  What	  problems	  did	  you	  have:	   	   Pre-­‐eclampsia	   	   ☐	  	   	   	   	   	   	   	   Hypertension	  	   	   ☐	  	   	   	   	   	   	   	   Gestational	  diabetes	   	   ☐	  	   	   	   	   	   	   	   Placenta	  previa	   	   ☐	  	   	   	   	   	   	   	   UTI	   	   	   	   ☐	  	   	   	   	   	   	   	   Other:	  	  	   Please	  give	  details	  of	  any	  problems	  you	  had	  in	  pregnancy:	  	  	  	  	  	  
	  
f)	  Did	  you	  have	  any	  problems	  during	  delivery?	   	   	   Yes	  /	  No	  	  
If	  yes:	  What	  problems	  did	  you	  have?	   	   Emergency	  C-­‐section	  	   ☐	  	   	   	   	   	   	   	   Forceps	  delivery	   	   ☐	  	   	   	   	   	   	   	   Ventouse	  delivery	   	   ☐	  	   	   	   	   	   	   	   Placenta	  previa	   	   ☐	  Post-­‐partum	  haemorrhage	   ☐	  Breech	  baby	   	   	   ☐	  	   	   	   	   	   	   	   Other:	  	  	   Please	  give	  details	  of	  any	  problems	  you	  had	  during	  delivery:	  	  	  	  	  	  
g)	  At	  how	  many	  weeks	  were	  each	  of	  you	  children	  born	  and	  were	  there	  any	  	  	  
post-­‐natal	  problems?	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Your	  channelopathy	  during	  pregnancy	  
h)	  Did	  the	  pregnancy	  make	  your	  disease:	   	   Better/	  Worse	  /	  No	  change	  	  
	   If	  your	  disease	  changed	  during	  pregnancy	  which	  symptoms	  changed?	  	   If	  your	  disease	  changed	  did	  the	  symptoms	  settle	  after	  birth?	  	   	   Yes	  /	  No	  	  	  If	  yes	  how	  long	  did	  it	  take	  to	  settle?	  	  
	  
i)	  Does	  Menstruation	  make	  your	  disease:	   	   Better/	  Worse	  /	  No	  change	  	  
Any	  other	  comments	  or	  details	  you	  would	  like	  to	  add?	  	  	  	  	  	  	  	  
Thank	  you	  for	  completing	  this	  form.	  
	  
Please	  return	  the	  form	  by	  post,	  email	  or	  fax	  to	  the	  address	  below.	  	  If	  you	  have	  any	  questions	  or	  comments	  about	  this	  form	  please	  feel	  free	  to	  contact	  me	  or	  another	  member	  of	  our	  team:	  
Dr	  Dipa	  Raja	  Rayan	  
MRC	  Centre	  for	  Neuromuscular	  Diseases	  
Box	  102	  
National	  Hospital	  for	  Neurology	  and	  Neurosurgery,	  
Queen	  Square,	  
London,	  
WC1N	  3BG	  	  
Tel:	  020	  3448	  8025	  
Fax:	  020	  3448	  3633	  
e-­‐mail:	  d.rayan@ucl.ac.uk	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